SEC Info℠  
    Home      Search      My Interests      Help      Sign In      Please Sign In

FSD Pharma Inc. – ‘20-F’ for 12/31/21 – ‘JSON’

On:  Thursday, 3/31/22, at 8:09am ET   ·   For:  12/31/21   ·   Accession #:  1062993-22-9034   ·   File #:  1-39152

Previous ‘20-F’:  None   ·   Next:  ‘20-F’ on 3/31/23 for 12/31/22   ·   Latest:  ‘20-F’ on 4/2/24 for 12/31/23   ·   7 References:   

Find Words in Filings emoji
 		  in    Show  and   ↓Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 3/31/22  FSD Pharma Inc.                   20-F       12/31/21  132:39M                                    Newsfile Corp./FA

Annual or Annual-Transition Report by a Foreign Non-Canadian Issuer   —   Form 20-F   —   SEA’34

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 20-F        Annual or Annual-Transition Report by a Foreign     HTML   2.06M 
                Non-Canadian Issuer -- form20f                                   
 2: EX-1.1      Underwriting Agreement or Conflict Minerals Report  HTML     43K 
                -- exhibit1-1                                                    
 3: EX-2.1      Plan of Acquisition, Reorganization, Arrangement,   HTML     58K 
                Liquidation or Succession -- exhibit2-1                          
 9: EX-4.10     Instrument Defining the Rights of Security Holders  HTML     35K 
                -- exhibit4-10                                                   
10: EX-4.11     Instrument Defining the Rights of Security Holders  HTML     36K 
                -- exhibit4-11                                                   
11: EX-4.12     Instrument Defining the Rights of Security Holders  HTML     34K 
                -- exhibit4-12                                                   
12: EX-4.14     Instrument Defining the Rights of Security Holders  HTML     70K 
                -- exhibit4-14                                                   
13: EX-4.15     Instrument Defining the Rights of Security Holders  HTML     78K 
                -- exhibit4-15                                                   
14: EX-4.16     Instrument Defining the Rights of Security Holders  HTML     82K 
                -- exhibit4-16                                                   
15: EX-4.17     Instrument Defining the Rights of Security Holders  HTML     82K 
                -- exhibit4-17                                                   
 4: EX-4.2      Instrument Defining the Rights of Security Holders  HTML    251K 
                -- exhibit4-2                                                    
 5: EX-4.4      Instrument Defining the Rights of Security Holders  HTML     33K 
                -- exhibit4-4                                                    
 6: EX-4.5      Instrument Defining the Rights of Security Holders  HTML     75K 
                -- exhibit4-5                                                    
 7: EX-4.6      Exhibit44.6                                         HTML     36K 
 8: EX-4.9      Instrument Defining the Rights of Security Holders  HTML     41K 
                -- exhibit4-9                                                    
16: EX-8.1      Opinion of Counsel re: Tax Matters -- exhibit8-1    HTML     33K 
19: EX-13.1     Annual or Quarterly Report to Security Holders --   HTML     35K 
                exhibit13-1                                                      
20: EX-13.2     Annual or Quarterly Report to Security Holders --   HTML     35K 
                exhibit13-2                                                      
22: EX-99.1     Miscellaneous Exhibit -- exhibit99-1                HTML     34K 
17: EX-12.1     Statement re: the Computation of Ratios --          HTML     37K 
                exhibit12-1                                                      
18: EX-12.2     Statement re: the Computation of Ratios --          HTML     37K 
                exhibit12-2                                                      
21: EX-15.1     Letter re: Unaudited Interim Financial Info --      HTML    359K 
                exhibit15-1                                                      
28: R1          Document And Entity Information                     HTML    116K 
29: R2          Consolidated Statements of Financial Position       HTML    107K 
30: R3          Consolidated Statements of Loss and Comprehensive   HTML     91K 
                Loss                                                             
31: R4          Consolidated Statements of Changes in               HTML     87K 
                Shareholder's Equity                                             
32: R5          Consolidated Statements of Cash Flows               HTML    116K 
33: R6          Nature of business                                  HTML     48K 
34: R7          Basis of presentation                               HTML     53K 
35: R8          Significant accounting policies                     HTML     81K 
36: R9          Acquisition of Prismic                              HTML     49K 
37: R10         Acquisition of Lucid                                HTML     50K 
38: R11         Assets held for sale                                HTML     99K 
39: R12         Other receivables                                   HTML     42K 
40: R13         Prepaid expenses and deposits                       HTML     42K 
41: R14         Investments                                         HTML     95K 
42: R15         Right-of-use asset                                  HTML     43K 
43: R16         Intangible assets                                   HTML     50K 
44: R17         Trade and other payables                            HTML     51K 
45: R18         Notes payable                                       HTML     43K 
46: R19         Lease obligations                                   HTML     52K 
47: R20         Warrants Liability                                  HTML     39K 
48: R21         Share capital                                       HTML    169K 
49: R22         Share-based compensation                            HTML    231K 
50: R23         Loss per share                                      HTML     44K 
51: R24         General and administrative                          HTML     53K 
52: R25         Income Taxes                                        HTML     66K 
53: R26         Commitments and contingencies                       HTML     56K 
54: R27         Related party transactions                          HTML     48K 
55: R28         Capital Management                                  HTML     38K 
56: R29         Financial Instruments and Risk Management           HTML     45K 
57: R30         Segmented information                               HTML     37K 
58: R31         Subsequent events                                   HTML     38K 
59: R32         Significant accounting policies (Policies)          HTML    109K 
60: R33         Nature of business (Tables)                         HTML     43K 
61: R34         Significant accounting policies (Tables)            HTML     40K 
62: R35         Acquisition of Prismic (Tables)                     HTML     49K 
63: R36         Acquisition of Lucid (Tables)                       HTML     48K 
64: R37         Assets held for sale (Tables)                       HTML     97K 
65: R38         Other receivables (Tables)                          HTML     42K 
66: R39         Prepaid expenses and deposits (Tables)              HTML     42K 
67: R40         Investments (Tables)                                HTML     85K 
68: R41         Right-of-use asset (Tables)                         HTML     42K 
69: R42         Intangible assets (Tables)                          HTML     48K 
70: R43         Trade and other payables (Tables)                   HTML     52K 
71: R44         Notes Payable (Tables)                              HTML     41K 
72: R45         Lease obligations (Tables)                          HTML     53K 
73: R46         Share capital (Tables)                              HTML    159K 
74: R47         Share-based compensation (Tables)                   HTML    234K 
75: R48         Loss per share (Tables)                             HTML     43K 
76: R49         General and administrative (Tables)                 HTML     52K 
77: R50         Income Taxes (Tables)                               HTML     69K 
78: R51         Related party transactions (Tables)                 HTML     43K 
79: R52         Nature of business - Schedule of ownership          HTML     51K 
                percentage in subsidiaries (Details)                             
80: R53         Significant accounting policies - Schedule of       HTML     55K 
                estimated useful lives of assets (Details)                       
81: R54         Acquisition of Prismic (Narrative) (Details)        HTML     51K 
82: R55         Acquisition of Prismic - Schedule of black scholes  HTML     78K 
                options pricing model (Details)                                  
83: R56         Acquisition of Prismic - Schedule of identifiable   HTML     50K 
                assets acquired and liabilities assumed (Details)                
84: R57         Acquisition of Lucid (Narrative) (Details)          HTML     56K 
85: R58         Acquisition of Lucid - Schedule of Black Scholes    HTML     77K 
                options pricing model (Details)                                  
86: R59         Acquisition of Lucid - Schedule of identifiable     HTML     49K 
                assets acquired and liabilities assumed (Details)                
87: R60         Assets held for sale (Narrative) (Details)          HTML     52K 
88: R61         Assets held for sale - Schedule of components of    HTML     39K 
                assets held for sale (Details)                                   
89: R62         Assets held for sale - Schedule of net loss and     HTML     77K 
                comprehensive loss from discontinued operations                  
                (Details)                                                        
90: R63         Assets held for sale - Schedule of cash flows from  HTML     75K 
                discontinued operations (Details)                                
91: R64         Other receivables - Schedule of other receivables   HTML     42K 
                (Details)                                                        
92: R65         Prepaid expenses and deposits - Schedule of         HTML     42K 
                prepaid expenses and deposits (Details)                          
93: R66         Investments (Narrative) (Details)                   HTML    206K 
94: R67         Investments - Schedule of investments (Details)     HTML     91K 
95: R68         Right-of-use asset (Narrative) (Details)            HTML     39K 
96: R69         Right-of-use asset - Schedule of right-of-use       HTML     45K 
                asset (Details)                                                  
97: R70         Intangible assets (Narrative) (Details)             HTML     52K 
98: R71         Intangible assets - Schedule of intangible assets   HTML     53K 
                (Details)                                                        
99: R72         Trade and other payables - Schedule of trade and    HTML     43K 
                other payables (Details)                                         
100: R73         Trade and other payables - Schedule of accrued      HTML     47K  
                liabilities (Details)                                            
101: R74         Notes Payable (Narrative) (Details)                 HTML     51K  
102: R75         Notes Payable - Schedule of notes payable           HTML     42K  
                (Details)                                                        
103: R76         Lease obligations - Schedule of lease obligations   HTML     49K  
                (Details)                                                        
104: R77         Lease obligations - Schedule of maturity analysis   HTML     48K  
                of operating lease payments (Details)                            
105: R78         Warrants Liability (Narrative) (Details)            HTML     72K  
106: R79         Share capital (Narrative) (Details)                 HTML    279K  
107: R80         Share capital - Schedule of reconciliation of the   HTML     89K  
                share capital (Details)                                          
108: R81         Share capital - Schedule of changes in number of    HTML     50K  
                warrants outstanding (Details)                                   
109: R82         Share capital - Schedule of fair value assumptions  HTML     52K  
                of warrants (Details)                                            
110: R83         Share capital - Schedule of warrants outstanding    HTML     95K  
                and exercise price (Details)                                     
111: R84         Share-based compensation (Narrative) (Details)      HTML     67K  
112: R85         Share-based compensation - Schedule of changes in   HTML     70K  
                number of share options (Details)                                
113: R86         Share-based compensation - Schedule of fair value   HTML     57K  
                assumptions of share options granted (Details)                   
114: R87         Share-based compensation - Schedule of exercise     HTML    216K  
                price and weighted average contractual term of                   
                share options outstanding and exercisable                        
                (Details)                                                        
115: R88         Share-based compensation - Schedule of share-based  HTML     47K  
                compensation (Details)                                           
116: R89         Loss per share - Schedule of loss per share         HTML     44K  
                (Details)                                                        
117: R90         General and administrative - Schedule of general    HTML     57K  
                and administrative expense (Details)                             
118: R91         Income Taxes (Narrative) (Details)                  HTML     41K  
119: R92         Income Taxes - Schedule of provision for income     HTML     53K  
                taxes (Details)                                                  
120: R93         Income Taxes - Schedule of deferred tax assets      HTML     40K  
                (Liabilities) (Details)                                          
121: R94         Income Taxes - Schedule of temporary differences    HTML     52K  
                for which deferred tax assets not recognised                     
                (Details)                                                        
122: R95         Income Taxes - Schedule of non-capital loss         HTML     43K  
                carryforwards (Details)                                          
123: R96         Commitments and contingencies (Narrative)           HTML     92K  
                (Details)                                                        
124: R97         Related party transactions (Narrative) (Details)    HTML     82K  
125: R98         Related party transactions - Schedule of key        HTML     42K  
                management personnel compensation (Details)                      
126: R99         Capital management (Narrative) (Details)            HTML     36K  
127: R100        Subsequent events (Narrative) (Details)             HTML     47K  
130: XML         IDEA XML File -- Filing Summary                      XML    223K  
128: XML         XBRL Instance -- form20f_htm                         XML   3.44M  
129: EXCEL       IDEA Workbook of Financial Reports                  XLSX    159K  
24: EX-101.CAL  XBRL Calculations -- huge-20211231_cal               XML    183K 
25: EX-101.DEF  XBRL Definitions -- huge-20211231_def                XML   1.17M 
26: EX-101.LAB  XBRL Labels -- huge-20211231_lab                     XML   4.85M 
27: EX-101.PRE  XBRL Presentations -- huge-20211231_pre              XML   1.53M 
23: EX-101.SCH  XBRL Schema -- huge-20211231                         XSD    613K 
131: JSON        XBRL Instance as JSON Data -- MetaLinks              490±   687K  
132: ZIP         XBRL Zipped Folder -- 0001062993-22-009034-xbrl      Zip    657K

‘JSON’   —   XBRL Instance as JSON Data — MetaLinks

This File is an XBRL Instance as JavaScript Object Notation (JSON) Data.


{
"instance":  {
    "form20f.htm":  {
        "axisCustom":  5,
        "axisStandard":  21,
        "contextCount":  467,
        "dts":  {
            "calculationLink":  {
                "local":  [
                    "huge-20211231_cal.xml"
                    ]
                },
            "definitionLink":  {
                "local":  [
                    "huge-20211231_def.xml"
                    ]
                },
            "inline":  {
                "local":  [
                    "form20f.htm"
                    ]
                },
            "labelLink":  {
                "local":  [
                    "huge-20211231_lab.xml"
                    ]
                },
            "presentationLink":  {
                "local":  [
                    "huge-20211231_pre.xml"
                    ]
                },
            "schema":  {
                "local":  [
                    "huge-20211231.xsd"
                    ],
                "remote":  [
                    "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
                    "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
                    "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
                    "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
                    "http://www.xbrl.org/2005/xbrldt-2005.xsd",
                    "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
                    "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
                    "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
                    "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
                    "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
                    "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
                    "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
                    "http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd",
                    "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
                    "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
                    "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
                    "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
                    "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
                    "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
                    "https://xbrl.sec.gov/country/2021/country-2021.xsd",
                    "https://xbrl.sec.gov/currency/2021/currency-2021.xsd",
                    "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd",
                    "https://xbrl.sec.gov/exch/2021/exch-2021.xsd",
                    "https://xbrl.sec.gov/naics/2021/naics-2021.xsd",
                    "https://xbrl.sec.gov/sic/2021/sic-2021.xsd",
                    "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd"
                    ]
                }
            },
        "elementCount":  821,
        "entityCount":  1,
        "hidden":  {
            "http://xbrl.sec.gov/dei/2021q4":  3,
            "total":  3
            },
        "keyCustom":  196,
        "keyStandard":  255,
        "memberCustom":  100,
        "memberStandard":  21,
        "nsprefix":  "huge",
        "nsuri":  "http://www.fsdpharma.com/20211231",
        "report":  {
            "R1":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "span",
                        "b",
                        "p",
                        "div",
                        "div",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210101to20211231",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "dei:EntityRegistrantName",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    },
                "groupType":  "document",
                "isDefault":  "true",
                "longName":  "0001 - Document - Document And Entity Information",
                "role":  "http://www.fsdpharma.com/role/DocumentAndEntityInformation",
                "shortName":  "Document And Entity Information",
                "subGroupType":  "",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "span",
                        "b",
                        "p",
                        "div",
                        "div",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210101to20211231",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "dei:EntityRegistrantName",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    }
                },
            "R10":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "div",
                        "div",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210101to20211231_hugeLegalEntitiesAxis_hugeLucidPsycheceuticalsIncMember",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "ifrs-full:DisclosureOfBusinessCombinationsExplanatory",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "0010 - Disclosure - Acquisition of Lucid",
                "role":  "http://www.fsdpharma.com/role/AcquisitionOfLucid",
                "shortName":  "Acquisition of Lucid",
                "subGroupType":  "",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "div",
                        "div",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210101to20211231_hugeLegalEntitiesAxis_hugeLucidPsycheceuticalsIncMember",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "ifrs-full:DisclosureOfBusinessCombinationsExplanatory",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    }
                },
            "R100":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "span",
                        "span",
                        "p",
                        "div",
                        "div",
                        "div",
                        "div",
                        "ifrs-full:DisclosureOfRelatedPartyExplanatory",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20220301to20220308",
                    "decimals":  "INF",
                    "first":  true,
                    "lang":  null,
                    "name":  "huge:MixedDecisionShareGrantPermitted",
                    "reportCount":  1,
                    "unitRef":  "shares",
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "0107 - Disclosure - Subsequent events (Narrative) (Details)",
                "role":  "http://www.fsdpharma.com/role/SubsequentEventsNarrativeDetails",
                "shortName":  "Subsequent events (Narrative) (Details)",
                "subGroupType":  "details",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "span",
                        "span",
                        "p",
                        "div",
                        "ifrs-full:DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20220201to20220223_ifrsfullNonadjustingEventsAfterReportingPeriodAxis_hugeSubsequentEventsMember",
                    "decimals":  "0",
                    "lang":  null,
                    "name":  "ifrs-full:ProceedsFromSalesOfInvestmentProperty",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  "CAD",
                    "xsiNil":  "false"
                    }
                },
            "R11":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "div",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210101to20211231",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "ifrs-full:DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "0011 - Disclosure - Assets held for sale",
                "role":  "http://www.fsdpharma.com/role/AssetsHeldForSale",
                "shortName":  "Assets held for sale",
                "subGroupType":  "",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "div",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210101to20211231",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "ifrs-full:DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    }
                },
            "R12":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210101to20211231",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "0012 - Disclosure - Other receivables",
                "role":  "http://www.fsdpharma.com/role/TradeAndOtherReceivables",
                "shortName":  "Other receivables",
                "subGroupType":  "",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210101to20211231",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    }
                },
            "R13":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "div",
                        "div",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210101to20211231",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "huge:PrepaidExpensesAndDepositsExplanatory",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "0013 - Disclosure - Prepaid expenses and deposits",
                "role":  "http://www.fsdpharma.com/role/PrepaidExpensesAndDeposits",
                "shortName":  "Prepaid expenses and deposits",
                "subGroupType":  "",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "div",
                        "div",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210101to20211231",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "huge:PrepaidExpensesAndDepositsExplanatory",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    }
                },
            "R14":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210101to20211231",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "ifrs-full:DisclosureOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "0014 - Disclosure - Investments",
                "role":  "http://www.fsdpharma.com/role/OtherInvestments",
                "shortName":  "Investments",
                "subGroupType":  "",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210101to20211231",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "ifrs-full:DisclosureOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    }
                },
            "R15":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210101to20211231",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "0015 - Disclosure - Right-of-use asset",
                "role":  "http://www.fsdpharma.com/role/RightofuseAsset",
                "shortName":  "Right-of-use asset",
                "subGroupType":  "",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210101to20211231",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    }
                },
            "R16":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210101to20211231",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "ifrs-full:DisclosureOfIntangibleAssetsExplanatory",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "0016 - Disclosure - Intangible assets",
                "role":  "http://www.fsdpharma.com/role/IntangibleAssets",
                "shortName":  "Intangible assets",
                "subGroupType":  "",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210101to20211231",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "ifrs-full:DisclosureOfIntangibleAssetsExplanatory",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    }
                },
            "R17":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "div",
                        "div",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210101to20211231",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "0017 - Disclosure - Trade and other payables",
                "role":  "http://www.fsdpharma.com/role/TradeAndOtherPayables",
                "shortName":  "Trade and other payables",
                "subGroupType":  "",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "div",
                        "div",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210101to20211231",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    }
                },
            "R18":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "div",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210101to20211231",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "ifrs-full:DisclosureOfBorrowingsExplanatory",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "0018 - Disclosure - Notes payable",
                "role":  "http://www.fsdpharma.com/role/NotesPayable",
                "shortName":  "Notes payable",
                "subGroupType":  "",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "div",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210101to20211231",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "ifrs-full:DisclosureOfBorrowingsExplanatory",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    }
                },
            "R19":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "div",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210101to20211231",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "ifrs-full:DisclosureOfLeasesExplanatory",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "0019 - Disclosure - Lease obligations",
                "role":  "http://www.fsdpharma.com/role/LeaseObligations",
                "shortName":  "Lease obligations",
                "subGroupType":  "",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "div",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210101to20211231",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "ifrs-full:DisclosureOfLeasesExplanatory",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    }
                },
            "R2":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "b",
                        "span",
                        "span",
                        "td",
                        "tr",
                        "table",
                        "div",
                        "div",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20211231",
                    "decimals":  "0",
                    "first":  true,
                    "lang":  null,
                    "name":  "ifrs-full:CashAndCashEquivalents",
                    "reportCount":  1,
                    "unitRef":  "USD",
                    "xsiNil":  "false"
                    },
                "groupType":  "statement",
                "isDefault":  "false",
                "longName":  "0002 - Statement - CONSOLIDATED STATEMENTS OF FINANCIAL POSITION",
                "role":  "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION",
                "shortName":  "CONSOLIDATED STATEMENTS OF FINANCIAL POSITION",
                "subGroupType":  "",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "b",
                        "span",
                        "span",
                        "td",
                        "tr",
                        "table",
                        "div",
                        "div",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20211231",
                    "decimals":  "0",
                    "lang":  null,
                    "name":  "ifrs-full:TradeAndOtherCurrentReceivables",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  "USD",
                    "xsiNil":  "false"
                    }
                },
            "R20":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "div",
                        "div",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210101to20211231",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "huge:DisclosureOfWarrantLiabilitiesExplanatory",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "0020 - Disclosure - Warrants Liability",
                "role":  "http://www.fsdpharma.com/role/WarrantsLiability",
                "shortName":  "Warrants Liability",
                "subGroupType":  "",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "div",
                        "div",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210101to20211231",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "huge:DisclosureOfWarrantLiabilitiesExplanatory",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    }
                },
            "R21":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210101to20211231",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "0021 - Disclosure - Share capital",
                "role":  "http://www.fsdpharma.com/role/ShareCapital",
                "shortName":  "Share capital",
                "subGroupType":  "",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210101to20211231",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    }
                },
            "R22":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "div",
                        "div",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210101to20211231",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "0022 - Disclosure - Share-based compensation",
                "role":  "http://www.fsdpharma.com/role/SharebasedCompensation",
                "shortName":  "Share-based compensation",
                "subGroupType":  "",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "div",
                        "div",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210101to20211231",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    }
                },
            "R23":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210101to20211231",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "ifrs-full:DisclosureOfEarningsPerShareExplanatory",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "0023 - Disclosure - Loss per share",
                "role":  "http://www.fsdpharma.com/role/LossPerShare",
                "shortName":  "Loss per share",
                "subGroupType":  "",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210101to20211231",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "ifrs-full:DisclosureOfEarningsPerShareExplanatory",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    }
                },
            "R24":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210101to20211231",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "ifrs-full:DisclosureOfGeneralAndAdministrativeExpenseExplanatory",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "0024 - Disclosure - General and administrative",
                "role":  "http://www.fsdpharma.com/role/GeneralAndAdministrative",
                "shortName":  "General and administrative",
                "subGroupType":  "",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210101to20211231",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "ifrs-full:DisclosureOfGeneralAndAdministrativeExpenseExplanatory",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    }
                },
            "R25":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "div",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210101to20211231",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "ifrs-full:DisclosureOfIncomeTaxExplanatory",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "0025 - Disclosure - Income Taxes",
                "role":  "http://www.fsdpharma.com/role/IncomeTaxes",
                "shortName":  "Income Taxes",
                "subGroupType":  "",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "div",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210101to20211231",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "ifrs-full:DisclosureOfIncomeTaxExplanatory",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    }
                },
            "R26":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "div",
                        "div",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210101to20211231",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "0026 - Disclosure - Commitments and contingencies",
                "role":  "http://www.fsdpharma.com/role/CommitmentsAndContingencies",
                "shortName":  "Commitments and contingencies",
                "subGroupType":  "",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "div",
                        "div",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210101to20211231",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    }
                },
            "R27":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210101to20211231",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "ifrs-full:DisclosureOfRelatedPartyExplanatory",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "0027 - Disclosure - Related party transactions",
                "role":  "http://www.fsdpharma.com/role/RelatedPartyTransactions",
                "shortName":  "Related party transactions",
                "subGroupType":  "",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210101to20211231",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "ifrs-full:DisclosureOfRelatedPartyExplanatory",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    }
                },
            "R28":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210101to20211231",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "ifrs-full:DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "0028 - Disclosure - Capital Management",
                "role":  "http://www.fsdpharma.com/role/CapitalManagement",
                "shortName":  "Capital Management",
                "subGroupType":  "",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210101to20211231",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "ifrs-full:DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    }
                },
            "R29":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210101to20211231",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "0029 - Disclosure - Financial Instruments and Risk Management",
                "role":  "http://www.fsdpharma.com/role/FinancialInstrumentsAndRiskManagement",
                "shortName":  "Financial Instruments and Risk Management",
                "subGroupType":  "",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210101to20211231",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    }
                },
            "R3":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "b",
                        "span",
                        "span",
                        "td",
                        "tr",
                        "table",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210101to20211231",
                    "decimals":  "0",
                    "first":  true,
                    "lang":  null,
                    "name":  "ifrs-full:GeneralAndAdministrativeExpense",
                    "reportCount":  1,
                    "unitRef":  "USD",
                    "xsiNil":  "false"
                    },
                "groupType":  "statement",
                "isDefault":  "false",
                "longName":  "0003 - Statement - CONSOLIDATED STATEMENTS OF LOSS AND COMPREHENSIVE LOSS",
                "role":  "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS",
                "shortName":  "CONSOLIDATED STATEMENTS OF LOSS AND COMPREHENSIVE LOSS",
                "subGroupType":  "",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "b",
                        "span",
                        "span",
                        "td",
                        "tr",
                        "table",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210101to20211231",
                    "decimals":  "0",
                    "lang":  null,
                    "name":  "ifrs-full:ResearchAndDevelopmentExpense",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  "USD",
                    "xsiNil":  "false"
                    }
                },
            "R30":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210101to20211231",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "ifrs-full:DisclosureOfOperatingSegmentsExplanatory",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "0030 - Disclosure - Segmented information",
                "role":  "http://www.fsdpharma.com/role/SegmentedInformation",
                "shortName":  "Segmented information",
                "subGroupType":  "",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210101to20211231",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "ifrs-full:DisclosureOfOperatingSegmentsExplanatory",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    }
                },
            "R31":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210101to20211231",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "ifrs-full:DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "0031 - Disclosure - Subsequent events",
                "role":  "http://www.fsdpharma.com/role/SubsequentEvents",
                "shortName":  "Subsequent events",
                "subGroupType":  "",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210101to20211231",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "ifrs-full:DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    }
                },
            "R32":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210101to20211231",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "ifrs-full:DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "0032 - Disclosure - Significant accounting policies (Policies)",
                "role":  "http://www.fsdpharma.com/role/SignificantAccountingPoliciesPolicies",
                "shortName":  "Significant accounting policies (Policies)",
                "subGroupType":  "policies",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210101to20211231",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "ifrs-full:DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    }
                },
            "R33":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "div",
                        "div",
                        "div",
                        "div",
                        "huge:DisclosureOfNatureOfBusinessExplanatoryTextBlock",
                        "div",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210101to20211231",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "ifrs-full:DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "0033 - Disclosure - Nature of business (Tables)",
                "role":  "http://www.fsdpharma.com/role/NatureOfBusinessTable",
                "shortName":  "Nature of business (Tables)",
                "subGroupType":  "tables",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "div",
                        "div",
                        "div",
                        "div",
                        "huge:DisclosureOfNatureOfBusinessExplanatoryTextBlock",
                        "div",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210101to20211231",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "ifrs-full:DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    }
                },
            "R34":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "div",
                        "div",
                        "div",
                        "ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210101to20211231",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "huge:SchedulesOfEstimatedUsefulLivesOfAssetsExplanatory",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "0034 - Disclosure - Significant accounting policies (Tables)",
                "role":  "http://www.fsdpharma.com/role/SignificantAccountingPoliciesTables",
                "shortName":  "Significant accounting policies (Tables)",
                "subGroupType":  "tables",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "div",
                        "div",
                        "div",
                        "ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210101to20211231",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "huge:SchedulesOfEstimatedUsefulLivesOfAssetsExplanatory",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    }
                },
            "R35":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "div",
                        "div",
                        "div",
                        "ifrs-full:DisclosureOfBusinessCombinationsExplanatory",
                        "div",
                        "div",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210101to20211231_hugeLegalEntitiesAxis_hugePrismicPharmaceuticalMember",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "huge:DisclosureOfDetailedInformationAboutShareOptionsAndWarrantsExplanatory",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "0035 - Disclosure - Acquisition of Prismic (Tables)",
                "role":  "http://www.fsdpharma.com/role/AcquisitionOfPrismicPharmaceuticalTables",
                "shortName":  "Acquisition of Prismic (Tables)",
                "subGroupType":  "tables",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "div",
                        "div",
                        "div",
                        "ifrs-full:DisclosureOfBusinessCombinationsExplanatory",
                        "div",
                        "div",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210101to20211231_hugeLegalEntitiesAxis_hugePrismicPharmaceuticalMember",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "huge:DisclosureOfDetailedInformationAboutShareOptionsAndWarrantsExplanatory",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    }
                },
            "R36":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "div",
                        "ifrs-full:DisclosureOfBusinessCombinationsExplanatory",
                        "div",
                        "div",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210101to20211231_hugeLegalEntitiesAxis_hugeLucidPsycheceuticalsIncMember",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "huge:DisclosureOfDetailedInformationAboutShareOptionsAndWarrantsExplanatory",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "0036 - Disclosure - Acquisition of Lucid (Tables)",
                "role":  "http://www.fsdpharma.com/role/AcquisitionOfLucidTables",
                "shortName":  "Acquisition of Lucid (Tables)",
                "subGroupType":  "tables",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "div",
                        "ifrs-full:DisclosureOfBusinessCombinationsExplanatory",
                        "div",
                        "div",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210101to20211231_hugeLegalEntitiesAxis_hugeLucidPsycheceuticalsIncMember",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "huge:DisclosureOfDetailedInformationAboutShareOptionsAndWarrantsExplanatory",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    }
                },
            "R37":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "div",
                        "div",
                        "div",
                        "ifrs-full:DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory",
                        "div",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210101to20211231",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "huge:ScheduleOfComponentsOfAssetsHeldForSaleExplanatory",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "0037 - Disclosure - Assets held for sale (Tables)",
                "role":  "http://www.fsdpharma.com/role/AssetsHeldForSaleTables",
                "shortName":  "Assets held for sale (Tables)",
                "subGroupType":  "tables",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "div",
                        "div",
                        "div",
                        "ifrs-full:DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory",
                        "div",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210101to20211231",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "huge:ScheduleOfComponentsOfAssetsHeldForSaleExplanatory",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    }
                },
            "R38":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "div",
                        "div",
                        "div",
                        "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210101to20211231",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "huge:DisclosureOfDetailInformationAboutTradeAndOtherReceivablesExplanatory",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "0038 - Disclosure - Other receivables (Tables)",
                "role":  "http://www.fsdpharma.com/role/TradeAndOtherReceivablesTables",
                "shortName":  "Other receivables (Tables)",
                "subGroupType":  "tables",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "div",
                        "div",
                        "div",
                        "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210101to20211231",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "huge:DisclosureOfDetailInformationAboutTradeAndOtherReceivablesExplanatory",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    }
                },
            "R39":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "div",
                        "huge:PrepaidExpensesAndDepositsExplanatory",
                        "div",
                        "div",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210101to20211231",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "huge:DisclosureOfPrepaidExpensesAndDepositsExplanatory",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "0039 - Disclosure - Prepaid expenses and deposits (Tables)",
                "role":  "http://www.fsdpharma.com/role/PrepaidExpensesAndDepositsTables",
                "shortName":  "Prepaid expenses and deposits (Tables)",
                "subGroupType":  "tables",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "div",
                        "huge:PrepaidExpensesAndDepositsExplanatory",
                        "div",
                        "div",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210101to20211231",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "huge:DisclosureOfPrepaidExpensesAndDepositsExplanatory",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    }
                },
            "R4":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "b",
                        "span",
                        "span",
                        "td",
                        "tr",
                        "table",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20181231_ifrsfullClassesOfShareCapitalAxis_hugeClassACommonStockSharesMember",
                    "decimals":  "0",
                    "first":  true,
                    "lang":  null,
                    "name":  "ifrs-full:Equity",
                    "reportCount":  1,
                    "unitRef":  "USD",
                    "xsiNil":  "false"
                    },
                "groupType":  "statement",
                "isDefault":  "false",
                "longName":  "0004 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDER'S EQUITY",
                "role":  "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
                "shortName":  "CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDER'S EQUITY",
                "subGroupType":  "",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "b",
                        "span",
                        "span",
                        "td",
                        "tr",
                        "table",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20181231_ifrsfullComponentsOfEquityAxis_ifrsfullReserveOfSharebasedPaymentsMember",
                    "decimals":  "0",
                    "lang":  null,
                    "name":  "ifrs-full:Equity",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  "USD",
                    "xsiNil":  "false"
                    }
                },
            "R40":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "div",
                        "div",
                        "div",
                        "div",
                        "ifrs-full:DisclosureOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210101to20211231",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "huge:DisclosureOfDetailedInformationAboutInvestmentsExplanatory",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "0040 - Disclosure - Investments (Tables)",
                "role":  "http://www.fsdpharma.com/role/OtherinvestmentsTables",
                "shortName":  "Investments (Tables)",
                "subGroupType":  "tables",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "div",
                        "div",
                        "div",
                        "div",
                        "ifrs-full:DisclosureOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210101to20211231",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "huge:DisclosureOfDetailedInformationAboutInvestmentsExplanatory",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    }
                },
            "R41":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210101to20211231",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "huge:DisclosureOfDetailedInformationAboutRightOfUseAssets",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "0041 - Disclosure - Right-of-use asset (Tables)",
                "role":  "http://www.fsdpharma.com/role/RightofuseAssetTables",
                "shortName":  "Right-of-use asset (Tables)",
                "subGroupType":  "tables",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210101to20211231",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "huge:DisclosureOfDetailedInformationAboutRightOfUseAssets",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    }
                },
            "R42":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "ifrs-full:DisclosureOfIntangibleAssetsExplanatory",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210101to20211231",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "0042 - Disclosure - Intangible assets (Tables)",
                "role":  "http://www.fsdpharma.com/role/IntangibleAssetsTables",
                "shortName":  "Intangible assets (Tables)",
                "subGroupType":  "tables",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "ifrs-full:DisclosureOfIntangibleAssetsExplanatory",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210101to20211231",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    }
                },
            "R43":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "div",
                        "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
                        "div",
                        "div",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210101to20211231",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "huge:DisclosureOfTradeAndOtherPayableExplanatory",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "0043 - Disclosure - Trade and other payables (Tables)",
                "role":  "http://www.fsdpharma.com/role/TradeAndOtherPayablesTables",
                "shortName":  "Trade and other payables (Tables)",
                "subGroupType":  "tables",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "div",
                        "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
                        "div",
                        "div",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210101to20211231",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "huge:DisclosureOfTradeAndOtherPayableExplanatory",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    }
                },
            "R44":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "div",
                        "div",
                        "div",
                        "ifrs-full:DisclosureOfBorrowingsExplanatory",
                        "div",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210101to20211231",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "0044 - Disclosure - Notes Payable (Tables)",
                "role":  "http://www.fsdpharma.com/role/NotesPayableTables",
                "shortName":  "Notes Payable (Tables)",
                "subGroupType":  "tables",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "div",
                        "div",
                        "div",
                        "ifrs-full:DisclosureOfBorrowingsExplanatory",
                        "div",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210101to20211231",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    }
                },
            "R45":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "ifrs-full:DisclosureOfLeasesExplanatory",
                        "div",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210101to20211231",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "huge:DisclosureOfOperatingLeaseObligationsTableTextBlock",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "0045 - Disclosure - Lease obligations (Tables)",
                "role":  "http://www.fsdpharma.com/role/LeaseObligationsTables",
                "shortName":  "Lease obligations (Tables)",
                "subGroupType":  "tables",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "ifrs-full:DisclosureOfLeasesExplanatory",
                        "div",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210101to20211231",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "huge:DisclosureOfOperatingLeaseObligationsTableTextBlock",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    }
                },
            "R46":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "div",
                        "div",
                        "div",
                        "div",
                        "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210101to20211231",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "0046 - Disclosure - Share capital (Tables)",
                "role":  "http://www.fsdpharma.com/role/ShareCapitalTables",
                "shortName":  "Share capital (Tables)",
                "subGroupType":  "tables",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "div",
                        "div",
                        "div",
                        "div",
                        "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210101to20211231",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    }
                },
            "R47":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "div",
                        "div",
                        "div",
                        "div",
                        "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
                        "div",
                        "div",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210101to20211231",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "0047 - Disclosure - Share-based compensation (Tables)",
                "role":  "http://www.fsdpharma.com/role/SharebasedCompensationTables",
                "shortName":  "Share-based compensation (Tables)",
                "subGroupType":  "tables",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "div",
                        "div",
                        "div",
                        "div",
                        "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
                        "div",
                        "div",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210101to20211231",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    }
                },
            "R48":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "div",
                        "ifrs-full:DisclosureOfEarningsPerShareExplanatory",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210101to20211231",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "ifrs-full:EarningsPerShareExplanatory",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "0048 - Disclosure - Loss per share (Tables)",
                "role":  "http://www.fsdpharma.com/role/LossPerShareTables",
                "shortName":  "Loss per share (Tables)",
                "subGroupType":  "tables",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "div",
                        "ifrs-full:DisclosureOfEarningsPerShareExplanatory",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210101to20211231",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "ifrs-full:EarningsPerShareExplanatory",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    }
                },
            "R49":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "div",
                        "ifrs-full:DisclosureOfGeneralAndAdministrativeExpenseExplanatory",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210101to20211231",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "huge:DisclosureOfDetailedInformationAboutGeneralAndAdministrativeExpenseExplanatory",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "0049 - Disclosure - General and administrative (Tables)",
                "role":  "http://www.fsdpharma.com/role/GeneralAndAdministrativeTables",
                "shortName":  "General and administrative (Tables)",
                "subGroupType":  "tables",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "div",
                        "ifrs-full:DisclosureOfGeneralAndAdministrativeExpenseExplanatory",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210101to20211231",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "huge:DisclosureOfDetailedInformationAboutGeneralAndAdministrativeExpenseExplanatory",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    }
                },
            "R5":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "b",
                        "span",
                        "span",
                        "td",
                        "tr",
                        "table",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210101to20211231",
                    "decimals":  "0",
                    "first":  true,
                    "lang":  null,
                    "name":  "ifrs-full:ProfitLossFromContinuingOperations",
                    "reportCount":  1,
                    "unitRef":  "USD",
                    "xsiNil":  "false"
                    },
                "groupType":  "statement",
                "isDefault":  "false",
                "longName":  "0005 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
                "role":  "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
                "shortName":  "CONSOLIDATED STATEMENTS OF CASH FLOWS",
                "subGroupType":  "",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "b",
                        "span",
                        "span",
                        "td",
                        "tr",
                        "table",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210101to20211231",
                    "decimals":  "0",
                    "lang":  null,
                    "name":  "ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  "USD",
                    "xsiNil":  "false"
                    }
                },
            "R50":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "div",
                        "div",
                        "ifrs-full:DisclosureOfIncomeTaxExplanatory",
                        "div",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210101to20211231",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "huge:DisclosureOfProvisionForIncomeTaxesExplanatory",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "0050 - Disclosure - Income Taxes (Tables)",
                "role":  "http://www.fsdpharma.com/role/IncometaxesTables",
                "shortName":  "Income Taxes (Tables)",
                "subGroupType":  "tables",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "div",
                        "div",
                        "ifrs-full:DisclosureOfIncomeTaxExplanatory",
                        "div",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210101to20211231",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "huge:DisclosureOfProvisionForIncomeTaxesExplanatory",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    }
                },
            "R51":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "div",
                        "div",
                        "div",
                        "ifrs-full:DisclosureOfRelatedPartyExplanatory",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210101to20211231",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "0052 - Disclosure - Related party transactions (Tables)",
                "role":  "http://www.fsdpharma.com/role/RelatedPartyTransactionsTables",
                "shortName":  "Related party transactions (Tables)",
                "subGroupType":  "tables",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "div",
                        "div",
                        "div",
                        "ifrs-full:DisclosureOfRelatedPartyExplanatory",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210101to20211231",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    }
                },
            "R52":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "span",
                        "span",
                        "p",
                        "td",
                        "tr",
                        "table",
                        "ifrs-full:DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory",
                        "div",
                        "div",
                        "div",
                        "div",
                        "huge:DisclosureOfNatureOfBusinessExplanatoryTextBlock",
                        "div",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210101to20211231_ifrsfullSignificantInvestmentsInSubsidiariesAxis_ifrsfullSubsidiariesMember",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "0054 - Disclosure - Nature of business - Schedule of ownership percentage in subsidiaries (Details)",
                "role":  "http://www.fsdpharma.com/role/NatureOfBusinessScheduleOfOwnershipPercentageInSubsidiariesDetails",
                "shortName":  "Nature of business - Schedule of ownership percentage in subsidiaries (Details)",
                "subGroupType":  "details",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "span",
                        "span",
                        "p",
                        "td",
                        "tr",
                        "table",
                        "ifrs-full:DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory",
                        "div",
                        "div",
                        "div",
                        "div",
                        "huge:DisclosureOfNatureOfBusinessExplanatoryTextBlock",
                        "div",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210101to20211231_ifrsfullSignificantInvestmentsInSubsidiariesAxis_ifrsfullSubsidiariesMember",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "ifrs-full:PrincipalPlaceOfBusinessOfSubsidiary",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    }
                },
            "R53":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "span",
                        "span",
                        "td",
                        "tr",
                        "table",
                        "huge:SchedulesOfEstimatedUsefulLivesOfAssetsExplanatory",
                        "div",
                        "div",
                        "div",
                        "ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210101to20211231_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_ifrsfullComputerEquipmentMember",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "ifrs-full:DescriptionOfUsefulLifePropertyPlantAndEquipment",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "0055 - Disclosure - Significant accounting policies - Schedule of estimated useful lives of assets (Details)",
                "role":  "http://www.fsdpharma.com/role/SignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfAssetsDetails",
                "shortName":  "Significant accounting policies - Schedule of estimated useful lives of assets (Details)",
                "subGroupType":  "details",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "span",
                        "span",
                        "td",
                        "tr",
                        "table",
                        "huge:SchedulesOfEstimatedUsefulLivesOfAssetsExplanatory",
                        "div",
                        "div",
                        "div",
                        "ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210101to20211231_ifrsfullClassesOfPropertyPlantAndEquipmentAxis_ifrsfullComputerEquipmentMember",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "ifrs-full:DescriptionOfUsefulLifePropertyPlantAndEquipment",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    }
                },
            "R54":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "span",
                        "span",
                        "p",
                        "div",
                        "div",
                        "div",
                        "ifrs-full:DisclosureOfBusinessCombinationsExplanatory",
                        "div",
                        "div",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20190628_hugeLegalEntitiesAxis_hugePrismicPharmaceuticalMember",
                    "decimals":  "0",
                    "first":  true,
                    "lang":  null,
                    "name":  "ifrs-full:EquityInterestsOfAcquirer",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  "USD",
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "0056 - Disclosure - Acquisition of Prismic (Narrative) (Details)",
                "role":  "http://www.fsdpharma.com/role/AcquisitionOfPrismicPharmaceuticalNarrativeDetails",
                "shortName":  "Acquisition of Prismic (Narrative) (Details)",
                "subGroupType":  "details",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "span",
                        "span",
                        "p",
                        "div",
                        "div",
                        "div",
                        "ifrs-full:DisclosureOfBusinessCombinationsExplanatory",
                        "div",
                        "div",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20190628_hugeLegalEntitiesAxis_hugePrismicPharmaceuticalMember",
                    "decimals":  "0",
                    "first":  true,
                    "lang":  null,
                    "name":  "ifrs-full:EquityInterestsOfAcquirer",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  "USD",
                    "xsiNil":  "false"
                    }
                },
            "R55":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "span",
                        "span",
                        "td",
                        "tr",
                        "table",
                        "huge:DisclosureOfFairValueAssumptionsOfWarrantsOutstandingExplanatory",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20191231",
                    "decimals":  "2",
                    "first":  true,
                    "lang":  null,
                    "name":  "huge:WeightedAverageSharePriceOfWarrants",
                    "reportCount":  1,
                    "unitRef":  "CAD_per_Share",
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "0057 - Disclosure - Acquisition of Prismic - Schedule of black scholes options pricing model (Details)",
                "role":  "http://www.fsdpharma.com/role/AcquisitionOfPrismicPharmaceuticalScheduleOfBlackScholesOptionsPricingModelDetails",
                "shortName":  "Acquisition of Prismic - Schedule of black scholes options pricing model (Details)",
                "subGroupType":  "details",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "span",
                        "span",
                        "p",
                        "td",
                        "tr",
                        "table",
                        "huge:DisclosureOfDetailedInformationAboutShareOptionsAndWarrantsExplanatory",
                        "div",
                        "div",
                        "div",
                        "ifrs-full:DisclosureOfBusinessCombinationsExplanatory",
                        "div",
                        "div",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20190601to20190628_hugeLegalEntitiesAxis_hugePrismicPharmaceuticalMember",
                    "decimals":  "2",
                    "lang":  null,
                    "name":  "ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  "CAD_per_Share",
                    "xsiNil":  "false"
                    }
                },
            "R56":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "span",
                        "span",
                        "td",
                        "tr",
                        "table",
                        "ifrs-full:DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory",
                        "div",
                        "div",
                        "div",
                        "ifrs-full:DisclosureOfBusinessCombinationsExplanatory",
                        "div",
                        "div",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20190628_hugeLegalEntitiesAxis_hugePrismicPharmaceuticalMember",
                    "decimals":  "0",
                    "first":  true,
                    "lang":  null,
                    "name":  "ifrs-full:CashAndCashEquivalentsRecognisedAsOfAcquisitionDate",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  "USD",
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "0058 - Disclosure - Acquisition of Prismic - Schedule of identifiable assets acquired and liabilities assumed (Details)",
                "role":  "http://www.fsdpharma.com/role/AcquisitionOfPrismicPharmaceuticalScheduleOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedDetails",
                "shortName":  "Acquisition of Prismic - Schedule of identifiable assets acquired and liabilities assumed (Details)",
                "subGroupType":  "details",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "span",
                        "span",
                        "td",
                        "tr",
                        "table",
                        "ifrs-full:DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory",
                        "div",
                        "div",
                        "div",
                        "ifrs-full:DisclosureOfBusinessCombinationsExplanatory",
                        "div",
                        "div",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20190628_hugeLegalEntitiesAxis_hugePrismicPharmaceuticalMember",
                    "decimals":  "0",
                    "first":  true,
                    "lang":  null,
                    "name":  "ifrs-full:CashAndCashEquivalentsRecognisedAsOfAcquisitionDate",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  "USD",
                    "xsiNil":  "false"
                    }
                },
            "R57":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "span",
                        "span",
                        "p",
                        "div",
                        "ifrs-full:DisclosureOfBusinessCombinationsExplanatory",
                        "div",
                        "div",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210921_hugeLegalEntitiesAxis_hugeLucidPsycheceuticalsIncMember",
                    "decimals":  "0",
                    "first":  true,
                    "lang":  null,
                    "name":  "ifrs-full:EquityInterestsOfAcquirer",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  "USD",
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "0059 - Disclosure - Acquisition of Lucid (Narrative) (Details)",
                "role":  "http://www.fsdpharma.com/role/AcquisitionOfLucidDetailTextuals",
                "shortName":  "Acquisition of Lucid (Narrative) (Details)",
                "subGroupType":  "details",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "span",
                        "span",
                        "p",
                        "div",
                        "ifrs-full:DisclosureOfBusinessCombinationsExplanatory",
                        "div",
                        "div",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210921_hugeLegalEntitiesAxis_hugeLucidPsycheceuticalsIncMember",
                    "decimals":  "0",
                    "first":  true,
                    "lang":  null,
                    "name":  "ifrs-full:EquityInterestsOfAcquirer",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  "USD",
                    "xsiNil":  "false"
                    }
                },
            "R58":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "span",
                        "span",
                        "td",
                        "tr",
                        "table",
                        "huge:DisclosureOfFairValueAssumptionsOfWarrantsOutstandingExplanatory",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20191231",
                    "decimals":  "2",
                    "first":  true,
                    "lang":  null,
                    "name":  "huge:WeightedAverageSharePriceOfWarrants",
                    "reportCount":  1,
                    "unitRef":  "CAD_per_Share",
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "0060 - Disclosure - Acquisition of Lucid - Schedule of Black Scholes options pricing model (Details)",
                "role":  "http://www.fsdpharma.com/role/AcquisitionOfLucidDetails",
                "shortName":  "Acquisition of Lucid - Schedule of Black Scholes options pricing model (Details)",
                "subGroupType":  "details",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "span",
                        "span",
                        "p",
                        "td",
                        "tr",
                        "table",
                        "huge:DisclosureOfDetailedInformationAboutShareOptionsAndWarrantsExplanatory",
                        "div",
                        "ifrs-full:DisclosureOfBusinessCombinationsExplanatory",
                        "div",
                        "div",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210901to20210921_hugeLegalEntitiesAxis_hugeLucidPsycheceuticalsIncMember",
                    "decimals":  "2",
                    "lang":  null,
                    "name":  "huge:ExpectedDividendYieldOfWarrantsGranted",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  "Pure",
                    "xsiNil":  "false"
                    }
                },
            "R59":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "span",
                        "span",
                        "td",
                        "tr",
                        "table",
                        "ifrs-full:DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory",
                        "div",
                        "ifrs-full:DisclosureOfBusinessCombinationsExplanatory",
                        "div",
                        "div",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210921_hugeLegalEntitiesAxis_hugeLucidPsycheceuticalsIncMember",
                    "decimals":  "0",
                    "first":  true,
                    "lang":  null,
                    "name":  "ifrs-full:CashAndCashEquivalentsRecognisedAsOfAcquisitionDate",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  "USD",
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "0061 - Disclosure - Acquisition of Lucid - Schedule of identifiable assets acquired and liabilities assumed (Details)",
                "role":  "http://www.fsdpharma.com/role/AcquisitionOfLucidDetails1",
                "shortName":  "Acquisition of Lucid - Schedule of identifiable assets acquired and liabilities assumed (Details)",
                "subGroupType":  "details",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "span",
                        "span",
                        "td",
                        "tr",
                        "table",
                        "ifrs-full:DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory",
                        "div",
                        "ifrs-full:DisclosureOfBusinessCombinationsExplanatory",
                        "div",
                        "div",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210921_hugeLegalEntitiesAxis_hugeLucidPsycheceuticalsIncMember",
                    "decimals":  "0",
                    "first":  true,
                    "lang":  null,
                    "name":  "ifrs-full:CashAndCashEquivalentsRecognisedAsOfAcquisitionDate",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  "USD",
                    "xsiNil":  "false"
                    }
                },
            "R6":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "div",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210101to20211231",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "huge:DisclosureOfNatureOfBusinessExplanatoryTextBlock",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "0006 - Disclosure - Nature of business",
                "role":  "http://www.fsdpharma.com/role/NatureOfBusiness",
                "shortName":  "Nature of business",
                "subGroupType":  "",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "div",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210101to20211231",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "huge:DisclosureOfNatureOfBusinessExplanatoryTextBlock",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    }
                },
            "R60":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "p",
                        "div",
                        "div",
                        "div",
                        "ifrs-full:DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory",
                        "div",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210101to20211231",
                    "decimals":  "0",
                    "first":  true,
                    "lang":  null,
                    "name":  "ifrs-full:ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  "CAD",
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "0062 - Disclosure - Assets held for sale (Narrative) (Details)",
                "role":  "http://www.fsdpharma.com/role/AssetsHeldForSaleDetailTextuals",
                "shortName":  "Assets held for sale (Narrative) (Details)",
                "subGroupType":  "details",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "p",
                        "div",
                        "div",
                        "div",
                        "ifrs-full:DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory",
                        "div",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210101to20211231",
                    "decimals":  "0",
                    "first":  true,
                    "lang":  null,
                    "name":  "ifrs-full:ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  "CAD",
                    "xsiNil":  "false"
                    }
                },
            "R61":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "b",
                        "span",
                        "span",
                        "td",
                        "tr",
                        "table",
                        "huge:ScheduleOfComponentsOfAssetsHeldForSaleExplanatory",
                        "div",
                        "div",
                        "div",
                        "ifrs-full:DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory",
                        "div",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20211231_ifrsfullAssetsAndLiabilitiesClassifiedAsHeldForSaleAxis_ifrsfullDisposalGroupsClassifiedAsHeldForSaleMember",
                    "decimals":  "0",
                    "first":  true,
                    "lang":  null,
                    "name":  "ifrs-full:PropertyPlantAndEquipment",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  "USD",
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "0063 - Disclosure - Assets held for sale - Schedule of components of assets held for sale (Details)",
                "role":  "http://www.fsdpharma.com/role/AssetsHeldForSaleDetails",
                "shortName":  "Assets held for sale - Schedule of components of assets held for sale (Details)",
                "subGroupType":  "details",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "b",
                        "span",
                        "span",
                        "td",
                        "tr",
                        "table",
                        "huge:ScheduleOfComponentsOfAssetsHeldForSaleExplanatory",
                        "div",
                        "div",
                        "div",
                        "ifrs-full:DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory",
                        "div",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20211231_ifrsfullAssetsAndLiabilitiesClassifiedAsHeldForSaleAxis_ifrsfullDisposalGroupsClassifiedAsHeldForSaleMember",
                    "decimals":  "0",
                    "first":  true,
                    "lang":  null,
                    "name":  "ifrs-full:PropertyPlantAndEquipment",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  "USD",
                    "xsiNil":  "false"
                    }
                },
            "R62":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "b",
                        "span",
                        "span",
                        "td",
                        "tr",
                        "table",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210101to20211231",
                    "decimals":  "0",
                    "first":  true,
                    "lang":  null,
                    "name":  "ifrs-full:GeneralAndAdministrativeExpense",
                    "reportCount":  1,
                    "unitRef":  "USD",
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "0064 - Disclosure - Assets held for sale - Schedule of net loss and comprehensive loss from discontinued operations (Details)",
                "role":  "http://www.fsdpharma.com/role/AssetsHeldForSaleDetails1",
                "shortName":  "Assets held for sale - Schedule of net loss and comprehensive loss from discontinued operations (Details)",
                "subGroupType":  "details",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "b",
                        "span",
                        "span",
                        "td",
                        "tr",
                        "table",
                        "huge:ScheduleOfNetLossAndComprehensiveLossFromDiscontinuedOperationsExplanatory",
                        "div",
                        "div",
                        "div",
                        "ifrs-full:DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory",
                        "div",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210101to20211231_ifrsfullAssetsAndLiabilitiesClassifiedAsHeldForSaleAxis_ifrsfullDisposalGroupsClassifiedAsHeldForSaleMember",
                    "decimals":  "0",
                    "lang":  null,
                    "name":  "ifrs-full:Revenue",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  "USD",
                    "xsiNil":  "false"
                    }
                },
            "R63":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "b",
                        "span",
                        "span",
                        "td",
                        "tr",
                        "table",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210101to20211231",
                    "decimals":  "0",
                    "first":  true,
                    "lang":  null,
                    "name":  "ifrs-full:ProfitLossFromDiscontinuedOperations",
                    "reportCount":  1,
                    "unitRef":  "USD",
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "0065 - Disclosure - Assets held for sale - Schedule of cash flows from discontinued operations (Details)",
                "role":  "http://www.fsdpharma.com/role/AssetsHeldForSaleDetails2",
                "shortName":  "Assets held for sale - Schedule of cash flows from discontinued operations (Details)",
                "subGroupType":  "details",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "b",
                        "span",
                        "span",
                        "td",
                        "tr",
                        "table",
                        "huge:ScheduleOfCashFlowsFromDiscontinuedOperationsExplanatory",
                        "div",
                        "div",
                        "div",
                        "ifrs-full:DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory",
                        "div",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210101to20211231_ifrsfullAssetsAndLiabilitiesClassifiedAsHeldForSaleAxis_ifrsfullDisposalGroupsClassifiedAsHeldForSaleMember",
                    "decimals":  "0",
                    "lang":  null,
                    "name":  "ifrs-full:AdjustmentsForDepreciationExpense",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  "USD",
                    "xsiNil":  "false"
                    }
                },
            "R64":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "b",
                        "span",
                        "span",
                        "td",
                        "tr",
                        "table",
                        "div",
                        "huge:DisclosureOfDetailInformationAboutTradeAndOtherReceivablesExplanatory",
                        "div",
                        "div",
                        "div",
                        "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20211231",
                    "decimals":  "0",
                    "first":  true,
                    "lang":  null,
                    "name":  "huge:SalesTaxRecoverable",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  "USD",
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "0066 - Disclosure - Other receivables - Schedule of other receivables (Details)",
                "role":  "http://www.fsdpharma.com/role/TradeAndOtherReceivablesScheduleOfTradeAndOtherReceivablesDetails",
                "shortName":  "Other receivables - Schedule of other receivables (Details)",
                "subGroupType":  "details",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "b",
                        "span",
                        "span",
                        "td",
                        "tr",
                        "table",
                        "div",
                        "huge:DisclosureOfDetailInformationAboutTradeAndOtherReceivablesExplanatory",
                        "div",
                        "div",
                        "div",
                        "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20211231",
                    "decimals":  "0",
                    "first":  true,
                    "lang":  null,
                    "name":  "huge:SalesTaxRecoverable",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  "USD",
                    "xsiNil":  "false"
                    }
                },
            "R65":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "b",
                        "span",
                        "span",
                        "td",
                        "tr",
                        "table",
                        "div",
                        "huge:DisclosureOfPrepaidExpensesAndDepositsExplanatory",
                        "div",
                        "huge:PrepaidExpensesAndDepositsExplanatory",
                        "div",
                        "div",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20211231",
                    "decimals":  "0",
                    "first":  true,
                    "lang":  null,
                    "name":  "huge:PrepaidInsurance",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  "USD",
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "0067 - Disclosure - Prepaid expenses and deposits - Schedule of prepaid expenses and deposits (Details)",
                "role":  "http://www.fsdpharma.com/role/PrepaidExpensesAndDepositsDetails",
                "shortName":  "Prepaid expenses and deposits - Schedule of prepaid expenses and deposits (Details)",
                "subGroupType":  "details",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "b",
                        "span",
                        "span",
                        "td",
                        "tr",
                        "table",
                        "div",
                        "huge:DisclosureOfPrepaidExpensesAndDepositsExplanatory",
                        "div",
                        "huge:PrepaidExpensesAndDepositsExplanatory",
                        "div",
                        "div",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20211231",
                    "decimals":  "0",
                    "first":  true,
                    "lang":  null,
                    "name":  "huge:PrepaidInsurance",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  "USD",
                    "xsiNil":  "false"
                    }
                },
            "R66":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "b",
                        "span",
                        "span",
                        "td",
                        "tr",
                        "table",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210101to20211231",
                    "decimals":  "0",
                    "first":  true,
                    "lang":  null,
                    "name":  "ifrs-full:ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod",
                    "reportCount":  1,
                    "unitRef":  "USD",
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "0068 - Disclosure - Investments (Narrative) (Details)",
                "role":  "http://www.fsdpharma.com/role/OtherInvestmentsNarrativeDetails",
                "shortName":  "Investments (Narrative) (Details)",
                "subGroupType":  "details",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "span",
                        "span",
                        "p",
                        "div",
                        "div",
                        "div",
                        "ifrs-full:DisclosureOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20200201to20200205_hugeOtherInvestmentsNameOfEntityAxis_hugeCannaraBiotechIncMember_ifrsfullClassesOfShareCapitalAxis_hugeClassBCommonStockSharesMember",
                    "decimals":  "INF",
                    "lang":  null,
                    "name":  "huge:NumberOfInvestmentSharesSold",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  "shares",
                    "xsiNil":  "false"
                    }
                },
            "R67":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "b",
                        "span",
                        "span",
                        "td",
                        "tr",
                        "table",
                        "div",
                        "huge:DisclosureOfDetailedInformationAboutInvestmentsExplanatory",
                        "div",
                        "div",
                        "div",
                        "div",
                        "ifrs-full:DisclosureOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20201231",
                    "decimals":  "0",
                    "first":  true,
                    "lang":  null,
                    "name":  "ifrs-full:InvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod",
                    "reportCount":  1,
                    "unitRef":  "USD",
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "0069 - Disclosure - Investments - Schedule of investments (Details)",
                "role":  "http://www.fsdpharma.com/role/OtherInvestmentsScheduleOfOtherInvestmentsDetails",
                "shortName":  "Investments - Schedule of investments (Details)",
                "subGroupType":  "details",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "b",
                        "span",
                        "span",
                        "td",
                        "tr",
                        "table",
                        "div",
                        "huge:DisclosureOfDetailedInformationAboutInvestmentsExplanatory",
                        "div",
                        "div",
                        "div",
                        "div",
                        "ifrs-full:DisclosureOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210101to20211231",
                    "decimals":  "0",
                    "lang":  null,
                    "name":  "huge:ChangeInFairValueThroughProfitOrLossOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  "USD",
                    "xsiNil":  "false"
                    }
                },
            "R68":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "b",
                        "span",
                        "span",
                        "td",
                        "tr",
                        "table",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210101to20211231",
                    "decimals":  "0",
                    "first":  true,
                    "lang":  null,
                    "name":  "huge:ImpairmentLossOnRightOfUseAsset",
                    "reportCount":  1,
                    "unitRef":  "USD",
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "0070 - Disclosure - Right-of-use asset (Narrative) (Details)",
                "role":  "http://www.fsdpharma.com/role/RightofuseAssetNarrativeDetails",
                "shortName":  "Right-of-use asset (Narrative) (Details)",
                "subGroupType":  "details",
                "uniqueAnchor":  null
                },
            "R69":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "span",
                        "span",
                        "td",
                        "tr",
                        "table",
                        "div",
                        "div",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20201231",
                    "decimals":  "0",
                    "first":  true,
                    "lang":  null,
                    "name":  "ifrs-full:RightofuseAssets",
                    "reportCount":  1,
                    "unitRef":  "USD",
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "0071 - Disclosure - Right-of-use asset - Schedule of right-of-use asset (Details)",
                "role":  "http://www.fsdpharma.com/role/RightofuseAssetScheduleOfRightofuseAssetDetails",
                "shortName":  "Right-of-use asset - Schedule of right-of-use asset (Details)",
                "subGroupType":  "details",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "span",
                        "span",
                        "td",
                        "tr",
                        "table",
                        "huge:DisclosureOfDetailedInformationAboutRightOfUseAssets",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210101to20211231",
                    "decimals":  "0",
                    "lang":  null,
                    "name":  "ifrs-full:DepreciationRightofuseAssets",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  "USD",
                    "xsiNil":  "false"
                    }
                },
            "R7":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "div",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210101to20211231",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "0007 - Disclosure - Basis of presentation",
                "role":  "http://www.fsdpharma.com/role/BasisOfPresentation",
                "shortName":  "Basis of presentation",
                "subGroupType":  "",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "div",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210101to20211231",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    }
                },
            "R70":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "span",
                        "span",
                        "p",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "ifrs-full:DisclosureOfIntangibleAssetsExplanatory",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210301to20210309_hugeTypeOfArrangementsAxis_hugeInnovetLicenseAgreementMember",
                    "decimals":  "0",
                    "first":  true,
                    "lang":  null,
                    "name":  "ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  "USD",
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "0072 - Disclosure - Intangible assets (Narrative) (Details)",
                "role":  "http://www.fsdpharma.com/role/IntangibleAssetsNarrativeDetails",
                "shortName":  "Intangible assets (Narrative) (Details)",
                "subGroupType":  "details",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "span",
                        "span",
                        "p",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "ifrs-full:DisclosureOfIntangibleAssetsExplanatory",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210301to20210309_hugeTypeOfArrangementsAxis_hugeInnovetLicenseAgreementMember",
                    "decimals":  "0",
                    "first":  true,
                    "lang":  null,
                    "name":  "ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  "USD",
                    "xsiNil":  "false"
                    }
                },
            "R71":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "span",
                        "span",
                        "td",
                        "tr",
                        "table",
                        "div",
                        "div",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20201231",
                    "decimals":  "0",
                    "first":  true,
                    "lang":  null,
                    "name":  "ifrs-full:IntangibleAssetsOtherThanGoodwill",
                    "reportCount":  1,
                    "unitRef":  "USD",
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "0073 - Disclosure - Intangible assets - Schedule of intangible assets (Details)",
                "role":  "http://www.fsdpharma.com/role/IntangibleAssetsScheduleOfIntangibleAssetsDetails",
                "shortName":  "Intangible assets - Schedule of intangible assets (Details)",
                "subGroupType":  "details",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "span",
                        "span",
                        "td",
                        "tr",
                        "table",
                        "div",
                        "ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "ifrs-full:DisclosureOfIntangibleAssetsExplanatory",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20191231_ifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrsfullGrossCarryingAmountMember",
                    "decimals":  "0",
                    "lang":  null,
                    "name":  "ifrs-full:IntangibleAssetsOtherThanGoodwill",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  "USD",
                    "xsiNil":  "false"
                    }
                },
            "R72":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "b",
                        "span",
                        "span",
                        "td",
                        "tr",
                        "table",
                        "div",
                        "huge:DisclosureOfTradeAndOtherPayableExplanatory",
                        "div",
                        "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
                        "div",
                        "div",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20211231",
                    "decimals":  "0",
                    "first":  true,
                    "lang":  null,
                    "name":  "ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  "USD",
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "0074 - Disclosure - Trade and other payables - Schedule of trade and other payables (Details)",
                "role":  "http://www.fsdpharma.com/role/TradeAndOtherPayablesDetails",
                "shortName":  "Trade and other payables - Schedule of trade and other payables (Details)",
                "subGroupType":  "details",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "b",
                        "span",
                        "span",
                        "td",
                        "tr",
                        "table",
                        "div",
                        "huge:DisclosureOfTradeAndOtherPayableExplanatory",
                        "div",
                        "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
                        "div",
                        "div",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20211231",
                    "decimals":  "0",
                    "first":  true,
                    "lang":  null,
                    "name":  "ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  "USD",
                    "xsiNil":  "false"
                    }
                },
            "R73":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "b",
                        "span",
                        "span",
                        "td",
                        "tr",
                        "table",
                        "div",
                        "ifrs-full:DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory",
                        "div",
                        "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
                        "div",
                        "div",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20211231",
                    "decimals":  "0",
                    "first":  true,
                    "lang":  null,
                    "name":  "huge:ExternalResearchAndDevelopmentFeesPayable",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  "USD",
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "0075 - Disclosure - Trade and other payables - Schedule of accrued liabilities (Details)",
                "role":  "http://www.fsdpharma.com/role/TradeAndOtherPayablesDetails1",
                "shortName":  "Trade and other payables - Schedule of accrued liabilities (Details)",
                "subGroupType":  "details",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "b",
                        "span",
                        "span",
                        "td",
                        "tr",
                        "table",
                        "div",
                        "ifrs-full:DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory",
                        "div",
                        "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
                        "div",
                        "div",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20211231",
                    "decimals":  "0",
                    "first":  true,
                    "lang":  null,
                    "name":  "huge:ExternalResearchAndDevelopmentFeesPayable",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  "USD",
                    "xsiNil":  "false"
                    }
                },
            "R74":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "span",
                        "span",
                        "p",
                        "div",
                        "div",
                        "div",
                        "ifrs-full:DisclosureOfBorrowingsExplanatory",
                        "div",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210101to20211231",
                    "decimals":  "0",
                    "first":  true,
                    "lang":  null,
                    "name":  "huge:CashReceiptsFromSalesOfDebtInstruments",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  "USD",
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "0076 - Disclosure - Notes Payable (Narrative) (Details)",
                "role":  "http://www.fsdpharma.com/role/NotesPayableNarrativeDetails",
                "shortName":  "Notes Payable (Narrative) (Details)",
                "subGroupType":  "details",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "span",
                        "span",
                        "p",
                        "div",
                        "div",
                        "div",
                        "ifrs-full:DisclosureOfBorrowingsExplanatory",
                        "div",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210101to20211231",
                    "decimals":  "0",
                    "first":  true,
                    "lang":  null,
                    "name":  "huge:CashReceiptsFromSalesOfDebtInstruments",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  "USD",
                    "xsiNil":  "false"
                    }
                },
            "R75":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "b",
                        "span",
                        "span",
                        "td",
                        "tr",
                        "table",
                        "div",
                        "div",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20211231",
                    "decimals":  "0",
                    "first":  true,
                    "lang":  null,
                    "name":  "ifrs-full:CurrentNotesAndDebenturesIssuedAndCurrentPortionOfNoncurrentNotesAndDebenturesIssued",
                    "reportCount":  1,
                    "unitRef":  "USD",
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "0077 - Disclosure - Notes Payable - Schedule of notes payable (Details)",
                "role":  "http://www.fsdpharma.com/role/NotesPayableScheduleOfNotesPayableDetails",
                "shortName":  "Notes Payable - Schedule of notes payable (Details)",
                "subGroupType":  "details",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "b",
                        "span",
                        "span",
                        "td",
                        "tr",
                        "table",
                        "div",
                        "ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory",
                        "div",
                        "div",
                        "div",
                        "ifrs-full:DisclosureOfBorrowingsExplanatory",
                        "div",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20211231_ifrsfullLiabilitiesArisingFromFinancingActivitiesAxis_ifrsfullShorttermBorrowingsMember",
                    "decimals":  "0",
                    "lang":  null,
                    "name":  "ifrs-full:CurrentNotesAndDebenturesIssuedAndCurrentPortionOfNoncurrentNotesAndDebenturesIssued",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  "USD",
                    "xsiNil":  "false"
                    }
                },
            "R76":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "b",
                        "span",
                        "span",
                        "td",
                        "tr",
                        "table",
                        "div",
                        "huge:DisclosureOfOperatingLeaseObligationsTableTextBlock",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "ifrs-full:DisclosureOfLeasesExplanatory",
                        "div",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20201231",
                    "decimals":  "0",
                    "first":  true,
                    "lang":  null,
                    "name":  "ifrs-full:LeaseLiabilities",
                    "reportCount":  1,
                    "unitRef":  "USD",
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "0078 - Disclosure - Lease obligations - Schedule of lease obligations (Details)",
                "role":  "http://www.fsdpharma.com/role/LeaseObligationsScheduleOfLeaseObligationsDetails",
                "shortName":  "Lease obligations - Schedule of lease obligations (Details)",
                "subGroupType":  "details",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "span",
                        "span",
                        "td",
                        "tr",
                        "table",
                        "div",
                        "huge:DisclosureOfOperatingLeaseObligationsTableTextBlock",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "ifrs-full:DisclosureOfLeasesExplanatory",
                        "div",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210101to20211231",
                    "decimals":  "0",
                    "lang":  null,
                    "name":  "ifrs-full:InterestExpenseOnLeaseLiabilities",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  "USD",
                    "xsiNil":  "false"
                    }
                },
            "R77":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "span",
                        "span",
                        "td",
                        "tr",
                        "table",
                        "div",
                        "ifrs-full:DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "ifrs-full:DisclosureOfLeasesExplanatory",
                        "div",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20211231",
                    "decimals":  "0",
                    "first":  true,
                    "lang":  null,
                    "name":  "huge:UndiscountedLeasePaymentsPayable",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  "USD",
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "0079 - Disclosure - Lease obligations - Schedule of maturity analysis of operating lease payments (Details)",
                "role":  "http://www.fsdpharma.com/role/LeaseObligationsScheduleOfMaturityAnalysisOfOperatingLeasePaymentsDetails",
                "shortName":  "Lease obligations - Schedule of maturity analysis of operating lease payments (Details)",
                "subGroupType":  "details",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "span",
                        "span",
                        "td",
                        "tr",
                        "table",
                        "div",
                        "ifrs-full:DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "ifrs-full:DisclosureOfLeasesExplanatory",
                        "div",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20211231",
                    "decimals":  "0",
                    "first":  true,
                    "lang":  null,
                    "name":  "huge:UndiscountedLeasePaymentsPayable",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  "USD",
                    "xsiNil":  "false"
                    }
                },
            "R78":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "span",
                        "span",
                        "td",
                        "tr",
                        "table",
                        "huge:DisclosureOfFairValueAssumptionsOfWarrantsOutstandingExplanatory",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20200101to20201231",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "huge:ExpectedLifeOfWarrants",
                    "reportCount":  1,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "0080 - Disclosure - Warrants Liability (Narrative) (Details)",
                "role":  "http://www.fsdpharma.com/role/WarrantsLiabilityDetailTextuals",
                "shortName":  "Warrants Liability (Narrative) (Details)",
                "subGroupType":  "details",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "span",
                        "span",
                        "p",
                        "div",
                        "div",
                        "div",
                        "huge:DisclosureOfWarrantLiabilitiesExplanatory",
                        "div",
                        "div",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20211231",
                    "decimals":  "0",
                    "lang":  null,
                    "name":  "huge:WarrantsLiability",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  "USD",
                    "xsiNil":  "false"
                    }
                },
            "R79":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "span",
                        "span",
                        "td",
                        "tr",
                        "table",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210101to20211231",
                    "decimals":  "0",
                    "first":  true,
                    "lang":  null,
                    "name":  "ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions",
                    "reportCount":  1,
                    "unitRef":  "USD",
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "0081 - Disclosure - Share capital (Narrative) (Details)",
                "role":  "http://www.fsdpharma.com/role/ShareCapitalNarrativeDetails",
                "shortName":  "Share capital (Narrative) (Details)",
                "subGroupType":  "details",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "span",
                        "span",
                        "p",
                        "div",
                        "div",
                        "div",
                        "div",
                        "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210701to20210726_ifrsfullComponentsOfEquityAxis_hugeWarrantsMember",
                    "decimals":  "INF",
                    "lang":  null,
                    "name":  "huge:WarrantsIssueToRelatedParty",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  "shares",
                    "xsiNil":  "false"
                    }
                },
            "R8":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210101to20211231",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "0008 - Disclosure - Significant accounting policies",
                "role":  "http://www.fsdpharma.com/role/SignificantAccountingPolicies",
                "shortName":  "Significant accounting policies",
                "subGroupType":  "",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210101to20211231",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    }
                },
            "R80":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "span",
                        "span",
                        "td",
                        "tr",
                        "table",
                        "div",
                        "div",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20201231",
                    "decimals":  "0",
                    "first":  true,
                    "lang":  null,
                    "name":  "ifrs-full:Equity",
                    "reportCount":  1,
                    "unitRef":  "USD",
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "0082 - Disclosure - Share capital - Schedule of reconciliation of the share capital (Details)",
                "role":  "http://www.fsdpharma.com/role/ShareCapitalScheduleOfReconciliationOfTheShareCapitalDetails",
                "shortName":  "Share capital - Schedule of reconciliation of the share capital (Details)",
                "subGroupType":  "details",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "span",
                        "span",
                        "td",
                        "tr",
                        "table",
                        "div",
                        "div",
                        "div",
                        "div",
                        "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory",
                        "div",
                        "div",
                        "div",
                        "div",
                        "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20190101to20191231_ifrsfullClassesOfShareCapitalAxis_hugeClassBCommonStockSharesMember",
                    "decimals":  "0",
                    "lang":  null,
                    "name":  "huge:IncreaseDecreaseThroughAcquisitionOfNetAssetsValue",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  "USD",
                    "xsiNil":  "false"
                    }
                },
            "R81":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "span",
                        "span",
                        "td",
                        "tr",
                        "table",
                        "div",
                        "div",
                        "huge:DisclosureOfChangesInWarrantsOutstandingAndWeightedAverageExercisePriceExplanatory",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20201231",
                    "decimals":  "INF",
                    "first":  true,
                    "lang":  null,
                    "name":  "huge:NumberOfWarrantsOutstanding",
                    "reportCount":  1,
                    "unitRef":  "shares",
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "0083 - Disclosure - Share capital - Schedule of changes in number of warrants outstanding (Details)",
                "role":  "http://www.fsdpharma.com/role/ShareCapitalScheduleOfChangesInNumberOfWarrantsOutstandingDetails",
                "shortName":  "Share capital - Schedule of changes in number of warrants outstanding (Details)",
                "subGroupType":  "details",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "span",
                        "span",
                        "td",
                        "tr",
                        "table",
                        "div",
                        "div",
                        "huge:DisclosureOfChangesInWarrantsOutstandingAndWeightedAverageExercisePriceExplanatory",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210101to20211231",
                    "decimals":  "INF",
                    "lang":  null,
                    "name":  "huge:NumberOfWarrantsIssued",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  "shares",
                    "xsiNil":  "false"
                    }
                },
            "R82":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "span",
                        "span",
                        "td",
                        "tr",
                        "table",
                        "huge:DisclosureOfFairValueAssumptionsOfWarrantsOutstandingExplanatory",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20191231",
                    "decimals":  "2",
                    "first":  true,
                    "lang":  null,
                    "name":  "huge:WeightedAverageSharePriceOfWarrants",
                    "reportCount":  1,
                    "unitRef":  "CAD_per_Share",
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "0084 - Disclosure - Share capital - Schedule of fair value assumptions of warrants (Details)",
                "role":  "http://www.fsdpharma.com/role/ShareCapitalScheduleOfFairValueAssumptionsOfWarrantsDetails",
                "shortName":  "Share capital - Schedule of fair value assumptions of warrants (Details)",
                "subGroupType":  "details",
                "uniqueAnchor":  null
                },
            "R83":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "b",
                        "span",
                        "span",
                        "td",
                        "tr",
                        "table",
                        "div",
                        "div",
                        "huge:DisclosureOfChangesInWarrantsOutstandingAndWeightedAverageExercisePriceExplanatory",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20211231",
                    "decimals":  "2",
                    "first":  true,
                    "lang":  null,
                    "name":  "huge:WeightedAverageExercisePriceWarrantsOutstanding",
                    "reportCount":  1,
                    "unitRef":  "CAD_per_Share",
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "0085 - Disclosure - Share capital - Schedule of warrants outstanding and exercise price (Details)",
                "role":  "http://www.fsdpharma.com/role/ShareCapitalScheduleOfWarrantsOutstandingAndExercisePriceDetails",
                "shortName":  "Share capital - Schedule of warrants outstanding and exercise price (Details)",
                "subGroupType":  "details",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "span",
                        "span",
                        "td",
                        "tr",
                        "table",
                        "div",
                        "ix:continuation",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20191231_hugeClassesOfWarrantsAxis_hugeWarrantsByExpiryDateAtJanuary5Th2020Member",
                    "decimals":  "2",
                    "lang":  null,
                    "name":  "huge:WeightedAverageExercisePriceWarrantsOutstanding",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  "CAD_per_Share",
                    "xsiNil":  "false"
                    }
                },
            "R84":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "b",
                        "span",
                        "span",
                        "td",
                        "tr",
                        "table",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210101to20211231",
                    "decimals":  "0",
                    "first":  true,
                    "lang":  null,
                    "name":  "ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees",
                    "reportCount":  1,
                    "unitRef":  "USD",
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "0086 - Disclosure - Share-based compensation (Narrative) (Details)",
                "role":  "http://www.fsdpharma.com/role/SharebasedCompensationNarrativeDetails",
                "shortName":  "Share-based compensation (Narrative) (Details)",
                "subGroupType":  "details",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "span",
                        "span",
                        "p",
                        "div",
                        "div",
                        "div",
                        "div",
                        "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
                        "div",
                        "div",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20200101to20201231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_hugeReplacementShareOptionsMember",
                    "decimals":  "0",
                    "lang":  null,
                    "name":  "ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  "Share",
                    "xsiNil":  "false"
                    }
                },
            "R85":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "b",
                        "span",
                        "span",
                        "td",
                        "tr",
                        "table",
                        "div",
                        "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory",
                        "div",
                        "div",
                        "div",
                        "div",
                        "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
                        "div",
                        "div",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20201231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_hugeStockOptionsMember",
                    "decimals":  "INF",
                    "first":  true,
                    "lang":  null,
                    "name":  "ifrs-full:NumberOfOutstandingShareOptions",
                    "reportCount":  1,
                    "unitRef":  "Share",
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "0087 - Disclosure - Share-based compensation - Schedule of changes in number of share options (Details)",
                "role":  "http://www.fsdpharma.com/role/SharebasedCompensationScheduleOfChangesInNumberOfShareOptionsDetails",
                "shortName":  "Share-based compensation - Schedule of changes in number of share options (Details)",
                "subGroupType":  "details",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "span",
                        "span",
                        "td",
                        "tr",
                        "table",
                        "div",
                        "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory",
                        "div",
                        "div",
                        "div",
                        "div",
                        "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
                        "div",
                        "div",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20200101to20201231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_hugeStockOptionsMember",
                    "decimals":  "INF",
                    "lang":  null,
                    "name":  "ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  "Share",
                    "xsiNil":  "false"
                    }
                },
            "R86":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "b",
                        "span",
                        "span",
                        "td",
                        "tr",
                        "table",
                        "div",
                        "ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory",
                        "div",
                        "div",
                        "div",
                        "div",
                        "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
                        "div",
                        "div",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210101to20211231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_hugeStockOptionsMember",
                    "decimals":  "2",
                    "first":  true,
                    "lang":  null,
                    "name":  "ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  "Pure",
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "0088 - Disclosure - Share-based compensation - Schedule of fair value assumptions of share options granted (Details)",
                "role":  "http://www.fsdpharma.com/role/SharebasedCompensationScheduleOfFairValueAssumptionsOfShareOptionsGrantedDetails",
                "shortName":  "Share-based compensation - Schedule of fair value assumptions of share options granted (Details)",
                "subGroupType":  "details",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "b",
                        "span",
                        "span",
                        "td",
                        "tr",
                        "table",
                        "div",
                        "ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory",
                        "div",
                        "div",
                        "div",
                        "div",
                        "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
                        "div",
                        "div",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210101to20211231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_hugeStockOptionsMember",
                    "decimals":  "2",
                    "first":  true,
                    "lang":  null,
                    "name":  "ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  "Pure",
                    "xsiNil":  "false"
                    }
                },
            "R87":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "b",
                        "span",
                        "span",
                        "td",
                        "tr",
                        "table",
                        "div",
                        "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory",
                        "div",
                        "div",
                        "div",
                        "div",
                        "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
                        "div",
                        "div",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20211231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_hugeStockOptionsMember",
                    "decimals":  "2",
                    "first":  true,
                    "lang":  null,
                    "name":  "ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019",
                    "reportCount":  1,
                    "unitRef":  "CAD_per_Share",
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "0089 - Disclosure - Share-based compensation - Schedule of exercise price and weighted average contractual term of share options outstanding and exercisable (Details)",
                "role":  "http://www.fsdpharma.com/role/SharebasedCompensationScheduleOfExercisePriceAndWeightedAverageContractualTermOfShareOptionsOutstandingAndExercisableDetails",
                "shortName":  "Share-based compensation - Schedule of exercise price and weighted average contractual term of share options outstanding and exercisable (Details)",
                "subGroupType":  "details",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "b",
                        "span",
                        "span",
                        "td",
                        "tr",
                        "table",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "ifrs-full:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory",
                        "div",
                        "div",
                        "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
                        "div",
                        "div",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210101to20211231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_hugeStockOptionsMember",
                    "decimals":  null,
                    "lang":  "en-US",
                    "name":  "ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    }
                },
            "R88":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "b",
                        "span",
                        "span",
                        "td",
                        "tr",
                        "table",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210101to20211231",
                    "decimals":  "0",
                    "first":  true,
                    "lang":  null,
                    "name":  "ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees",
                    "reportCount":  1,
                    "unitRef":  "USD",
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "0090 - Disclosure - Share-based compensation - Schedule of share-based compensation (Details)",
                "role":  "http://www.fsdpharma.com/role/SharebasedCompensationScheduleOfSharebasedCompensationDetails",
                "shortName":  "Share-based compensation - Schedule of share-based compensation (Details)",
                "subGroupType":  "details",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "b",
                        "span",
                        "span",
                        "td",
                        "tr",
                        "table",
                        "div",
                        "huge:DisclosureOfShareBasedCompensationExplanatory",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
                        "div",
                        "div",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210101to20211231_ifrsfullTypesOfSharebasedPaymentArrangementsAxis_hugeWarrantsMember",
                    "decimals":  "0",
                    "lang":  null,
                    "name":  "ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  "USD",
                    "xsiNil":  "false"
                    }
                },
            "R89":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "b",
                        "span",
                        "span",
                        "td",
                        "tr",
                        "table",
                        "div",
                        "div",
                        "div",
                        "ifrs-full:EarningsPerShareExplanatory",
                        "div",
                        "ifrs-full:DisclosureOfEarningsPerShareExplanatory",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210101to20211231",
                    "decimals":  "0",
                    "first":  true,
                    "lang":  null,
                    "name":  "ifrs-full:DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  "shares",
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "0091 - Disclosure - Loss per share - Schedule of loss per share (Details)",
                "role":  "http://www.fsdpharma.com/role/LossPerShareDetails",
                "shortName":  "Loss per share - Schedule of loss per share (Details)",
                "subGroupType":  "details",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "b",
                        "span",
                        "span",
                        "td",
                        "tr",
                        "table",
                        "div",
                        "div",
                        "div",
                        "ifrs-full:EarningsPerShareExplanatory",
                        "div",
                        "ifrs-full:DisclosureOfEarningsPerShareExplanatory",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210101to20211231",
                    "decimals":  "0",
                    "first":  true,
                    "lang":  null,
                    "name":  "ifrs-full:DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  "shares",
                    "xsiNil":  "false"
                    }
                },
            "R9":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "div",
                        "div",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210101to20211231_hugeLegalEntitiesAxis_hugePrismicPharmaceuticalMember",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "ifrs-full:DisclosureOfBusinessCombinationsExplanatory",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "0009 - Disclosure - Acquisition of Prismic",
                "role":  "http://www.fsdpharma.com/role/AcquisitionOfPrismicPharmaceutical",
                "shortName":  "Acquisition of Prismic",
                "subGroupType":  "",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "div",
                        "div",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210101to20211231_hugeLegalEntitiesAxis_hugePrismicPharmaceuticalMember",
                    "decimals":  null,
                    "first":  true,
                    "lang":  "en-US",
                    "name":  "ifrs-full:DisclosureOfBusinessCombinationsExplanatory",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  null,
                    "xsiNil":  "false"
                    }
                },
            "R90":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "b",
                        "span",
                        "span",
                        "td",
                        "tr",
                        "table",
                        "div",
                        "div",
                        "div",
                        "div",
                        "huge:DisclosureOfDetailedInformationAboutGeneralAndAdministrativeExpenseExplanatory",
                        "div",
                        "ifrs-full:DisclosureOfGeneralAndAdministrativeExpenseExplanatory",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210101to20211231",
                    "decimals":  "0",
                    "first":  true,
                    "lang":  null,
                    "name":  "ifrs-full:ProfessionalFeesExpense",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  "USD",
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "0092 - Disclosure - General and administrative - Schedule of general and administrative expense (Details)",
                "role":  "http://www.fsdpharma.com/role/GeneralAndAdministrativeDetails",
                "shortName":  "General and administrative - Schedule of general and administrative expense (Details)",
                "subGroupType":  "details",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "b",
                        "span",
                        "span",
                        "td",
                        "tr",
                        "table",
                        "div",
                        "div",
                        "div",
                        "div",
                        "huge:DisclosureOfDetailedInformationAboutGeneralAndAdministrativeExpenseExplanatory",
                        "div",
                        "ifrs-full:DisclosureOfGeneralAndAdministrativeExpenseExplanatory",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210101to20211231",
                    "decimals":  "0",
                    "first":  true,
                    "lang":  null,
                    "name":  "ifrs-full:ProfessionalFeesExpense",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  "USD",
                    "xsiNil":  "false"
                    }
                },
            "R91":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "b",
                        "span",
                        "span",
                        "td",
                        "tr",
                        "table",
                        "div",
                        "div",
                        "div",
                        "huge:DisclosureOfTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognisedExplanatory",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "ifrs-full:DisclosureOfIncomeTaxExplanatory",
                        "div",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20211231",
                    "decimals":  "0",
                    "first":  true,
                    "lang":  null,
                    "name":  "huge:DeductibleTemporaryDifferencesOfDomesticNonCapitalLossesCarriedForwardForWhichNoDeferredTaxAssetIsRecognised",
                    "reportCount":  1,
                    "unitRef":  "USD",
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "0093 - Disclosure - Income Taxes (Narrative) (Details)",
                "role":  "http://www.fsdpharma.com/role/IncomeTaxesNarrativeDetails",
                "shortName":  "Income Taxes (Narrative) (Details)",
                "subGroupType":  "details",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "huge:NetOperatingLossCarryforwardsLimitationsInUse",
                        "span",
                        "span",
                        "p",
                        "div",
                        "div",
                        "div",
                        "ifrs-full:DisclosureOfIncomeTaxExplanatory",
                        "div",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210101to20211231",
                    "decimals":  "-4",
                    "lang":  null,
                    "name":  "huge:PreacquisitionNetOperatingLossCarryforwards",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  "USD",
                    "xsiNil":  "false"
                    }
                },
            "R92":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "b",
                        "span",
                        "span",
                        "td",
                        "tr",
                        "table",
                        "div",
                        "div",
                        "div",
                        "huge:DisclosureOfProvisionForIncomeTaxesExplanatory",
                        "div",
                        "div",
                        "ifrs-full:DisclosureOfIncomeTaxExplanatory",
                        "div",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210101to20211231",
                    "decimals":  "0",
                    "first":  true,
                    "lang":  null,
                    "name":  "ifrs-full:AccountingProfit",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  "USD",
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "0094 - Disclosure - Income Taxes - Schedule of provision for income taxes (Details)",
                "role":  "http://www.fsdpharma.com/role/IncomeTaxesScheduleOfProvisionForIncomeTaxesDetails",
                "shortName":  "Income Taxes - Schedule of provision for income taxes (Details)",
                "subGroupType":  "details",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "b",
                        "span",
                        "span",
                        "td",
                        "tr",
                        "table",
                        "div",
                        "div",
                        "div",
                        "huge:DisclosureOfProvisionForIncomeTaxesExplanatory",
                        "div",
                        "div",
                        "ifrs-full:DisclosureOfIncomeTaxExplanatory",
                        "div",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210101to20211231",
                    "decimals":  "0",
                    "first":  true,
                    "lang":  null,
                    "name":  "ifrs-full:AccountingProfit",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  "USD",
                    "xsiNil":  "false"
                    }
                },
            "R93":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "b",
                        "span",
                        "span",
                        "td",
                        "tr",
                        "table",
                        "div",
                        "div",
                        "ifrs-full:DisclosureOfDeferredTaxesExplanatory",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "ifrs-full:DisclosureOfIncomeTaxExplanatory",
                        "div",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20211231",
                    "decimals":  "0",
                    "first":  true,
                    "lang":  null,
                    "name":  "huge:DeferredTaxAssetsOtherInvestments",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  "USD",
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "0095 - Disclosure - Income Taxes - Schedule of deferred tax assets (liabilities) (Details)",
                "role":  "http://www.fsdpharma.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsLiabilitiesDetails",
                "shortName":  "Income Taxes - Schedule of deferred tax assets (liabilities) (Details)",
                "subGroupType":  "details",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "b",
                        "span",
                        "span",
                        "td",
                        "tr",
                        "table",
                        "div",
                        "div",
                        "ifrs-full:DisclosureOfDeferredTaxesExplanatory",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "ifrs-full:DisclosureOfIncomeTaxExplanatory",
                        "div",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20211231",
                    "decimals":  "0",
                    "first":  true,
                    "lang":  null,
                    "name":  "huge:DeferredTaxAssetsOtherInvestments",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  "USD",
                    "xsiNil":  "false"
                    }
                },
            "R94":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "b",
                        "span",
                        "span",
                        "td",
                        "tr",
                        "table",
                        "div",
                        "div",
                        "div",
                        "huge:DisclosureOfTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognisedExplanatory",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "ifrs-full:DisclosureOfIncomeTaxExplanatory",
                        "div",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20211231",
                    "decimals":  "0",
                    "first":  true,
                    "lang":  null,
                    "name":  "huge:DeductibleTemporaryDifferencesOfForeignNonCapitalLossesCarriedForwardForWhichNoDeferredTaxAssetIsRecognised",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  "USD",
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "0096 - Disclosure - Income Taxes - Schedule of temporary differences for which deferred tax assets not recognised (Details)",
                "role":  "http://www.fsdpharma.com/role/IncomeTaxesScheduleOfTemporaryDifferencesForWhichDeferredTaxAssetsNotRecognisedDetails",
                "shortName":  "Income Taxes - Schedule of temporary differences for which deferred tax assets not recognised (Details)",
                "subGroupType":  "details",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "b",
                        "span",
                        "span",
                        "td",
                        "tr",
                        "table",
                        "div",
                        "div",
                        "div",
                        "huge:DisclosureOfTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognisedExplanatory",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "ifrs-full:DisclosureOfIncomeTaxExplanatory",
                        "div",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20211231",
                    "decimals":  "0",
                    "first":  true,
                    "lang":  null,
                    "name":  "huge:DeductibleTemporaryDifferencesOfForeignNonCapitalLossesCarriedForwardForWhichNoDeferredTaxAssetIsRecognised",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  "USD",
                    "xsiNil":  "false"
                    }
                },
            "R95":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "b",
                        "span",
                        "span",
                        "td",
                        "tr",
                        "table",
                        "div",
                        "div",
                        "huge:ScheduleOfNonCapitalLossCarryforwardsTableTextBlock",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "ifrs-full:DisclosureOfIncomeTaxExplanatory",
                        "div",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20211231",
                    "decimals":  "0",
                    "first":  true,
                    "lang":  null,
                    "name":  "huge:NonCapitalIncomeTaxLossesExpireOnTwoThousandThirtySeven",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  "USD",
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "0097 - Disclosure - Income Taxes - Schedule of non-capital loss carryforwards (Details)",
                "role":  "http://www.fsdpharma.com/role/IncomeTaxesScheduleOfNoncapitalLossCarryforwardsDetails",
                "shortName":  "Income Taxes - Schedule of non-capital loss carryforwards (Details)",
                "subGroupType":  "details",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "b",
                        "span",
                        "span",
                        "td",
                        "tr",
                        "table",
                        "div",
                        "div",
                        "huge:ScheduleOfNonCapitalLossCarryforwardsTableTextBlock",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "ifrs-full:DisclosureOfIncomeTaxExplanatory",
                        "div",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20211231",
                    "decimals":  "0",
                    "first":  true,
                    "lang":  null,
                    "name":  "huge:NonCapitalIncomeTaxLossesExpireOnTwoThousandThirtySeven",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  "USD",
                    "xsiNil":  "false"
                    }
                },
            "R96":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "span",
                        "span",
                        "p",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory",
                        "div",
                        "div",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210301to20210309",
                    "decimals":  "0",
                    "first":  true,
                    "lang":  null,
                    "name":  "huge:ClaimantValue",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  "GBP",
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "0098 - Disclosure - Commitments and contingencies (Narrative) (Details)",
                "role":  "http://www.fsdpharma.com/role/CommitmentsAndContingenciesNarrativeDetails",
                "shortName":  "Commitments and contingencies (Narrative) (Details)",
                "subGroupType":  "details",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "span",
                        "span",
                        "p",
                        "div",
                        "div",
                        "div",
                        "div",
                        "div",
                        "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory",
                        "div",
                        "div",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210301to20210309",
                    "decimals":  "0",
                    "first":  true,
                    "lang":  null,
                    "name":  "huge:ClaimantValue",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  "GBP",
                    "xsiNil":  "false"
                    }
                },
            "R97":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "span",
                        "span",
                        "p",
                        "div",
                        "div",
                        "div",
                        "div",
                        "ifrs-full:DisclosureOfRelatedPartyExplanatory",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20220301to20220308",
                    "decimals":  "INF",
                    "first":  true,
                    "lang":  null,
                    "name":  "huge:MixedDecisionShareGrantPermitted",
                    "reportCount":  1,
                    "unitRef":  "shares",
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "0100 - Disclosure - Related party transactions (Narrative) (Details)",
                "role":  "http://www.fsdpharma.com/role/RelatedPartyTransactionsNarrativeDetails",
                "shortName":  "Related party transactions (Narrative) (Details)",
                "subGroupType":  "details",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "span",
                        "span",
                        "p",
                        "div",
                        "div",
                        "div",
                        "div",
                        "ifrs-full:DisclosureOfRelatedPartyExplanatory",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210101to20211231_ifrsfullCategoriesOfRelatedPartiesAxis_hugeDirectorsMember",
                    "decimals":  "0",
                    "lang":  null,
                    "name":  "ifrs-full:DirectorsRemunerationExpense",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  "USD",
                    "xsiNil":  "false"
                    }
                },
            "R98":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "b",
                        "span",
                        "span",
                        "td",
                        "tr",
                        "table",
                        "div",
                        "div",
                        "div",
                        "ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory",
                        "div",
                        "div",
                        "div",
                        "ifrs-full:DisclosureOfRelatedPartyExplanatory",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210101to20211231",
                    "decimals":  "0",
                    "first":  true,
                    "lang":  null,
                    "name":  "ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  "USD",
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "0101 - Disclosure - Related party transactions - Schedule of key management personnel compensation (Details)",
                "role":  "http://www.fsdpharma.com/role/RelatedPartyTransactionsScheduleOfKeyManagementPersonnelCompensationDetails",
                "shortName":  "Related party transactions - Schedule of key management personnel compensation (Details)",
                "subGroupType":  "details",
                "uniqueAnchor":  {
                    "ancestors":  [
                        "b",
                        "span",
                        "span",
                        "td",
                        "tr",
                        "table",
                        "div",
                        "div",
                        "div",
                        "ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory",
                        "div",
                        "div",
                        "div",
                        "ifrs-full:DisclosureOfRelatedPartyExplanatory",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20210101to20211231",
                    "decimals":  "0",
                    "first":  true,
                    "lang":  null,
                    "name":  "ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits",
                    "reportCount":  1,
                    "unique":  true,
                    "unitRef":  "USD",
                    "xsiNil":  "false"
                    }
                },
            "R99":  {
                "firstAnchor":  {
                    "ancestors":  [
                        "span",
                        "span",
                        "p",
                        "div",
                        "div",
                        "ifrs-full:DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory",
                        "div",
                        "div",
                        "body",
                        "html"
                        ],
                    "baseRef":  "form20f.htm",
                    "contextRef":  "C_20211231",
                    "decimals":  "0",
                    "first":  true,
                    "lang":  null,
                    "name":  "ifrs-full:IssuedCapital",
                    "reportCount":  1,
                    "unitRef":  "USD",
                    "xsiNil":  "false"
                    },
                "groupType":  "disclosure",
                "isDefault":  "false",
                "longName":  "0102 - Disclosure - Capital management (Narrative) (Details)",
                "role":  "http://www.fsdpharma.com/role/CapitalManagementNarrativeDetails",
                "shortName":  "Capital management (Narrative) (Details)",
                "subGroupType":  "details",
                "uniqueAnchor":  null
                }
            },
        "segmentCount":  131,
        "tag":  {
            "dei_AddressTypeDomain":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "An entity may have several addresses for different purposes and this domain represents all such types.",
                            "label":  "Address Type [Domain]"
                            }
                        }
                    },
                "localname":  "AddressTypeDomain",
                "nsuri":  "http://xbrl.sec.gov/dei/2021q4",
                "presentation":  [
                    "http://www.fsdpharma.com/role/DocumentAndEntityInformation"
                    ],
                "xbrltype":  "domainItemType"
                },
            "dei_AmendmentFlag":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
                            "label":  "Amendment Flag"
                            }
                        }
                    },
                "localname":  "AmendmentFlag",
                "nsuri":  "http://xbrl.sec.gov/dei/2021q4",
                "presentation":  [
                    "http://www.fsdpharma.com/role/DocumentAndEntityInformation"
                    ],
                "xbrltype":  "booleanItemType"
                },
            "dei_AnnualInformationForm":  {
                "auth_ref":  [
                    "r238"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
                            "label":  "Annual Information Form"
                            }
                        }
                    },
                "localname":  "AnnualInformationForm",
                "nsuri":  "http://xbrl.sec.gov/dei/2021q4",
                "presentation":  [
                    "http://www.fsdpharma.com/role/DocumentAndEntityInformation"
                    ],
                "xbrltype":  "booleanItemType"
                },
            "dei_AuditedAnnualFinancialStatements":  {
                "auth_ref":  [
                    "r238"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
                            "label":  "Audited Annual Financial Statements"
                            }
                        }
                    },
                "localname":  "AuditedAnnualFinancialStatements",
                "nsuri":  "http://xbrl.sec.gov/dei/2021q4",
                "presentation":  [
                    "http://www.fsdpharma.com/role/DocumentAndEntityInformation"
                    ],
                "xbrltype":  "booleanItemType"
                },
            "dei_AuditorFirmId":  {
                "auth_ref":  [
                    "r236",
                    "r237",
                    "r238"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "PCAOB issued Audit Firm Identifier",
                            "label":  "Auditor Firm ID"
                            }
                        }
                    },
                "localname":  "AuditorFirmId",
                "nsuri":  "http://xbrl.sec.gov/dei/2021q4",
                "presentation":  [
                    "http://www.fsdpharma.com/role/DocumentAndEntityInformation"
                    ],
                "xbrltype":  "nonemptySequenceNumberItemType"
                },
            "dei_AuditorLocation":  {
                "auth_ref":  [
                    "r236",
                    "r237",
                    "r238"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "label":  "Auditor Location"
                            }
                        }
                    },
                "localname":  "AuditorLocation",
                "nsuri":  "http://xbrl.sec.gov/dei/2021q4",
                "presentation":  [
                    "http://www.fsdpharma.com/role/DocumentAndEntityInformation"
                    ],
                "xbrltype":  "internationalNameItemType"
                },
            "dei_AuditorName":  {
                "auth_ref":  [
                    "r236",
                    "r237",
                    "r238"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "label":  "Auditor Name"
                            }
                        }
                    },
                "localname":  "AuditorName",
                "nsuri":  "http://xbrl.sec.gov/dei/2021q4",
                "presentation":  [
                    "http://www.fsdpharma.com/role/DocumentAndEntityInformation"
                    ],
                "xbrltype":  "internationalNameItemType"
                },
            "dei_BusinessContactMember":  {
                "auth_ref":  [
                    "r237",
                    "r238"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Business contact for the entity",
                            "label":  "Business Contact [Member]"
                            }
                        }
                    },
                "localname":  "BusinessContactMember",
                "nsuri":  "http://xbrl.sec.gov/dei/2021q4",
                "presentation":  [
                    "http://www.fsdpharma.com/role/DocumentAndEntityInformation"
                    ],
                "xbrltype":  "domainItemType"
                },
            "dei_CityAreaCode":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Area code of city",
                            "label":  "City Area Code"
                            }
                        }
                    },
                "localname":  "CityAreaCode",
                "nsuri":  "http://xbrl.sec.gov/dei/2021q4",
                "presentation":  [
                    "http://www.fsdpharma.com/role/DocumentAndEntityInformation"
                    ],
                "xbrltype":  "normalizedStringItemType"
                },
            "dei_ContactPersonnelEmailAddress":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Email address of contact personnel.",
                            "label":  "Contact Personnel Email Address"
                            }
                        }
                    },
                "localname":  "ContactPersonnelEmailAddress",
                "nsuri":  "http://xbrl.sec.gov/dei/2021q4",
                "presentation":  [
                    "http://www.fsdpharma.com/role/DocumentAndEntityInformation"
                    ],
                "xbrltype":  "normalizedStringItemType"
                },
            "dei_ContactPersonnelName":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Name of contact personnel",
                            "label":  "Contact Personnel Name"
                            }
                        }
                    },
                "localname":  "ContactPersonnelName",
                "nsuri":  "http://xbrl.sec.gov/dei/2021q4",
                "presentation":  [
                    "http://www.fsdpharma.com/role/DocumentAndEntityInformation"
                    ],
                "xbrltype":  "normalizedStringItemType"
                },
            "dei_CoverAbstract":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Cover page.",
                            "label":  "Cover [Abstract]"
                            }
                        }
                    },
                "localname":  "CoverAbstract",
                "nsuri":  "http://xbrl.sec.gov/dei/2021q4",
                "xbrltype":  "stringItemType"
                },
            "dei_CurrentFiscalYearEndDate":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "End date of current fiscal year in the format --MM-DD.",
                            "label":  "Current Fiscal Year End Date"
                            }
                        }
                    },
                "localname":  "CurrentFiscalYearEndDate",
                "nsuri":  "http://xbrl.sec.gov/dei/2021q4",
                "presentation":  [
                    "http://www.fsdpharma.com/role/DocumentAndEntityInformation"
                    ],
                "xbrltype":  "gMonthDayItemType"
                },
            "dei_DocumentAccountingStandard":  {
                "auth_ref":  [
                    "r237"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S.  GAAP', 'International Financial Reporting Standards', or 'Other'.",
                            "label":  "Document Accounting Standard"
                            }
                        }
                    },
                "localname":  "DocumentAccountingStandard",
                "nsuri":  "http://xbrl.sec.gov/dei/2021q4",
                "presentation":  [
                    "http://www.fsdpharma.com/role/DocumentAndEntityInformation"
                    ],
                "xbrltype":  "accountingStandardItemType"
                },
            "dei_DocumentAnnualReport":  {
                "auth_ref":  [
                    "r236",
                    "r237",
                    "r238"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Boolean flag that is true only for a form used as an annual report.",
                            "label":  "Document Annual Report"
                            }
                        }
                    },
                "localname":  "DocumentAnnualReport",
                "nsuri":  "http://xbrl.sec.gov/dei/2021q4",
                "presentation":  [
                    "http://www.fsdpharma.com/role/DocumentAndEntityInformation"
                    ],
                "xbrltype":  "booleanItemType"
                },
            "dei_DocumentFiscalPeriodFocus":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
                            "label":  "Document Fiscal Period Focus"
                            }
                        }
                    },
                "localname":  "DocumentFiscalPeriodFocus",
                "nsuri":  "http://xbrl.sec.gov/dei/2021q4",
                "presentation":  [
                    "http://www.fsdpharma.com/role/DocumentAndEntityInformation"
                    ],
                "xbrltype":  "fiscalPeriodItemType"
                },
            "dei_DocumentFiscalYearFocus":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "This is focus fiscal year of the document report in YYYY format.  For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus.  Example: 2006.",
                            "label":  "Document Fiscal Year Focus"
                            }
                        }
                    },
                "localname":  "DocumentFiscalYearFocus",
                "nsuri":  "http://xbrl.sec.gov/dei/2021q4",
                "presentation":  [
                    "http://www.fsdpharma.com/role/DocumentAndEntityInformation"
                    ],
                "xbrltype":  "gYearItemType"
                },
            "dei_DocumentPeriodEndDate":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
                            "label":  "Document Period End Date"
                            }
                        }
                    },
                "localname":  "DocumentPeriodEndDate",
                "nsuri":  "http://xbrl.sec.gov/dei/2021q4",
                "presentation":  [
                    "http://www.fsdpharma.com/role/DocumentAndEntityInformation"
                    ],
                "xbrltype":  "dateItemType"
                },
            "dei_DocumentRegistrationStatement":  {
                "auth_ref":  [
                    "r232"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Boolean flag that is true only for a form used as a registration statement.",
                            "label":  "Document Registration Statement"
                            }
                        }
                    },
                "localname":  "DocumentRegistrationStatement",
                "nsuri":  "http://xbrl.sec.gov/dei/2021q4",
                "presentation":  [
                    "http://www.fsdpharma.com/role/DocumentAndEntityInformation"
                    ],
                "xbrltype":  "booleanItemType"
                },
            "dei_DocumentShellCompanyReport":  {
                "auth_ref":  [
                    "r237"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
                            "label":  "Document Shell Company Report"
                            }
                        }
                    },
                "localname":  "DocumentShellCompanyReport",
                "nsuri":  "http://xbrl.sec.gov/dei/2021q4",
                "presentation":  [
                    "http://www.fsdpharma.com/role/DocumentAndEntityInformation"
                    ],
                "xbrltype":  "booleanItemType"
                },
            "dei_DocumentTransitionReport":  {
                "auth_ref":  [
                    "r239"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Boolean flag that is true only for a form used as a transition report.",
                            "label":  "Document Transition Report"
                            }
                        }
                    },
                "localname":  "DocumentTransitionReport",
                "nsuri":  "http://xbrl.sec.gov/dei/2021q4",
                "presentation":  [
                    "http://www.fsdpharma.com/role/DocumentAndEntityInformation"
                    ],
                "xbrltype":  "booleanItemType"
                },
            "dei_DocumentType":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc).  The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
                            "label":  "Document Type"
                            }
                        }
                    },
                "localname":  "DocumentType",
                "nsuri":  "http://xbrl.sec.gov/dei/2021q4",
                "presentation":  [
                    "http://www.fsdpharma.com/role/DocumentAndEntityInformation"
                    ],
                "xbrltype":  "submissionTypeItemType"
                },
            "dei_EntityAddressAddressLine1":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Address Line 1 such as Attn, Building Name, Street Name",
                            "label":  "Entity Address, Address Line One"
                            }
                        }
                    },
                "localname":  "EntityAddressAddressLine1",
                "nsuri":  "http://xbrl.sec.gov/dei/2021q4",
                "presentation":  [
                    "http://www.fsdpharma.com/role/DocumentAndEntityInformation"
                    ],
                "xbrltype":  "normalizedStringItemType"
                },
            "dei_EntityAddressAddressLine2":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Address Line 2 such as Street or Suite number",
                            "label":  "Entity Address, Address Line two"
                            }
                        }
                    },
                "localname":  "EntityAddressAddressLine2",
                "nsuri":  "http://xbrl.sec.gov/dei/2021q4",
                "presentation":  [
                    "http://www.fsdpharma.com/role/DocumentAndEntityInformation"
                    ],
                "xbrltype":  "normalizedStringItemType"
                },
            "dei_EntityAddressAddressLine3":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Address Line 3 such as an Office Park",
                            "label":  "Entity Address, Address Line Three"
                            }
                        }
                    },
                "localname":  "EntityAddressAddressLine3",
                "nsuri":  "http://xbrl.sec.gov/dei/2021q4",
                "presentation":  [
                    "http://www.fsdpharma.com/role/DocumentAndEntityInformation"
                    ],
                "xbrltype":  "normalizedStringItemType"
                },
            "dei_EntityAddressCityOrTown":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Name of the City or Town",
                            "label":  "Entity Address, City or Town"
                            }
                        }
                    },
                "localname":  "EntityAddressCityOrTown",
                "nsuri":  "http://xbrl.sec.gov/dei/2021q4",
                "presentation":  [
                    "http://www.fsdpharma.com/role/DocumentAndEntityInformation"
                    ],
                "xbrltype":  "normalizedStringItemType"
                },
            "dei_EntityAddressCountry":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "ISO 3166-1 alpha-2 country code.",
                            "label":  "Entity Address, Country"
                            }
                        }
                    },
                "localname":  "EntityAddressCountry",
                "nsuri":  "http://xbrl.sec.gov/dei/2021q4",
                "presentation":  [
                    "http://www.fsdpharma.com/role/DocumentAndEntityInformation"
                    ],
                "xbrltype":  "countryCodeItemType"
                },
            "dei_EntityAddressPostalZipCode":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Code for the postal or zip code",
                            "label":  "Entity Address, Postal Zip Code"
                            }
                        }
                    },
                "localname":  "EntityAddressPostalZipCode",
                "nsuri":  "http://xbrl.sec.gov/dei/2021q4",
                "presentation":  [
                    "http://www.fsdpharma.com/role/DocumentAndEntityInformation"
                    ],
                "xbrltype":  "normalizedStringItemType"
                },
            "dei_EntityAddressStateOrProvince":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Name of the state or province.",
                            "label":  "Entity Address, State or Province"
                            }
                        }
                    },
                "localname":  "EntityAddressStateOrProvince",
                "nsuri":  "http://xbrl.sec.gov/dei/2021q4",
                "presentation":  [
                    "http://www.fsdpharma.com/role/DocumentAndEntityInformation"
                    ],
                "xbrltype":  "stateOrProvinceItemType"
                },
            "dei_EntityAddressesAddressTypeAxis":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.",
                            "label":  "Entity Addresses, Address Type [Axis]"
                            }
                        }
                    },
                "localname":  "EntityAddressesAddressTypeAxis",
                "nsuri":  "http://xbrl.sec.gov/dei/2021q4",
                "presentation":  [
                    "http://www.fsdpharma.com/role/DocumentAndEntityInformation"
                    ],
                "xbrltype":  "stringItemType"
                },
            "dei_EntityAddressesLineItems":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Line items represent financial concepts included in a table.  These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
                            "label":  "Entity Addresses [Line Items]"
                            }
                        }
                    },
                "localname":  "EntityAddressesLineItems",
                "nsuri":  "http://xbrl.sec.gov/dei/2021q4",
                "presentation":  [
                    "http://www.fsdpharma.com/role/DocumentAndEntityInformation"
                    ],
                "xbrltype":  "stringItemType"
                },
            "dei_EntityAddressesTable":  {
                "auth_ref":  [
                    "r234"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Container of address information for the entity",
                            "label":  "Entity Addresses [Table]"
                            }
                        }
                    },
                "localname":  "EntityAddressesTable",
                "nsuri":  "http://xbrl.sec.gov/dei/2021q4",
                "presentation":  [
                    "http://www.fsdpharma.com/role/DocumentAndEntityInformation"
                    ],
                "xbrltype":  "stringItemType"
                },
            "dei_EntityCentralIndexKey":  {
                "auth_ref":  [
                    "r234"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC.  It is commonly abbreviated as CIK.",
                            "label":  "Entity Central Index Key"
                            }
                        }
                    },
                "localname":  "EntityCentralIndexKey",
                "nsuri":  "http://xbrl.sec.gov/dei/2021q4",
                "presentation":  [
                    "http://www.fsdpharma.com/role/DocumentAndEntityInformation"
                    ],
                "xbrltype":  "centralIndexKeyItemType"
                },
            "dei_EntityCommonStockSharesOutstanding":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report.  Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
                            "label":  "Entity Common Stock, Shares Outstanding"
                            }
                        }
                    },
                "localname":  "EntityCommonStockSharesOutstanding",
                "nsuri":  "http://xbrl.sec.gov/dei/2021q4",
                "presentation":  [
                    "http://www.fsdpharma.com/role/DocumentAndEntityInformation"
                    ],
                "xbrltype":  "sharesItemType"
                },
            "dei_EntityCurrentReportingStatus":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days.  This information should be based on the registrant's current or most recent filing containing the related disclosure.",
                            "label":  "Entity Current Reporting Status"
                            }
                        }
                    },
                "localname":  "EntityCurrentReportingStatus",
                "nsuri":  "http://xbrl.sec.gov/dei/2021q4",
                "presentation":  [
                    "http://www.fsdpharma.com/role/DocumentAndEntityInformation"
                    ],
                "xbrltype":  "yesNoItemType"
                },
            "dei_EntityDomain":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "All the names of the entities being reported upon in a document.  Any legal structure used to conduct activities or to hold assets.  Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts.  This item does not include business and geographical segments which are included in the geographical or business segments domains.",
                            "label":  "Entity [Domain]"
                            }
                        }
                    },
                "localname":  "EntityDomain",
                "nsuri":  "http://xbrl.sec.gov/dei/2021q4",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CommitmentsAndContingenciesNarrativeDetails",
                    "http://www.fsdpharma.com/role/CommitmentsAndContingenciesScheduleOfQuantitiesOfCannabisAvailableToSupplyByFiscalPeriodDetails",
                    "http://www.fsdpharma.com/role/RelatedPartyTransactionsNarrativeDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "dei_EntityEmergingGrowthCompany":  {
                "auth_ref":  [
                    "r234"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Indicate if registrant meets the emerging growth company criteria.",
                            "label":  "Entity Emerging Growth Company"
                            }
                        }
                    },
                "localname":  "EntityEmergingGrowthCompany",
                "nsuri":  "http://xbrl.sec.gov/dei/2021q4",
                "presentation":  [
                    "http://www.fsdpharma.com/role/DocumentAndEntityInformation"
                    ],
                "xbrltype":  "booleanItemType"
                },
            "dei_EntityExTransitionPeriod":  {
                "auth_ref":  [
                    "r242"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
                            "label":  "Entity Ex Transition Period"
                            }
                        }
                    },
                "localname":  "EntityExTransitionPeriod",
                "nsuri":  "http://xbrl.sec.gov/dei/2021q4",
                "presentation":  [
                    "http://www.fsdpharma.com/role/DocumentAndEntityInformation"
                    ],
                "xbrltype":  "booleanItemType"
                },
            "dei_EntityFileNumber":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Commission file number.  The field allows up to 17 characters.  The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
                            "label":  "Entity File Number"
                            }
                        }
                    },
                "localname":  "EntityFileNumber",
                "nsuri":  "http://xbrl.sec.gov/dei/2021q4",
                "presentation":  [
                    "http://www.fsdpharma.com/role/DocumentAndEntityInformation"
                    ],
                "xbrltype":  "fileNumberItemType"
                },
            "dei_EntityFilerCategory":  {
                "auth_ref":  [
                    "r234"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Indicate whether the registrant is one of the following:  Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer.  Definitions of these categories are stated in Rule 12b-2 of the Exchange Act.  This information should be based on the registrant's current or most recent filing containing the related disclosure.",
                            "label":  "Entity Filer Category"
                            }
                        }
                    },
                "localname":  "EntityFilerCategory",
                "nsuri":  "http://xbrl.sec.gov/dei/2021q4",
                "presentation":  [
                    "http://www.fsdpharma.com/role/DocumentAndEntityInformation"
                    ],
                "xbrltype":  "filerCategoryItemType"
                },
            "dei_EntityIncorporationStateCountryCode":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Two-character EDGAR code representing the state or country of incorporation.",
                            "label":  "Entity Incorporation, State or Country Code"
                            }
                        }
                    },
                "localname":  "EntityIncorporationStateCountryCode",
                "nsuri":  "http://xbrl.sec.gov/dei/2021q4",
                "presentation":  [
                    "http://www.fsdpharma.com/role/DocumentAndEntityInformation"
                    ],
                "xbrltype":  "edgarStateCountryItemType"
                },
            "dei_EntityInteractiveDataCurrent":  {
                "auth_ref":  [
                    "r240"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
                            "label":  "Entity Interactive Data Current"
                            }
                        }
                    },
                "localname":  "EntityInteractiveDataCurrent",
                "nsuri":  "http://xbrl.sec.gov/dei/2021q4",
                "presentation":  [
                    "http://www.fsdpharma.com/role/DocumentAndEntityInformation"
                    ],
                "xbrltype":  "yesNoItemType"
                },
            "dei_EntityRegistrantName":  {
                "auth_ref":  [
                    "r234"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
                            "label":  "Entity Registrant Name"
                            }
                        }
                    },
                "localname":  "EntityRegistrantName",
                "nsuri":  "http://xbrl.sec.gov/dei/2021q4",
                "presentation":  [
                    "http://www.fsdpharma.com/role/DocumentAndEntityInformation"
                    ],
                "xbrltype":  "normalizedStringItemType"
                },
            "dei_EntityShellCompany":  {
                "auth_ref":  [
                    "r234"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
                            "label":  "Entity Shell Company"
                            }
                        }
                    },
                "localname":  "EntityShellCompany",
                "nsuri":  "http://xbrl.sec.gov/dei/2021q4",
                "presentation":  [
                    "http://www.fsdpharma.com/role/DocumentAndEntityInformation"
                    ],
                "xbrltype":  "booleanItemType"
                },
            "dei_EntityVoluntaryFilers":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
                            "label":  "Entity Voluntary Filers"
                            }
                        }
                    },
                "localname":  "EntityVoluntaryFilers",
                "nsuri":  "http://xbrl.sec.gov/dei/2021q4",
                "presentation":  [
                    "http://www.fsdpharma.com/role/DocumentAndEntityInformation"
                    ],
                "xbrltype":  "yesNoItemType"
                },
            "dei_EntityWellKnownSeasonedIssuer":  {
                "auth_ref":  [
                    "r241"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.  Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
                            "label":  "Entity Well-known Seasoned Issuer"
                            }
                        }
                    },
                "localname":  "EntityWellKnownSeasonedIssuer",
                "nsuri":  "http://xbrl.sec.gov/dei/2021q4",
                "presentation":  [
                    "http://www.fsdpharma.com/role/DocumentAndEntityInformation"
                    ],
                "xbrltype":  "yesNoItemType"
                },
            "dei_IcfrAuditorAttestationFlag":  {
                "auth_ref":  [
                    "r236",
                    "r237",
                    "r238"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "label":  "ICFR Auditor Attestation Flag"
                            }
                        }
                    },
                "localname":  "IcfrAuditorAttestationFlag",
                "nsuri":  "http://xbrl.sec.gov/dei/2021q4",
                "presentation":  [
                    "http://www.fsdpharma.com/role/DocumentAndEntityInformation"
                    ],
                "xbrltype":  "booleanItemType"
                },
            "dei_LegalEntityAxis":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "The set of legal entities associated with a report.",
                            "label":  "Legal Entity [Axis]"
                            }
                        }
                    },
                "localname":  "LegalEntityAxis",
                "nsuri":  "http://xbrl.sec.gov/dei/2021q4",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CommitmentsAndContingenciesNarrativeDetails",
                    "http://www.fsdpharma.com/role/CommitmentsAndContingenciesScheduleOfQuantitiesOfCannabisAvailableToSupplyByFiscalPeriodDetails",
                    "http://www.fsdpharma.com/role/RelatedPartyTransactionsNarrativeDetails"
                    ],
                "xbrltype":  "stringItemType"
                },
            "dei_LocalPhoneNumber":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Local phone number for entity.",
                            "label":  "Local Phone Number"
                            }
                        }
                    },
                "localname":  "LocalPhoneNumber",
                "nsuri":  "http://xbrl.sec.gov/dei/2021q4",
                "presentation":  [
                    "http://www.fsdpharma.com/role/DocumentAndEntityInformation"
                    ],
                "xbrltype":  "normalizedStringItemType"
                },
            "dei_Security12bTitle":  {
                "auth_ref":  [
                    "r233"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Title of a 12(b) registered security.",
                            "label":  "Title of 12(b) Security"
                            }
                        }
                    },
                "localname":  "Security12bTitle",
                "nsuri":  "http://xbrl.sec.gov/dei/2021q4",
                "presentation":  [
                    "http://www.fsdpharma.com/role/DocumentAndEntityInformation"
                    ],
                "xbrltype":  "securityTitleItemType"
                },
            "dei_SecurityExchangeName":  {
                "auth_ref":  [
                    "r235"
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Name of the Exchange on which a security is registered.",
                            "label":  "Security Exchange Name"
                            }
                        }
                    },
                "localname":  "SecurityExchangeName",
                "nsuri":  "http://xbrl.sec.gov/dei/2021q4",
                "presentation":  [
                    "http://www.fsdpharma.com/role/DocumentAndEntityInformation"
                    ],
                "xbrltype":  "edgarExchangeCodeItemType"
                },
            "dei_TradingSymbol":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Trading symbol of an instrument as listed on an exchange.",
                            "label":  "Trading Symbol"
                            }
                        }
                    },
                "localname":  "TradingSymbol",
                "nsuri":  "http://xbrl.sec.gov/dei/2021q4",
                "presentation":  [
                    "http://www.fsdpharma.com/role/DocumentAndEntityInformation"
                    ],
                "xbrltype":  "tradingSymbolItemType"
                },
            "huge_AccruedBonusPayable":  {
                "auth_ref":  [
                    ],
                "calculation":  {
                    "http://www.fsdpharma.com/role/TradeAndOtherPayablesDetails1":  {
                        "order":  40.0,
                        "parentTag":  "ifrs-full_AccrualsClassifiedAsCurrent",
                        "weight":  1.0
                        }
                    },
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represent the amount of accrued bonus payable.",
                            "label":  "Accrued Bonus Payable",
                            "terseLabel":  "Bonus"
                            }
                        }
                    },
                "localname":  "AccruedBonusPayable",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/TradeAndOtherPayablesDetails1"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "huge_AccruedInterestPayable":  {
                "auth_ref":  [
                    ],
                "calculation":  {
                    "http://www.fsdpharma.com/role/TradeAndOtherPayablesDetails1":  {
                        "order":  20.0,
                        "parentTag":  "ifrs-full_AccrualsClassifiedAsCurrent",
                        "weight":  1.0
                        }
                    },
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represent the amount of accrued accrued interest payable.",
                            "label":  "Accrued Interest Payable",
                            "terseLabel":  "Accrued interest"
                            }
                        }
                    },
                "localname":  "AccruedInterestPayable",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/TradeAndOtherPayablesDetails1"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "huge_AddDeductItemsNotAffectingCashAbstract":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "label":  "Add (Deduct) Items Not Affecting Cash [Abstract]",
                            "verboseLabel":  "Add (deduct) items not affecting cash"
                            }
                        }
                    },
                "localname":  "AddDeductItemsNotAffectingCashAbstract",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/AssetsHeldForSaleDetails2"
                    ],
                "xbrltype":  "stringItemType"
                },
            "huge_AdditionalRemunerationAsChairmanOfAuditCommittee":  {
                "auth_ref":  [
                    ],
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Amount of additional remuneration as chairman of audit committee.",
                            "label":  "Additional Remuneration As Chairman Of Audit Committee",
                            "terseLabel":  "Additional remuneration as chairman of audit committee"
                            }
                        }
                    },
                "localname":  "AdditionalRemunerationAsChairmanOfAuditCommittee",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/RelatedPartyTransactionsNarrativeDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "huge_AdditionalRemunerationAsChairmanOfCompensationCommittee":  {
                "auth_ref":  [
                    ],
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Amount of additional remuneration as chairman of compensation committee.",
                            "label":  "Additional Remuneration As Chairman Of Compensation Committee",
                            "terseLabel":  "Additional remuneration as chairman of compensation committee"
                            }
                        }
                    },
                "localname":  "AdditionalRemunerationAsChairmanOfCompensationCommittee",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/RelatedPartyTransactionsNarrativeDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "huge_AdjustmentsForDecreaseIncreaseInPrepaidExpensesAndDeposit":  {
                "auth_ref":  [
                    ],
                "calculation":  {
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS":  {
                        "order":  90.0,
                        "parentTag":  "ifrs-full_CashFlowsFromUsedInOperatingActivitiesContinuingOperations",
                        "weight":  1.0
                        }
                    },
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Adjustments for decrease (increase) in prepaid and deposits to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer:  Other assets; Profit (loss)]",
                            "label":  "Adjustments For Decrease Increase In Prepaid Expenses and deposit",
                            "verboseLabel":  "Prepaid expenses and deposits"
                            }
                        }
                    },
                "localname":  "AdjustmentsForDecreaseIncreaseInPrepaidExpensesAndDeposit",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "huge_AdjustmentsForGainsLossesOnChangeInFairValueOfInventorySold":  {
                "auth_ref":  [
                    ],
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Adjustments for gains losses on changes in the fair value of inventory sold to reconcile profit (loss) to net cash flow from used in operating activities.",
                            "label":  "Adjustments For Gains Losses On Change In Fair Value Of Inventory Sold",
                            "negatedLabel":  "Change in fair value adjustments on inventory sold",
                            "verboseLabel":  "Change in fair value adjustments on inventory sold"
                            }
                        }
                    },
                "localname":  "AdjustmentsForGainsLossesOnChangeInFairValueOfInventorySold",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/AssetsHeldForSaleDetails2"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "huge_AdjustmentsForIncreaseDecreaseInPrepaidExpensesAndDeposits":  {
                "auth_ref":  [
                    ],
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Adjustments for increase (decrease) in prepaid expenses and deposits to reconcile profit (loss) to net cash flow from (used in) operating activities",
                            "label":  "Adjustments For Increase (Decrease) In Prepaid Expenses And Deposits",
                            "verboseLabel":  "Prepaid expenses and deposits"
                            }
                        }
                    },
                "localname":  "AdjustmentsForIncreaseDecreaseInPrepaidExpensesAndDeposits",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/AssetsHeldForSaleDetails2"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "huge_AdjustmentsForLossesGainsOnDisposalOfEquipment":  {
                "auth_ref":  [
                    ],
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Adjustments for losses (gains) on disposal of equipment to reconcile profit (loss) to net cash flow from (used in) operating activities.",
                            "label":  "Adjustments For Losses (Gains) On Disposal Of Equipment",
                            "verboseLabel":  "Loss on sale of equipment"
                            }
                        }
                    },
                "localname":  "AdjustmentsForLossesGainsOnDisposalOfEquipment",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/AssetsHeldForSaleDetails2"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "huge_AdjustmentsForLossesGainsOnDisposalOfInventory":  {
                "auth_ref":  [
                    ],
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Adjustments for losses (gains) on disposal of inventory to reconcile profit (loss) to net cash flow from (used in) operating activities.",
                            "label":  "Adjustments For Losses (Gains) On Disposal Of Inventory",
                            "verboseLabel":  "Loss on disposal of inventory"
                            }
                        }
                    },
                "localname":  "AdjustmentsForLossesGainsOnDisposalOfInventory",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/AssetsHeldForSaleDetails2"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "huge_AllianceGlobalPartnersMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "This member stands for Alliance Global Partners.",
                            "label":  "Alliance Global Partners [Member]",
                            "verboseLabel":  "A.G.P/Alliance Global Partners"
                            }
                        }
                    },
                "localname":  "AllianceGlobalPartnersMember",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/ShareCapitalNarrativeDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_AmountOfSharesIssuedFromTreasuryUnderPrivatePlacement":  {
                "auth_ref":  [
                    ],
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents the amount of shares issued from entitys treasury by way of private placement.",
                            "label":  "Amount Of Shares Issued From Treasury Under Private Placement",
                            "verboseLabel":  "Amount of Class B shares issued from treasury under private placement"
                            }
                        }
                    },
                "localname":  "AmountOfSharesIssuedFromTreasuryUnderPrivatePlacement",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CommitmentsAndContingenciesNarrativeDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "huge_AuxlyCannabisGroupIncMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Auxly Cannabis Group Inc.",
                            "label":  "Auxly Cannabis Group Inc [Member]",
                            "verboseLabel":  "Auxly Cannabis Group Inc."
                            }
                        }
                    },
                "localname":  "AuxlyCannabisGroupIncMember",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CommitmentsAndContingenciesNarrativeDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_BasisOfPresentationAbstract":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "label":  "Basis Of Presentation [Abstract]"
                            }
                        }
                    },
                "localname":  "BasisOfPresentationAbstract",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "xbrltype":  "stringItemType"
                },
            "huge_BoardChairAndChiefExecutiveOfficerAndCertainOtherDirectorsMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "This member stands for Board Chair and Chief Executive Officer, and to certain other directors.",
                            "label":  "Board Chair And Chief Executive Officer And Certain Other Directors [Member]",
                            "terseLabel":  "Board Chair and Chief Executive Officer, and certain other directors"
                            }
                        }
                    },
                "localname":  "BoardChairAndChiefExecutiveOfficerAndCertainOtherDirectorsMember",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/RelatedPartyTransactionsNarrativeDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_BookToFilingAdjustments":  {
                "auth_ref":  [
                    ],
                "calculation":  {
                    "http://www.fsdpharma.com/role/IncomeTaxesScheduleOfProvisionForIncomeTaxesDetails":  {
                        "order":  50.0,
                        "parentTag":  "ifrs-full_DeferredTaxExpenseIncome",
                        "weight":  1.0
                        }
                    },
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "It represents book to filing adjustments.",
                            "label":  "Book To Filing Adjustments",
                            "verboseLabel":  "Book to filing adjustments"
                            }
                        }
                    },
                "localname":  "BookToFilingAdjustments",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/IncomeTaxesScheduleOfProvisionForIncomeTaxesDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "huge_BorrowingsSettled":  {
                "auth_ref":  [
                    ],
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents amount of borrowings settled.",
                            "label":  "Borrowings Settled",
                            "verboseLabel":  "Settlement of notes payable"
                            }
                        }
                    },
                "localname":  "BorrowingsSettled",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/NotesPayableNarrativeDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "huge_BorrowingsSettledAccruedInterestSettled":  {
                "auth_ref":  [
                    ],
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents amount of borrowings settled accrued interest settled.",
                            "label":  "Borrowings Settled Accrued Interest Settled",
                            "verboseLabel":  "Accrued interest settled"
                            }
                        }
                    },
                "localname":  "BorrowingsSettledAccruedInterestSettled",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/NotesPayableNarrativeDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "huge_BuildingAndFacilityCosts":  {
                "auth_ref":  [
                    ],
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "The amount of expenses arising from building and facility costs.",
                            "label":  "Building And Facility Costs",
                            "verboseLabel":  "Building and facility costs"
                            }
                        }
                    },
                "localname":  "BuildingAndFacilityCosts",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/GeneralAndAdministrativeDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "huge_CannaraBiotechIncMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Cannara Biotech Inc.",
                            "label":  "Cannara Biotech Inc [Member]",
                            "verboseLabel":  "Cannara Biotech Inc."
                            }
                        }
                    },
                "localname":  "CannaraBiotechIncMember",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/OtherInvestmentsNarrativeDetails",
                    "http://www.fsdpharma.com/role/OtherInvestmentsScheduleOfOtherInvestmentsDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_CanntabTherapeuticsLtdWorldClassExtractionsIncMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Information about Canntab Therapeutics Ltd. and World Class Extractions Inc.",
                            "label":  "Canntab Therapeutics Ltd World Class Extractions Inc [Member]",
                            "verboseLabel":  "Canntab Therapeutics Ltd (\"Canntab\") World Class Extractions Inc (\"World Class\")"
                            }
                        }
                    },
                "localname":  "CanntabTherapeuticsLtdWorldClassExtractionsIncMember",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CommitmentsAndContingenciesNarrativeDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_CashAcquiredOnAcquisition":  {
                "auth_ref":  [
                    ],
                "calculation":  {
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS":  {
                        "order":  0.0,
                        "parentTag":  "ifrs-full_CashFlowsFromUsedInInvestingActivitiesContinuingOperations",
                        "weight":  1.0
                        }
                    },
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents amount related to cash inflow during acquisition.",
                            "label":  "Cash acquired On acquisition",
                            "terseLabel":  "Cash acquired from acquisition Prismic Pharmaceuticals Inc.",
                            "verboseLabel":  "Cash acquired from acquisition of Prismic Pharmaceuticals Inc."
                            }
                        }
                    },
                "localname":  "CashAcquiredOnAcquisition",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "huge_CashAcquiredOnAcquisitionTwo":  {
                "auth_ref":  [
                    ],
                "calculation":  {
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS":  {
                        "order":  30.0,
                        "parentTag":  "ifrs-full_CashFlowsFromUsedInInvestingActivitiesContinuingOperations",
                        "weight":  1.0
                        }
                    },
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents amount related to cash inflow during acquisition.",
                            "label":  "Cash Acquired On Acquisition Two",
                            "terseLabel":  "Cash acquired from acquisition of Lucid Psycheceuticals Inc."
                            }
                        }
                    },
                "localname":  "CashAcquiredOnAcquisitionTwo",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "huge_CashProceedsFromIssuanceOfPrivatePlacement":  {
                "auth_ref":  [
                    ],
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "It represents cash proceeds from issuance of private placement.",
                            "label":  "Cash Proceeds From Issuance Of Private Placement",
                            "verboseLabel":  "Cash proceeds from issuance of private placement"
                            }
                        }
                    },
                "localname":  "CashProceedsFromIssuanceOfPrivatePlacement",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/ShareCapitalNarrativeDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "huge_CashReceiptsFromSalesOfDebtInstruments":  {
                "auth_ref":  [
                    ],
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents the amount of cash receipt from sale of debt instrument.",
                            "label":  "Cash Receipts From Sales Of Debt Instruments",
                            "terseLabel":  "Cash receipts from sales of debt instruments"
                            }
                        }
                    },
                "localname":  "CashReceiptsFromSalesOfDebtInstruments",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/NotesPayableNarrativeDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "huge_CertainOtherDirectorsMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "This member stands for certain other directors.",
                            "label":  "Certain Other Directors [Member]",
                            "terseLabel":  "Certain other directors"
                            }
                        }
                    },
                "localname":  "CertainOtherDirectorsMember",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/RelatedPartyTransactionsNarrativeDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_ChangeInFairValueOfInvestmentDueToTenPercentChangeInAssumptionsUsed":  {
                "auth_ref":  [
                    ],
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Change in fair value of investment due to ten percent change in assumptions used.",
                            "label":  "Change In Fair Value Of Investment Due To Ten Percent Change In Assumptions Used",
                            "verboseLabel":  "Change in fair value of investment due to ten percent change in assumptions used"
                            }
                        }
                    },
                "localname":  "ChangeInFairValueOfInvestmentDueToTenPercentChangeInAssumptionsUsed",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/OtherInvestmentsNarrativeDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "huge_ChangeInFairValueThroughProfitOrLossOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod":  {
                "auth_ref":  [
                    ],
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents the amount related to change in fair value through profit or loss of investments other than investments accounted for using equity method.",
                            "label":  "Change in fair value through profit or loss of investments other than investments accounted for using equity method",
                            "verboseLabel":  "Change in fair value through profit or loss"
                            }
                        }
                    },
                "localname":  "ChangeInFairValueThroughProfitOrLossOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/OtherInvestmentsScheduleOfOtherInvestmentsDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "huge_ChangesInNonCashWorkingCapitalItemsAbstract":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "label":  "Changes In Non Cash Working Capital Items Abstract",
                            "terseLabel":  "Changes in non-cash working capital balances"
                            }
                        }
                    },
                "localname":  "ChangesInNonCashWorkingCapitalItemsAbstract",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
                    ],
                "xbrltype":  "stringItemType"
                },
            "huge_ChangesInNoncashWorkingCapitalBalancesAbstract":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "label":  "Changes In Noncash Working Capital Balances [Abstract]",
                            "verboseLabel":  "Changes in non-cash working capital balances"
                            }
                        }
                    },
                "localname":  "ChangesInNoncashWorkingCapitalBalancesAbstract",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/AssetsHeldForSaleDetails2"
                    ],
                "xbrltype":  "stringItemType"
                },
            "huge_ChiefExecutiveOfficersMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "This member stands for chief executive officer.",
                            "label":  "Chief Executive Officers [Member]",
                            "terseLabel":  "Chief Executive Officer",
                            "verboseLabel":  "Raza Bokhari"
                            }
                        }
                    },
                "localname":  "ChiefExecutiveOfficersMember",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CommitmentsAndContingenciesNarrativeDetails",
                    "http://www.fsdpharma.com/role/RelatedPartyTransactionsNarrativeDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_ChiefFinancialOfficersMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "This member stands for chief financial officer.",
                            "label":  "Chief Financial Officers [Member]",
                            "terseLabel":  "Chief Financial Officer"
                            }
                        }
                    },
                "localname":  "ChiefFinancialOfficersMember",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/RelatedPartyTransactionsNarrativeDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_ChiefOperatingConsultantMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Chief Operating Consultant [Member]",
                            "label":  "Chief Operating Consultant [Member]",
                            "verboseLabel":  "Chief Operating Consultant"
                            }
                        }
                    },
                "localname":  "ChiefOperatingConsultantMember",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/RelatedPartyTransactionsNarrativeDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_ClaimForLienComponent":  {
                "auth_ref":  [
                    ],
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents information about claim for lien component.",
                            "label":  "claim for lien component",
                            "terseLabel":  "Claim for lien component"
                            }
                        }
                    },
                "localname":  "ClaimForLienComponent",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CommitmentsAndContingenciesNarrativeDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "huge_ClaimIssuedByContractorForVariousPurportedDamages":  {
                "auth_ref":  [
                    ],
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents information about claim issued by contractor for various purported damages.",
                            "label":  "claim issued by contractor for various purported damages",
                            "verboseLabel":  "Claim issued by contractor for various purported damages"
                            }
                        }
                    },
                "localname":  "ClaimIssuedByContractorForVariousPurportedDamages",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CommitmentsAndContingenciesNarrativeDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "huge_ClaimSettlementAmount":  {
                "auth_ref":  [
                    ],
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents the claim settlement amount.",
                            "label":  "Claim Settlement Amount",
                            "terseLabel":  "Claim Settlement Amount",
                            "verboseLabel":  "Claim settlement amount"
                            }
                        }
                    },
                "localname":  "ClaimSettlementAmount",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CommitmentsAndContingenciesNarrativeDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "huge_ClaimSettlementAmountCoveredByInsurance":  {
                "auth_ref":  [
                    ],
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents amount of claim settlement amount covered by insurance.",
                            "label":  "Claim Settlement Amount Covered By Insurance",
                            "terseLabel":  "Claim settlement amount covered by insurance"
                            }
                        }
                    },
                "localname":  "ClaimSettlementAmountCoveredByInsurance",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CommitmentsAndContingenciesNarrativeDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "huge_ClaimantValue":  {
                "auth_ref":  [
                    ],
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents amount of Claimant value.",
                            "label":  "Claimant Value",
                            "verboseLabel":  "Claimant value"
                            }
                        }
                    },
                "localname":  "ClaimantValue",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CommitmentsAndContingenciesNarrativeDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "huge_ClassACommonStockSharesMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "This member stands for Class A common stock.",
                            "label":  "Class A Common Stock Shares [Member]",
                            "verboseLabel":  "Class A share capital"
                            }
                        }
                    },
                "localname":  "ClassACommonStockSharesMember",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION",
                    "http://www.fsdpharma.com/role/ShareCapitalNarrativeDetails",
                    "http://www.fsdpharma.com/role/ShareCapitalScheduleOfReconciliationOfTheShareCapitalDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_ClassAMultipleVotingSharesMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "This member stands for Class A Multiple Voting Shares.",
                            "label":  "Class A Multiple Voting Shares [Member]",
                            "terseLabel":  "Class A Multiple Voting Shares [Member]"
                            }
                        }
                    },
                "localname":  "ClassAMultipleVotingSharesMember",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/DocumentAndEntityInformation"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_ClassBCommonSharesIssuedForServicesMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "This member stands for Class B Common Shares issued for services.",
                            "label":  "Class B Common Shares Issued For Services [Member]",
                            "terseLabel":  "Class B Common Shares issued for services"
                            }
                        }
                    },
                "localname":  "ClassBCommonSharesIssuedForServicesMember",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/SharebasedCompensationScheduleOfSharebasedCompensationDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_ClassBCommonSharesMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents information of Class B common shares.",
                            "label":  "Class B Common Shares [Member]",
                            "verboseLabel":  "Class B Common Shares"
                            }
                        }
                    },
                "localname":  "ClassBCommonSharesMember",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/SubsequentEventsNarrativeDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_ClassBCommonStockSharesMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents information of class B common stock shares.",
                            "label":  "Class B Common Stock Shares Member",
                            "terseLabel":  "Class B Common Shares issued for compensation",
                            "verboseLabel":  "Class B share capital"
                            }
                        }
                    },
                "localname":  "ClassBCommonStockSharesMember",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION",
                    "http://www.fsdpharma.com/role/OtherInvestmentsNarrativeDetails",
                    "http://www.fsdpharma.com/role/RelatedPartyTransactionsNarrativeDetails",
                    "http://www.fsdpharma.com/role/ShareCapitalNarrativeDetails",
                    "http://www.fsdpharma.com/role/ShareCapitalScheduleOfReconciliationOfTheShareCapitalDetails",
                    "http://www.fsdpharma.com/role/SharebasedCompensationScheduleOfSharebasedCompensationDetails",
                    "http://www.fsdpharma.com/role/WarrantsLiabilityDetailTextuals"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_ClassBVotingSharesMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents Class B subordinate voting shares member.",
                            "label":  "Class B voting shares [Member]",
                            "terseLabel":  "Class B Subordinate Voting Shares [Member]",
                            "verboseLabel":  "Class B subordinate voting shares"
                            }
                        }
                    },
                "localname":  "ClassBVotingSharesMember",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/AcquisitionOfLucidDetailTextuals",
                    "http://www.fsdpharma.com/role/AcquisitionOfPrismicPharmaceuticalNarrativeDetails",
                    "http://www.fsdpharma.com/role/DocumentAndEntityInformation"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_ClassOfStockAxis":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents class of stock.",
                            "label":  "Class Of Stock [Axis]"
                            }
                        }
                    },
                "localname":  "ClassOfStockAxis",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/DocumentAndEntityInformation"
                    ],
                "xbrltype":  "stringItemType"
                },
            "huge_ClassOfStockDomain":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents class of stock.",
                            "label":  "Class Of Stock [Domain]"
                            }
                        }
                    },
                "localname":  "ClassOfStockDomain",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/DocumentAndEntityInformation"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_ClassesOfWarrantsAxis":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents different classes of warrants.",
                            "label":  "Classes of warrants [Axis]"
                            }
                        }
                    },
                "localname":  "ClassesOfWarrantsAxis",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/ShareCapitalNarrativeDetails",
                    "http://www.fsdpharma.com/role/ShareCapitalScheduleOfWarrantsOutstandingAndExercisePriceDetails"
                    ],
                "xbrltype":  "stringItemType"
                },
            "huge_ClassesOfWarrantsDomain":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents the different classes of warrants.",
                            "label":  "Classes of warrants [Domain]"
                            }
                        }
                    },
                "localname":  "ClassesOfWarrantsDomain",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/ShareCapitalNarrativeDetails",
                    "http://www.fsdpharma.com/role/ShareCapitalScheduleOfWarrantsOutstandingAndExercisePriceDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_CloverCannastripThinFilmTechnologiesCorpMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Clover Cannastrip Thin Film Technologies Corp.",
                            "label":  "Clover Cannastrip Thin Film Technologies Corp [Member]",
                            "terseLabel":  "Clover Cannastrip",
                            "verboseLabel":  "Clover Cannastrip Thin Film Technologies Corp."
                            }
                        }
                    },
                "localname":  "CloverCannastripThinFilmTechnologiesCorpMember",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/OtherInvestmentsNarrativeDetails",
                    "http://www.fsdpharma.com/role/OtherInvestmentsScheduleOfOtherInvestmentsDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_CommonStockIssuedForPrivatePlacement":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "It represents common stock issued for private placement.",
                            "label":  "Common Stock Issued For Private Placement",
                            "verboseLabel":  "Common stock issued for private placement"
                            }
                        }
                    },
                "localname":  "CommonStockIssuedForPrivatePlacement",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/ShareCapitalNarrativeDetails"
                    ],
                "xbrltype":  "sharesItemType"
                },
            "huge_ConsultingFeesExpenses":  {
                "auth_ref":  [
                    ],
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Amount of expenses of consulting fees.",
                            "label":  "Consulting Fees Expenses",
                            "terseLabel":  "Consulting fees",
                            "verboseLabel":  "Consulting fees expenses"
                            }
                        }
                    },
                "localname":  "ConsultingFeesExpenses",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/GeneralAndAdministrativeDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "huge_ContingentLiabilityForConstructionAndDevelopmentCostsMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Contingent liability for construction and development costs.",
                            "label":  "Contingent Liability For Construction And Development Costs [Member]",
                            "verboseLabel":  "Contingent liability for construction and development costs"
                            }
                        }
                    },
                "localname":  "ContingentLiabilityForConstructionAndDevelopmentCostsMember",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CommitmentsAndContingenciesNarrativeDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_ConvertibleDebentureMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder.",
                            "label":  "Convertible debenture [Member]",
                            "verboseLabel":  "Convertible debenture"
                            }
                        }
                    },
                "localname":  "ConvertibleDebentureMember",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/OtherInvestmentsScheduleOfOtherInvestmentsDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_ConvertibleNotesMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "This member stands for convertible notes.",
                            "label":  "Convertible Notes [Member]",
                            "verboseLabel":  "Convertible notes"
                            }
                        }
                    },
                "localname":  "ConvertibleNotesMember",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/NotesPayableNarrativeDetails",
                    "http://www.fsdpharma.com/role/NotesPayableScheduleOfNotesPayableDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_CostOrder":  {
                "auth_ref":  [
                    ],
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents amount of cost order.",
                            "label":  "Cost Order",
                            "verboseLabel":  "Cost order"
                            }
                        }
                    },
                "localname":  "CostOrder",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CommitmentsAndContingenciesNarrativeDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "huge_CurrentWarrantsLiability":  {
                "auth_ref":  [
                    ],
                "calculation":  {
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION":  {
                        "order":  40.0,
                        "parentTag":  "ifrs-full_CurrentLiabilities",
                        "weight":  1.0
                        }
                    },
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Amount of warrants liability.",
                            "label":  "Current Warrants Liability",
                            "terseLabel":  "Warrants liability"
                            }
                        }
                    },
                "localname":  "CurrentWarrantsLiability",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "huge_DebtConversionRatio":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents the Debt conversion ratio.",
                            "label":  "Debt conversion ratio"
                            }
                        }
                    },
                "localname":  "DebtConversionRatio",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/OtherInvestmentsNarrativeDetails"
                    ],
                "xbrltype":  "pureItemType"
                },
            "huge_DeductibleTemporaryDifferencesOfCapitalLossesCarriedForwardForWhichNoDeferredTaxAssetIsRecognised":  {
                "auth_ref":  [
                    ],
                "calculation":  {
                    "http://www.fsdpharma.com/role/IncomeTaxesScheduleOfTemporaryDifferencesForWhichDeferredTaxAssetsNotRecognisedDetails":  {
                        "order":  60.0,
                        "parentTag":  "ifrs-full_NetDeferredTaxAssets",
                        "weight":  1.0
                        }
                    },
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "The amount of deductible temporary differences of capital losses carried forward for which no deferred tax asset is recognised in the statement of financial position.",
                            "label":  "Deductible Temporary Differences Of Capital losses carried forward, For Which No Deferred Tax Asset Is Recognised",
                            "verboseLabel":  "Capital losses carried forward"
                            }
                        }
                    },
                "localname":  "DeductibleTemporaryDifferencesOfCapitalLossesCarriedForwardForWhichNoDeferredTaxAssetIsRecognised",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/IncomeTaxesScheduleOfTemporaryDifferencesForWhichDeferredTaxAssetsNotRecognisedDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "huge_DeductibleTemporaryDifferencesOfDomesticNonCapitalLossesCarriedForwardForWhichNoDeferredTaxAssetIsRecognised":  {
                "auth_ref":  [
                    ],
                "calculation":  {
                    "http://www.fsdpharma.com/role/IncomeTaxesScheduleOfTemporaryDifferencesForWhichDeferredTaxAssetsNotRecognisedDetails":  {
                        "order":  50.0,
                        "parentTag":  "ifrs-full_NetDeferredTaxAssets",
                        "weight":  1.0
                        }
                    },
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "The amount of deductible temporary differences of domestic non-capital losses carried forward for which no deferred tax asset is recognised in the statement of financial position.",
                            "label":  "Deductible Temporary Differences Of Domestic Non capital losses carried forward, For Which No Deferred Tax Asset Is Recognised",
                            "terseLabel":  "Net-operating loss - US",
                            "verboseLabel":  "Net operating losses carried forward - US"
                            }
                        }
                    },
                "localname":  "DeductibleTemporaryDifferencesOfDomesticNonCapitalLossesCarriedForwardForWhichNoDeferredTaxAssetIsRecognised",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/IncomeTaxesNarrativeDetails",
                    "http://www.fsdpharma.com/role/IncomeTaxesScheduleOfTemporaryDifferencesForWhichDeferredTaxAssetsNotRecognisedDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "huge_DeductibleTemporaryDifferencesOfForeignNonCapitalLossesCarriedForwardForWhichNoDeferredTaxAssetIsRecognised":  {
                "auth_ref":  [
                    ],
                "calculation":  {
                    "http://www.fsdpharma.com/role/IncomeTaxesScheduleOfTemporaryDifferencesForWhichDeferredTaxAssetsNotRecognisedDetails":  {
                        "order":  20.0,
                        "parentTag":  "ifrs-full_NetDeferredTaxAssets",
                        "weight":  1.0
                        }
                    },
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "The amount of deductible temporary differences of foreign non-capital losses carried forward for which no deferred tax asset is recognised in the statement of financial position.",
                            "label":  "Deductible Temporary Differences Of Foreign Non capital losses carried forward, For Which No Deferred Tax Asset Is Recognised",
                            "verboseLabel":  "Non-capital losses - Canada"
                            }
                        }
                    },
                "localname":  "DeductibleTemporaryDifferencesOfForeignNonCapitalLossesCarriedForwardForWhichNoDeferredTaxAssetIsRecognised",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/IncomeTaxesScheduleOfTemporaryDifferencesForWhichDeferredTaxAssetsNotRecognisedDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "huge_DeductibleTemporaryDifferencesOfForeignUnrealizedForeignExchangeLossCarriedForwardForWhichNoDeferredTaxAssetIsRecognised":  {
                "auth_ref":  [
                    ],
                "calculation":  {
                    "http://www.fsdpharma.com/role/IncomeTaxesScheduleOfTemporaryDifferencesForWhichDeferredTaxAssetsNotRecognisedDetails":  {
                        "order":  30.0,
                        "parentTag":  "ifrs-full_NetDeferredTaxAssets",
                        "weight":  1.0
                        }
                    },
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "It represents deductible temporary differences of foreign unrealized foreign exchange loss carried forward for which no deferred tax asset is recognised.",
                            "label":  "Deductible Temporary Differences Of Foreign Unrealized Foreign Exchange Loss Carried Forward For Which No Deferred Tax Asset Is Recognised",
                            "verboseLabel":  "Unrealized foreign exchange loss"
                            }
                        }
                    },
                "localname":  "DeductibleTemporaryDifferencesOfForeignUnrealizedForeignExchangeLossCarriedForwardForWhichNoDeferredTaxAssetIsRecognised",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/IncomeTaxesScheduleOfTemporaryDifferencesForWhichDeferredTaxAssetsNotRecognisedDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "huge_DeductibleTemporaryDifferencesOfIfrs16ForWhichNoDeferredTaxAssetIsRecognised":  {
                "auth_ref":  [
                    ],
                "calculation":  {
                    "http://www.fsdpharma.com/role/IncomeTaxesScheduleOfTemporaryDifferencesForWhichDeferredTaxAssetsNotRecognisedDetails":  {
                        "order":  0.0,
                        "parentTag":  "ifrs-full_NetDeferredTaxAssets",
                        "weight":  1.0
                        }
                    },
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "The amount of deductible temporary differences of IFRS 16 for which no deferred tax asset is recognised in the statement of financial position.",
                            "label":  "Deductible Temporary Differences Of Ifrs 16 For Which No Deferred Tax Asset Is Recognised",
                            "terseLabel":  "IFRS 16"
                            }
                        }
                    },
                "localname":  "DeductibleTemporaryDifferencesOfIfrs16ForWhichNoDeferredTaxAssetIsRecognised",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/IncomeTaxesScheduleOfTemporaryDifferencesForWhichDeferredTaxAssetsNotRecognisedDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "huge_DeductibleTemporaryDifferencesOfOtherInvestmentsForWhichNoDeferredTaxAssetIsRecognised":  {
                "auth_ref":  [
                    ],
                "calculation":  {
                    "http://www.fsdpharma.com/role/IncomeTaxesScheduleOfTemporaryDifferencesForWhichDeferredTaxAssetsNotRecognisedDetails":  {
                        "order":  40.0,
                        "parentTag":  "ifrs-full_NetDeferredTaxAssets",
                        "weight":  1.0
                        }
                    },
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "The amount of deductible temporary differences of other Investments for which no deferred tax asset is recognised in the statement of financial position.",
                            "label":  "Deductible Temporary Differences Of Other Investments, For Which No Deferred Tax Asset Is Recognised",
                            "verboseLabel":  "Other investments"
                            }
                        }
                    },
                "localname":  "DeductibleTemporaryDifferencesOfOtherInvestmentsForWhichNoDeferredTaxAssetIsRecognised",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/IncomeTaxesScheduleOfTemporaryDifferencesForWhichDeferredTaxAssetsNotRecognisedDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "huge_DeductibleTemporaryDifferencesOfPropertyPlantAndEquipmentForWhichNoDeferredTaxAssetIsRecognised":  {
                "auth_ref":  [
                    ],
                "calculation":  {
                    "http://www.fsdpharma.com/role/IncomeTaxesScheduleOfTemporaryDifferencesForWhichDeferredTaxAssetsNotRecognisedDetails":  {
                        "order":  10.0,
                        "parentTag":  "ifrs-full_NetDeferredTaxAssets",
                        "weight":  1.0
                        }
                    },
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "The amount of deductible temporary differences of Property, plant and equipment for which no deferred tax asset is recognised in the statement of financial position.",
                            "label":  "Deductible Temporary Differences of property, Plant And Equipment, For Which No Deferred Tax Asset Is Recognised",
                            "verboseLabel":  "Property, plant and equipment"
                            }
                        }
                    },
                "localname":  "DeductibleTemporaryDifferencesOfPropertyPlantAndEquipmentForWhichNoDeferredTaxAssetIsRecognised",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/IncomeTaxesScheduleOfTemporaryDifferencesForWhichDeferredTaxAssetsNotRecognisedDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "huge_DeductibleTemporaryDifferencesOfShareIssuanceCostsForWhichNoDeferredTaxAssetIsRecognised":  {
                "auth_ref":  [
                    ],
                "calculation":  {
                    "http://www.fsdpharma.com/role/IncomeTaxesScheduleOfTemporaryDifferencesForWhichDeferredTaxAssetsNotRecognisedDetails":  {
                        "order":  70.0,
                        "parentTag":  "ifrs-full_NetDeferredTaxAssets",
                        "weight":  1.0
                        }
                    },
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "The amount of deductible temporary differences of share issuance costs for which no deferred tax asset is recognised in the statement of financial position.",
                            "label":  "Deductible Temporary Differences Of Share issuance costs, For Which No Deferred Tax Asset Is Recognised",
                            "verboseLabel":  "Share-issuance costs"
                            }
                        }
                    },
                "localname":  "DeductibleTemporaryDifferencesOfShareIssuanceCostsForWhichNoDeferredTaxAssetIsRecognised",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/IncomeTaxesScheduleOfTemporaryDifferencesForWhichDeferredTaxAssetsNotRecognisedDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "huge_DeferredTaxAssetLiabilityNotRecognized":  {
                "auth_ref":  [
                    ],
                "calculation":  {
                    "http://www.fsdpharma.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsLiabilitiesDetails":  {
                        "order":  null,
                        "parentTag":  null,
                        "root":  true,
                        "weight":  null
                        }
                    },
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Deferred tax (asset) / liability not recognized.",
                            "label":  "Deferred tax asset liability not recognized",
                            "negatedLabel":  "Property, plant and equipment",
                            "terseLabel":  "Deferred tax liabilities not recognized",
                            "totalLabel":  "Total"
                            }
                        }
                    },
                "localname":  "DeferredTaxAssetLiabilityNotRecognized",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsLiabilitiesDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "huge_DeferredTaxAssetsOtherInvestments":  {
                "auth_ref":  [
                    ],
                "calculation":  {
                    "http://www.fsdpharma.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsLiabilitiesDetails":  {
                        "order":  0.0,
                        "parentTag":  "huge_DeferredTaxAssetLiabilityNotRecognized",
                        "weight":  -1.0
                        }
                    },
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Amount of other investments.",
                            "label":  "Deferred Tax Assets Other investments",
                            "negatedLabel":  "Other investments",
                            "terseLabel":  "Other investments"
                            }
                        }
                    },
                "localname":  "DeferredTaxAssetsOtherInvestments",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsLiabilitiesDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "huge_DeferredTaxLiabilitiesCapitalLossesCarriedForward":  {
                "auth_ref":  [
                    ],
                "calculation":  {
                    "http://www.fsdpharma.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsLiabilitiesDetails":  {
                        "order":  10.0,
                        "parentTag":  "huge_DeferredTaxAssetLiabilityNotRecognized",
                        "weight":  -1.0
                        }
                    },
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents amount of capital losses carried forward.",
                            "label":  "Deferred Tax Liabilities Capital Losses Carried Forward",
                            "negatedLabel":  "Property, plant and equipment",
                            "terseLabel":  "Capital losses carried forward"
                            }
                        }
                    },
                "localname":  "DeferredTaxLiabilitiesCapitalLossesCarriedForward",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsLiabilitiesDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "huge_DefinitiveSettlementAgreementMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents definitive settlement agreement member.",
                            "label":  "Definitive Settlement Agreement [Member]",
                            "terseLabel":  "Definitive settlement agreement"
                            }
                        }
                    },
                "localname":  "DefinitiveSettlementAgreementMember",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CommitmentsAndContingenciesNarrativeDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_DefinitiveStrategicAllianceAndStreamingAgreementMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Definitive Strategic Alliance and Streaming Agreement.",
                            "label":  "Definitive Strategic Alliance And Streaming Agreement [Member]",
                            "verboseLabel":  "Definitive Strategic Alliance and Streaming Agreement"
                            }
                        }
                    },
                "localname":  "DefinitiveStrategicAllianceAndStreamingAgreementMember",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CommitmentsAndContingenciesNarrativeDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_DepositReceivedForSaleOfAssetsHeldForSale":  {
                "auth_ref":  [
                    ],
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Deposit received for sale of assets held for sale",
                            "label":  "Deposit received for sale of assets held for sale"
                            }
                        }
                    },
                "localname":  "DepositReceivedForSaleOfAssetsHeldForSale",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/AssetsHeldForSaleDetailTextuals"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "huge_DescriptionOfRecentAccountingPronouncementsAdoptedExplanatory":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents description of recent accounting pronouncements adopted policy.",
                            "label":  "Description Of Recent Accounting Pronouncements Adopted Explanatory",
                            "verboseLabel":  "New standards, amendments and interpretations adopted by the Company"
                            }
                        }
                    },
                "localname":  "DescriptionOfRecentAccountingPronouncementsAdoptedExplanatory",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/SignificantAccountingPoliciesPolicies"
                    ],
                "xbrltype":  "textBlockItemType"
                },
            "huge_DescriptionOfVotingRights":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Description of voting rights.",
                            "label":  "Description Of Voting Rights",
                            "verboseLabel":  "Description of voting rights"
                            }
                        }
                    },
                "localname":  "DescriptionOfVotingRights",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/ShareCapitalNarrativeDetails"
                    ],
                "xbrltype":  "stringItemType"
                },
            "huge_DirectorsAndOfficersMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "This member stands for directors and officers.",
                            "label":  "Directors And Officers [Member]",
                            "terseLabel":  "Directors and officers",
                            "verboseLabel":  "Officers and Directors"
                            }
                        }
                    },
                "localname":  "DirectorsAndOfficersMember",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/RelatedPartyTransactionsNarrativeDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_DirectorsMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "This member stands for director's.",
                            "label":  "Directors [Member]",
                            "terseLabel":  "Director"
                            }
                        }
                    },
                "localname":  "DirectorsMember",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/RelatedPartyTransactionsNarrativeDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_DisclosureOfAssetsHeldForSaleAbstract":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "label":  "Disclosure Of Assets Held For Sale [Abstract]"
                            }
                        }
                    },
                "localname":  "DisclosureOfAssetsHeldForSaleAbstract",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "xbrltype":  "stringItemType"
                },
            "huge_DisclosureOfAssetsHeldForSaleLineItems":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Line items represent concepts included in a table.  These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.",
                            "label":  "Disclosure Of Assets Held For Sale [Line Items]"
                            }
                        }
                    },
                "localname":  "DisclosureOfAssetsHeldForSaleLineItems",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/AssetsHeldForSaleDetailTextuals",
                    "http://www.fsdpharma.com/role/AssetsHeldForSaleDetails",
                    "http://www.fsdpharma.com/role/AssetsHeldForSaleDetails1",
                    "http://www.fsdpharma.com/role/AssetsHeldForSaleDetails2"
                    ],
                "xbrltype":  "stringItemType"
                },
            "huge_DisclosureOfAssetsHeldForSaleTable":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Schedule disclosing information related to the assets held for sale.",
                            "label":  "Disclosure Of Assets Held For Sale [Table]"
                            }
                        }
                    },
                "localname":  "DisclosureOfAssetsHeldForSaleTable",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/AssetsHeldForSaleDetailTextuals",
                    "http://www.fsdpharma.com/role/AssetsHeldForSaleDetails",
                    "http://www.fsdpharma.com/role/AssetsHeldForSaleDetails2"
                    ],
                "xbrltype":  "stringItemType"
                },
            "huge_DisclosureOfCapitalManagementAbstract":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "label":  "Disclosure Of Capital Management [Abstract]"
                            }
                        }
                    },
                "localname":  "DisclosureOfCapitalManagementAbstract",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "xbrltype":  "stringItemType"
                },
            "huge_DisclosureOfChangesInWarrantsOutstandingAndWeightedAverageExercisePriceExplanatory":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents the tabular disclosure of changes in warrants outstanding and weighted average exercise price.",
                            "label":  "Disclosure of changes in warrants outstanding and weighted average exercise price explanatory",
                            "verboseLabel":  "Schedule of changes in warrants outstanding and weighted average exercise price"
                            }
                        }
                    },
                "localname":  "DisclosureOfChangesInWarrantsOutstandingAndWeightedAverageExercisePriceExplanatory",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/ShareCapitalTables"
                    ],
                "xbrltype":  "textBlockItemType"
                },
            "huge_DisclosureOfCommitmentsAndContingentLiabilitiesAbstract":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "label":  "Disclosure Of Commitments And Contingent Liabilities [abstract]"
                            }
                        }
                    },
                "localname":  "DisclosureOfCommitmentsAndContingentLiabilitiesAbstract",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "xbrltype":  "stringItemType"
                },
            "huge_DisclosureOfDetailInformationAboutTradeAndOtherReceivablesExplanatory":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "The entire disclosure for trade and other receivables.",
                            "label":  "Disclosure of detail information about trade and other receivables explanatory",
                            "verboseLabel":  "Schedule of other receivables"
                            }
                        }
                    },
                "localname":  "DisclosureOfDetailInformationAboutTradeAndOtherReceivablesExplanatory",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/TradeAndOtherReceivablesTables"
                    ],
                "xbrltype":  "textBlockItemType"
                },
            "huge_DisclosureOfDetailedInformationAboutGeneralAndAdministrativeExpenseExplanatory":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Tabular disclosure of General and administrative expenses.",
                            "label":  "Disclosure Of Detailed Information About General And Administrative Expense Explanatory",
                            "terseLabel":  "General and administrative",
                            "verboseLabel":  "Schedule of general and administrative expense"
                            }
                        }
                    },
                "localname":  "DisclosureOfDetailedInformationAboutGeneralAndAdministrativeExpenseExplanatory",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/GeneralAndAdministrativeTables"
                    ],
                "xbrltype":  "textBlockItemType"
                },
            "huge_DisclosureOfDetailedInformationAboutInvestmentsExplanatory":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents the tabular disclosure of other investments.",
                            "label":  "Disclosure Of Detailed Information About Investments Explanatory",
                            "terseLabel":  "Schedule of investments",
                            "verboseLabel":  "Schedule of interests held in other companies related to cannabis industry"
                            }
                        }
                    },
                "localname":  "DisclosureOfDetailedInformationAboutInvestmentsExplanatory",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/OtherinvestmentsTables"
                    ],
                "xbrltype":  "textBlockItemType"
                },
            "huge_DisclosureOfDetailedInformationAboutRightOfUseAssets":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents information on right of use assets.",
                            "label":  "Disclosure Of Detailed Information About Right Of Use Assets",
                            "verboseLabel":  "Schedule of Right-of-use asset"
                            }
                        }
                    },
                "localname":  "DisclosureOfDetailedInformationAboutRightOfUseAssets",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/RightofuseAssetTables"
                    ],
                "xbrltype":  "textBlockItemType"
                },
            "huge_DisclosureOfDetailedInformationAboutShareOptionsAndWarrantsExplanatory":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "The disclosure of detailed information about Share Options and Warrants.",
                            "label":  "Disclosure Of Detailed Information About Share Options And Warrants Explanatory",
                            "terseLabel":  "Schedule of share options and warrants"
                            }
                        }
                    },
                "localname":  "DisclosureOfDetailedInformationAboutShareOptionsAndWarrantsExplanatory",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/AcquisitionOfLucidTables",
                    "http://www.fsdpharma.com/role/AcquisitionOfPrismicPharmaceuticalTables"
                    ],
                "xbrltype":  "textBlockItemType"
                },
            "huge_DisclosureOfFairValueAssumptionsOfWarrantsOutstandingExplanatory":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents the tabular disclosure of fair value assumption of warrants outstanding.",
                            "label":  "Disclosure Of fair value assumptions of warrants outstanding explanatory",
                            "verboseLabel":  "Schedule of fair value assumptions of warrants outstanding"
                            }
                        }
                    },
                "localname":  "DisclosureOfFairValueAssumptionsOfWarrantsOutstandingExplanatory",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/ShareCapitalTables"
                    ],
                "xbrltype":  "textBlockItemType"
                },
            "huge_DisclosureOfInvestmentsAbstract":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "label":  "Disclosure Of Investments [Abstract]"
                            }
                        }
                    },
                "localname":  "DisclosureOfInvestmentsAbstract",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "xbrltype":  "stringItemType"
                },
            "huge_DisclosureOfInvestmentsLineItems":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "label":  "Disclosure Of Investments [Line Items]"
                            }
                        }
                    },
                "localname":  "DisclosureOfInvestmentsLineItems",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/OtherInvestmentsNarrativeDetails",
                    "http://www.fsdpharma.com/role/OtherInvestmentsScheduleOfOtherInvestmentsDetails"
                    ],
                "xbrltype":  "stringItemType"
                },
            "huge_DisclosureOfInvestmentsTable":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents the tabular information of other investments.",
                            "label":  "Disclosure Of Investments [Table]"
                            }
                        }
                    },
                "localname":  "DisclosureOfInvestmentsTable",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/OtherInvestmentsNarrativeDetails",
                    "http://www.fsdpharma.com/role/OtherInvestmentsScheduleOfOtherInvestmentsDetails"
                    ],
                "xbrltype":  "stringItemType"
                },
            "huge_DisclosureOfNatureOfBusinessAbstract":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents Nature of business abstract.",
                            "label":  "Disclosure of Nature of business [abstract]",
                            "verboseLabel":  "Nature of business"
                            }
                        }
                    },
                "localname":  "DisclosureOfNatureOfBusinessAbstract",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "xbrltype":  "stringItemType"
                },
            "huge_DisclosureOfNatureOfBusinessExplanatoryTextBlock":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents nature of business.",
                            "label":  "Disclosure Of Nature Of Business Explanatory [Text Block]",
                            "verboseLabel":  "Nature of business"
                            }
                        }
                    },
                "localname":  "DisclosureOfNatureOfBusinessExplanatoryTextBlock",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/NatureOfBusiness"
                    ],
                "xbrltype":  "textBlockItemType"
                },
            "huge_DisclosureOfNumberOfWarrantsOutstandingAndExercisePriceExplanatory":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents the tabular disclosure of number of warrants outstanding and exercise price.",
                            "label":  "Disclosure Of number of warrants outstanding and exercise price explanatory",
                            "verboseLabel":  "Schedule of number of warrants outstanding and exercise price"
                            }
                        }
                    },
                "localname":  "DisclosureOfNumberOfWarrantsOutstandingAndExercisePriceExplanatory",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/ShareCapitalTables"
                    ],
                "xbrltype":  "textBlockItemType"
                },
            "huge_DisclosureOfOperatingLeaseObligationsTableTextBlock":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "The disclosure of operating lease obligations.",
                            "label":  "Disclosure Of Operating Lease obligations [Table Text Block]",
                            "verboseLabel":  "Schedule of lease obligations"
                            }
                        }
                    },
                "localname":  "DisclosureOfOperatingLeaseObligationsTableTextBlock",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/LeaseObligationsTables"
                    ],
                "xbrltype":  "textBlockItemType"
                },
            "huge_DisclosureOfPrepaidExpensesAndDepositsExplanatory":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "The disclosure of prepaid expenses and deposits.",
                            "label":  "Disclosure Of Prepaid Expenses And Deposits Explanatory",
                            "terseLabel":  "Schedule of prepaid expenses and deposits"
                            }
                        }
                    },
                "localname":  "DisclosureOfPrepaidExpensesAndDepositsExplanatory",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/PrepaidExpensesAndDepositsTables"
                    ],
                "xbrltype":  "textBlockItemType"
                },
            "huge_DisclosureOfProvisionForIncomeTaxesExplanatory":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents the tabular disclosure of provision for income taxes.",
                            "label":  "Disclosure Of Provision For Income Taxes Explanatory",
                            "verboseLabel":  "Schedule of provision for income taxes"
                            }
                        }
                    },
                "localname":  "DisclosureOfProvisionForIncomeTaxesExplanatory",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/IncometaxesTables"
                    ],
                "xbrltype":  "textBlockItemType"
                },
            "huge_DisclosureOfQuantitiesAvailableToSupplyByFiscalPeriodUnderCommitmentExplanatory":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents the tabular disclosure of quantities available to supply by fiscal period, under the supply commitment.",
                            "label":  "Disclosure Of Quantities Available To Supply By Fiscal Period Under Commitment Explanatory",
                            "verboseLabel":  "Disclosure of quantities available to supply by fiscal period"
                            }
                        }
                    },
                "localname":  "DisclosureOfQuantitiesAvailableToSupplyByFiscalPeriodUnderCommitmentExplanatory",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CommitmentsAndContingenciesTables"
                    ],
                "xbrltype":  "textBlockItemType"
                },
            "huge_DisclosureOfShareBasedCompensationAndWarrantReserveAbstract":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "label":  "Disclosure of Share based compensation and warrant reserve [Abstract]"
                            }
                        }
                    },
                "localname":  "DisclosureOfShareBasedCompensationAndWarrantReserveAbstract",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "xbrltype":  "stringItemType"
                },
            "huge_DisclosureOfShareBasedCompensationExplanatory":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "The entire disclosure for share-based payment arrangements.",
                            "label":  "Disclosure Of Share Based Compensation Explanatory",
                            "terseLabel":  "Schedule of share-based compensation"
                            }
                        }
                    },
                "localname":  "DisclosureOfShareBasedCompensationExplanatory",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/SharebasedCompensationTables"
                    ],
                "xbrltype":  "textBlockItemType"
                },
            "huge_DisclosureOfTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognisedExplanatory":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents the tabular disclosure of temporary differences for which no deferred tax asset is recognised.",
                            "label":  "Disclosure of temporary differences for which no deferred tax asset is recognised explanatory",
                            "verboseLabel":  "Schedule of temporary differences for which no deferred tax asset is recognised"
                            }
                        }
                    },
                "localname":  "DisclosureOfTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognisedExplanatory",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/IncometaxesTables"
                    ],
                "xbrltype":  "textBlockItemType"
                },
            "huge_DisclosureOfTradeAndOtherPayableExplanatory":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "The disclosure of trade and other payables.",
                            "label":  "Disclosure Of Trade And Other Payable Explanatory",
                            "terseLabel":  "Schedule of trade and other payables"
                            }
                        }
                    },
                "localname":  "DisclosureOfTradeAndOtherPayableExplanatory",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/TradeAndOtherPayablesTables"
                    ],
                "xbrltype":  "textBlockItemType"
                },
            "huge_DisclosureOfWarrantLiabilitiesExplanatory":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "The entire disclosure of warrant liabilities.",
                            "label":  "Disclosure Of Warrant Liabilities Explanatory",
                            "verboseLabel":  "Warrants Liability"
                            }
                        }
                    },
                "localname":  "DisclosureOfWarrantLiabilitiesExplanatory",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/WarrantsLiability"
                    ],
                "xbrltype":  "textBlockItemType"
                },
            "huge_DisclosureOfWarrantsLineItems":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Disclosure of warrants",
                            "label":  "Disclosure of warrants [Line Items]"
                            }
                        }
                    },
                "localname":  "DisclosureOfWarrantsLineItems",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/ShareCapitalScheduleOfFairValueAssumptionsOfWarrantsDetails",
                    "http://www.fsdpharma.com/role/ShareCapitalScheduleOfWarrantsOutstandingAndExercisePriceDetails"
                    ],
                "xbrltype":  "stringItemType"
                },
            "huge_DisclosureOfWarrantsTable":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents the tabular information of warrants.",
                            "label":  "Disclosure of warrants [Table]"
                            }
                        }
                    },
                "localname":  "DisclosureOfWarrantsTable",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/ShareCapitalScheduleOfFairValueAssumptionsOfWarrantsDetails",
                    "http://www.fsdpharma.com/role/ShareCapitalScheduleOfWarrantsOutstandingAndExercisePriceDetails"
                    ],
                "xbrltype":  "stringItemType"
                },
            "huge_DiscountOnProceedsOfSharesAndWarrantsSold":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents the percentage for discount on proceeds of shares and warrants sold.",
                            "label":  "Discount on proceeds of shares and warrants sold",
                            "verboseLabel":  "Discount on proceeds of shares and warrants sold"
                            }
                        }
                    },
                "localname":  "DiscountOnProceedsOfSharesAndWarrantsSold",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/OtherInvestmentsNarrativeDetails"
                    ],
                "xbrltype":  "percentItemType"
                },
            "huge_EffectsOfForeignExchangeOnLeaseLiabilities":  {
                "auth_ref":  [
                    ],
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents the effect of foreign exchange on lease liabilities.",
                            "label":  "Effects Of Foreign Exchange On Lease Liabilities",
                            "terseLabel":  "Effects of foreign exchange"
                            }
                        }
                    },
                "localname":  "EffectsOfForeignExchangeOnLeaseLiabilities",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/LeaseObligationsScheduleOfLeaseObligationsDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "huge_EffectsOfForeignExchangeOnRightOfUseAsset":  {
                "auth_ref":  [
                    ],
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents the amount related to effects of foreign exchange on right of use asset.",
                            "label":  "Effects Of Foreign Exchange On Right Of Use Asset",
                            "terseLabel":  "Effects of foreign exchange"
                            }
                        }
                    },
                "localname":  "EffectsOfForeignExchangeOnRightOfUseAsset",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/RightofuseAssetScheduleOfRightofuseAssetDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "huge_EpitechLicenseAgreementMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Epitech License Agreement",
                            "label":  "Epitech License Agreement [Member]",
                            "verboseLabel":  "Epitech License Agreement"
                            }
                        }
                    },
                "localname":  "EpitechLicenseAgreementMember",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CommitmentsAndContingenciesNarrativeDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_EquityDistributionAgreementMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "This member stands for Equity Distribution Agreement.",
                            "label":  "Equity Distribution Agreement [Member]",
                            "verboseLabel":  "Equity distribution agreement"
                            }
                        }
                    },
                "localname":  "EquityDistributionAgreementMember",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/ShareCapitalNarrativeDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_EstimatedCostOfRestorationInCommitment":  {
                "auth_ref":  [
                    ],
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents the amount related to estimated cost of restoration.",
                            "label":  "Estimated cost of restoration in commitment"
                            }
                        }
                    },
                "localname":  "EstimatedCostOfRestorationInCommitment",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CommitmentsAndContingenciesNarrativeDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "huge_ExercisePriceEighteenPointZeroNineMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Exercise price 18.09",
                            "label":  "Exercise Price Eighteen Point Zero Nine [member]",
                            "verboseLabel":  "18.09"
                            }
                        }
                    },
                "localname":  "ExercisePriceEighteenPointZeroNineMember",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/SharebasedCompensationScheduleOfExercisePriceAndWeightedAverageContractualTermOfShareOptionsOutstandingAndExercisableDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_ExercisePriceEightyEightPointFortyFourMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Exercise price 88.44",
                            "label":  "Exercise Price Eighty eight point forty four [Member]",
                            "verboseLabel":  "88.44"
                            }
                        }
                    },
                "localname":  "ExercisePriceEightyEightPointFortyFourMember",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/SharebasedCompensationScheduleOfExercisePriceAndWeightedAverageContractualTermOfShareOptionsOutstandingAndExercisableDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_ExercisePriceEightySixPointFortyThreeMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Exercise price 86.43",
                            "label":  "Exercise Price Eighty Six Point Forty Three [Member]",
                            "verboseLabel":  "86.43"
                            }
                        }
                    },
                "localname":  "ExercisePriceEightySixPointFortyThreeMember",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/SharebasedCompensationScheduleOfExercisePriceAndWeightedAverageContractualTermOfShareOptionsOutstandingAndExercisableDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_ExercisePriceFiftyFivePointTwentyEightMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Exercise price 55.28",
                            "label":  "Exercise Price Fifty Five Point Twenty Eight [Member]",
                            "verboseLabel":  "55.28"
                            }
                        }
                    },
                "localname":  "ExercisePriceFiftyFivePointTwentyEightMember",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/SharebasedCompensationScheduleOfExercisePriceAndWeightedAverageContractualTermOfShareOptionsOutstandingAndExercisableDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_ExercisePriceFiftyNinePointThirtyMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Exercise price 59.30",
                            "label":  "Exercise Price Fifty Nine Point Thirty [Member]",
                            "verboseLabel":  "59.30"
                            }
                        }
                    },
                "localname":  "ExercisePriceFiftyNinePointThirtyMember",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/SharebasedCompensationScheduleOfExercisePriceAndWeightedAverageContractualTermOfShareOptionsOutstandingAndExercisableDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_ExercisePriceFiftyPointTwentyFiveMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Exercise price 50.25",
                            "label":  "Exercise Price Fifty Point Twenty Five [Member]",
                            "verboseLabel":  "50.25"
                            }
                        }
                    },
                "localname":  "ExercisePriceFiftyPointTwentyFiveMember",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/SharebasedCompensationScheduleOfExercisePriceAndWeightedAverageContractualTermOfShareOptionsOutstandingAndExercisableDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_ExercisePriceFiftySixPointTwentyEightMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Exercise price 56.28",
                            "label":  "Exercise price Fifty Six Point Twenty Eight [Member]",
                            "verboseLabel":  "56.28"
                            }
                        }
                    },
                "localname":  "ExercisePriceFiftySixPointTwentyEightMember",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/SharebasedCompensationScheduleOfExercisePriceAndWeightedAverageContractualTermOfShareOptionsOutstandingAndExercisableDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_ExercisePriceFiftyTwoPointTwentySixMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Exercise price 52.26",
                            "label":  "Exercise Price Fifty Two Point Twenty Six [Member]",
                            "verboseLabel":  "52.26"
                            }
                        }
                    },
                "localname":  "ExercisePriceFiftyTwoPointTwentySixMember",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/SharebasedCompensationScheduleOfExercisePriceAndWeightedAverageContractualTermOfShareOptionsOutstandingAndExercisableDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_ExercisePriceFivePointFourThreeMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Exercise price 5.43",
                            "label":  "Exercise Price Five Point Four Three [Member]",
                            "verboseLabel":  "5.43"
                            }
                        }
                    },
                "localname":  "ExercisePriceFivePointFourThreeMember",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/SharebasedCompensationScheduleOfExercisePriceAndWeightedAverageContractualTermOfShareOptionsOutstandingAndExercisableDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_ExercisePriceFivePointZeroThreeMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Exercise price 5.03",
                            "label":  "Exercise price Five Point Zero Three [Member]",
                            "verboseLabel":  "5.03"
                            }
                        }
                    },
                "localname":  "ExercisePriceFivePointZeroThreeMember",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/SharebasedCompensationScheduleOfExercisePriceAndWeightedAverageContractualTermOfShareOptionsOutstandingAndExercisableDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_ExercisePriceFortyFourPointTwentyTwoMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Exercise price 44.22",
                            "label":  "Exercise Price Forty Four Point Twenty Two [Member]",
                            "verboseLabel":  "44.22"
                            }
                        }
                    },
                "localname":  "ExercisePriceFortyFourPointTwentyTwoMember",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/SharebasedCompensationScheduleOfExercisePriceAndWeightedAverageContractualTermOfShareOptionsOutstandingAndExercisableDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_ExercisePriceFortyPointTwentyMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Exercise price 40.20",
                            "label":  "Exercise Price Forty Point Twenty [Member]",
                            "verboseLabel":  "40.20"
                            }
                        }
                    },
                "localname":  "ExercisePriceFortyPointTwentyMember",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/SharebasedCompensationScheduleOfExercisePriceAndWeightedAverageContractualTermOfShareOptionsOutstandingAndExercisableDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_ExercisePriceFortySevenPointTwentyFourMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Exercise price 47.24",
                            "label":  "Exercise Price Forty Seven Point Twenty Four [member]",
                            "verboseLabel":  "47.24"
                            }
                        }
                    },
                "localname":  "ExercisePriceFortySevenPointTwentyFourMember",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/SharebasedCompensationScheduleOfExercisePriceAndWeightedAverageContractualTermOfShareOptionsOutstandingAndExercisableDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_ExercisePriceFourPointFourTwoMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Exercise price 4.42",
                            "label":  "Exercise Price Four Point Four Two [Member]",
                            "verboseLabel":  "4.42"
                            }
                        }
                    },
                "localname":  "ExercisePriceFourPointFourTwoMember",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/SharebasedCompensationScheduleOfExercisePriceAndWeightedAverageContractualTermOfShareOptionsOutstandingAndExercisableDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_ExercisePriceFourPointSevenFiveMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Exercise price 4.75",
                            "label":  "Exercise Price Four Point Seven Five [Member]",
                            "verboseLabel":  "4.75"
                            }
                        }
                    },
                "localname":  "ExercisePriceFourPointSevenFiveMember",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/SharebasedCompensationScheduleOfExercisePriceAndWeightedAverageContractualTermOfShareOptionsOutstandingAndExercisableDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_ExercisePriceNinePointFiveFourMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Exercise price 9.54",
                            "label":  "Exercise Price Nine Point Five Four [Member]",
                            "verboseLabel":  "9.54"
                            }
                        }
                    },
                "localname":  "ExercisePriceNinePointFiveFourMember",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/SharebasedCompensationScheduleOfExercisePriceAndWeightedAverageContractualTermOfShareOptionsOutstandingAndExercisableDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_ExercisePriceOfWarrantIssue":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "It represents exercise price of warrant issue.",
                            "label":  "Exercise Price Of Warrant Issue",
                            "verboseLabel":  "Exercise price of warrant issue"
                            }
                        }
                    },
                "localname":  "ExercisePriceOfWarrantIssue",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/ShareCapitalNarrativeDetails",
                    "http://www.fsdpharma.com/role/WarrantsLiabilityDetailTextuals"
                    ],
                "xbrltype":  "perShareItemType"
                },
            "huge_ExercisePriceOfWarrants":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents the price per share of excercise price of warrants.",
                            "label":  "Exercise price of warrants"
                            }
                        }
                    },
                "localname":  "ExercisePriceOfWarrants",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/OtherInvestmentsNarrativeDetails"
                    ],
                "xbrltype":  "perShareItemType"
                },
            "huge_ExercisePriceOfWarrantsGranted":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents the exercise price of warrants granted.",
                            "label":  "Exercise price of warrants granted",
                            "terseLabel":  "Exercise price",
                            "verboseLabel":  "Warrants exercise price"
                            }
                        }
                    },
                "localname":  "ExercisePriceOfWarrantsGranted",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/AcquisitionOfLucidDetails",
                    "http://www.fsdpharma.com/role/AcquisitionOfPrismicPharmaceuticalScheduleOfBlackScholesOptionsPricingModelDetails",
                    "http://www.fsdpharma.com/role/ShareCapitalNarrativeDetails",
                    "http://www.fsdpharma.com/role/ShareCapitalScheduleOfFairValueAssumptionsOfWarrantsDetails"
                    ],
                "xbrltype":  "perShareItemType"
                },
            "huge_ExercisePriceOfWarrantsLiability":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "It represents exercise price of warrants liability.",
                            "label":  "Exercise Price Of Warrants Liability"
                            }
                        }
                    },
                "localname":  "ExercisePriceOfWarrantsLiability",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/WarrantsLiabilityDetailTextuals"
                    ],
                "xbrltype":  "perShareItemType"
                },
            "huge_ExercisePriceOneHundredFortyEightPointSeventyFourMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Exercise price 148.74",
                            "label":  "Exercise Price One Hundred Forty Eight Point Seventy Four [Member]",
                            "terseLabel":  "148.74"
                            }
                        }
                    },
                "localname":  "ExercisePriceOneHundredFortyEightPointSeventyFourMember",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/SharebasedCompensationScheduleOfExercisePriceAndWeightedAverageContractualTermOfShareOptionsOutstandingAndExercisableDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_ExercisePriceOneHundredFortyTwoPointSeventyOneMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Exercise price 142.71",
                            "label":  "Exercise Price One Hundred Forty Two Point Seventy One [Member]",
                            "verboseLabel":  "142.71"
                            }
                        }
                    },
                "localname":  "ExercisePriceOneHundredFortyTwoPointSeventyOneMember",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/SharebasedCompensationScheduleOfExercisePriceAndWeightedAverageContractualTermOfShareOptionsOutstandingAndExercisableDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_ExercisePriceOneHundredTwentyPointSixtyMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Exercise price 120.60",
                            "label":  "Exercise Price One Hundred Twenty Point Sixty [Member]",
                            "verboseLabel":  "120.60"
                            }
                        }
                    },
                "localname":  "ExercisePriceOneHundredTwentyPointSixtyMember",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/SharebasedCompensationScheduleOfExercisePriceAndWeightedAverageContractualTermOfShareOptionsOutstandingAndExercisableDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_ExercisePriceSevenPointFiftyMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Exercise price 7.50",
                            "label":  "Exercise Price Seven Point Fifty [member]",
                            "verboseLabel":  "7.50"
                            }
                        }
                    },
                "localname":  "ExercisePriceSevenPointFiftyMember",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/SharebasedCompensationScheduleOfExercisePriceAndWeightedAverageContractualTermOfShareOptionsOutstandingAndExercisableDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_ExercisePriceSevenPointSeventeenMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Exercise price 7.17",
                            "label":  "Exercise Price Seven Point Seventeen [Member]",
                            "verboseLabel":  "7.17"
                            }
                        }
                    },
                "localname":  "ExercisePriceSevenPointSeventeenMember",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/SharebasedCompensationScheduleOfExercisePriceAndWeightedAverageContractualTermOfShareOptionsOutstandingAndExercisableDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_ExercisePriceSevenPointSixtyThreeMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Exercise price 7.63",
                            "label":  "Exercise price Seven Point Sixty Three [Member]",
                            "verboseLabel":  "7.63"
                            }
                        }
                    },
                "localname":  "ExercisePriceSevenPointSixtyThreeMember",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/SharebasedCompensationScheduleOfExercisePriceAndWeightedAverageContractualTermOfShareOptionsOutstandingAndExercisableDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_ExercisePriceSevenPointZeroZeroMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Exercise price 7.00",
                            "label":  "Exercise Price Seven Point Zero Zero [Member]",
                            "verboseLabel":  "7.00"
                            }
                        }
                    },
                "localname":  "ExercisePriceSevenPointZeroZeroMember",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/SharebasedCompensationScheduleOfExercisePriceAndWeightedAverageContractualTermOfShareOptionsOutstandingAndExercisableDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_ExercisePriceSeventeenPointEightNineMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Exercise price 17.89",
                            "label":  "Exercise Price Seventeen Point Eight Nine [Member]",
                            "verboseLabel":  "17.89"
                            }
                        }
                    },
                "localname":  "ExercisePriceSeventeenPointEightNineMember",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/SharebasedCompensationScheduleOfExercisePriceAndWeightedAverageContractualTermOfShareOptionsOutstandingAndExercisableDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_ExercisePriceSeventyFivePointThirtyEightMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Exercise price 75.38",
                            "label":  "Exercise price seventy five point thirty eight [Member]",
                            "verboseLabel":  "75.38"
                            }
                        }
                    },
                "localname":  "ExercisePriceSeventyFivePointThirtyEightMember",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/SharebasedCompensationScheduleOfExercisePriceAndWeightedAverageContractualTermOfShareOptionsOutstandingAndExercisableDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_ExercisePriceSeventyOnePointZeroSevenMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Exercise price 71.07",
                            "label":  "Exercise Price Seventy One Point Zero Seven [Member]",
                            "verboseLabel":  "71.07"
                            }
                        }
                    },
                "localname":  "ExercisePriceSeventyOnePointZeroSevenMember",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/SharebasedCompensationScheduleOfExercisePriceAndWeightedAverageContractualTermOfShareOptionsOutstandingAndExercisableDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_ExercisePriceSixPointSixteenMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Exercise price 6.16",
                            "label":  "Exercise Price Six Point Sixteen [Member]",
                            "verboseLabel":  "6.16"
                            }
                        }
                    },
                "localname":  "ExercisePriceSixPointSixteenMember",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/SharebasedCompensationScheduleOfExercisePriceAndWeightedAverageContractualTermOfShareOptionsOutstandingAndExercisableDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_ExercisePriceSixteenPointZeroEightMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Exercise price 16.08",
                            "label":  "Exercise Price Sixteen Point Zero Eight [Member]",
                            "verboseLabel":  "16.08"
                            }
                        }
                    },
                "localname":  "ExercisePriceSixteenPointZeroEightMember",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/SharebasedCompensationScheduleOfExercisePriceAndWeightedAverageContractualTermOfShareOptionsOutstandingAndExercisableDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_ExercisePriceSixtyEightPointZeroOneMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Exercise price 68.01",
                            "label":  "Exercise Price Sixty Eight Point Zero One [Member]",
                            "verboseLabel":  "68.01"
                            }
                        }
                    },
                "localname":  "ExercisePriceSixtyEightPointZeroOneMember",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/SharebasedCompensationScheduleOfExercisePriceAndWeightedAverageContractualTermOfShareOptionsOutstandingAndExercisableDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_ExercisePriceTenPointSixFiveMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Exercise price 10.65",
                            "label":  "Exercise Price Ten point six five [Member]",
                            "terseLabel":  "10.65"
                            }
                        }
                    },
                "localname":  "ExercisePriceTenPointSixFiveMember",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/SharebasedCompensationScheduleOfExercisePriceAndWeightedAverageContractualTermOfShareOptionsOutstandingAndExercisableDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_ExercisePriceThirteenPointFourSevenMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Exercise price 13.47",
                            "label":  "Exercise Price Thirteen Point Four Seven [Member]",
                            "verboseLabel":  "13.47"
                            }
                        }
                    },
                "localname":  "ExercisePriceThirteenPointFourSevenMember",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/SharebasedCompensationScheduleOfExercisePriceAndWeightedAverageContractualTermOfShareOptionsOutstandingAndExercisableDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_ExercisePriceThirteenPointZeroSevenMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Exercise price 13.07",
                            "label":  "Exercise Price Thirteen Point Zero Seven [Member]",
                            "verboseLabel":  "13.07"
                            }
                        }
                    },
                "localname":  "ExercisePriceThirteenPointZeroSevenMember",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/SharebasedCompensationScheduleOfExercisePriceAndWeightedAverageContractualTermOfShareOptionsOutstandingAndExercisableDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_ExercisePriceThreePointEightSixMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Exercise price 3.86",
                            "label":  "Exercise Price Three Point Eight Six [Member]",
                            "verboseLabel":  "3.86"
                            }
                        }
                    },
                "localname":  "ExercisePriceThreePointEightSixMember",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/SharebasedCompensationScheduleOfExercisePriceAndWeightedAverageContractualTermOfShareOptionsOutstandingAndExercisableDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_ExercisePriceThreePointSevenFiveMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Exercise price 3.75",
                            "label":  "Exercise Price Three Point Seven Five [Member]",
                            "verboseLabel":  "3.75"
                            }
                        }
                    },
                "localname":  "ExercisePriceThreePointSevenFiveMember",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/SharebasedCompensationScheduleOfExercisePriceAndWeightedAverageContractualTermOfShareOptionsOutstandingAndExercisableDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_ExercisePriceTwentyFourPointTwelveMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "24.12",
                            "label":  "Exercise price Twenty Four Point Twelve [Member]",
                            "verboseLabel":  "24.12"
                            }
                        }
                    },
                "localname":  "ExercisePriceTwentyFourPointTwelveMember",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/SharebasedCompensationScheduleOfExercisePriceAndWeightedAverageContractualTermOfShareOptionsOutstandingAndExercisableDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_ExercisePriceTwentyOnePointElevenMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Exercise price 21.11",
                            "label":  "Exercise Price Twenty One Point Eleven [Member]",
                            "verboseLabel":  "21.11"
                            }
                        }
                    },
                "localname":  "ExercisePriceTwentyOnePointElevenMember",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/SharebasedCompensationScheduleOfExercisePriceAndWeightedAverageContractualTermOfShareOptionsOutstandingAndExercisableDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_ExercisePriceTwentyOnePointNinetyOneMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Exercise price 21.91",
                            "label":  "Exercise Price Twenty One Point Ninety One [Member]",
                            "verboseLabel":  "21.91"
                            }
                        }
                    },
                "localname":  "ExercisePriceTwentyOnePointNinetyOneMember",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/SharebasedCompensationScheduleOfExercisePriceAndWeightedAverageContractualTermOfShareOptionsOutstandingAndExercisableDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_ExercisePriceTwentyOnePointTwentyTwoMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Exercise price 21.22",
                            "label":  "Exercise Price Twenty One Point Twenty Two [Member]",
                            "verboseLabel":  "21.22"
                            }
                        }
                    },
                "localname":  "ExercisePriceTwentyOnePointTwentyTwoMember",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/SharebasedCompensationScheduleOfExercisePriceAndWeightedAverageContractualTermOfShareOptionsOutstandingAndExercisableDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_ExercisePriceTwentyPointOneZeroMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Exercise price 20.10",
                            "label":  "Exercise Price Twenty Point One Zero [Member]",
                            "verboseLabel":  "20.10"
                            }
                        }
                    },
                "localname":  "ExercisePriceTwentyPointOneZeroMember",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/SharebasedCompensationScheduleOfExercisePriceAndWeightedAverageContractualTermOfShareOptionsOutstandingAndExercisableDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_ExercisePriceTwentySixPointThirteenMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Exercise price 26.13",
                            "label":  "Exercise price Twenty Six Point Thirteen [Member]",
                            "verboseLabel":  "26.13"
                            }
                        }
                    },
                "localname":  "ExercisePriceTwentySixPointThirteenMember",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/SharebasedCompensationScheduleOfExercisePriceAndWeightedAverageContractualTermOfShareOptionsOutstandingAndExercisableDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_ExercisePriceTwoPointSixOneMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Exercise price 2.61",
                            "label":  "Exercise Price Two Point Six One [Member]",
                            "verboseLabel":  "2.61"
                            }
                        }
                    },
                "localname":  "ExercisePriceTwoPointSixOneMember",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/SharebasedCompensationScheduleOfExercisePriceAndWeightedAverageContractualTermOfShareOptionsOutstandingAndExercisableDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_ExpectedDividendYieldOfWarrants":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Expected dividend yield of warrants.",
                            "label":  "Expected Dividend Yield Of Warrants",
                            "verboseLabel":  "Expected dividend yield"
                            }
                        }
                    },
                "localname":  "ExpectedDividendYieldOfWarrants",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/OtherInvestmentsNarrativeDetails"
                    ],
                "xbrltype":  "percentItemType"
                },
            "huge_ExpectedDividendYieldOfWarrantsGranted":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents expected dividend yield of warrants granted.",
                            "label":  "Expected dividend yield of warrants granted",
                            "terseLabel":  "Expected dividend yield"
                            }
                        }
                    },
                "localname":  "ExpectedDividendYieldOfWarrantsGranted",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/AcquisitionOfLucidDetails",
                    "http://www.fsdpharma.com/role/AcquisitionOfPrismicPharmaceuticalScheduleOfBlackScholesOptionsPricingModelDetails",
                    "http://www.fsdpharma.com/role/ShareCapitalScheduleOfFairValueAssumptionsOfWarrantsDetails"
                    ],
                "xbrltype":  "percentItemType"
                },
            "huge_ExpectedLifeOfWarrants":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents expected life of warrants.",
                            "label":  "Expected life of warrants",
                            "terseLabel":  "Expected life (years)"
                            }
                        }
                    },
                "localname":  "ExpectedLifeOfWarrants",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/AcquisitionOfLucidDetails",
                    "http://www.fsdpharma.com/role/AcquisitionOfPrismicPharmaceuticalScheduleOfBlackScholesOptionsPricingModelDetails",
                    "http://www.fsdpharma.com/role/ShareCapitalScheduleOfFairValueAssumptionsOfWarrantsDetails",
                    "http://www.fsdpharma.com/role/WarrantsLiabilityDetailTextuals"
                    ],
                "xbrltype":  "durationItemType"
                },
            "huge_ExpectedTermOfWarrants":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents the expected term of warrants.",
                            "label":  "Expected Term Of Warrants",
                            "verboseLabel":  "Expected term of warrants"
                            }
                        }
                    },
                "localname":  "ExpectedTermOfWarrants",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/OtherInvestmentsNarrativeDetails"
                    ],
                "xbrltype":  "durationItemType"
                },
            "huge_ExpectedVolatilityOfWarrants":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents expected volatility of warrants.",
                            "label":  "Expected Volatility Of Warrants",
                            "terseLabel":  "Expected volatility of warrants",
                            "verboseLabel":  "Expected Volatility Range"
                            }
                        }
                    },
                "localname":  "ExpectedVolatilityOfWarrants",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/OtherInvestmentsNarrativeDetails"
                    ],
                "xbrltype":  "percentItemType"
                },
            "huge_ExpectedVolatilityOfWarrantsGranted":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents expected volatility of warrants granted.",
                            "label":  "Expected volatility of warrants granted",
                            "terseLabel":  "Annualized volatility",
                            "verboseLabel":  "Warrants annualized volatility"
                            }
                        }
                    },
                "localname":  "ExpectedVolatilityOfWarrantsGranted",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/AcquisitionOfLucidDetails",
                    "http://www.fsdpharma.com/role/AcquisitionOfPrismicPharmaceuticalScheduleOfBlackScholesOptionsPricingModelDetails",
                    "http://www.fsdpharma.com/role/ShareCapitalNarrativeDetails",
                    "http://www.fsdpharma.com/role/ShareCapitalScheduleOfFairValueAssumptionsOfWarrantsDetails",
                    "http://www.fsdpharma.com/role/WarrantsLiabilityDetailTextuals"
                    ],
                "xbrltype":  "percentItemType"
                },
            "huge_ExternalResearchAndDevelopmentFeesPayable":  {
                "auth_ref":  [
                    ],
                "calculation":  {
                    "http://www.fsdpharma.com/role/TradeAndOtherPayablesDetails1":  {
                        "order":  50.0,
                        "parentTag":  "ifrs-full_AccrualsClassifiedAsCurrent",
                        "weight":  1.0
                        }
                    },
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represent the amount of accrued external research and development fees payable.",
                            "label":  "External Research And Development Fees Payable",
                            "terseLabel":  "External research and development fees"
                            }
                        }
                    },
                "localname":  "ExternalResearchAndDevelopmentFeesPayable",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/TradeAndOtherPayablesDetails1"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "huge_FSDBiosciencesEmployeesMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "FSD Biosciences Employees",
                            "label":  "F S D Biosciences Employees [Member]",
                            "verboseLabel":  "FSD Biosciences Employees"
                            }
                        }
                    },
                "localname":  "FSDBiosciencesEmployeesMember",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CommitmentsAndContingenciesNarrativeDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_FSDBiosciencesMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "FSD Biosciences [Member]",
                            "label":  "F S D Biosciences [Member]",
                            "verboseLabel":  "FSD Biosciences"
                            }
                        }
                    },
                "localname":  "FSDBiosciencesMember",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/RelatedPartyTransactionsNarrativeDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_FailedToPayForServices":  {
                "auth_ref":  [
                    ],
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents failed to pay for services.",
                            "label":  "Failed To Pay For Services",
                            "verboseLabel":  "Failed to pay for services"
                            }
                        }
                    },
                "localname":  "FailedToPayForServices",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CommitmentsAndContingenciesNarrativeDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "huge_FairValueAdjustmentsOnInventorySold":  {
                "auth_ref":  [
                    ],
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents amount of Fair value adjustments on inventory sold.",
                            "label":  "Fair value adjustments on inventory sold",
                            "negatedLabel":  "Fair value adjustments on inventory sold",
                            "verboseLabel":  "Fair value adjustments on inventory sold"
                            }
                        }
                    },
                "localname":  "FairValueAdjustmentsOnInventorySold",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/AssetsHeldForSaleDetails1"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "huge_FairValueOfCommonSharesIssued":  {
                "auth_ref":  [
                    ],
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "label":  "Fair Value Of Common Shares Issued",
                            "verboseLabel":  "Fair value of common shares issued"
                            }
                        }
                    },
                "localname":  "FairValueOfCommonSharesIssued",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/ShareCapitalNarrativeDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "huge_FairValueOfCommonStockToSettleNotesPayable":  {
                "auth_ref":  [
                    ],
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents amount of fair value of common stock to settle notes payable.",
                            "label":  "Fair Value Of Common Stock To Settle Notes Payable",
                            "verboseLabel":  "Fair value of common stock to settle notes payable"
                            }
                        }
                    },
                "localname":  "FairValueOfCommonStockToSettleNotesPayable",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/NotesPayableNarrativeDetails",
                    "http://www.fsdpharma.com/role/ShareCapitalNarrativeDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "huge_FairValueOfShareBasedCompensationBonus":  {
                "auth_ref":  [
                    ],
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents amount of fair value of share based compensation bonus.",
                            "label":  "Fair Value Of Share Based Compensation Bonus",
                            "verboseLabel":  "Fair value of share-based compensation bonus"
                            }
                        }
                    },
                "localname":  "FairValueOfShareBasedCompensationBonus",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/ShareCapitalNarrativeDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "huge_FairValueOfShares":  {
                "auth_ref":  [
                    ],
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents the amount related to fair value of shares.",
                            "label":  "Fair Value Of Shares",
                            "terseLabel":  "Fair value of shares issued",
                            "verboseLabel":  "Fair value of shares"
                            }
                        }
                    },
                "localname":  "FairValueOfShares",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/OtherInvestmentsNarrativeDetails",
                    "http://www.fsdpharma.com/role/ShareCapitalNarrativeDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "huge_FairValueOfSharesAndWarrantsAcquired":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents the fair value of shares and warrants acquired.",
                            "label":  "Fair Value Of Shares And Warrants acquired",
                            "verboseLabel":  "Fair value of shares and warrants acquired"
                            }
                        }
                    },
                "localname":  "FairValueOfSharesAndWarrantsAcquired",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/OtherInvestmentsNarrativeDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "huge_FairValueOfWarrantLiability":  {
                "auth_ref":  [
                    ],
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "It represents fair value of warrant liability.",
                            "label":  "Fair Value Of Warrant Liability",
                            "verboseLabel":  "Fair value of warrant liability"
                            }
                        }
                    },
                "localname":  "FairValueOfWarrantLiability",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/ShareCapitalNarrativeDetails",
                    "http://www.fsdpharma.com/role/WarrantsLiabilityDetailTextuals"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "huge_FairValueOfWarrantLiabilityOfResidualAmount":  {
                "auth_ref":  [
                    ],
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "It represents fair value of warrant liability of residual amount.",
                            "label":  "Fair Value Of Warrant Liability Of Residual Amount",
                            "verboseLabel":  "Fair value of warrant liability of residual amount"
                            }
                        }
                    },
                "localname":  "FairValueOfWarrantLiabilityOfResidualAmount",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/ShareCapitalNarrativeDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "huge_FairValueOfWarrants":  {
                "auth_ref":  [
                    ],
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents fair value of warrants.",
                            "label":  "Fair Value Of Warrants",
                            "terseLabel":  "Fair Values",
                            "verboseLabel":  "Fair value of warrants"
                            }
                        }
                    },
                "localname":  "FairValueOfWarrants",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/OtherInvestmentsNarrativeDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "huge_FairValueOfWarrantsIssued":  {
                "auth_ref":  [
                    ],
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents amount of fair value of warrants issued.",
                            "label":  "Fair Value Of Warrants Issued",
                            "verboseLabel":  "Fair value of warrants issued"
                            }
                        }
                    },
                "localname":  "FairValueOfWarrantsIssued",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/ShareCapitalNarrativeDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "huge_FormerChiefExecutiveOfficerMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents information about former chief executive officer.",
                            "label":  "Former Chief executive Officer [Member]",
                            "verboseLabel":  "Former CEO"
                            }
                        }
                    },
                "localname":  "FormerChiefExecutiveOfficerMember",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/RelatedPartyTransactionsNarrativeDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_FormerChiefOperatingOfficerMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "This members stands for former chief operating officer.",
                            "label":  "Former Chief Operating Officer [Member]",
                            "terseLabel":  "Former Chief Operating Officer"
                            }
                        }
                    },
                "localname":  "FormerChiefOperatingOfficerMember",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/RelatedPartyTransactionsNarrativeDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_FundsPaidForSettlementAgreement":  {
                "auth_ref":  [
                    ],
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents the amount of fund paid for the Settlement Agreement.",
                            "label":  "Funds Paid For Settlement Agreement",
                            "terseLabel":  "Funds paid for settlement agreement"
                            }
                        }
                    },
                "localname":  "FundsPaidForSettlementAgreement",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CommitmentsAndContingenciesNarrativeDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "huge_FvPharmaIncMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents information for FV Pharma Inc.",
                            "label":  "Fv Pharma Inc [Member]",
                            "terseLabel":  "FV Pharma Inc"
                            }
                        }
                    },
                "localname":  "FvPharmaIncMember",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CommitmentsAndContingenciesScheduleOfQuantitiesOfCannabisAvailableToSupplyByFiscalPeriodDetails",
                    "http://www.fsdpharma.com/role/RelatedPartyTransactionsNarrativeDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_GainLossOnSettlementOfFinancialLiability":  {
                "auth_ref":  [
                    ],
                "calculation":  {
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS":  {
                        "order":  20.0,
                        "parentTag":  "ifrs-full_ProfitLossFromContinuingOperations",
                        "weight":  1.0
                        }
                    },
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents amount of gain loss on settlement of financial liability.",
                            "label":  "Gain Loss On Settlement Of Financial Liability",
                            "negatedLabel":  "Loss (gain) on settlement of financial liability",
                            "netLabel":  "Gain (loss) on settlement of financial liability",
                            "terseLabel":  "Loss (gain) on settlement of financial liability",
                            "verboseLabel":  "Gain on settlement of financial liability"
                            }
                        }
                    },
                "localname":  "GainLossOnSettlementOfFinancialLiability",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS",
                    "http://www.fsdpharma.com/role/ShareCapitalNarrativeDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "huge_GainOnSettlementOfDerivativeLiability":  {
                "auth_ref":  [
                    ],
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Gain on settlement of derivative liability.",
                            "label":  "Gain On Settlement Of Derivative Liability",
                            "verboseLabel":  "Gain on settlement of derivative liability"
                            }
                        }
                    },
                "localname":  "GainOnSettlementOfDerivativeLiability",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/OtherInvestmentsNarrativeDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "huge_GainOnSettlementOfFinancialLiability":  {
                "auth_ref":  [
                    ],
                "calculation":  {
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS":  {
                        "order":  50.0,
                        "parentTag":  "ifrs-full_CashFlowsFromUsedInOperatingActivitiesContinuingOperations",
                        "weight":  -1.0
                        }
                    },
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents amount of gain on settlement of financial liability.",
                            "label":  "Gain On Settlement Of Financial Liability",
                            "negatedLabel":  "Loss (gain) on settlement of financial liability",
                            "terseLabel":  "Loss on settlement of financial liability",
                            "verboseLabel":  "Gain on settlement of financial liability"
                            }
                        }
                    },
                "localname":  "GainOnSettlementOfFinancialLiability",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
                    "http://www.fsdpharma.com/role/NotesPayableNarrativeDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "huge_GeneralAndAdministrativeExpenseContinuedAndDiscontinuedOperations":  {
                "auth_ref":  [
                    ],
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents amount of general and administrative expense continued and discontinued operations.",
                            "label":  "General And Administrative Expense Continued And Discontinued Operations",
                            "verboseLabel":  "General and administrative"
                            }
                        }
                    },
                "localname":  "GeneralAndAdministrativeExpenseContinuedAndDiscontinuedOperations",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/GeneralAndAdministrativeDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "huge_GeneralAndAdministrativeExpenseDiscontinuedOperations":  {
                "auth_ref":  [
                    ],
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents amount of general and administrative expense discontinued operations",
                            "label":  "General And Administrative Expense Discontinued Operations",
                            "verboseLabel":  "Discontinued operations"
                            }
                        }
                    },
                "localname":  "GeneralAndAdministrativeExpenseDiscontinuedOperations",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/GeneralAndAdministrativeDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "huge_GeneralOfficeInsuranceAndAdministrationExpenditures":  {
                "auth_ref":  [
                    ],
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "The amount of expense arising from general office, insurance and administration expenditures.",
                            "label":  "General Office Insurance And Administration Expenditures",
                            "verboseLabel":  "General office, insurance and administration expenditures"
                            }
                        }
                    },
                "localname":  "GeneralOfficeInsuranceAndAdministrationExpenditures",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/GeneralAndAdministrativeDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "huge_GrossProfitLossBeforeFairValueAdjustments":  {
                "auth_ref":  [
                    ],
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents the amount of gross profit (loss) before fair value adjustments.",
                            "label":  "Gross Profit (Loss) Before Fair Value Adjustments",
                            "verboseLabel":  "Gross loss before fair value adjustments"
                            }
                        }
                    },
                "localname":  "GrossProfitLossBeforeFairValueAdjustments",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/AssetsHeldForSaleDetails1"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "huge_GuaranteedMinimumLiquidationValueOfShares":  {
                "auth_ref":  [
                    ],
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents guaranteed minimum liquidation value of shares.",
                            "label":  "Guaranteed minimum liquidation value of shares"
                            }
                        }
                    },
                "localname":  "GuaranteedMinimumLiquidationValueOfShares",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/OtherInvestmentsNarrativeDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "huge_HeritageBuildingRestorationCommitmentMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Heritage Building Restoration Commitment",
                            "label":  "Heritage Building Restoration Commitment [Member]",
                            "verboseLabel":  "Heritage Building Restoration Commitment"
                            }
                        }
                    },
                "localname":  "HeritageBuildingRestorationCommitmentMember",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CommitmentsAndContingenciesNarrativeDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_HighTideIncMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "High Tide Inc.",
                            "label":  "High Tide Inc [Member]",
                            "verboseLabel":  "High Tide Inc."
                            }
                        }
                    },
                "localname":  "HighTideIncMember",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/OtherInvestmentsNarrativeDetails",
                    "http://www.fsdpharma.com/role/OtherInvestmentsScheduleOfOtherInvestmentsDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_HugeShopsMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "HUGE Shops",
                            "label":  "Huge Shops [Member]",
                            "verboseLabel":  "HUGE Shops"
                            }
                        }
                    },
                "localname":  "HugeShopsMember",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/OtherInvestmentsNarrativeDetails",
                    "http://www.fsdpharma.com/role/OtherInvestmentsScheduleOfOtherInvestmentsDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_ImpairmentLossOnRightOfUseAsset":  {
                "auth_ref":  [
                    ],
                "calculation":  {
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS":  {
                        "order":  40.0,
                        "parentTag":  "ifrs-full_ExpenseByNature",
                        "weight":  1.0
                        }
                    },
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents the amount related to impairment Loss of right-of-use asset.",
                            "label":  "Impairment Loss On Right Of Use Asset",
                            "negatedLabel":  "Impairment",
                            "terseLabel":  "Impairment loss on right of use asset",
                            "verboseLabel":  "Impairment of right-of-use asset"
                            }
                        }
                    },
                "localname":  "ImpairmentLossOnRightOfUseAsset",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS",
                    "http://www.fsdpharma.com/role/RightofuseAssetNarrativeDetails",
                    "http://www.fsdpharma.com/role/RightofuseAssetScheduleOfRightofuseAssetDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "huge_IncreaseDecreaseThroughAcquisitionOfNetAssetsShares":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "The increase (decrease) in equity shares resulting from acquisition of net assets.",
                            "label":  "Increase (decrease) Through acquisition of net assets, Shares",
                            "verboseLabel":  "Issued on acquisition of net assets of Prismic Pharmaceuticals, Inc (shares)"
                            }
                        }
                    },
                "localname":  "IncreaseDecreaseThroughAcquisitionOfNetAssetsShares",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/AcquisitionOfLucidDetailTextuals",
                    "http://www.fsdpharma.com/role/AcquisitionOfPrismicPharmaceuticalNarrativeDetails",
                    "http://www.fsdpharma.com/role/ShareCapitalNarrativeDetails",
                    "http://www.fsdpharma.com/role/ShareCapitalScheduleOfReconciliationOfTheShareCapitalDetails"
                    ],
                "xbrltype":  "sharesItemType"
                },
            "huge_IncreaseDecreaseThroughAcquisitionOfNetAssetsValue":  {
                "auth_ref":  [
                    ],
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "The increase (decrease) in equity resulting from acquisition of net assets.",
                            "label":  "Increase (decrease) Through acquisition of net assets, Value",
                            "verboseLabel":  "Issued on acquisition of net assets of Prismic Pharmaceuticals, Inc"
                            }
                        }
                    },
                "localname":  "IncreaseDecreaseThroughAcquisitionOfNetAssetsValue",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/ShareCapitalScheduleOfReconciliationOfTheShareCapitalDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "huge_IncreaseDecreaseThroughAcquisitionOfSubsidiaryShares":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents the increase (decrease) in equity resulting from the acquisition.",
                            "label":  "Increase Decrease Through Acquisition Of Subsidiary Shares",
                            "terseLabel":  "Lucid acquisition (shares)",
                            "verboseLabel":  "Lucid acquisition"
                            }
                        }
                    },
                "localname":  "IncreaseDecreaseThroughAcquisitionOfSubsidiaryShares",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
                    "http://www.fsdpharma.com/role/ShareCapitalNarrativeDetails",
                    "http://www.fsdpharma.com/role/ShareCapitalScheduleOfReconciliationOfTheShareCapitalDetails"
                    ],
                "xbrltype":  "sharesItemType"
                },
            "huge_IncreaseDecreaseThroughExerciseOfOptionShares":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "The increase (decrease) in equity resulting from exercise of option.",
                            "label":  "Increase Decrease Through Exercise Of Option Shares",
                            "terseLabel":  "Stock options exercised (shares)",
                            "verboseLabel":  "Share options exercised (shares)"
                            }
                        }
                    },
                "localname":  "IncreaseDecreaseThroughExerciseOfOptionShares",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
                    "http://www.fsdpharma.com/role/ShareCapitalScheduleOfReconciliationOfTheShareCapitalDetails"
                    ],
                "xbrltype":  "sharesItemType"
                },
            "huge_IncreaseDecreaseThroughExerciseOfWarrantsShares":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "The increase (decrease) in equity shares resulting from warrants exercised.",
                            "label":  "Increase Decrease Through Exercise Of Warrants Shares",
                            "terseLabel":  "Warrants exercised (shares)"
                            }
                        }
                    },
                "localname":  "IncreaseDecreaseThroughExerciseOfWarrantsShares",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
                    "http://www.fsdpharma.com/role/ShareCapitalScheduleOfReconciliationOfTheShareCapitalDetails"
                    ],
                "xbrltype":  "sharesItemType"
                },
            "huge_IncreaseDecreaseThroughExpiryOfWarrantsShares":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "The increase (decrease) in equity shares resulting from warrants expired.",
                            "label":  "Increase (decrease) Through expiry Of Warrants Shares",
                            "negatedLabel":  "Warrants expired (shares)",
                            "verboseLabel":  "Warrants expired (shares)"
                            }
                        }
                    },
                "localname":  "IncreaseDecreaseThroughExpiryOfWarrantsShares",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
                    "http://www.fsdpharma.com/role/ShareCapitalScheduleOfReconciliationOfTheShareCapitalDetails"
                    ],
                "xbrltype":  "sharesItemType"
                },
            "huge_IncreaseDecreaseThroughExpiryOfWarrantsValue":  {
                "auth_ref":  [
                    ],
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "The increase (decrease) in equity resulting from warrants expired.",
                            "label":  "Increase (decrease) Through expiry Of Warrants Value",
                            "negatedLabel":  "Warrants expired",
                            "verboseLabel":  "Warrants expired"
                            }
                        }
                    },
                "localname":  "IncreaseDecreaseThroughExpiryOfWarrantsValue",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
                    "http://www.fsdpharma.com/role/ShareCapitalScheduleOfReconciliationOfTheShareCapitalDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "huge_IncreaseDecreaseThroughIssuedOnAcquisitionOfNetAsset":  {
                "auth_ref":  [
                    ],
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "It represents Increase Decrease Through issued on acquisition of net assets.",
                            "label":  "Increase Decrease Through issued on acquisition of net asset",
                            "verboseLabel":  "Issued on acquisition of net assets of Prismic Pharmaceuticals, Inc."
                            }
                        }
                    },
                "localname":  "IncreaseDecreaseThroughIssuedOnAcquisitionOfNetAsset",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "huge_IncreaseDecreaseThroughIssuedOnAcquisitionOfNetAssetsShares":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "It represents Increase Decrease Through issued on acquisition of net assets shares.",
                            "label":  "Increase Decrease Through issued on acquisition of net assets shares",
                            "verboseLabel":  "Issued on acquisition of net assets of Prismic Pharmaceuticals, Inc. (shares)"
                            }
                        }
                    },
                "localname":  "IncreaseDecreaseThroughIssuedOnAcquisitionOfNetAssetsShares",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
                    ],
                "xbrltype":  "sharesItemType"
                },
            "huge_IncreaseDecreaseThroughReverseAcquisition":  {
                "auth_ref":  [
                    ],
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "The increase (decrease) in equity resulting from reverse acquisition.",
                            "label":  "Increase Decrease Through Reverse Acquisition",
                            "terseLabel":  "Reverse acquisition"
                            }
                        }
                    },
                "localname":  "IncreaseDecreaseThroughReverseAcquisition",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/ShareCapitalScheduleOfReconciliationOfTheShareCapitalDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "huge_IncreaseDecreaseThroughReverseAcquisitionShares":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "The increase (decrease) in equity shares resulting from reverse acquisition.",
                            "label":  "Increase Decrease Through Reverse Acquisition Shares",
                            "terseLabel":  "Reverse acquisition (shares)",
                            "verboseLabel":  "Warrant valuations (shares)"
                            }
                        }
                    },
                "localname":  "IncreaseDecreaseThroughReverseAcquisitionShares",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/ShareCapitalScheduleOfReconciliationOfTheShareCapitalDetails"
                    ],
                "xbrltype":  "sharesItemType"
                },
            "huge_IncreaseDecreaseThroughShareBasedPaymentTransactionsShares":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "It represents increase decrease through share based payment transactions shares.",
                            "label":  "Increase Decrease Through Share Based Payment Transactions Shares",
                            "terseLabel":  "Number of shares issued as share-based compensation",
                            "verboseLabel":  "Share-based payments (shares)"
                            }
                        }
                    },
                "localname":  "IncreaseDecreaseThroughShareBasedPaymentTransactionsShares",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
                    "http://www.fsdpharma.com/role/ShareCapitalNarrativeDetails",
                    "http://www.fsdpharma.com/role/ShareCapitalScheduleOfReconciliationOfTheShareCapitalDetails"
                    ],
                "xbrltype":  "sharesItemType"
                },
            "huge_IncreaseDecreaseThroughShareCancelationShare":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents the increase (decrease) in equity resulting from cancellation of shares.",
                            "label":  "Increase Decrease Through Share Cancelation Share",
                            "negatedLabel":  "Share cancelation (shares)",
                            "terseLabel":  "Share cancelation (shares)"
                            }
                        }
                    },
                "localname":  "IncreaseDecreaseThroughShareCancelationShare",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
                    ],
                "xbrltype":  "sharesItemType"
                },
            "huge_IncreaseDecreaseThroughShareCancelationValue":  {
                "auth_ref":  [
                    ],
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents the increase (decrease) in equity resulting from cancellation of shares.",
                            "label":  "Increase Decrease Through Share Cancelation Value",
                            "terseLabel":  "Share cancelation"
                            }
                        }
                    },
                "localname":  "IncreaseDecreaseThroughShareCancelationValue",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "huge_IncreaseDecreaseThroughShareCancellationShares":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "The increase (decrease) in equity resulting from shares cancellation.",
                            "label":  "Increase Decrease Through Share Cancellation Shares",
                            "verboseLabel":  "Share cancellation (shares)"
                            }
                        }
                    },
                "localname":  "IncreaseDecreaseThroughShareCancellationShares",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/ShareCapitalScheduleOfReconciliationOfTheShareCapitalDetails"
                    ],
                "xbrltype":  "sharesItemType"
                },
            "huge_IncreaseDecreaseThroughShareIssueRelatedCostShares":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Increase decrease through share issue related cost shares.",
                            "label":  "Increase Decrease Through Share Issue Related Cost Shares",
                            "terseLabel":  "Number of broker warrants representing fees and commissions",
                            "verboseLabel":  "Shares issued (shares)"
                            }
                        }
                    },
                "localname":  "IncreaseDecreaseThroughShareIssueRelatedCostShares",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/ShareCapitalScheduleOfReconciliationOfTheShareCapitalDetails"
                    ],
                "xbrltype":  "sharesItemType"
                },
            "huge_IncreaseDecreaseThroughSharesCancellation":  {
                "auth_ref":  [
                    ],
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "The increase (decrease) in equity resulting from shares cancellation.",
                            "label":  "Increase Decrease Through Shares Cancellation",
                            "positiveLabel":  "Share cancellation",
                            "terseLabel":  "Stock options cancelled",
                            "verboseLabel":  "Share options cancelled"
                            }
                        }
                    },
                "localname":  "IncreaseDecreaseThroughSharesCancellation",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/ShareCapitalScheduleOfReconciliationOfTheShareCapitalDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "huge_IncreaseDecreaseThroughStockOptionsCancelledShares":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents number of cancelled shares.",
                            "label":  "Increase Decrease Through Stock Options Cancelled Shares",
                            "positiveLabel":  "Shares repurchased and cancelled",
                            "terseLabel":  "Shares cancelled",
                            "verboseLabel":  "Share cancellation (shares)"
                            }
                        }
                    },
                "localname":  "IncreaseDecreaseThroughStockOptionsCancelledShares",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CommitmentsAndContingenciesNarrativeDetails",
                    "http://www.fsdpharma.com/role/ShareCapitalNarrativeDetails",
                    "http://www.fsdpharma.com/role/SubsequentEventsNarrativeDetails"
                    ],
                "xbrltype":  "sharesItemType"
                },
            "huge_IncreaseDecreaseThroughWarrantValuations":  {
                "auth_ref":  [
                    ],
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "The increase (decrease) in equity resulting from warrant valuations.",
                            "label":  "Increase Decrease Through Warrant Valuations",
                            "terseLabel":  "Warrant valuations"
                            }
                        }
                    },
                "localname":  "IncreaseDecreaseThroughWarrantValuations",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/ShareCapitalScheduleOfReconciliationOfTheShareCapitalDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "huge_IncreaseDecreaseThroughWarrantValuationsShares":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "The increase (decrease) in equity shares resulting from warrant valuations.",
                            "label":  "Increase Decrease Through Warrant Valuations Shares",
                            "terseLabel":  "Warrant valuations (shares)",
                            "verboseLabel":  "Increase Decrease Through Warrant Valuations Shares"
                            }
                        }
                    },
                "localname":  "IncreaseDecreaseThroughWarrantValuationsShares",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/ShareCapitalScheduleOfReconciliationOfTheShareCapitalDetails"
                    ],
                "xbrltype":  "sharesItemType"
                },
            "huge_IndependentDirectorMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "This member stands for independent director.",
                            "label":  "Independent Director [Member]",
                            "terseLabel":  "Former Chief Operating Officer",
                            "verboseLabel":  "Independent directors"
                            }
                        }
                    },
                "localname":  "IndependentDirectorMember",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/RelatedPartyTransactionsNarrativeDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_InnovetLicenseAgreementMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "This member stands for Innovet License Agreement.",
                            "label":  "Innovet License Agreement [Member]",
                            "terseLabel":  "Innovet License Agreement"
                            }
                        }
                    },
                "localname":  "InnovetLicenseAgreementMember",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CommitmentsAndContingenciesNarrativeDetails",
                    "http://www.fsdpharma.com/role/IntangibleAssetsNarrativeDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_InputTaxCreditReceivable":  {
                "auth_ref":  [
                    ],
                "calculation":  {
                    "http://www.fsdpharma.com/role/TradeAndOtherReceivablesScheduleOfTradeAndOtherReceivablesDetails":  {
                        "order":  30.0,
                        "parentTag":  "ifrs-full_TradeAndOtherReceivables",
                        "weight":  1.0
                        }
                    },
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represent the amount of input tax credit receivable.",
                            "label":  "Input Tax Credit Receivable",
                            "terseLabel":  "ITC Receivable"
                            }
                        }
                    },
                "localname":  "InputTaxCreditReceivable",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/TradeAndOtherReceivablesScheduleOfTradeAndOtherReceivablesDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "huge_InsuredAmountForClaimSettlemnt":  {
                "auth_ref":  [
                    ],
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents the insured claim settlement amount.",
                            "label":  "Insured Amount For Claim Settlemnt",
                            "terseLabel":  "Insured amount for settlement of claim"
                            }
                        }
                    },
                "localname":  "InsuredAmountForClaimSettlemnt",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CommitmentsAndContingenciesNarrativeDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "huge_InvestorRelationsExpenses":  {
                "auth_ref":  [
                    ],
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Information about investor relations.",
                            "label":  "Investor Relations Expenses",
                            "terseLabel":  "Investor relations"
                            }
                        }
                    },
                "localname":  "InvestorRelationsExpenses",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/GeneralAndAdministrativeDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "huge_IssuanceCostOfCommonSharesAndWarrants":  {
                "auth_ref":  [
                    ],
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "It represents issuance cost of common shares and warrants.",
                            "label":  "Issuance Cost Of Common Shares And Warrants",
                            "verboseLabel":  "Issuance cost of common shares and warrants"
                            }
                        }
                    },
                "localname":  "IssuanceCostOfCommonSharesAndWarrants",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/ShareCapitalNarrativeDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "huge_IssuanceOfCommonSharesOfShareBasedBonusToEmployeesForPerformance":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "It represents issuance of common shares of share based bonus to employees for performance.",
                            "label":  "Issuance Of Common Shares Of Share Based Bonus To Employees For Performance",
                            "verboseLabel":  "Issuance of common shares of share based bonus to employees for performance"
                            }
                        }
                    },
                "localname":  "IssuanceOfCommonSharesOfShareBasedBonusToEmployeesForPerformance",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/ShareCapitalNarrativeDetails"
                    ],
                "xbrltype":  "sharesItemType"
                },
            "huge_IssuanceOfCommonStockForNotesPayable":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "It represents issuance of common stock for notes payable.",
                            "label":  "Issuance Of Common Stock For Notes Payable",
                            "verboseLabel":  "Issuance of common stock for notes payable"
                            }
                        }
                    },
                "localname":  "IssuanceOfCommonStockForNotesPayable",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/NotesPayableNarrativeDetails",
                    "http://www.fsdpharma.com/role/ShareCapitalNarrativeDetails"
                    ],
                "xbrltype":  "sharesItemType"
                },
            "huge_IssuanceOfCommonStockOfBoardOfDirectorsInLieuOfCash":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "It represents issuance of common stock of board of directors in lieu of cash.",
                            "label":  "Issuance Of Common Stock Of Board Of Directors In Lieu Of Cash",
                            "verboseLabel":  "Issuance of common stock of board of directors in lieu of cash"
                            }
                        }
                    },
                "localname":  "IssuanceOfCommonStockOfBoardOfDirectorsInLieuOfCash",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/ShareCapitalNarrativeDetails"
                    ],
                "xbrltype":  "sharesItemType"
                },
            "huge_IssuanceOfCommonStockOfDirectOffering":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "It represents Issuance of common stock of direct offering.",
                            "label":  "Issuance Of Common Stock Of Direct Offering",
                            "verboseLabel":  "Issuance of common stock of direct offering"
                            }
                        }
                    },
                "localname":  "IssuanceOfCommonStockOfDirectOffering",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/ShareCapitalNarrativeDetails",
                    "http://www.fsdpharma.com/role/WarrantsLiabilityDetailTextuals"
                    ],
                "xbrltype":  "sharesItemType"
                },
            "huge_IssuanceOfCommonStockOfShareBasedCompensation":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "It represents issuance of common stock of share based compensation.",
                            "label":  "Issuance Of Common Stock Of Share Based Compensation",
                            "verboseLabel":  "Issuance of common stock of share based compensation"
                            }
                        }
                    },
                "localname":  "IssuanceOfCommonStockOfShareBasedCompensation",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/ShareCapitalNarrativeDetails"
                    ],
                "xbrltype":  "sharesItemType"
                },
            "huge_IssuanceOfShares":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Number of shares issued.",
                            "label":  "Issuance Of Shares",
                            "terseLabel":  "Number of shares issued",
                            "verboseLabel":  "Shares issued (shares)"
                            }
                        }
                    },
                "localname":  "IssuanceOfShares",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
                    "http://www.fsdpharma.com/role/ShareCapitalScheduleOfReconciliationOfTheShareCapitalDetails"
                    ],
                "xbrltype":  "sharesItemType"
                },
            "huge_IssuanceOfWarrantsOfDirectOffering":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "It represents Issuance of warrants of direct offering.",
                            "label":  "Issuance Of Warrants Of Direct Offering",
                            "verboseLabel":  "Issuance of warrants of direct offering"
                            }
                        }
                    },
                "localname":  "IssuanceOfWarrantsOfDirectOffering",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/ShareCapitalNarrativeDetails",
                    "http://www.fsdpharma.com/role/WarrantsLiabilityDetailTextuals"
                    ],
                "xbrltype":  "sharesItemType"
                },
            "huge_KeyManagementAndDirectorsMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Information about key management and directors.",
                            "label":  "Key Management And Directors [Member]",
                            "terseLabel":  "Key management and directors"
                            }
                        }
                    },
                "localname":  "KeyManagementAndDirectorsMember",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/RelatedPartyTransactionsNarrativeDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_LegalEntitiesAxis":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents legal entities axis.",
                            "label":  "Legal Entities [Axis]"
                            }
                        }
                    },
                "localname":  "LegalEntitiesAxis",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/AcquisitionOfLucid",
                    "http://www.fsdpharma.com/role/AcquisitionOfLucidDetailTextuals",
                    "http://www.fsdpharma.com/role/AcquisitionOfLucidDetails",
                    "http://www.fsdpharma.com/role/AcquisitionOfLucidDetails1",
                    "http://www.fsdpharma.com/role/AcquisitionOfLucidTables",
                    "http://www.fsdpharma.com/role/AcquisitionOfPrismicPharmaceutical",
                    "http://www.fsdpharma.com/role/AcquisitionOfPrismicPharmaceuticalNarrativeDetails",
                    "http://www.fsdpharma.com/role/AcquisitionOfPrismicPharmaceuticalScheduleOfBlackScholesOptionsPricingModelDetails",
                    "http://www.fsdpharma.com/role/AcquisitionOfPrismicPharmaceuticalScheduleOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedDetails",
                    "http://www.fsdpharma.com/role/AcquisitionOfPrismicPharmaceuticalTables",
                    "http://www.fsdpharma.com/role/IntangibleAssetsNarrativeDetails",
                    "http://www.fsdpharma.com/role/NotesPayableNarrativeDetails",
                    "http://www.fsdpharma.com/role/ShareCapitalNarrativeDetails"
                    ],
                "xbrltype":  "stringItemType"
                },
            "huge_LegalEntitiesDomain":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents legal entities domain.",
                            "label":  "Legal Entities [Domain]"
                            }
                        }
                    },
                "localname":  "LegalEntitiesDomain",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/AcquisitionOfLucid",
                    "http://www.fsdpharma.com/role/AcquisitionOfLucidDetailTextuals",
                    "http://www.fsdpharma.com/role/AcquisitionOfLucidDetails",
                    "http://www.fsdpharma.com/role/AcquisitionOfLucidDetails1",
                    "http://www.fsdpharma.com/role/AcquisitionOfLucidTables",
                    "http://www.fsdpharma.com/role/AcquisitionOfPrismicPharmaceutical",
                    "http://www.fsdpharma.com/role/AcquisitionOfPrismicPharmaceuticalNarrativeDetails",
                    "http://www.fsdpharma.com/role/AcquisitionOfPrismicPharmaceuticalScheduleOfBlackScholesOptionsPricingModelDetails",
                    "http://www.fsdpharma.com/role/AcquisitionOfPrismicPharmaceuticalScheduleOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedDetails",
                    "http://www.fsdpharma.com/role/AcquisitionOfPrismicPharmaceuticalTables",
                    "http://www.fsdpharma.com/role/IntangibleAssetsNarrativeDetails",
                    "http://www.fsdpharma.com/role/NotesPayableNarrativeDetails",
                    "http://www.fsdpharma.com/role/ShareCapitalNarrativeDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_LegalProvision":  {
                "auth_ref":  [
                    ],
                "calculation":  {
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS":  {
                        "order":  30.0,
                        "parentTag":  "ifrs-full_ExpenseByNature",
                        "weight":  1.0
                        }
                    },
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents the amount of legal provision.",
                            "label":  "Legal Provision",
                            "terseLabel":  "Legal provision"
                            }
                        }
                    },
                "localname":  "LegalProvision",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "huge_LicenseAgreementMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "This member stands for license agreement.",
                            "label":  "License Agreement [Member]",
                            "verboseLabel":  "License agreement"
                            }
                        }
                    },
                "localname":  "LicenseAgreementMember",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CommitmentsAndContingenciesNarrativeDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_LicenseMaintenanceFee":  {
                "auth_ref":  [
                    ],
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents amount of license maintenance fee.",
                            "label":  "License Maintenance Fee",
                            "verboseLabel":  "License maintenance fee"
                            }
                        }
                    },
                "localname":  "LicenseMaintenanceFee",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CommitmentsAndContingenciesNarrativeDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "huge_LossGainOnChangesInFairValueOfOtherInvestments":  {
                "auth_ref":  [
                    ],
                "calculation":  {
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS":  {
                        "order":  30.0,
                        "parentTag":  "ifrs-full_ProfitLossFromContinuingOperations",
                        "weight":  -1.0
                        }
                    },
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents amount of Loss (gain) on changes in fair value of other investments.",
                            "label":  "Loss gain on changes in fair value of other investments",
                            "negatedLabel":  "Loss on changes in fair value of investments",
                            "verboseLabel":  "Loss (gain) on changes in fair value of investments"
                            }
                        }
                    },
                "localname":  "LossGainOnChangesInFairValueOfOtherInvestments",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "huge_LossOnSaleOfEquipment":  {
                "auth_ref":  [
                    ],
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents the amount of Loss on sale of equipment.",
                            "label":  "Loss On Sale Of Equipment",
                            "verboseLabel":  "Loss on sale of equipment"
                            }
                        }
                    },
                "localname":  "LossOnSaleOfEquipment",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/AssetsHeldForSaleDetailTextuals",
                    "http://www.fsdpharma.com/role/AssetsHeldForSaleDetails1"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "huge_LossOnSaleOfInventory":  {
                "auth_ref":  [
                    ],
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents the amount of Loss on sale of inventory.",
                            "label":  "Loss On Sale Of Inventory",
                            "verboseLabel":  "Loss on disposal of inventory"
                            }
                        }
                    },
                "localname":  "LossOnSaleOfInventory",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/AssetsHeldForSaleDetailTextuals"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "huge_LucidMsAndLucidPsychMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "This member stands for Lucid-MS and Lucid-Psych.",
                            "label":  "Lucid Ms And Lucid Psych [Member]",
                            "verboseLabel":  "Lucid-MS and Lucid-Psych"
                            }
                        }
                    },
                "localname":  "LucidMsAndLucidPsychMember",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CommitmentsAndContingenciesNarrativeDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_LucidPsycheceuticalsIncMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "This member stands for Lucid Psycheceuticals Inc.",
                            "label":  "Lucid Psycheceuticals Inc [Member]",
                            "terseLabel":  "Lucid Psycheceuticals Inc.",
                            "verboseLabel":  "Lucid"
                            }
                        }
                    },
                "localname":  "LucidPsycheceuticalsIncMember",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/AcquisitionOfLucid",
                    "http://www.fsdpharma.com/role/AcquisitionOfLucidDetailTextuals",
                    "http://www.fsdpharma.com/role/AcquisitionOfLucidDetails",
                    "http://www.fsdpharma.com/role/AcquisitionOfLucidDetails1",
                    "http://www.fsdpharma.com/role/AcquisitionOfLucidTables",
                    "http://www.fsdpharma.com/role/IntangibleAssetsNarrativeDetails",
                    "http://www.fsdpharma.com/role/NatureOfBusinessScheduleOfOwnershipPercentageInSubsidiariesDetails",
                    "http://www.fsdpharma.com/role/ShareCapitalNarrativeDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_MarketPriceOfShares":  {
                "auth_ref":  [
                    ],
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents the market price of shares.",
                            "label":  "Market price of shares",
                            "verboseLabel":  "Market price of shares"
                            }
                        }
                    },
                "localname":  "MarketPriceOfShares",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/OtherInvestmentsNarrativeDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "huge_MilestonesPayments":  {
                "auth_ref":  [
                    ],
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents amount of milestones payments.",
                            "label":  "Milestones Payments",
                            "verboseLabel":  "Milestones payments"
                            }
                        }
                    },
                "localname":  "MilestonesPayments",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CommitmentsAndContingenciesNarrativeDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "huge_MixedDecisionShareGrantCancelled":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "label":  "Mixed Decision Share Grant Cancelled",
                            "verboseLabel":  "Mixed decision - share grant cancelled"
                            }
                        }
                    },
                "localname":  "MixedDecisionShareGrantCancelled",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/RelatedPartyTransactionsNarrativeDetails",
                    "http://www.fsdpharma.com/role/SubsequentEventsNarrativeDetails"
                    ],
                "xbrltype":  "sharesItemType"
                },
            "huge_MixedDecisionShareGrantPermitted":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "label":  "Mixed Decision Share Grant Permitted",
                            "verboseLabel":  "Mixed decision - share grant permitted"
                            }
                        }
                    },
                "localname":  "MixedDecisionShareGrantPermitted",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/RelatedPartyTransactionsNarrativeDetails",
                    "http://www.fsdpharma.com/role/SubsequentEventsNarrativeDetails"
                    ],
                "xbrltype":  "sharesItemType"
                },
            "huge_NetOperatingLossCarryforwardsLimitationsInUse":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents limitations in utilization of net operating loss carryforwards.",
                            "label":  "Net Operating Loss Carryforwards Limitations In Use",
                            "terseLabel":  "Description for limitations of utilization of net operating loss carryforwards"
                            }
                        }
                    },
                "localname":  "NetOperatingLossCarryforwardsLimitationsInUse",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/IncomeTaxesNarrativeDetails"
                    ],
                "xbrltype":  "stringItemType"
                },
            "huge_NonCapitalIncomeTaxLossesExpireOnTwoThousandFourty":  {
                "auth_ref":  [
                    ],
                "calculation":  {
                    "http://www.fsdpharma.com/role/IncomeTaxesScheduleOfNoncapitalLossCarryforwardsDetails":  {
                        "order":  80.0,
                        "parentTag":  "huge_NonCapitalLossCarryforwards",
                        "weight":  1.0
                        }
                    },
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents amount of Non capital income tax losses expire on 2040.",
                            "label":  "Non Capital Income Tax Losses Expire On Two Thousand Fourty",
                            "terseLabel":  "2041"
                            }
                        }
                    },
                "localname":  "NonCapitalIncomeTaxLossesExpireOnTwoThousandFourty",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/IncomeTaxesScheduleOfNoncapitalLossCarryforwardsDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "huge_NonCapitalIncomeTaxLossesExpireOnTwoThousandThirtyEight":  {
                "auth_ref":  [
                    ],
                "calculation":  {
                    "http://www.fsdpharma.com/role/IncomeTaxesScheduleOfNoncapitalLossCarryforwardsDetails":  {
                        "order":  60.0,
                        "parentTag":  "huge_NonCapitalLossCarryforwards",
                        "weight":  1.0
                        }
                    },
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents amount of Non capital income tax losses expire on 2038.",
                            "label":  "Non Capital Income Tax Losses Expire on Two Thousand Thirty Eight",
                            "terseLabel":  "2039"
                            }
                        }
                    },
                "localname":  "NonCapitalIncomeTaxLossesExpireOnTwoThousandThirtyEight",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/IncomeTaxesScheduleOfNoncapitalLossCarryforwardsDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "huge_NonCapitalIncomeTaxLossesExpireOnTwoThousandThirtyFive":  {
                "auth_ref":  [
                    ],
                "calculation":  {
                    "http://www.fsdpharma.com/role/IncomeTaxesScheduleOfNoncapitalLossCarryforwardsDetails":  {
                        "order":  30.0,
                        "parentTag":  "huge_NonCapitalLossCarryforwards",
                        "weight":  1.0
                        }
                    },
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents amount of Non capital income tax losses expire on 2035.",
                            "label":  "Non Capital Income Tax Losses Expire On Two Thousand Thirty Five",
                            "verboseLabel":  "2035"
                            }
                        }
                    },
                "localname":  "NonCapitalIncomeTaxLossesExpireOnTwoThousandThirtyFive",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "xbrltype":  "monetaryItemType"
                },
            "huge_NonCapitalIncomeTaxLossesExpireOnTwoThousandThirtyFour":  {
                "auth_ref":  [
                    ],
                "calculation":  {
                    "http://www.fsdpharma.com/role/IncomeTaxesScheduleOfNoncapitalLossCarryforwardsDetails":  {
                        "order":  20.0,
                        "parentTag":  "huge_NonCapitalLossCarryforwards",
                        "weight":  1.0
                        }
                    },
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents amount of Non capital income tax losses expire on 2034.",
                            "label":  "Non Capital Income Tax Losses Expire On Two Thousand Thirty Four",
                            "verboseLabel":  "2034"
                            }
                        }
                    },
                "localname":  "NonCapitalIncomeTaxLossesExpireOnTwoThousandThirtyFour",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "xbrltype":  "monetaryItemType"
                },
            "huge_NonCapitalIncomeTaxLossesExpireOnTwoThousandThirtyNine":  {
                "auth_ref":  [
                    ],
                "calculation":  {
                    "http://www.fsdpharma.com/role/IncomeTaxesScheduleOfNoncapitalLossCarryforwardsDetails":  {
                        "order":  70.0,
                        "parentTag":  "huge_NonCapitalLossCarryforwards",
                        "weight":  1.0
                        }
                    },
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents amount of Non capital income tax losses expire on 2039.",
                            "label":  "Non capital income tax losses expire On Two Thousand Thirty Nine",
                            "verboseLabel":  "2040"
                            }
                        }
                    },
                "localname":  "NonCapitalIncomeTaxLossesExpireOnTwoThousandThirtyNine",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/IncomeTaxesScheduleOfNoncapitalLossCarryforwardsDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "huge_NonCapitalIncomeTaxLossesExpireOnTwoThousandThirtySeven":  {
                "auth_ref":  [
                    ],
                "calculation":  {
                    "http://www.fsdpharma.com/role/IncomeTaxesScheduleOfNoncapitalLossCarryforwardsDetails":  {
                        "order":  50.0,
                        "parentTag":  "huge_NonCapitalLossCarryforwards",
                        "weight":  1.0
                        }
                    },
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents amount of Non capital income tax losses expire on 2037.",
                            "label":  "Non Capital Income Tax Losses Expire On Two Thousand Thirty Seven",
                            "verboseLabel":  "2038"
                            }
                        }
                    },
                "localname":  "NonCapitalIncomeTaxLossesExpireOnTwoThousandThirtySeven",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/IncomeTaxesScheduleOfNoncapitalLossCarryforwardsDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "huge_NonCapitalIncomeTaxLossesExpireOnTwoThousandThirtySix":  {
                "auth_ref":  [
                    ],
                "calculation":  {
                    "http://www.fsdpharma.com/role/IncomeTaxesScheduleOfNoncapitalLossCarryforwardsDetails":  {
                        "order":  40.0,
                        "parentTag":  "huge_NonCapitalLossCarryforwards",
                        "weight":  1.0
                        }
                    },
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents amount of Non capital income tax losses expire on 2036.",
                            "label":  "Non Capital Income Tax Losses Expire On Two Thousand Thirty Six",
                            "verboseLabel":  "2036"
                            }
                        }
                    },
                "localname":  "NonCapitalIncomeTaxLossesExpireOnTwoThousandThirtySix",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "xbrltype":  "monetaryItemType"
                },
            "huge_NonCapitalIncomeTaxLossesExpireOnTwoThousandThirtyThree":  {
                "auth_ref":  [
                    ],
                "calculation":  {
                    "http://www.fsdpharma.com/role/IncomeTaxesScheduleOfNoncapitalLossCarryforwardsDetails":  {
                        "order":  10.0,
                        "parentTag":  "huge_NonCapitalLossCarryforwards",
                        "weight":  1.0
                        }
                    },
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents amount of Non capital income tax losses expire on 2033.",
                            "label":  "Non Capital Income Tax Losses Expire On Two Thousand Thirty Three",
                            "verboseLabel":  "2033"
                            }
                        }
                    },
                "localname":  "NonCapitalIncomeTaxLossesExpireOnTwoThousandThirtyThree",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "xbrltype":  "monetaryItemType"
                },
            "huge_NonCapitalIncomeTaxLossesExpireOnTwoThousandThirtyTwo":  {
                "auth_ref":  [
                    ],
                "calculation":  {
                    "http://www.fsdpharma.com/role/IncomeTaxesScheduleOfNoncapitalLossCarryforwardsDetails":  {
                        "order":  0.0,
                        "parentTag":  "huge_NonCapitalLossCarryforwards",
                        "weight":  1.0
                        }
                    },
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents amount of Non capital income tax losses expire on 2032.",
                            "label":  "Non Capital Income Tax Losses Expire On Two Thousand Thirty Two",
                            "verboseLabel":  "2032"
                            }
                        }
                    },
                "localname":  "NonCapitalIncomeTaxLossesExpireOnTwoThousandThirtyTwo",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "xbrltype":  "monetaryItemType"
                },
            "huge_NonCapitalLossCarryforwards":  {
                "auth_ref":  [
                    ],
                "calculation":  {
                    "http://www.fsdpharma.com/role/IncomeTaxesScheduleOfNoncapitalLossCarryforwardsDetails":  {
                        "order":  null,
                        "parentTag":  null,
                        "root":  true,
                        "weight":  null
                        }
                    },
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Amount of non-capital loss carryforwards.",
                            "label":  "Non Capital loss carryforwards",
                            "totalLabel":  "Non-capital income tax losses expire"
                            }
                        }
                    },
                "localname":  "NonCapitalLossCarryforwards",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/IncomeTaxesScheduleOfNoncapitalLossCarryforwardsDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "huge_NonRefundableSumDueAndPayableThirtyDaysUponFirstNotificationOfFda":  {
                "auth_ref":  [
                    ],
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Non refundable sum due and payable thirty days upon first notification of FDA",
                            "label":  "Non Refundable Sum Due And Payable Thirty Days Upon First Notification Of Fda",
                            "verboseLabel":  "Non refundable sum due and payable thirty days upon first notification of FDA"
                            }
                        }
                    },
                "localname":  "NonRefundableSumDueAndPayableThirtyDaysUponFirstNotificationOfFda",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CommitmentsAndContingenciesNarrativeDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "huge_NonRefundableSumDueAndPayableUponFirstNotificationOfFda":  {
                "auth_ref":  [
                    ],
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "label":  "Non Refundable Sum Due And Payable Upon First Notification Of Fda",
                            "verboseLabel":  "Non refundable sum due and payable upon first notification of FDA"
                            }
                        }
                    },
                "localname":  "NonRefundableSumDueAndPayableUponFirstNotificationOfFda",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CommitmentsAndContingenciesNarrativeDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "huge_NonRefundableSumPayableWithinRequiredBusinessDaysOfFirstNotificationFda":  {
                "auth_ref":  [
                    ],
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents the amount related to non refundable sum payable within ten business days of first notification FDA.",
                            "label":  "Non Refundable Sum Payable Within Required Business Days Of First Notification Fda",
                            "verboseLabel":  "Non refundable sum payable within required business days of first notification FDA"
                            }
                        }
                    },
                "localname":  "NonRefundableSumPayableWithinRequiredBusinessDaysOfFirstNotificationFda",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CommitmentsAndContingenciesNarrativeDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "huge_NotesPayableMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "A written promise to pay a note to a bank.",
                            "label":  "Notes payable [Member]",
                            "verboseLabel":  "Notes payable"
                            }
                        }
                    },
                "localname":  "NotesPayableMember",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/NotesPayableNarrativeDetails",
                    "http://www.fsdpharma.com/role/NotesPayableScheduleOfNotesPayableDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_NotesSettledThroughIssuanceOfShares":  {
                "auth_ref":  [
                    ],
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents amount of notes settled through issuance of shares.",
                            "label":  "Notes Settled Through Issuance Of Shares",
                            "verboseLabel":  "Notes settled through issuance of shares"
                            }
                        }
                    },
                "localname":  "NotesSettledThroughIssuanceOfShares",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/ShareCapitalNarrativeDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "huge_NumberOfAdditionalSharesIssuedToSettleDerivativeLiability":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents the number of additional shares issued to settle derivative liability.",
                            "label":  "Number Of Additional Shares Issued to settle derivative liability",
                            "verboseLabel":  "Number of additional shares issued to settle derivative liability"
                            }
                        }
                    },
                "localname":  "NumberOfAdditionalSharesIssuedToSettleDerivativeLiability",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/OtherInvestmentsNarrativeDetails"
                    ],
                "xbrltype":  "sharesItemType"
                },
            "huge_NumberOfBusinessDays":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents number of business days.",
                            "label":  "Number Of Business Days",
                            "verboseLabel":  "Number of business days"
                            }
                        }
                    },
                "localname":  "NumberOfBusinessDays",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CommitmentsAndContingenciesNarrativeDetails"
                    ],
                "xbrltype":  "integerItemType"
                },
            "huge_NumberOfInvestmentSharesSold":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents the number of investment shares sold",
                            "label":  "Number Of Investment Shares Sold",
                            "terseLabel":  "Number of investment shares sold"
                            }
                        }
                    },
                "localname":  "NumberOfInvestmentSharesSold",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/OtherInvestmentsNarrativeDetails"
                    ],
                "xbrltype":  "sharesItemType"
                },
            "huge_NumberOfShareOptionExpiredInShareBasedPaymentArrangement":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "The number of share options expired in a share-based payment arrangement.",
                            "label":  "Number Of Share Option Expired In Share Based Payment Arrangement",
                            "negatedLabel":  "Expired",
                            "terseLabel":  "Number of share options expired"
                            }
                        }
                    },
                "localname":  "NumberOfShareOptionExpiredInShareBasedPaymentArrangement",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/SharebasedCompensationNarrativeDetails",
                    "http://www.fsdpharma.com/role/SharebasedCompensationScheduleOfChangesInNumberOfShareOptionsDetails"
                    ],
                "xbrltype":  "decimalItemType"
                },
            "huge_NumberOfSharesAcquired":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Number of shares acquired.",
                            "label":  "Number Of Shares Acquired",
                            "verboseLabel":  "Number of shares acquired"
                            }
                        }
                    },
                "localname":  "NumberOfSharesAcquired",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/OtherInvestmentsNarrativeDetails",
                    "http://www.fsdpharma.com/role/ShareCapitalNarrativeDetails"
                    ],
                "xbrltype":  "sharesItemType"
                },
            "huge_NumberOfSharesCancelledForCompensationBonus":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represent the number of shares cancelled for compensation bonus.",
                            "label":  "Number Of Shares Cancelled For Compensation Bonus",
                            "terseLabel":  "Number of shares cancelled for compensation bonus"
                            }
                        }
                    },
                "localname":  "NumberOfSharesCancelledForCompensationBonus",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/RelatedPartyTransactionsNarrativeDetails"
                    ],
                "xbrltype":  "sharesItemType"
                },
            "huge_NumberOfSharesHeld":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents the number of shares held.",
                            "label":  "Number Of Shares Held",
                            "verboseLabel":  "Number of shares held"
                            }
                        }
                    },
                "localname":  "NumberOfSharesHeld",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/OtherInvestmentsNarrativeDetails"
                    ],
                "xbrltype":  "sharesItemType"
                },
            "huge_NumberOfSharesIssuedForCompensationBonus":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents number of number of shares issued for compensation bonus.",
                            "label":  "Number Of Shares Issued For Compensation Bonus",
                            "verboseLabel":  "Number of shares issued for compensation bonus"
                            }
                        }
                    },
                "localname":  "NumberOfSharesIssuedForCompensationBonus",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/RelatedPartyTransactionsNarrativeDetails"
                    ],
                "xbrltype":  "sharesItemType"
                },
            "huge_NumberOfSharesIssuedForDebtSettlement":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents the number of shares issued for debt settlement.",
                            "label":  "Number of shares issued for debt settlement",
                            "terseLabel":  "Number of shares issued for debt settlement"
                            }
                        }
                    },
                "localname":  "NumberOfSharesIssuedForDebtSettlement",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/ShareCapitalNarrativeDetails"
                    ],
                "xbrltype":  "sharesItemType"
                },
            "huge_NumberOfSharesIssuedFromTreasuryUnderPrivatePlacement":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents the number of shares issued from entitys treasury by way of private placement.",
                            "label":  "Number Of Shares Issued From Treasury Under Private Placement",
                            "verboseLabel":  "Number of Class B shares issued from treasury under private placement"
                            }
                        }
                    },
                "localname":  "NumberOfSharesIssuedFromTreasuryUnderPrivatePlacement",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CommitmentsAndContingenciesNarrativeDetails"
                    ],
                "xbrltype":  "sharesItemType"
                },
            "huge_NumberOfSharesIssuedInPrivatePlacement":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents number of shares issued in private placement.",
                            "label":  "Number Of Shares Issued In Private Placement",
                            "terseLabel":  "Number of shares issued in private placement",
                            "verboseLabel":  "Number of shares issued in private placement"
                            }
                        }
                    },
                "localname":  "NumberOfSharesIssuedInPrivatePlacement",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/ShareCapitalNarrativeDetails"
                    ],
                "xbrltype":  "sharesItemType"
                },
            "huge_NumberOfSharesIssuedInShareExchange":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents the number of shares issued in share exchange.",
                            "label":  "Number of shares issued in share exchange",
                            "verboseLabel":  "Number of shares issued in share exchange"
                            }
                        }
                    },
                "localname":  "NumberOfSharesIssuedInShareExchange",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/OtherInvestmentsNarrativeDetails",
                    "http://www.fsdpharma.com/role/ShareCapitalNarrativeDetails"
                    ],
                "xbrltype":  "sharesItemType"
                },
            "huge_NumberOfSharesIssuedThroughEquityDistributionAgreement":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents number of shares issued through equity distribution agreement.",
                            "label":  "Number Of Shares Issued Through Equity Distribution Agreement",
                            "verboseLabel":  "Number of shares issued through equity distribution agreement"
                            }
                        }
                    },
                "localname":  "NumberOfSharesIssuedThroughEquityDistributionAgreement",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/ShareCapitalNarrativeDetails"
                    ],
                "xbrltype":  "sharesItemType"
                },
            "huge_NumberOfWarrantsAcquired":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents the number of warrants acquired.",
                            "label":  "Number of warrants acquired"
                            }
                        }
                    },
                "localname":  "NumberOfWarrantsAcquired",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/OtherInvestmentsNarrativeDetails"
                    ],
                "xbrltype":  "sharesItemType"
                },
            "huge_NumberOfWarrantsExercised":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents number of number of warrants exercised.",
                            "label":  "Number of warrants Exercised",
                            "negatedLabel":  "Warrants, Exercised",
                            "verboseLabel":  "Warrants, Exercised"
                            }
                        }
                    },
                "localname":  "NumberOfWarrantsExercised",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/ShareCapitalScheduleOfChangesInNumberOfWarrantsOutstandingDetails"
                    ],
                "xbrltype":  "sharesItemType"
                },
            "huge_NumberOfWarrantsExpired":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents number of warrants expired.",
                            "label":  "Number of warrants Expired",
                            "negatedLabel":  "Warrants, Expired",
                            "verboseLabel":  "Warrants, Expired"
                            }
                        }
                    },
                "localname":  "NumberOfWarrantsExpired",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/ShareCapitalScheduleOfChangesInNumberOfWarrantsOutstandingDetails"
                    ],
                "xbrltype":  "sharesItemType"
                },
            "huge_NumberOfWarrantsHeld":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents the number of warrants held.",
                            "label":  "Number Of Warrants Held",
                            "verboseLabel":  "Number of warrants held"
                            }
                        }
                    },
                "localname":  "NumberOfWarrantsHeld",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/OtherInvestmentsNarrativeDetails"
                    ],
                "xbrltype":  "sharesItemType"
                },
            "huge_NumberOfWarrantsIssued":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents number of warrants issued during period.",
                            "label":  "Number Of Warrants Issued",
                            "terseLabel":  "Number of warrants issued",
                            "verboseLabel":  "Warrants, Issued"
                            }
                        }
                    },
                "localname":  "NumberOfWarrantsIssued",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/ShareCapitalScheduleOfChangesInNumberOfWarrantsOutstandingDetails"
                    ],
                "xbrltype":  "sharesItemType"
                },
            "huge_NumberOfWarrantsOutstanding":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents number of warrants outstanding.",
                            "label":  "Number of warrants Outstanding",
                            "periodEndLabel":  "Warrants outstanding, Closing Balance",
                            "periodStartLabel":  "Warrants outstanding, Opening balance",
                            "verboseLabel":  "Number of warrants outstanding"
                            }
                        }
                    },
                "localname":  "NumberOfWarrantsOutstanding",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/ShareCapitalScheduleOfChangesInNumberOfWarrantsOutstandingDetails",
                    "http://www.fsdpharma.com/role/ShareCapitalScheduleOfWarrantsOutstandingAndExercisePriceDetails"
                    ],
                "xbrltype":  "sharesItemType"
                },
            "huge_OnePointSevenZeroMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Exercise price 1.70.",
                            "label":  "One Point Seven Zero [Member]",
                            "terseLabel":  "1.70"
                            }
                        }
                    },
                "localname":  "OnePointSevenZeroMember",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/SharebasedCompensationScheduleOfExercisePriceAndWeightedAverageContractualTermOfShareOptionsOutstandingAndExercisableDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_OperatingExpensesAbstract":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "label":  "Operating Expenses [Abstract]",
                            "verboseLabel":  "Expenses"
                            }
                        }
                    },
                "localname":  "OperatingExpensesAbstract",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/AssetsHeldForSaleDetails1"
                    ],
                "xbrltype":  "stringItemType"
                },
            "huge_OperatingLeaseImpactOfPresentValue":  {
                "auth_ref":  [
                    ],
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents operating lease impact of present value.",
                            "label":  "Operating Lease impact of present value",
                            "negatedLabel":  "Less: impact of present value",
                            "verboseLabel":  "Less: impact of present value"
                            }
                        }
                    },
                "localname":  "OperatingLeaseImpactOfPresentValue",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/LeaseObligationsScheduleOfMaturityAnalysisOfOperatingLeasePaymentsDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "huge_OperationalExpensesPayable":  {
                "auth_ref":  [
                    ],
                "calculation":  {
                    "http://www.fsdpharma.com/role/TradeAndOtherPayablesDetails1":  {
                        "order":  0.0,
                        "parentTag":  "ifrs-full_AccrualsClassifiedAsCurrent",
                        "weight":  1.0
                        }
                    },
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represent the amount of accrued operational expenses payable.",
                            "label":  "Operational Expenses Payable",
                            "terseLabel":  "Operational expenses"
                            }
                        }
                    },
                "localname":  "OperationalExpensesPayable",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/TradeAndOtherPayablesDetails1"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "huge_OtherInvestmentsNameOfEntityAxis":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents the name of entities in which company hold interests in other investments.",
                            "label":  "Other Investments, Name Of Entity [Axis]"
                            }
                        }
                    },
                "localname":  "OtherInvestmentsNameOfEntityAxis",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/OtherInvestmentsNarrativeDetails",
                    "http://www.fsdpharma.com/role/OtherInvestmentsScheduleOfOtherInvestmentsDetails",
                    "http://www.fsdpharma.com/role/ShareCapitalNarrativeDetails"
                    ],
                "xbrltype":  "stringItemType"
                },
            "huge_OtherInvestmentsNameOfEntityDomain":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents the name of entities in which company hold interests in other investments.",
                            "label":  "Other Investments, Name Of Entity [Domain]"
                            }
                        }
                    },
                "localname":  "OtherInvestmentsNameOfEntityDomain",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/OtherInvestmentsNarrativeDetails",
                    "http://www.fsdpharma.com/role/OtherInvestmentsScheduleOfOtherInvestmentsDetails",
                    "http://www.fsdpharma.com/role/ShareCapitalNarrativeDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_OtherPrepaidsAndDeposits":  {
                "auth_ref":  [
                    ],
                "calculation":  {
                    "http://www.fsdpharma.com/role/PrepaidExpensesAndDepositsDetails":  {
                        "order":  20.0,
                        "parentTag":  "ifrs-full_CurrentPrepaidExpenses",
                        "weight":  1.0
                        }
                    },
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "The amount of other prepaids and deposits.",
                            "label":  "Other Prepaids And Deposits",
                            "terseLabel":  "Other prepaids and deposits"
                            }
                        }
                    },
                "localname":  "OtherPrepaidsAndDeposits",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/PrepaidExpensesAndDepositsDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "huge_OtherReceivablesRecognisedAsOfAcquisitionDate":  {
                "auth_ref":  [
                    ],
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "The amount recognised as of the acquisition date for other receivables acquired in a business combination.",
                            "label":  "Other Receivables Recognised As Of Acquisition Date",
                            "verboseLabel":  "Other receivables"
                            }
                        }
                    },
                "localname":  "OtherReceivablesRecognisedAsOfAcquisitionDate",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/AcquisitionOfLucidDetails1"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "huge_ParkwayClinicalLaboratoriesMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "This member stands for parkway clinical laboratories.",
                            "label":  "Parkway Clinical Laboratories [Member]",
                            "verboseLabel":  "Parkway Clinical Laboratories"
                            }
                        }
                    },
                "localname":  "ParkwayClinicalLaboratoriesMember",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CommitmentsAndContingenciesNarrativeDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_PartialPaymentOfSettlementAmount":  {
                "auth_ref":  [
                    ],
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents the amount of partial payment for settlement amount.",
                            "label":  "Partial Payment Of Settlement Amount",
                            "terseLabel":  "Partial payment for settlement amount"
                            }
                        }
                    },
                "localname":  "PartialPaymentOfSettlementAmount",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CommitmentsAndContingenciesNarrativeDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "huge_PaymentMadeToBeUnpaidWagesAndUnpaidHoliday":  {
                "auth_ref":  [
                    ],
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents the amount of payment made to be unpaid wages and unpaid holiday.",
                            "label":  "Payment Made To Be Unpaid Wages And Unpaid Holiday",
                            "terseLabel":  "Payment made to be unpaid wages and unpaid holiday"
                            }
                        }
                    },
                "localname":  "PaymentMadeToBeUnpaidWagesAndUnpaidHoliday",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CommitmentsAndContingenciesNarrativeDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "huge_PaymentOfExpenses":  {
                "auth_ref":  [
                    ],
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents the amount of payment of expenses.",
                            "label":  "Payment of expenses"
                            }
                        }
                    },
                "localname":  "PaymentOfExpenses",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/RelatedPartyTransactionsNarrativeDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "huge_PercentageOfDeclineInFairValueOfInvestment":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents the percentage of decline in fair value of investment.",
                            "label":  "Percentage Of Decline In Fair value of investment",
                            "verboseLabel":  "Percentage of decline in fair value of investment"
                            }
                        }
                    },
                "localname":  "PercentageOfDeclineInFairValueOfInvestment",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/OtherInvestmentsNarrativeDetails"
                    ],
                "xbrltype":  "percentItemType"
                },
            "huge_PercentageOfLumpSumPaymentReceivedToPayForNonPrescriptionDrugRights":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents the percentage of lump sum payment received to pay for non prescription drug rights.",
                            "label":  "Percentage of lump sum payment received to pay for non prescription drug rights"
                            }
                        }
                    },
                "localname":  "PercentageOfLumpSumPaymentReceivedToPayForNonPrescriptionDrugRights",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CommitmentsAndContingenciesNarrativeDetails"
                    ],
                "xbrltype":  "percentItemType"
                },
            "huge_PercentageOfNetReceiptsFromCommercialPartnersAsSecondPaymentCondition":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents the percentage of net receipts from commercial partners as second payment condition under the agreement.",
                            "label":  "Percentage of net receipts from commercial partners as second payment condition"
                            }
                        }
                    },
                "localname":  "PercentageOfNetReceiptsFromCommercialPartnersAsSecondPaymentCondition",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CommitmentsAndContingenciesNarrativeDetails"
                    ],
                "xbrltype":  "percentItemType"
                },
            "huge_PercentageOfNetSalesOfLicensedProductAsFirstPaymentCondition":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents the percentage of net sale of licensed product as first payment condition under the agreement.",
                            "label":  "Percentage of net sales of Licensed Product as first payment condition"
                            }
                        }
                    },
                "localname":  "PercentageOfNetSalesOfLicensedProductAsFirstPaymentCondition",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CommitmentsAndContingenciesNarrativeDetails"
                    ],
                "xbrltype":  "percentItemType"
                },
            "huge_PercentageOfNetSalesOrNetReceiptsOfLicensedProductsAsThirdPaymentCondition":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents the percentage of net sales of net receipts of licensed products as third payment condition under the agreement.",
                            "label":  "Percentage of net sales or net receipts of licensed products as third payment condition"
                            }
                        }
                    },
                "localname":  "PercentageOfNetSalesOrNetReceiptsOfLicensedProductsAsThirdPaymentCondition",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CommitmentsAndContingenciesNarrativeDetails"
                    ],
                "xbrltype":  "percentItemType"
                },
            "huge_PercentageOfOneOffLumpSumPaymentToPayForPrescriptionDrugRights":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents the percentage of one off lump sum payment to pay for prescription drug rights.",
                            "label":  "Percentage of one off lump sum payment to pay for prescription drug rights"
                            }
                        }
                    },
                "localname":  "PercentageOfOneOffLumpSumPaymentToPayForPrescriptionDrugRights",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CommitmentsAndContingenciesNarrativeDetails"
                    ],
                "xbrltype":  "percentItemType"
                },
            "huge_PharmadrugIncMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Pharmadrug Inc",
                            "label":  "Pharmadrug Inc [Member]",
                            "verboseLabel":  "Pharmadrug Inc."
                            }
                        }
                    },
                "localname":  "PharmadrugIncMember",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/OtherInvestmentsNarrativeDetails",
                    "http://www.fsdpharma.com/role/OtherInvestmentsScheduleOfOtherInvestmentsDetails",
                    "http://www.fsdpharma.com/role/ShareCapitalNarrativeDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_PharmadrugProductionGMBHMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Pharmadrug Production GMBH",
                            "label":  "Pharmadrug Production G M B H [Member]",
                            "verboseLabel":  "Pharmadrug Production GMBH"
                            }
                        }
                    },
                "localname":  "PharmadrugProductionGMBHMember",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CommitmentsAndContingenciesScheduleOfQuantitiesOfCannabisAvailableToSupplyByFiscalPeriodDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_PreacquisitionNetOperatingLossCarryforwards":  {
                "auth_ref":  [
                    ],
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents preacquisition net operating loss carryforwards.",
                            "label":  "Preacquisition Net Operating Loss Carryforwards",
                            "terseLabel":  "Preacquisition net operating loss carryforwards"
                            }
                        }
                    },
                "localname":  "PreacquisitionNetOperatingLossCarryforwards",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/IncomeTaxesNarrativeDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "huge_PrepaidExpensesAndDepositsAbstract":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "label":  "Prepaid Expenses And Deposits [Abstract]"
                            }
                        }
                    },
                "localname":  "PrepaidExpensesAndDepositsAbstract",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "xbrltype":  "stringItemType"
                },
            "huge_PrepaidExpensesAndDepositsExplanatory":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "The disclosure of prepaid expenses and deposits.",
                            "label":  "Prepaid Expenses And Deposits Explanatory",
                            "terseLabel":  "Prepaid expenses and deposits"
                            }
                        }
                    },
                "localname":  "PrepaidExpensesAndDepositsExplanatory",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/PrepaidExpensesAndDeposits"
                    ],
                "xbrltype":  "textBlockItemType"
                },
            "huge_PrepaidInsurance":  {
                "auth_ref":  [
                    ],
                "calculation":  {
                    "http://www.fsdpharma.com/role/PrepaidExpensesAndDepositsDetails":  {
                        "order":  0.0,
                        "parentTag":  "ifrs-full_CurrentPrepaidExpenses",
                        "weight":  1.0
                        }
                    },
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "The amount of prepaid insurance.",
                            "label":  "Prepaid Insurance",
                            "terseLabel":  "Insurance"
                            }
                        }
                    },
                "localname":  "PrepaidInsurance",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/PrepaidExpensesAndDepositsDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "huge_PrepaidResearchAndDevelopment":  {
                "auth_ref":  [
                    ],
                "calculation":  {
                    "http://www.fsdpharma.com/role/PrepaidExpensesAndDepositsDetails":  {
                        "order":  10.0,
                        "parentTag":  "ifrs-full_CurrentPrepaidExpenses",
                        "weight":  1.0
                        }
                    },
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "The amount of prepaid research and development.",
                            "label":  "Prepaid Research And Development",
                            "terseLabel":  "Research and development"
                            }
                        }
                    },
                "localname":  "PrepaidResearchAndDevelopment",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/PrepaidExpensesAndDepositsDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "huge_PresidentAndChiefExecutiveOfficerMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "This member stands for president and chief executive officer.",
                            "label":  "President And Chief Executive Officer [Member]",
                            "terseLabel":  "Former President and CEO"
                            }
                        }
                    },
                "localname":  "PresidentAndChiefExecutiveOfficerMember",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/RelatedPartyTransactionsNarrativeDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_PresidentOfFSDMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents president of FSD member.",
                            "label":  "President Of F S D [Member]",
                            "verboseLabel":  "President of FSD"
                            }
                        }
                    },
                "localname":  "PresidentOfFSDMember",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/RelatedPartyTransactionsNarrativeDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_PresidentsMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "label":  "Presidents [Member]",
                            "verboseLabel":  "President"
                            }
                        }
                    },
                "localname":  "PresidentsMember",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/RelatedPartyTransactionsNarrativeDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_PrincipalAmountOfBorrowings":  {
                "auth_ref":  [
                    ],
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents the amount related to principal amount of borrowings.",
                            "label":  "Principal amount of borrowings",
                            "verboseLabel":  "Principal amount of convertible debenture"
                            }
                        }
                    },
                "localname":  "PrincipalAmountOfBorrowings",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/OtherInvestmentsNarrativeDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "huge_PrismicPharmaceuticalMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents prismic pharmaceutical member.",
                            "label":  "Prismic Pharmaceutical [Member]",
                            "terseLabel":  "Prismic",
                            "verboseLabel":  "Prismic Pharmaceuticals Inc. (\"Prismic\")"
                            }
                        }
                    },
                "localname":  "PrismicPharmaceuticalMember",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/AcquisitionOfPrismicPharmaceutical",
                    "http://www.fsdpharma.com/role/AcquisitionOfPrismicPharmaceuticalNarrativeDetails",
                    "http://www.fsdpharma.com/role/AcquisitionOfPrismicPharmaceuticalScheduleOfBlackScholesOptionsPricingModelDetails",
                    "http://www.fsdpharma.com/role/AcquisitionOfPrismicPharmaceuticalScheduleOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedDetails",
                    "http://www.fsdpharma.com/role/AcquisitionOfPrismicPharmaceuticalTables",
                    "http://www.fsdpharma.com/role/NotesPayableNarrativeDetails",
                    "http://www.fsdpharma.com/role/ShareCapitalNarrativeDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_PrismicPharmaceuticalsIncMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Information about Prismic Pharmaceuticals Inc.",
                            "label":  "Prismic Pharmaceuticals Inc [Member]",
                            "terseLabel":  "Prismic",
                            "verboseLabel":  "Prismic Pharmaceuticals Inc. (\"Prismic\")"
                            }
                        }
                    },
                "localname":  "PrismicPharmaceuticalsIncMember",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/IntangibleAssetsNarrativeDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_ProceedsFromSaleOfSharesAndWarrants":  {
                "auth_ref":  [
                    ],
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents the amount related to proceeds from sale of shares and warrants.",
                            "label":  "Proceeds from sale of shares and warrants"
                            }
                        }
                    },
                "localname":  "ProceedsFromSaleOfSharesAndWarrants",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/OtherInvestmentsNarrativeDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "huge_ProceedsFromSalesOfInventory":  {
                "auth_ref":  [
                    ],
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "The cash inflow from sales of inventory.",
                            "label":  "Proceeds From Sales Of Inventory",
                            "verboseLabel":  "Proceeds from sales of inventories"
                            }
                        }
                    },
                "localname":  "ProceedsFromSalesOfInventory",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/AssetsHeldForSaleDetailTextuals"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "huge_ProductionEquipmentMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents production equipment.",
                            "label":  "Production equipment [Member]",
                            "terseLabel":  "Production equipment",
                            "verboseLabel":  "Production equipment"
                            }
                        }
                    },
                "localname":  "ProductionEquipmentMember",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/SignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfAssetsDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_ProfessionalFeesPayable":  {
                "auth_ref":  [
                    ],
                "calculation":  {
                    "http://www.fsdpharma.com/role/TradeAndOtherPayablesDetails1":  {
                        "order":  10.0,
                        "parentTag":  "ifrs-full_AccrualsClassifiedAsCurrent",
                        "weight":  1.0
                        }
                    },
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represent the amount of accrued professional fees payable.",
                            "label":  "Professional Fees Payable",
                            "terseLabel":  "Professional fees"
                            }
                        }
                    },
                "localname":  "ProfessionalFeesPayable",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/TradeAndOtherPayablesDetails1"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "huge_ProfitLossBeforeOtherIncomeAndGainLossOnSaleOfEquipmentFromDiscontinuedOperations":  {
                "auth_ref":  [
                    ],
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents the profit (loss) before other income and gain (loss) on sale of equipment from discontinued operations.",
                            "label":  "Profit (Loss) Before Other Income And Gain (Loss) On Sale Of Equipment From Discontinued Operations",
                            "verboseLabel":  "Loss from discontinued operations"
                            }
                        }
                    },
                "localname":  "ProfitLossBeforeOtherIncomeAndGainLossOnSaleOfEquipmentFromDiscontinuedOperations",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/AssetsHeldForSaleDetails1"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "huge_ProfitLossOnChangeInFairValue":  {
                "auth_ref":  [
                    ],
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "It represents profit loss on change in fair value.",
                            "label":  "Profit Loss On Change In Fair Value",
                            "verboseLabel":  "Gain on change in fair value"
                            }
                        }
                    },
                "localname":  "ProfitLossOnChangeInFairValue",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/WarrantsLiabilityDetailTextuals"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "huge_ProvisionForEmployeeRelatedLiability":  {
                "auth_ref":  [
                    ],
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents information about provision for employee related liability.",
                            "label":  "Provision For Employee Related Liability",
                            "terseLabel":  "Provision for employee related liability"
                            }
                        }
                    },
                "localname":  "ProvisionForEmployeeRelatedLiability",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CommitmentsAndContingenciesNarrativeDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "huge_PunitiveDamagesAmount":  {
                "auth_ref":  [
                    ],
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents punitive damages amount.",
                            "label":  "Punitive Damages Amount",
                            "verboseLabel":  "Punitive damages"
                            }
                        }
                    },
                "localname":  "PunitiveDamagesAmount",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CommitmentsAndContingenciesNarrativeDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "huge_QuantitiesAvailableToSupplyInFifthFiscalYear":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents the quantities available to supply in fifth fiscal year from the balance sheet fiscal year.",
                            "label":  "Quantities available to supply in fifth fiscal year",
                            "verboseLabel":  "2023"
                            }
                        }
                    },
                "localname":  "QuantitiesAvailableToSupplyInFifthFiscalYear",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CommitmentsAndContingenciesScheduleOfQuantitiesOfCannabisAvailableToSupplyByFiscalPeriodDetails"
                    ],
                "xbrltype":  "massItemType"
                },
            "huge_QuantitiesAvailableToSupplyInFourthFiscalYear":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents the quantities available to supply in fourth fiscal year from the balance sheet fiscal year.",
                            "label":  "Quantities available to supply in fourth fiscal year",
                            "verboseLabel":  "2024"
                            }
                        }
                    },
                "localname":  "QuantitiesAvailableToSupplyInFourthFiscalYear",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CommitmentsAndContingenciesScheduleOfQuantitiesOfCannabisAvailableToSupplyByFiscalPeriodDetails"
                    ],
                "xbrltype":  "massItemType"
                },
            "huge_QuantitiesAvailableToSupplyInNextFiscalYear":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents the quantities available to supply in next fiscal year from the balance sheet fiscal year.",
                            "label":  "Quantities Available To Supply in Next Fiscal Year",
                            "verboseLabel":  "2020"
                            }
                        }
                    },
                "localname":  "QuantitiesAvailableToSupplyInNextFiscalYear",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CommitmentsAndContingenciesScheduleOfQuantitiesOfCannabisAvailableToSupplyByFiscalPeriodDetails"
                    ],
                "xbrltype":  "massItemType"
                },
            "huge_QuantitiesAvailableToSupplyInSecondFiscalYear":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents the quantities available to supply in second fiscal year from the balance sheet fiscal year.",
                            "label":  "Quantities available to supply in second fiscal year",
                            "verboseLabel":  "2021"
                            }
                        }
                    },
                "localname":  "QuantitiesAvailableToSupplyInSecondFiscalYear",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CommitmentsAndContingenciesScheduleOfQuantitiesOfCannabisAvailableToSupplyByFiscalPeriodDetails"
                    ],
                "xbrltype":  "massItemType"
                },
            "huge_QuantitiesAvailableToSupplyInThirdFiscalYear":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents the quantities available to supply in third fiscal year from the balance sheet fiscal year.",
                            "label":  "Quantities available to supply in third fiscal year",
                            "verboseLabel":  "2022"
                            }
                        }
                    },
                "localname":  "QuantitiesAvailableToSupplyInThirdFiscalYear",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CommitmentsAndContingenciesScheduleOfQuantitiesOfCannabisAvailableToSupplyByFiscalPeriodDetails"
                    ],
                "xbrltype":  "massItemType"
                },
            "huge_QuotedMarketPriceOfInvestments":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents the price per share related to quoted market price of investment.",
                            "label":  "Quoted Market Price Of Investments",
                            "verboseLabel":  "Quoted market price of investments"
                            }
                        }
                    },
                "localname":  "QuotedMarketPriceOfInvestments",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/OtherInvestmentsNarrativeDetails"
                    ],
                "xbrltype":  "perShareItemType"
                },
            "huge_RazaBokhariMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "This member stands for Raza Bokhari.",
                            "label":  "Raza Bokhari [Member]",
                            "terseLabel":  "Raza Bokhari"
                            }
                        }
                    },
                "localname":  "RazaBokhariMember",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/RelatedPartyTransactionsNarrativeDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_ReimbursedExpenses":  {
                "auth_ref":  [
                    ],
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represent the amount of reimbursed expenses.",
                            "label":  "Reimbursed Expenses",
                            "terseLabel":  "Reimbursed expenses incurred in relation to requisitioning, calling and holding the shareholders' meeting"
                            }
                        }
                    },
                "localname":  "ReimbursedExpenses",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/RelatedPartyTransactionsNarrativeDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "huge_ReplacementShareOptionsMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "This member stands for replacement share options.",
                            "label":  "Replacement Share Options [Member]",
                            "terseLabel":  "Replacement share options"
                            }
                        }
                    },
                "localname":  "ReplacementShareOptionsMember",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/SharebasedCompensationNarrativeDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_RiskFreeInterestRateOfWarrantsGranted":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents risk free interest rate of warrants granted.",
                            "label":  "Risk free interest rate of warrants granted",
                            "terseLabel":  "Risk free interest rate",
                            "verboseLabel":  "Warrants risk free interest rate"
                            }
                        }
                    },
                "localname":  "RiskFreeInterestRateOfWarrantsGranted",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/AcquisitionOfLucidDetails",
                    "http://www.fsdpharma.com/role/AcquisitionOfPrismicPharmaceuticalScheduleOfBlackScholesOptionsPricingModelDetails",
                    "http://www.fsdpharma.com/role/ShareCapitalNarrativeDetails",
                    "http://www.fsdpharma.com/role/ShareCapitalScheduleOfFairValueAssumptionsOfWarrantsDetails",
                    "http://www.fsdpharma.com/role/WarrantsLiabilityDetailTextuals"
                    ],
                "xbrltype":  "percentItemType"
                },
            "huge_RiskFreeInterestRateOfWarrantsLiability":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents risk free interest rate of warrants liability.",
                            "label":  "Risk Free Interest Rate Of Warrants Liability"
                            }
                        }
                    },
                "localname":  "RiskFreeInterestRateOfWarrantsLiability",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/WarrantsLiabilityDetailTextuals"
                    ],
                "xbrltype":  "percentItemType"
                },
            "huge_RiskFreeRateOfWarrants":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents the risk free rate of warrants.",
                            "label":  "Risk Free Rate Of Warrants",
                            "verboseLabel":  "Risk free rate of warrants"
                            }
                        }
                    },
                "localname":  "RiskFreeRateOfWarrants",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/OtherInvestmentsNarrativeDetails"
                    ],
                "xbrltype":  "percentItemType"
                },
            "huge_SalesTaxRecoverable":  {
                "auth_ref":  [
                    ],
                "calculation":  {
                    "http://www.fsdpharma.com/role/TradeAndOtherReceivablesScheduleOfTradeAndOtherReceivablesDetails":  {
                        "order":  0.0,
                        "parentTag":  "ifrs-full_TradeAndOtherReceivables",
                        "weight":  1.0
                        }
                    },
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "The amount for sales taxes recoverable.",
                            "label":  "Sales tax recoverable",
                            "terseLabel":  "Sales tax recoverable",
                            "verboseLabel":  "Sales taxes recoverable"
                            }
                        }
                    },
                "localname":  "SalesTaxRecoverable",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/TradeAndOtherReceivablesScheduleOfTradeAndOtherReceivablesDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "huge_ScheduleOfCashFlowsFromDiscontinuedOperationsExplanatory":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "The disclosure of detailed information about the cash flows from discontinued operations.",
                            "label":  "Schedule Of Cash Flows From Discontinued Operations Explanatory",
                            "verboseLabel":  "Schedule of cash flows from discontinued operations"
                            }
                        }
                    },
                "localname":  "ScheduleOfCashFlowsFromDiscontinuedOperationsExplanatory",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/AssetsHeldForSaleTables"
                    ],
                "xbrltype":  "textBlockItemType"
                },
            "huge_ScheduleOfComponentsOfAssetsHeldForSaleExplanatory":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "The disclosure of detailed information about the assets held for sale.",
                            "label":  "Schedule Of Components Of Assets Held For Sale Explanatory",
                            "verboseLabel":  "Schedule of components of assets held for sale"
                            }
                        }
                    },
                "localname":  "ScheduleOfComponentsOfAssetsHeldForSaleExplanatory",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/AssetsHeldForSaleTables"
                    ],
                "xbrltype":  "textBlockItemType"
                },
            "huge_ScheduleOfNetLossAndComprehensiveLossFromDiscontinuedOperationsExplanatory":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "The disclosure of detailed information about the net loss and comprehensive loss from discontinued operations.",
                            "label":  "Schedule Of Net Loss And Comprehensive Loss From Discontinued Operations Explanatory",
                            "verboseLabel":  "Schedule of net loss and comprehensive loss from discontinued operations"
                            }
                        }
                    },
                "localname":  "ScheduleOfNetLossAndComprehensiveLossFromDiscontinuedOperationsExplanatory",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/AssetsHeldForSaleTables"
                    ],
                "xbrltype":  "textBlockItemType"
                },
            "huge_ScheduleOfNonCapitalLossCarryforwardsTableTextBlock":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Schedule of non-capital loss carryforwards.",
                            "label":  "Schedule Of Non Capital Loss Carryforwards [Table Text Block]",
                            "terseLabel":  "Schedule of non-capital loss carryforwards"
                            }
                        }
                    },
                "localname":  "ScheduleOfNonCapitalLossCarryforwardsTableTextBlock",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/IncometaxesTables"
                    ],
                "xbrltype":  "textBlockItemType"
                },
            "huge_ScheduleOfStockClassLineItems":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents schedule of stock by class [Line item].",
                            "label":  "Schedule Of Stock Class [Line Items]"
                            }
                        }
                    },
                "localname":  "ScheduleOfStockClassLineItems",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
                    ],
                "xbrltype":  "stringItemType"
                },
            "huge_ScheduleOfStockClassTable":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents schedule of stock by class [Table].",
                            "label":  "Schedule Of Stock Class [Table]"
                            }
                        }
                    },
                "localname":  "ScheduleOfStockClassTable",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
                    ],
                "xbrltype":  "stringItemType"
                },
            "huge_SchedulesOfEstimatedUsefulLivesOfAssetsExplanatory":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents information related to estimated useful lives of assets.",
                            "label":  "Schedules Of Estimated Useful Lives Of Assets Explanatory",
                            "verboseLabel":  "Schedule of estimated useful lives of assets"
                            }
                        }
                    },
                "localname":  "SchedulesOfEstimatedUsefulLivesOfAssetsExplanatory",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/SignificantAccountingPoliciesTables"
                    ],
                "xbrltype":  "textBlockItemType"
                },
            "huge_ScicannTherapeuticsIncMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "SciCann Therapeutics Inc",
                            "label":  "Scicann Therapeutics Inc [Member]",
                            "verboseLabel":  "SciCann Therapeutics Inc."
                            }
                        }
                    },
                "localname":  "ScicannTherapeuticsIncMember",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/OtherInvestmentsNarrativeDetails",
                    "http://www.fsdpharma.com/role/OtherInvestmentsScheduleOfOtherInvestmentsDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_SecuritiesExchangeAgreementMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "label":  "Securities Exchange Agreement [Member]",
                            "verboseLabel":  "Share Exchange Agreement"
                            }
                        }
                    },
                "localname":  "SecuritiesExchangeAgreementMember",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/OtherInvestmentsNarrativeDetails",
                    "http://www.fsdpharma.com/role/ShareCapitalNarrativeDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_SecurityDepositInRespectOfAmountClaimedAndEstimatedLegalFees":  {
                "auth_ref":  [
                    ],
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents the amount of security deposit with the court in respect of amount claimed and estimated legal fees.",
                            "label":  "Security Deposit In Respect Of Amount Claimed And Estimated Legal Fees",
                            "verboseLabel":  "Security deposit in respect of amount claimed and estimated legal fees"
                            }
                        }
                    },
                "localname":  "SecurityDepositInRespectOfAmountClaimedAndEstimatedLegalFees",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CommitmentsAndContingenciesNarrativeDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "huge_SeveranceAndDamagesAmount":  {
                "auth_ref":  [
                    ],
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents amount of severance and damages.",
                            "label":  "Severance And Damages Amount",
                            "verboseLabel":  "Severance and damages amount"
                            }
                        }
                    },
                "localname":  "SeveranceAndDamagesAmount",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CommitmentsAndContingenciesNarrativeDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "huge_SeverancePayable":  {
                "auth_ref":  [
                    ],
                "calculation":  {
                    "http://www.fsdpharma.com/role/TradeAndOtherPayablesDetails1":  {
                        "order":  30.0,
                        "parentTag":  "ifrs-full_AccrualsClassifiedAsCurrent",
                        "weight":  1.0
                        }
                    },
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represent the amount of accrued severance payable.",
                            "label":  "Severance Payable",
                            "terseLabel":  "Severance"
                            }
                        }
                    },
                "localname":  "SeverancePayable",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/TradeAndOtherPayablesDetails1"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "huge_ShareBasedPaymentExpenses":  {
                "auth_ref":  [
                    ],
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "It represents share based payment expenses.",
                            "label":  "Share Based Payment Expenses",
                            "verboseLabel":  "Share based payment expenses"
                            }
                        }
                    },
                "localname":  "ShareBasedPaymentExpenses",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/ShareCapitalNarrativeDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "huge_ShareExchangeAgreementMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Share Exchange Agreement.",
                            "label":  "Share Exchange Agreement [Member]",
                            "verboseLabel":  "Share exchange agreement"
                            }
                        }
                    },
                "localname":  "ShareExchangeAgreementMember",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/OtherInvestmentsNarrativeDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_ShareIssuanceCostBookedDirectlyToEquity":  {
                "auth_ref":  [
                    ],
                "calculation":  {
                    "http://www.fsdpharma.com/role/IncomeTaxesScheduleOfProvisionForIncomeTaxesDetails":  {
                        "order":  0.0,
                        "parentTag":  "ifrs-full_DeferredTaxExpenseIncome",
                        "weight":  1.0
                        }
                    },
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "It represents share issuance cost booked directly to equity.",
                            "label":  "Share Issuance Cost Booked Directly To Equity",
                            "verboseLabel":  "Share issuance cost booked directly to equity"
                            }
                        }
                    },
                "localname":  "ShareIssuanceCostBookedDirectlyToEquity",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/IncomeTaxesScheduleOfProvisionForIncomeTaxesDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "huge_ShareIssuePricePerShare":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents the price per share of shares issued.",
                            "label":  "Share issue price per share"
                            }
                        }
                    },
                "localname":  "ShareIssuePricePerShare",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/AcquisitionOfLucidDetailTextuals",
                    "http://www.fsdpharma.com/role/AcquisitionOfPrismicPharmaceuticalNarrativeDetails",
                    "http://www.fsdpharma.com/role/OtherInvestmentsNarrativeDetails",
                    "http://www.fsdpharma.com/role/ShareCapitalNarrativeDetails"
                    ],
                "xbrltype":  "perShareItemType"
                },
            "huge_ShareOptionsAbstract":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "label":  "Share Options [Abstract]"
                            }
                        }
                    },
                "localname":  "ShareOptionsAbstract",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/AcquisitionOfLucidDetails",
                    "http://www.fsdpharma.com/role/AcquisitionOfPrismicPharmaceuticalScheduleOfBlackScholesOptionsPricingModelDetails"
                    ],
                "xbrltype":  "stringItemType"
                },
            "huge_SharePriceOfSharesAndWarrants":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents the price per share related to share price of shares and warrants.",
                            "label":  "Share price of shares and warrants"
                            }
                        }
                    },
                "localname":  "SharePriceOfSharesAndWarrants",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/OtherInvestmentsNarrativeDetails"
                    ],
                "xbrltype":  "perShareItemType"
                },
            "huge_SharePrices":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents Share price per share.",
                            "label":  "Share Prices",
                            "terseLabel":  "Share price per share",
                            "verboseLabel":  "Par value of shares issued"
                            }
                        }
                    },
                "localname":  "SharePrices",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/OtherInvestmentsNarrativeDetails",
                    "http://www.fsdpharma.com/role/ShareCapitalNarrativeDetails",
                    "http://www.fsdpharma.com/role/WarrantsLiabilityDetailTextuals"
                    ],
                "xbrltype":  "perShareItemType"
                },
            "huge_SharePricesOfWarrantsLiability":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "It represents share price of warrants liability.",
                            "label":  "Share Prices Of Warrants Liability"
                            }
                        }
                    },
                "localname":  "SharePricesOfWarrantsLiability",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/WarrantsLiabilityDetailTextuals"
                    ],
                "xbrltype":  "perShareItemType"
                },
            "huge_SharePurchaseAndSaleAgreementsMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "This member stands for share purchase and sale agreements.",
                            "label":  "Share Purchase and Sale Agreements [Member]",
                            "verboseLabel":  "Share Purchase and Sale Agreements"
                            }
                        }
                    },
                "localname":  "SharePurchaseAndSaleAgreementsMember",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/OtherInvestmentsNarrativeDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_ShareSplitRatio":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents the share split ratio.",
                            "label":  "Share Split Ratio",
                            "terseLabel":  "Share split ratio"
                            }
                        }
                    },
                "localname":  "ShareSplitRatio",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/ShareCapitalNarrativeDetails"
                    ],
                "xbrltype":  "pureItemType"
                },
            "huge_SharesAuthorizedForIssuanceAsSharebasedAwards":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Shares authorized for issuance as share-based awards",
                            "label":  "Shares authorized for issuance as share-based awards"
                            }
                        }
                    },
                "localname":  "SharesAuthorizedForIssuanceAsSharebasedAwards",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CommitmentsAndContingenciesNarrativeDetails"
                    ],
                "xbrltype":  "sharesItemType"
                },
            "huge_SolarvestBioEnergyIncMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Solarvest BioEnergy Inc.",
                            "label":  "Solarvest Bio Energy Inc [Member]",
                            "verboseLabel":  "Solarvest BioEnergy Inc."
                            }
                        }
                    },
                "localname":  "SolarvestBioEnergyIncMember",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/OtherInvestmentsNarrativeDetails",
                    "http://www.fsdpharma.com/role/OtherInvestmentsScheduleOfOtherInvestmentsDetails",
                    "http://www.fsdpharma.com/role/ShareCapitalNarrativeDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_StockIssuedDuringPeriodSharesIssuedForService":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Number of shares issued in lieu of cash for services contributed to the entity.",
                            "label":  "Stock Issued During Period, Shares, Issued For Service",
                            "terseLabel":  "Shares issued for service"
                            }
                        }
                    },
                "localname":  "StockIssuedDuringPeriodSharesIssuedForService",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/SubsequentEventsNarrativeDetails"
                    ],
                "xbrltype":  "sharesItemType"
                },
            "huge_StockOptionsMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represenr the information of stock option.",
                            "label":  "Stock Options [Member]",
                            "verboseLabel":  "Stock options"
                            }
                        }
                    },
                "localname":  "StockOptionsMember",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/AcquisitionOfLucidDetailTextuals",
                    "http://www.fsdpharma.com/role/AcquisitionOfPrismicPharmaceuticalNarrativeDetails",
                    "http://www.fsdpharma.com/role/LossPerShareDetails",
                    "http://www.fsdpharma.com/role/SharebasedCompensationNarrativeDetails",
                    "http://www.fsdpharma.com/role/SharebasedCompensationScheduleOfChangesInNumberOfShareOptionsDetails",
                    "http://www.fsdpharma.com/role/SharebasedCompensationScheduleOfExercisePriceAndWeightedAverageContractualTermOfShareOptionsOutstandingAndExercisableDetails",
                    "http://www.fsdpharma.com/role/SharebasedCompensationScheduleOfFairValueAssumptionsOfShareOptionsGrantedDetails",
                    "http://www.fsdpharma.com/role/SharebasedCompensationScheduleOfSharebasedCompensationDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_SubscriptionPricePerShare":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents the subscription price per share.",
                            "label":  "Subscription Price Per Share",
                            "verboseLabel":  "Subscription price per share"
                            }
                        }
                    },
                "localname":  "SubscriptionPricePerShare",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/OtherInvestmentsNarrativeDetails"
                    ],
                "xbrltype":  "perShareItemType"
                },
            "huge_SubsequentEventsMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Information about subsequent events.",
                            "label":  "Subsequent Events [Member]",
                            "verboseLabel":  "Subsequent events"
                            }
                        }
                    },
                "localname":  "SubsequentEventsMember",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/OtherInvestmentsNarrativeDetails",
                    "http://www.fsdpharma.com/role/SubsequentEventsNarrativeDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_SubsidiariesOneMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "label":  "Subsidiaries one [Member]",
                            "verboseLabel":  "Prismic Pharmaceuticals Inc."
                            }
                        }
                    },
                "localname":  "SubsidiariesOneMember",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/NatureOfBusinessScheduleOfOwnershipPercentageInSubsidiariesDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_SubsidiariesTwoMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents subsidiaries two member.",
                            "label":  "Subsidiaries two [Member]",
                            "verboseLabel":  "FV Pharma Inc."
                            }
                        }
                    },
                "localname":  "SubsidiariesTwoMember",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/NatureOfBusinessScheduleOfOwnershipPercentageInSubsidiariesDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_SummaryOfSignificantAccountingPoliciesAbstract":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "label":  "Summary Of Significant Accounting Policies [Abstract]"
                            }
                        }
                    },
                "localname":  "SummaryOfSignificantAccountingPoliciesAbstract",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "xbrltype":  "stringItemType"
                },
            "huge_SummaryOfSignificantAccountingPoliciesTable":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents summary of significant accounting policies table.",
                            "label":  "Summary Of Significant Accounting Policies [Table]"
                            }
                        }
                    },
                "localname":  "SummaryOfSignificantAccountingPoliciesTable",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/SignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfAssetsDetails"
                    ],
                "xbrltype":  "stringItemType"
                },
            "huge_SupplyAgreementMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Information about supply agreement.",
                            "label":  "Supply Agreement [Member]",
                            "verboseLabel":  "Supply agreement"
                            }
                        }
                    },
                "localname":  "SupplyAgreementMember",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CommitmentsAndContingenciesNarrativeDetails",
                    "http://www.fsdpharma.com/role/CommitmentsAndContingenciesScheduleOfQuantitiesOfCannabisAvailableToSupplyByFiscalPeriodDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_TaxEffectOfDeferredTaxAssetNotRecognized":  {
                "auth_ref":  [
                    ],
                "calculation":  {
                    "http://www.fsdpharma.com/role/IncomeTaxesScheduleOfProvisionForIncomeTaxesDetails":  {
                        "order":  10.0,
                        "parentTag":  "ifrs-full_DeferredTaxExpenseIncome",
                        "weight":  1.0
                        }
                    },
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents the amount related to tax effect of deferred tax asset not recognized.",
                            "label":  "Tax effect of deferred tax asset not recognized",
                            "terseLabel":  "Change in tax benefits not recognized"
                            }
                        }
                    },
                "localname":  "TaxEffectOfDeferredTaxAssetNotRecognized",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/IncomeTaxesScheduleOfProvisionForIncomeTaxesDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "huge_TotalCashTransactionCosts":  {
                "auth_ref":  [
                    ],
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "It represents total cash transaction costs.",
                            "label":  "Total Cash Transaction Costs",
                            "verboseLabel":  "Total cash transaction costs"
                            }
                        }
                    },
                "localname":  "TotalCashTransactionCosts",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/ShareCapitalNarrativeDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "huge_TransactionCostsAllocatedToWarrants":  {
                "auth_ref":  [
                    ],
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "It represents transaction costs allocated to warrants.",
                            "label":  "Transaction Costs Allocated To Warrants",
                            "verboseLabel":  "Transaction costs allocated to warrants"
                            }
                        }
                    },
                "localname":  "TransactionCostsAllocatedToWarrants",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/ShareCapitalNarrativeDetails",
                    "http://www.fsdpharma.com/role/WarrantsLiabilityDetailTextuals"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "huge_TruePharmaStripIncMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "This member stands for True Pharma Strip Inc.",
                            "label":  "True Pharma Strip Inc [Member]",
                            "terseLabel":  "True Pharma Strip Inc."
                            }
                        }
                    },
                "localname":  "TruePharmaStripIncMember",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/OtherInvestmentsNarrativeDetails",
                    "http://www.fsdpharma.com/role/OtherInvestmentsScheduleOfOtherInvestmentsDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_TwoPointNineOneMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Exercise price 2.91.",
                            "label":  "Two Point Nine One [Member]",
                            "terseLabel":  "2.91"
                            }
                        }
                    },
                "localname":  "TwoPointNineOneMember",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/SharebasedCompensationScheduleOfExercisePriceAndWeightedAverageContractualTermOfShareOptionsOutstandingAndExercisableDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_TwoPointTwoFiveMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Exercise price 2.25.",
                            "label":  "Two Point Two Five [Member]",
                            "terseLabel":  "2.25"
                            }
                        }
                    },
                "localname":  "TwoPointTwoFiveMember",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/SharebasedCompensationScheduleOfExercisePriceAndWeightedAverageContractualTermOfShareOptionsOutstandingAndExercisableDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_TypeOfArrangementsAxis":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "label":  "Type Of Arrangements [Axis]"
                            }
                        }
                    },
                "localname":  "TypeOfArrangementsAxis",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CommitmentsAndContingenciesNarrativeDetails",
                    "http://www.fsdpharma.com/role/CommitmentsAndContingenciesScheduleOfQuantitiesOfCannabisAvailableToSupplyByFiscalPeriodDetails",
                    "http://www.fsdpharma.com/role/IntangibleAssetsNarrativeDetails",
                    "http://www.fsdpharma.com/role/OtherInvestmentsNarrativeDetails",
                    "http://www.fsdpharma.com/role/ShareCapitalNarrativeDetails"
                    ],
                "xbrltype":  "stringItemType"
                },
            "huge_TypeOfArrangementsDomain":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "label":  "Type Of Arrangements [Domain]"
                            }
                        }
                    },
                "localname":  "TypeOfArrangementsDomain",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CommitmentsAndContingenciesNarrativeDetails",
                    "http://www.fsdpharma.com/role/CommitmentsAndContingenciesScheduleOfQuantitiesOfCannabisAvailableToSupplyByFiscalPeriodDetails",
                    "http://www.fsdpharma.com/role/IntangibleAssetsNarrativeDetails",
                    "http://www.fsdpharma.com/role/OtherInvestmentsNarrativeDetails",
                    "http://www.fsdpharma.com/role/ShareCapitalNarrativeDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_UndiscountedLeasePaymentsPayable":  {
                "auth_ref":  [
                    ],
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents the amount related to undiscounted lease payments payable.",
                            "label":  "Undiscounted lease payments payable",
                            "verboseLabel":  "Total undiscounted lease payments payable"
                            }
                        }
                    },
                "localname":  "UndiscountedLeasePaymentsPayable",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/LeaseObligationsScheduleOfMaturityAnalysisOfOperatingLeasePaymentsDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "huge_UnrestrictedClassBSharesMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents unrestricted Class B shares.",
                            "label":  "Unrestricted Class B Shares [Member]",
                            "verboseLabel":  "Unrestricted Class B shares"
                            }
                        }
                    },
                "localname":  "UnrestrictedClassBSharesMember",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/OtherInvestmentsNarrativeDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_ValueOfSharesAcquired":  {
                "auth_ref":  [
                    ],
                "crdr":  "debit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents value of shares acquired.",
                            "label":  "Value Of Shares Acquired",
                            "verboseLabel":  "Value of shares acquired"
                            }
                        }
                    },
                "localname":  "ValueOfSharesAcquired",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/OtherInvestmentsNarrativeDetails",
                    "http://www.fsdpharma.com/role/ShareCapitalNarrativeDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "huge_ValueOfSharesIssued":  {
                "auth_ref":  [
                    ],
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents the amount related to shares issued during the period.",
                            "label":  "Value of shares issued",
                            "negatedLabel":  "Gain (loss) on sale of investment"
                            }
                        }
                    },
                "localname":  "ValueOfSharesIssued",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/ShareCapitalNarrativeDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "huge_ValueOfSharesIssuedForDebtSettlement":  {
                "auth_ref":  [
                    ],
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents amount of shares issued for debt settlement.",
                            "label":  "Value of shares issued for debt settlement",
                            "verboseLabel":  "Value of shares issued for debt settlement"
                            }
                        }
                    },
                "localname":  "ValueOfSharesIssuedForDebtSettlement",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/ShareCapitalNarrativeDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "huge_ValueOfSharesIssuedInShareExchange":  {
                "auth_ref":  [
                    ],
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents the amount related to shares issued in share exchange.",
                            "label":  "Value of shares issued in share exchange",
                            "verboseLabel":  "Value of shares issued in share exchange"
                            }
                        }
                    },
                "localname":  "ValueOfSharesIssuedInShareExchange",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/OtherInvestmentsNarrativeDetails",
                    "http://www.fsdpharma.com/role/ShareCapitalNarrativeDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "huge_ValueOfSubscribedEquityUnitsInBrokeredPrivatePlacement":  {
                "auth_ref":  [
                    ],
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents the value of subscribed equity units in brokered private placement.",
                            "label":  "Value Of Subscribed equity units in brokered private placement",
                            "terseLabel":  "Value of subscribed equity units in brokered private placement"
                            }
                        }
                    },
                "localname":  "ValueOfSubscribedEquityUnitsInBrokeredPrivatePlacement",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/OtherInvestmentsNarrativeDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "huge_ValueOfTradeAndOtherPayableOfSharesBasedCompensation":  {
                "auth_ref":  [
                    ],
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "It represents value of trade and other payable of shares based compensation.",
                            "label":  "Value Of Trade And Other Payable Of Shares Based Compensation",
                            "verboseLabel":  "Value of trade and other payable of shares based compensation"
                            }
                        }
                    },
                "localname":  "ValueOfTradeAndOtherPayableOfSharesBasedCompensation",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/ShareCapitalNarrativeDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "huge_ValueOfWarrantsExercised":  {
                "auth_ref":  [
                    ],
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents value of warrants exercised.",
                            "label":  "Value Of Warrants Exercised",
                            "verboseLabel":  "Value of warrants exercised"
                            }
                        }
                    },
                "localname":  "ValueOfWarrantsExercised",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "huge_WarrantLiabilitiesAbstract":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Warrant Liabilities [Abstract]",
                            "label":  "Warrant Liabilities [Abstract]"
                            }
                        }
                    },
                "localname":  "WarrantLiabilitiesAbstract",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "xbrltype":  "stringItemType"
                },
            "huge_WarrantLiabilitiesTable":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Warrant Liabilities [Table]",
                            "label":  "Warrant Liabilities [Table]"
                            }
                        }
                    },
                "localname":  "WarrantLiabilitiesTable",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/WarrantsLiabilityDetailTextuals"
                    ],
                "xbrltype":  "stringItemType"
                },
            "huge_WarrantLineItems":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents information of warrants.",
                            "label":  "Warrant [Line Items]"
                            }
                        }
                    },
                "localname":  "WarrantLineItems",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/WarrantsLiabilityDetailTextuals"
                    ],
                "xbrltype":  "stringItemType"
                },
            "huge_Warrants":  {
                "auth_ref":  [
                    ],
                "calculation":  {
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION":  {
                        "order":  10.0,
                        "parentTag":  "ifrs-full_Equity",
                        "weight":  1.0
                        }
                    },
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents amount related to warrants.",
                            "label":  "Warrants",
                            "terseLabel":  "Warrant liability",
                            "verboseLabel":  "Warrants"
                            }
                        }
                    },
                "localname":  "Warrants",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "huge_WarrantsAbstract":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "label":  "Warrants [Abstract]"
                            }
                        }
                    },
                "localname":  "WarrantsAbstract",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/AcquisitionOfLucidDetails",
                    "http://www.fsdpharma.com/role/AcquisitionOfPrismicPharmaceuticalScheduleOfBlackScholesOptionsPricingModelDetails"
                    ],
                "xbrltype":  "stringItemType"
                },
            "huge_WarrantsByExpiryDateAtAugust1St2021Member":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Warrants by expiry date at August 1st 2021.",
                            "label":  "Warrants By Expiry Date At August 1 St 2021 [Member]",
                            "verboseLabel":  "Warrants by expiry date at August 1, 2021"
                            }
                        }
                    },
                "localname":  "WarrantsByExpiryDateAtAugust1St2021Member",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/ShareCapitalScheduleOfWarrantsOutstandingAndExercisePriceDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_WarrantsByExpiryDateAtAugust6Th2020Member":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Warrants by expiry date at August 6th 2020.",
                            "label":  "Warrants By Expiry Date At August 6 Th 2020 [Member]",
                            "verboseLabel":  "Warrants by expiry date at August 6, 2020"
                            }
                        }
                    },
                "localname":  "WarrantsByExpiryDateAtAugust6Th2020Member",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/ShareCapitalNarrativeDetails",
                    "http://www.fsdpharma.com/role/ShareCapitalScheduleOfWarrantsOutstandingAndExercisePriceDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_WarrantsByExpiryDateAtAugust6Th2025Member":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Warrants by expiry date at August 6th, 2025.",
                            "label":  "Warrants By Expiry Date At August 6 Th, 2025 [Member]",
                            "verboseLabel":  "Warrants by expiry date at August 6, 2025"
                            }
                        }
                    },
                "localname":  "WarrantsByExpiryDateAtAugust6Th2025Member",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/ShareCapitalScheduleOfWarrantsOutstandingAndExercisePriceDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_WarrantsByExpiryDateAtDecember12Th2019Member":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Warrants by expiry date at December 12st 2019.",
                            "label":  "Warrants By Expiry Date At December 12 Th 2019 [Member]",
                            "verboseLabel":  "Warrants by expiry date at December 12, 2019"
                            }
                        }
                    },
                "localname":  "WarrantsByExpiryDateAtDecember12Th2019Member",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/ShareCapitalScheduleOfWarrantsOutstandingAndExercisePriceDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_WarrantsByExpiryDateAtDecember29Th2019Member":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Warrants by expiry date at December 29th 2019.",
                            "label":  "Warrants By Expiry Date At December 29 Th 2019 [Member]",
                            "verboseLabel":  "Warrants by expiry date at December 29, 2019"
                            }
                        }
                    },
                "localname":  "WarrantsByExpiryDateAtDecember29Th2019Member",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/ShareCapitalScheduleOfWarrantsOutstandingAndExercisePriceDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_WarrantsByExpiryDateAtDecember31St2022Member":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Warrants by expiry date at December 31st 2022.",
                            "label":  "Warrants By Expiry Date At December 31 St 2022 [Member]",
                            "verboseLabel":  "Warrants by expiry date at December 31, 2022"
                            }
                        }
                    },
                "localname":  "WarrantsByExpiryDateAtDecember31St2022Member",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/ShareCapitalScheduleOfWarrantsOutstandingAndExercisePriceDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_WarrantsByExpiryDateAtJanuary16Th2026Member":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Warrants by expiry date at January 16th 2026.",
                            "label":  "Warrants By Expiry Date At January 16 Th 2026 [Member]",
                            "verboseLabel":  "Warrants by expiry date at January 16, 2026"
                            }
                        }
                    },
                "localname":  "WarrantsByExpiryDateAtJanuary16Th2026Member",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/ShareCapitalScheduleOfWarrantsOutstandingAndExercisePriceDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_WarrantsByExpiryDateAtJanuary20Th2026Member":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Warrants by expiry date at January 20th 2026.",
                            "label":  "Warrants By Expiry Date At January 20 Th 2026 [Member]",
                            "verboseLabel":  "Warrants by expiry date at January 20, 2026"
                            }
                        }
                    },
                "localname":  "WarrantsByExpiryDateAtJanuary20Th2026Member",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/ShareCapitalScheduleOfWarrantsOutstandingAndExercisePriceDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_WarrantsByExpiryDateAtJanuary5Th2020Member":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Warrants by expiry date at January 5th 2020.",
                            "label":  "Warrants By Expiry Date At January 5 Th 2020 [Member]",
                            "verboseLabel":  "Warrants by expiry date at January 5, 2020"
                            }
                        }
                    },
                "localname":  "WarrantsByExpiryDateAtJanuary5Th2020Member",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/ShareCapitalScheduleOfWarrantsOutstandingAndExercisePriceDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_WarrantsByExpiryDateAtJuly24Th2023Member":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Warrants by expiry date at July 24th 2023.",
                            "label":  "Warrants By Expiry Date At July 24 Th 2023 [Member]",
                            "verboseLabel":  "Warrants by expiry date at July 24, 2023"
                            }
                        }
                    },
                "localname":  "WarrantsByExpiryDateAtJuly24Th2023Member",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/ShareCapitalScheduleOfWarrantsOutstandingAndExercisePriceDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_WarrantsByExpiryDateAtJune23Rd2023Member":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Warrants by expiry date at June 23rd 2023.",
                            "label":  "Warrants By Expiry Date At June 23 Rd 2023 [Member]",
                            "verboseLabel":  "Warrants by expiry date at June 23, 2023"
                            }
                        }
                    },
                "localname":  "WarrantsByExpiryDateAtJune23Rd2023Member",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/ShareCapitalScheduleOfWarrantsOutstandingAndExercisePriceDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_WarrantsByExpiryDateAtJune8Th2025Member":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Warrants by expiry date at June 8th 2025.",
                            "label":  "Warrants By Expiry Date At June 8 Th 2025 [Member]",
                            "verboseLabel":  "Warrants by expiry date at June 8, 2025"
                            }
                        }
                    },
                "localname":  "WarrantsByExpiryDateAtJune8Th2025Member",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/ShareCapitalScheduleOfWarrantsOutstandingAndExercisePriceDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_WarrantsByExpiryDateAtMay10Th2025Member":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Warrants by expiry date at May 10th 2025.",
                            "label":  "Warrants By Expiry Date At May 10 Th 2025 [Member]",
                            "verboseLabel":  "Warrants by expiry date at May 10, 2025"
                            }
                        }
                    },
                "localname":  "WarrantsByExpiryDateAtMay10Th2025Member",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/ShareCapitalScheduleOfWarrantsOutstandingAndExercisePriceDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_WarrantsByExpiryDateAtMay17Th2025Member":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Warrants by expiry date at May 17th, 2025.",
                            "label":  "Warrants By Expiry Date At May 17 Th, 2025 [Member]",
                            "verboseLabel":  "Warrants by expiry date at May 17, 2025"
                            }
                        }
                    },
                "localname":  "WarrantsByExpiryDateAtMay17Th2025Member",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/ShareCapitalScheduleOfWarrantsOutstandingAndExercisePriceDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_WarrantsByExpiryDateAtMay20Th2023Member":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Warrants by expiry date at May 20th 2023.",
                            "label":  "Warrants By Expiry Date At May 20 Th 2023 [Member]",
                            "verboseLabel":  "Warrants by expiry date at May 20, 2023"
                            }
                        }
                    },
                "localname":  "WarrantsByExpiryDateAtMay20Th2023Member",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/ShareCapitalScheduleOfWarrantsOutstandingAndExercisePriceDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_WarrantsByExpiryDateAtMay24Th2022Member":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Warrants by expiry date at May 24th 2022.",
                            "label":  "Warrants By Expiry Date At May 24 Th 2022 [Member]",
                            "verboseLabel":  "Warrants by expiry date at May 24, 2022"
                            }
                        }
                    },
                "localname":  "WarrantsByExpiryDateAtMay24Th2022Member",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/ShareCapitalScheduleOfWarrantsOutstandingAndExercisePriceDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_WarrantsByExpiryDateAtMay31St2025Member":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Warrants by expiry date at May 31st 2025.",
                            "label":  "Warrants By Expiry Date At May 31 St 2025 [Member]",
                            "verboseLabel":  "Warrants by expiry date at May 31, 2025"
                            }
                        }
                    },
                "localname":  "WarrantsByExpiryDateAtMay31St2025Member",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/ShareCapitalScheduleOfWarrantsOutstandingAndExercisePriceDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_WarrantsByExpiryDateAtMay4Th2025Member":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Warrants by expiry date at May 4th 2025.",
                            "label":  "Warrants By Expiry Date At May 4 Th 2025 [Member]",
                            "verboseLabel":  "Warrants by expiry date at May 4, 2025"
                            }
                        }
                    },
                "localname":  "WarrantsByExpiryDateAtMay4Th2025Member",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/ShareCapitalScheduleOfWarrantsOutstandingAndExercisePriceDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_WarrantsByExpiryDateAtNovember14Th2019Member":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Warrants by expiry date at November 14th 2019.",
                            "label":  "Warrants By Expiry Date At November 14 Th 2019 [Member]",
                            "verboseLabel":  "Warrants by expiry date at November 14, 2019"
                            }
                        }
                    },
                "localname":  "WarrantsByExpiryDateAtNovember14Th2019Member",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/ShareCapitalScheduleOfWarrantsOutstandingAndExercisePriceDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_WarrantsByExpiryDateAtNovember1St2019Member":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Warrants by expiry date at November 1st 2019.",
                            "label":  "Warrants By Expiry Date At November 1 St 2019 [Member]",
                            "verboseLabel":  "Warrants by expiry date at November 1, 2019"
                            }
                        }
                    },
                "localname":  "WarrantsByExpiryDateAtNovember1St2019Member",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/ShareCapitalScheduleOfWarrantsOutstandingAndExercisePriceDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_WarrantsByExpiryDateAtNovember21St2019Member":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Warrants by expiry date at November 21st 2019.",
                            "label":  "Warrants By Expiry Date At November 21 St 2019 [Member]",
                            "verboseLabel":  "Warrants by expiry date at November 21, 2019"
                            }
                        }
                    },
                "localname":  "WarrantsByExpiryDateAtNovember21St2019Member",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/ShareCapitalScheduleOfWarrantsOutstandingAndExercisePriceDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_WarrantsByExpiryDateAtNovember30Th2020Member":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Warrants by expiry date at November 30th 2020.",
                            "label":  "Warrants By Expiry Date At November 30 Th 2020 [Member]",
                            "verboseLabel":  "Warrants by expiry date at November 30, 2020"
                            }
                        }
                    },
                "localname":  "WarrantsByExpiryDateAtNovember30Th2020Member",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/ShareCapitalScheduleOfWarrantsOutstandingAndExercisePriceDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_WarrantsByExpiryDateAtNovember30Th2022Member":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Warrants by expiry date at November 30th 2022.",
                            "label":  "Warrants By Expiry Date At November 30 Th 2022 [Member]",
                            "verboseLabel":  "Warrants by expiry date at November 30, 2022"
                            }
                        }
                    },
                "localname":  "WarrantsByExpiryDateAtNovember30Th2022Member",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/ShareCapitalScheduleOfWarrantsOutstandingAndExercisePriceDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_WarrantsByExpiryDateAtOctober20Th2020Member":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Warrants by expiry date at October 20th 2020.",
                            "label":  "Warrants By Expiry Date At October 20 Th 2020 [Member]",
                            "verboseLabel":  "Warrants by expiry date at October 20, 2020"
                            }
                        }
                    },
                "localname":  "WarrantsByExpiryDateAtOctober20Th2020Member",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/ShareCapitalNarrativeDetails",
                    "http://www.fsdpharma.com/role/ShareCapitalScheduleOfWarrantsOutstandingAndExercisePriceDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_WarrantsByExpiryDateAtOctober20Th2025Member":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Warrants by expiry date at October 20th, 2025.",
                            "label":  "Warrants By Expiry Date At October 20 Th, 2025 [Member]",
                            "verboseLabel":  "Warrants by expiry date at October 20, 2025"
                            }
                        }
                    },
                "localname":  "WarrantsByExpiryDateAtOctober20Th2025Member",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/ShareCapitalScheduleOfWarrantsOutstandingAndExercisePriceDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_WarrantsByExpiryDateAtSeptember11Th2023Member":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Warrants by expiry date at September 11th 2023.",
                            "label":  "Warrants By Expiry Date At September 11 Th 2023 [Member]",
                            "verboseLabel":  "Warrants by expiry date at September 11, 2023"
                            }
                        }
                    },
                "localname":  "WarrantsByExpiryDateAtSeptember11Th2023Member",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/ShareCapitalScheduleOfWarrantsOutstandingAndExercisePriceDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_WarrantsByExpiryDateAtSeptember15Th2022Member":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Warrants by expiry date at September 15th 2022.",
                            "label":  "Warrants By Expiry Date At September 15 Th 2022 [Member]",
                            "verboseLabel":  "Warrants by expiry date at September 15, 2022"
                            }
                        }
                    },
                "localname":  "WarrantsByExpiryDateAtSeptember15Th2022Member",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/ShareCapitalScheduleOfWarrantsOutstandingAndExercisePriceDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_WarrantsIssueToRelatedParty":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents number of warrants issue to related party.",
                            "label":  "Warrants Issue To Related Party",
                            "verboseLabel":  "Warrants issue to a related party"
                            }
                        }
                    },
                "localname":  "WarrantsIssueToRelatedParty",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/ShareCapitalNarrativeDetails"
                    ],
                "xbrltype":  "sharesItemType"
                },
            "huge_WarrantsIssuedForPrivatePlacement":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents warrants issued for private placement.",
                            "label":  "Warrants Issued For Private Placement",
                            "verboseLabel":  "Warrants issued for private placement"
                            }
                        }
                    },
                "localname":  "WarrantsIssuedForPrivatePlacement",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/ShareCapitalNarrativeDetails"
                    ],
                "xbrltype":  "sharesItemType"
                },
            "huge_WarrantsLiability":  {
                "auth_ref":  [
                    ],
                "crdr":  "credit",
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents the value of warrants liability.",
                            "label":  "Warrants Liability",
                            "terseLabel":  "Warrant liability",
                            "verboseLabel":  "Warrant reserve"
                            }
                        }
                    },
                "localname":  "WarrantsLiability",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/WarrantsLiabilityDetailTextuals"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "huge_WarrantsMember":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents information of warrant.",
                            "label":  "Warrants [Member]",
                            "terseLabel":  "Warrants",
                            "verboseLabel":  "Options or warrants"
                            }
                        }
                    },
                "localname":  "WarrantsMember",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/AcquisitionOfLucidDetailTextuals",
                    "http://www.fsdpharma.com/role/AcquisitionOfPrismicPharmaceuticalNarrativeDetails",
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
                    "http://www.fsdpharma.com/role/LossPerShareDetails",
                    "http://www.fsdpharma.com/role/OtherInvestmentsScheduleOfOtherInvestmentsDetails",
                    "http://www.fsdpharma.com/role/ShareCapitalNarrativeDetails",
                    "http://www.fsdpharma.com/role/ShareCapitalScheduleOfReconciliationOfTheShareCapitalDetails",
                    "http://www.fsdpharma.com/role/SharebasedCompensationScheduleOfSharebasedCompensationDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "huge_WeightedAverageExercisePriceOfShareOptionExpiredInShareBasedPaymentArrangement":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "The weighted average exercise price of share options expired in a share-based payment arrangement.",
                            "label":  "Weighted Average Exercise Price Of Share Option Expired In Share Based Payment Arrangement",
                            "terseLabel":  "Weighted average exercise price, Expired"
                            }
                        }
                    },
                "localname":  "WeightedAverageExercisePriceOfShareOptionExpiredInShareBasedPaymentArrangement",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/SharebasedCompensationScheduleOfChangesInNumberOfShareOptionsDetails"
                    ],
                "xbrltype":  "perShareItemType"
                },
            "huge_WeightedAverageExercisePriceWarrantsOutstanding":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents weighted average exercise Price warrants outstanding.",
                            "label":  "Weighted average exercise Price warrants Outstanding",
                            "periodEndLabel":  "Weighted average exercise price, Warrants outstanding closing balance",
                            "periodStartLabel":  "Weighted average exercise price, Warrants outstanding opening balance",
                            "verboseLabel":  "Exercise price of warrants outstanding"
                            }
                        }
                    },
                "localname":  "WeightedAverageExercisePriceWarrantsOutstanding",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/ShareCapitalScheduleOfChangesInNumberOfWarrantsOutstandingDetails",
                    "http://www.fsdpharma.com/role/ShareCapitalScheduleOfWarrantsOutstandingAndExercisePriceDetails"
                    ],
                "xbrltype":  "perShareItemType"
                },
            "huge_WeightedAverageExercisePricesWarrantExercised":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents weighted average exercise price warrants exercised.",
                            "label":  "Weighted Average Exercise Prices Warrant Exercised",
                            "verboseLabel":  "Weighted average exercise price warrants exercised"
                            }
                        }
                    },
                "localname":  "WeightedAverageExercisePricesWarrantExercised",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/ShareCapitalScheduleOfChangesInNumberOfWarrantsOutstandingDetails"
                    ],
                "xbrltype":  "perShareItemType"
                },
            "huge_WeightedAverageExercisePricesWarrantExpired":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents weighted average exercise price warrants expired.",
                            "label":  "Weighted Average Exercise Prices Warrant Expired",
                            "terseLabel":  "Weighted average exercise price warrants expired"
                            }
                        }
                    },
                "localname":  "WeightedAverageExercisePricesWarrantExpired",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/ShareCapitalScheduleOfChangesInNumberOfWarrantsOutstandingDetails"
                    ],
                "xbrltype":  "perShareItemType"
                },
            "huge_WeightedAverageExercisePricesWarrantIssued":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents weighted average exercise price warrants issued.",
                            "label":  "Weighted Average Exercise Prices Warrant Issued",
                            "verboseLabel":  "Weighted average exercise price warrants issued"
                            }
                        }
                    },
                "localname":  "WeightedAverageExercisePricesWarrantIssued",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/ShareCapitalScheduleOfChangesInNumberOfWarrantsOutstandingDetails"
                    ],
                "xbrltype":  "perShareItemType"
                },
            "huge_WeightedAverageSharePriceOfWarrants":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "documentation":  "Represents the weighted average share price of warrants.",
                            "label":  "Weighted average share price of warrants",
                            "terseLabel":  "Grant date share price",
                            "verboseLabel":  "Warrants share price"
                            }
                        }
                    },
                "localname":  "WeightedAverageSharePriceOfWarrants",
                "nsuri":  "http://www.fsdpharma.com/20211231",
                "presentation":  [
                    "http://www.fsdpharma.com/role/AcquisitionOfLucidDetails",
                    "http://www.fsdpharma.com/role/AcquisitionOfPrismicPharmaceuticalScheduleOfBlackScholesOptionsPricingModelDetails",
                    "http://www.fsdpharma.com/role/ShareCapitalNarrativeDetails",
                    "http://www.fsdpharma.com/role/ShareCapitalScheduleOfFairValueAssumptionsOfWarrantsDetails"
                    ],
                "xbrltype":  "perShareItemType"
                },
            "ifrs-full_AccountingProfit":  {
                "auth_ref":  [
                    "r48",
                    "r49"
                    ],
                "crdr":  "credit",
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The amount of profit (loss) for a period before deducting tax expense. [Refer:  Profit (loss)]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Accounting profit",
                            "verboseLabel":  "Loss from continuing operations before income taxes"
                            }
                        }
                    },
                "localname":  "AccountingProfit",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/IncomeTaxesScheduleOfProvisionForIncomeTaxesDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "ifrs-full_AccrualsClassifiedAsCurrent":  {
                "auth_ref":  [
                    "r31"
                    ],
                "calculation":  {
                    "http://www.fsdpharma.com/role/TradeAndOtherPayablesDetails":  {
                        "order":  20.0,
                        "parentTag":  "ifrs-full_TradeAndOtherCurrentPayables",
                        "weight":  1.0
                        },
                    "http://www.fsdpharma.com/role/TradeAndOtherPayablesDetails1":  {
                        "order":  null,
                        "parentTag":  null,
                        "root":  true,
                        "weight":  null
                        }
                    },
                "crdr":  "credit",
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The amount of accruals classified as current. [Refer:  Accruals]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Accruals classified as current",
                            "terseLabel":  "Accrued liabilities",
                            "totalLabel":  "Accrued liabilities"
                            }
                        }
                    },
                "localname":  "AccrualsClassifiedAsCurrent",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/TradeAndOtherPayablesDetails",
                    "http://www.fsdpharma.com/role/TradeAndOtherPayablesDetails1"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "ifrs-full_AccumulatedDepreciationAndAmortisationMember":  {
                "auth_ref":  [
                    "r58",
                    "r62",
                    "r95",
                    "r106",
                    "r110"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "This member stands for accumulated depreciation and amortisation. [Refer:  Depreciation and amortisation expense]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Accumulated depreciation and amortisation [member]",
                            "terseLabel":  "Accumulated amortization",
                            "verboseLabel":  "Accumulated depreciation:"
                            }
                        }
                    },
                "localname":  "AccumulatedDepreciationAndAmortisationMember",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/IntangibleAssetsScheduleOfIntangibleAssetsDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred":  {
                "auth_ref":  [
                    "r183"
                    ],
                "crdr":  "credit",
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The fair value, at acquisition date, of the consideration transferred in a business combination. [Refer:  Business combinations [member]]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Consideration transferred, acquisition-date fair value",
                            "terseLabel":  "Total consideration",
                            "totalLabel":  "Total consideration transferred, acquisition-date fair value",
                            "verboseLabel":  "Total consideration transferred, acquisition-date fair value"
                            }
                        }
                    },
                "localname":  "AcquisitiondateFairValueOfTotalConsiderationTransferred",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/AcquisitionOfLucidDetails1",
                    "http://www.fsdpharma.com/role/AcquisitionOfPrismicPharmaceuticalScheduleOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "ifrs-full_AcquisitionrelatedCostsRecognisedAsExpenseForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination":  {
                "auth_ref":  [
                    "r185"
                    ],
                "crdr":  "debit",
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The amount of acquisition-related costs recognised as an expense for transactions that are recognised separately from the acquisition of assets and the assumption of liabilities in business combinations. [Refer:  Business combinations [member]]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Acquisition-related costs recognised as expense for transaction recognised separately from acquisition of assets and assumption of liabilities in business combination",
                            "positiveLabel":  "Acquisition related costs",
                            "terseLabel":  "Listing expense",
                            "verboseLabel":  "Listing expense"
                            }
                        }
                    },
                "localname":  "AcquisitionrelatedCostsRecognisedAsExpenseForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/AcquisitionOfLucidDetailTextuals",
                    "http://www.fsdpharma.com/role/IntangibleAssetsNarrativeDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "ifrs-full_AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill":  {
                "auth_ref":  [
                    "r96"
                    ],
                "crdr":  "debit",
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The increase in intangible assets other than goodwill resulting from acquisitions through business combinations. [Refer:  Business combinations [member]; Intangible assets other than goodwill]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Acquisitions through business combinations, intangible assets other than goodwill",
                            "positiveLabel":  "Acquisition",
                            "terseLabel":  "Acquisition of Lucid",
                            "verboseLabel":  "Acquisition of Prismic Pharmaceuticals Inc"
                            }
                        }
                    },
                "localname":  "AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/IntangibleAssetsNarrativeDetails",
                    "http://www.fsdpharma.com/role/IntangibleAssetsScheduleOfIntangibleAssetsDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill":  {
                "auth_ref":  [
                    "r96"
                    ],
                "crdr":  "debit",
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The amount of additions to intangible assets other than goodwill, other than those acquired through business combinations. [Refer:  Business combinations [member]; Intangible assets other than goodwill]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Additions other than through business combinations, intangible assets other than goodwill",
                            "verboseLabel":  "Additions"
                            }
                        }
                    },
                "localname":  "AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/IntangibleAssetsScheduleOfIntangibleAssetsDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "ifrs-full_AdditionsToRightofuseAssets":  {
                "auth_ref":  [
                    "r160"
                    ],
                "crdr":  "debit",
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The amount of additions to right-of-use assets. [Refer:  Right-of-use assets]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Additions to right-of-use assets",
                            "terseLabel":  "Additions"
                            }
                        }
                    },
                "localname":  "AdditionsToRightofuseAssets",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/LeaseObligationsScheduleOfLeaseObligationsDetails",
                    "http://www.fsdpharma.com/role/RightofuseAssetScheduleOfRightofuseAssetDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "ifrs-full_AdjustedWeightedAverageShares":  {
                "auth_ref":  [
                    "r89"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The weighted average number of ordinary shares outstanding plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential ordinary shares into ordinary shares. [Refer:  Ordinary shares [member]; Weighted average [member]]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Adjusted weighted average number of ordinary shares outstanding",
                            "terseLabel":  "Weighted average number of shares outstanding - diluted (in shares)",
                            "totalLabel":  "Balance, end of year",
                            "verboseLabel":  "Weighted average number of shares outstanding \u2013 basic and diluted"
                            }
                        }
                    },
                "localname":  "AdjustedWeightedAverageShares",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS"
                    ],
                "xbrltype":  "sharesItemType"
                },
            "ifrs-full_AdjustmentsForDecreaseIncreaseInBiologicalAssets":  {
                "auth_ref":  [
                    "r122"
                    ],
                "crdr":  "debit",
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "Adjustments for decrease (increase) in biological assets to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer:  Biological assets; Profit (loss)]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Adjustments for decrease (increase) in biological assets",
                            "terseLabel":  "Biological assets",
                            "verboseLabel":  "Change in fair value of biological assets"
                            }
                        }
                    },
                "localname":  "AdjustmentsForDecreaseIncreaseInBiologicalAssets",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/AssetsHeldForSaleDetails2"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "ifrs-full_AdjustmentsForDecreaseIncreaseInInventories":  {
                "auth_ref":  [
                    "r120"
                    ],
                "crdr":  "debit",
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "Adjustments for decrease (increase) in inventories to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer:  Inventories; Profit (loss)]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Adjustments for decrease (increase) in inventories",
                            "negatedLabel":  "Inventories",
                            "verboseLabel":  "Inventories"
                            }
                        }
                    },
                "localname":  "AdjustmentsForDecreaseIncreaseInInventories",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/AssetsHeldForSaleDetails2"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables":  {
                "auth_ref":  [
                    "r122"
                    ],
                "calculation":  {
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS":  {
                        "order":  80.0,
                        "parentTag":  "ifrs-full_CashFlowsFromUsedInOperatingActivitiesContinuingOperations",
                        "weight":  1.0
                        }
                    },
                "crdr":  "debit",
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "Adjustments for decrease (increase) in trade and other receivables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer:  Trade and other receivables; Profit (loss)]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Adjustments for decrease (increase) in trade and other receivables",
                            "positiveVerboseLabel":  "Other receivables",
                            "verboseLabel":  "Other receivables"
                            }
                        }
                    },
                "localname":  "AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/AssetsHeldForSaleDetails2",
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense":  {
                "auth_ref":  [
                    "r121"
                    ],
                "calculation":  {
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS":  {
                        "order":  0.0,
                        "parentTag":  "ifrs-full_CashFlowsFromUsedInOperatingActivitiesContinuingOperations",
                        "weight":  1.0
                        }
                    },
                "crdr":  "debit",
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "Adjustments for depreciation and amortisation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer:  Depreciation and amortisation expense; Profit (loss)]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Depreciation and amortization"
                            }
                        }
                    },
                "localname":  "AdjustmentsForDepreciationAndAmortisationExpense",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "ifrs-full_AdjustmentsForDepreciationExpense":  {
                "auth_ref":  [
                    "r122"
                    ],
                "crdr":  "debit",
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "Adjustments for depreciation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer:  Profit (loss)]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Adjustments for depreciation expense",
                            "verboseLabel":  "Depreciation and amortization"
                            }
                        }
                    },
                "localname":  "AdjustmentsForDepreciationExpense",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/AssetsHeldForSaleDetails2"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "ifrs-full_AdjustmentsForFairValueGainsLosses":  {
                "auth_ref":  [
                    "r121"
                    ],
                "calculation":  {
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS":  {
                        "order":  30.0,
                        "parentTag":  "ifrs-full_CashFlowsFromUsedInOperatingActivitiesContinuingOperations",
                        "weight":  1.0
                        }
                    },
                "crdr":  "debit",
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "Adjustments for fair value losses (gains) to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer:  Profit (loss)]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Adjustments for fair value losses (gains)",
                            "verboseLabel":  "Change in fair value of other investments"
                            }
                        }
                    },
                "localname":  "AdjustmentsForFairValueGainsLosses",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "ifrs-full_AdjustmentsForGainsLossesOnChangeInFairValueLessCostsToSellBiologicalAssets":  {
                "auth_ref":  [
                    "r122"
                    ],
                "crdr":  "credit",
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "Adjustments for gains (losses) on changes in the fair value less costs to sell of biological assets to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer:  Biological assets; Profit (loss)]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Adjustments for gains (losses) on change in fair value less costs to sell, biological assets",
                            "negatedLabel":  "Change in fair value of biological assets",
                            "negatedTerseLabel":  "Unrealized loss on changes in fair value of biological assets",
                            "terseLabel":  "Unrealized loss on changes in fair value of biological assets",
                            "verboseLabel":  "Change in fair value of biological assets"
                            }
                        }
                    },
                "localname":  "AdjustmentsForGainsLossesOnChangeInFairValueLessCostsToSellBiologicalAssets",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/AssetsHeldForSaleDetails2"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "ifrs-full_AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives":  {
                "auth_ref":  [
                    "r122"
                    ],
                "calculation":  {
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS":  {
                        "order":  70.0,
                        "parentTag":  "ifrs-full_CashFlowsFromUsedInOperatingActivitiesContinuingOperations",
                        "weight":  -1.0
                        }
                    },
                "crdr":  "credit",
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "Adjustments for gains (losses) on changes in the fair value of derivatives to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer:  At fair value [member]; Derivatives [member]; Profit (loss)]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Adjustments for gains (losses) on change in fair value of derivatives",
                            "negatedLabel":  "Change in fair value of derivative liability",
                            "verboseLabel":  "Change in fair value of derivative liability"
                            }
                        }
                    },
                "localname":  "AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss":  {
                "auth_ref":  [
                    "r121"
                    ],
                "calculation":  {
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS":  {
                        "order":  10.0,
                        "parentTag":  "ifrs-full_CashFlowsFromUsedInOperatingActivitiesContinuingOperations",
                        "weight":  1.0
                        }
                    },
                "crdr":  "debit",
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "Adjustments for impairment loss (reversal of impairment loss) recognised in profit or loss to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer:  Impairment loss (reversal of impairment loss) recognised in profit or loss]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Adjustments for impairment loss (reversal of impairment loss) recognised in profit or loss",
                            "positiveTerseLabel":  "Impairment of right-of-use asset",
                            "terseLabel":  "Impairment loss",
                            "verboseLabel":  "Impairment of property, plant and equipment and right-of-use asset"
                            }
                        }
                    },
                "localname":  "AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossInventories":  {
                "auth_ref":  [
                    "r122"
                    ],
                "crdr":  "debit",
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "Adjustments for impairment loss (reversal of impairment loss) on inventories recognised in profit or loss to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer:  Inventories; Impairment loss; Adjustments for impairment loss (reversal of impairment loss) recognised in profit or loss; Impairment loss (reversal of impairment loss) recognised in profit or loss]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Adjustments for impairment loss (reversal of impairment loss) recognised in profit or loss, inventories",
                            "verboseLabel":  "Impairment of inventory"
                            }
                        }
                    },
                "localname":  "AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossInventories",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/AssetsHeldForSaleDetails2"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment":  {
                "auth_ref":  [
                    "r122"
                    ],
                "crdr":  "debit",
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "Adjustments for impairment loss (reversal of impairment loss) on property, plant and equipment recognised in profit or loss to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer:  Adjustments for impairment loss (reversal of impairment loss) recognised in profit or loss; Property, plant and equipment]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Adjustments for impairment loss (reversal of impairment loss) recognised in profit or loss, property, plant and equipment",
                            "verboseLabel":  "Impairment of equipment"
                            }
                        }
                    },
                "localname":  "AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/AssetsHeldForSaleDetailTextuals",
                    "http://www.fsdpharma.com/role/AssetsHeldForSaleDetails2"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables":  {
                "auth_ref":  [
                    "r122"
                    ],
                "calculation":  {
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS":  {
                        "order":  100.0,
                        "parentTag":  "ifrs-full_CashFlowsFromUsedInOperatingActivitiesContinuingOperations",
                        "weight":  1.0
                        }
                    },
                "crdr":  "debit",
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "Adjustments for increase (decrease) in trade and other payables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer:  Trade and other payables; Profit (loss)]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Adjustments for increase (decrease) in trade and other payables",
                            "positiveTerseLabel":  "Trade and other payables",
                            "terseLabel":  "Adjustments for increase (decrease) in trade and other payables",
                            "verboseLabel":  "Trade and other payables"
                            }
                        }
                    },
                "localname":  "AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/AssetsHeldForSaleDetails2",
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "ifrs-full_AdjustmentsForInterestExpense":  {
                "auth_ref":  [
                    "r122"
                    ],
                "calculation":  {
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS":  {
                        "order":  20.0,
                        "parentTag":  "ifrs-full_CashFlowsFromUsedInOperatingActivitiesContinuingOperations",
                        "weight":  1.0
                        }
                    },
                "crdr":  "debit",
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "Adjustments for interest expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer:  Interest expense; Profit (loss)]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Adjustments for interest expense",
                            "verboseLabel":  "Interest expense"
                            }
                        }
                    },
                "localname":  "AdjustmentsForInterestExpense",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "ifrs-full_AdjustmentsForReconcileProfitLossAbstract":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "label":  "Adjustments for:",
                            "terseLabel":  "Add (deduct) items not affecting cash"
                            }
                        }
                    },
                "localname":  "AdjustmentsForReconcileProfitLossAbstract",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
                    ],
                "xbrltype":  "stringItemType"
                },
            "ifrs-full_AdjustmentsForSharebasedPayments":  {
                "auth_ref":  [
                    "r121"
                    ],
                "calculation":  {
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS":  {
                        "order":  40.0,
                        "parentTag":  "ifrs-full_CashFlowsFromUsedInOperatingActivitiesContinuingOperations",
                        "weight":  1.0
                        }
                    },
                "crdr":  "debit",
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer:  Profit (loss)]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Adjustments for share based payments",
                            "terseLabel":  "Share-based payments",
                            "verboseLabel":  "Adjustments for share-based payments"
                            }
                        }
                    },
                "localname":  "AdjustmentsForSharebasedPayments",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains":  {
                "auth_ref":  [
                    "r121",
                    "r128"
                    ],
                "calculation":  {
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS":  {
                        "order":  60.0,
                        "parentTag":  "ifrs-full_CashFlowsFromUsedInOperatingActivitiesContinuingOperations",
                        "weight":  1.0
                        }
                    },
                "crdr":  "debit",
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "Adjustments for unrealised foreign exchange losses (gains) to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer:  Profit (loss)]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Adjustments for unrealised foreign exchange losses (gains)",
                            "terseLabel":  "Unrealized foreign exchange gain (loss)"
                            }
                        }
                    },
                "localname":  "AdjustmentsForUnrealisedForeignExchangeLossesGains",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "ifrs-full_AggregatedMeasurementMember":  {
                "auth_ref":  [
                    "r104",
                    "r108",
                    "r148"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "This member stands for all types of measurement.  It also represents the standard value for the 'Measurement' axis if no other member is used."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Aggregated measurement [member]"
                            }
                        }
                    },
                "localname":  "AggregatedMeasurementMember",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/OtherInvestmentsScheduleOfOtherInvestmentsDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "ifrs-full_AggregatedTimeBandsMember":  {
                "auth_ref":  [
                    "r24",
                    "r64",
                    "r155",
                    "r163",
                    "r164",
                    "r198",
                    "r207",
                    "r209",
                    "r223",
                    "r224",
                    "r226",
                    "r227"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "This member stands for aggregated time bands.  It also represents the standard value for the 'Maturity' axis if no other member is used."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Aggregated time bands [member]"
                            }
                        }
                    },
                "localname":  "AggregatedTimeBandsMember",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/LeaseObligationsScheduleOfMaturityAnalysisOfOperatingLeasePaymentsDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "ifrs-full_AllLevelsOfFairValueHierarchyMember":  {
                "auth_ref":  [
                    "r63",
                    "r149"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "This member stands for all levels of the fair value hierarchy.  It also represents the standard value for the 'Levels of fair value hierarchy' axis if no other member is used."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "All levels of fair value hierarchy [member]"
                            }
                        }
                    },
                "localname":  "AllLevelsOfFairValueHierarchyMember",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/OtherInvestmentsNarrativeDetails",
                    "http://www.fsdpharma.com/role/WarrantsLiabilityDetailTextuals"
                    ],
                "xbrltype":  "domainItemType"
                },
            "ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill":  {
                "auth_ref":  [
                    "r97"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The amount of amortisation of intangible assets other than goodwill. [Refer:  Depreciation and amortisation expense; Intangible assets other than goodwill]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Amortisation, intangible assets other than goodwill",
                            "negatedLabel":  "Amortisation, intangible assets other than goodwill",
                            "verboseLabel":  "Amortization"
                            }
                        }
                    },
                "localname":  "AmortisationIntangibleAssetsOtherThanGoodwill",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/IntangibleAssetsNarrativeDetails",
                    "http://www.fsdpharma.com/role/IntangibleAssetsScheduleOfIntangibleAssetsDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "ifrs-full_AmountsPayableRelatedPartyTransactions":  {
                "auth_ref":  [
                    "r72",
                    "r75"
                    ],
                "crdr":  "credit",
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The amounts payable resulting from related party transactions. [Refer:  Related parties [member]]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Amounts payable, related party transactions",
                            "verboseLabel":  "Related party payables"
                            }
                        }
                    },
                "localname":  "AmountsPayableRelatedPartyTransactions",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/RelatedPartyTransactionsNarrativeDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "ifrs-full_ApplicableTaxRate":  {
                "auth_ref":  [
                    "r49"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The applicable income tax rate."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Statutory Rate",
                            "verboseLabel":  "Statutory federal and provincial tax rate"
                            }
                        }
                    },
                "localname":  "ApplicableTaxRate",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/IncomeTaxesScheduleOfProvisionForIncomeTaxesDetails"
                    ],
                "xbrltype":  "percentItemType"
                },
            "ifrs-full_Assets":  {
                "auth_ref":  [
                    "r22",
                    "r148",
                    "r149",
                    "r150",
                    "r214",
                    "r217"
                    ],
                "calculation":  {
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION":  {
                        "order":  null,
                        "parentTag":  null,
                        "root":  true,
                        "weight":  null
                        }
                    },
                "crdr":  "debit",
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The amount of a present economic resource controlled by the entity as a result of past events.  Economic resource is a right that has the potential to produce economic benefits."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Assets",
                            "totalLabel":  "Total assets"
                            }
                        }
                    },
                "localname":  "Assets",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "ifrs-full_AssetsAbstract":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "label":  "ASSETS"
                            }
                        }
                    },
                "localname":  "AssetsAbstract",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
                    ],
                "xbrltype":  "stringItemType"
                },
            "ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis":  {
                "auth_ref":  [
                    "r196"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Assets and liabilities classified as held for sale [axis]"
                            }
                        }
                    },
                "localname":  "AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/AssetsHeldForSaleDetailTextuals",
                    "http://www.fsdpharma.com/role/AssetsHeldForSaleDetails",
                    "http://www.fsdpharma.com/role/AssetsHeldForSaleDetails1",
                    "http://www.fsdpharma.com/role/AssetsHeldForSaleDetails2"
                    ],
                "xbrltype":  "stringItemType"
                },
            "ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleMember":  {
                "auth_ref":  [
                    "r196"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "This member stands for assets and liabilities that are classified as held for sale. [Refer:  Non-current assets held for sale [member]; Liabilities included in disposal groups classified as held for sale; Disposal groups classified as held for sale [member]]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Assets and liabilities classified as held for sale [member]"
                            }
                        }
                    },
                "localname":  "AssetsAndLiabilitiesClassifiedAsHeldForSaleMember",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/AssetsHeldForSaleDetailTextuals",
                    "http://www.fsdpharma.com/role/AssetsHeldForSaleDetails",
                    "http://www.fsdpharma.com/role/AssetsHeldForSaleDetails1",
                    "http://www.fsdpharma.com/role/AssetsHeldForSaleDetails2"
                    ],
                "xbrltype":  "domainItemType"
                },
            "ifrs-full_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember":  {
                "auth_ref":  [
                    "r196"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "This member stands for assets and liabilities that are not classified as held for sale.  It also represents the standard value for the 'Assets and liabilities classified as held for sale' axis if no other member is used. [Refer:  Non-current assets held for sale [member]; Liabilities included in disposal groups classified as held for sale; Disposal groups classified as held for sale [member]]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Assets and liabilities not classified as held for sale [member]"
                            }
                        }
                    },
                "localname":  "AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/AssetsHeldForSaleDetailTextuals",
                    "http://www.fsdpharma.com/role/AssetsHeldForSaleDetails",
                    "http://www.fsdpharma.com/role/AssetsHeldForSaleDetails1",
                    "http://www.fsdpharma.com/role/AssetsHeldForSaleDetails2"
                    ],
                "xbrltype":  "domainItemType"
                },
            "ifrs-full_AtFairValueMember":  {
                "auth_ref":  [
                    "r104",
                    "r108",
                    "r148"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "This member stands for measurement based on fair value.  Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "At fair value [member]",
                            "verboseLabel":  "Fair value"
                            }
                        }
                    },
                "localname":  "AtFairValueMember",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/OtherInvestmentsScheduleOfOtherInvestmentsDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "ifrs-full_BasicEarningsLossPerShareFromContinuingOperations":  {
                "auth_ref":  [
                    "r86",
                    "r87"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "Basic earnings (loss) per share from continuing operations. [Refer:  Basic earnings (loss) per share; Continuing operations [member]]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Basic earnings (loss) per share",
                            "terseLabel":  "Basic and diluted - continuing operations (in dollars per share)"
                            }
                        }
                    },
                "localname":  "BasicEarningsLossPerShareFromContinuingOperations",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS"
                    ],
                "xbrltype":  "perShareItemType"
                },
            "ifrs-full_BasicEarningsLossPerShareFromDiscontinuedOperations":  {
                "auth_ref":  [
                    "r87",
                    "r88"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "Basic earnings (loss) per share from discontinued operations. [Refer:  Basic earnings (loss) per share; Discontinued operations [member]]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Basic and diluted earnings (loss) per share from discontinued operations",
                            "terseLabel":  "Basic and diluted - discontinued operations (in dollars per share)"
                            }
                        }
                    },
                "localname":  "BasicEarningsLossPerShareFromDiscontinuedOperations",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS"
                    ],
                "xbrltype":  "perShareItemType"
                },
            "ifrs-full_BorrowingsInterestRate":  {
                "auth_ref":  [
                    "r206"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The interest rate on borrowings. [Refer:  Borrowings]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Borrowings, interest rate",
                            "terseLabel":  "Notes payable, interest rate"
                            }
                        }
                    },
                "localname":  "BorrowingsInterestRate",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/NotesPayableNarrativeDetails"
                    ],
                "xbrltype":  "percentItemType"
                },
            "ifrs-full_BorrowingsRecognisedAsOfAcquisitionDate":  {
                "auth_ref":  [
                    "r184"
                    ],
                "crdr":  "credit",
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The amount recognised as of the acquisition date for borrowings assumed in a business combination. [Refer:  Borrowings; Business combinations [member]]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Borrowings recognised as of acquisition date",
                            "negatedLabel":  "Notes payable",
                            "verboseLabel":  "Convertible notes"
                            }
                        }
                    },
                "localname":  "BorrowingsRecognisedAsOfAcquisitionDate",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/AcquisitionOfPrismicPharmaceuticalScheduleOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "ifrs-full_BottomOfRangeMember":  {
                "auth_ref":  [
                    "r152",
                    "r153",
                    "r154",
                    "r177",
                    "r206",
                    "r226"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "This member stands for the bottom of a range."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Bottom of range [member]",
                            "terseLabel":  "Minimum",
                            "verboseLabel":  "Bottom of range"
                            }
                        }
                    },
                "localname":  "BottomOfRangeMember",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/AcquisitionOfLucidDetails",
                    "http://www.fsdpharma.com/role/AcquisitionOfPrismicPharmaceuticalScheduleOfBlackScholesOptionsPricingModelDetails",
                    "http://www.fsdpharma.com/role/CommitmentsAndContingenciesNarrativeDetails",
                    "http://www.fsdpharma.com/role/ShareCapitalScheduleOfFairValueAssumptionsOfWarrantsDetails",
                    "http://www.fsdpharma.com/role/SharebasedCompensationScheduleOfFairValueAssumptionsOfShareOptionsGrantedDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "ifrs-full_BusinessCombinationsAxis":  {
                "auth_ref":  [
                    "r186"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Business combinations [axis]"
                            }
                        }
                    },
                "localname":  "BusinessCombinationsAxis",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/AcquisitionOfLucidDetailTextuals",
                    "http://www.fsdpharma.com/role/AcquisitionOfPrismicPharmaceuticalNarrativeDetails"
                    ],
                "xbrltype":  "stringItemType"
                },
            "ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis":  {
                "auth_ref":  [
                    "r58",
                    "r60",
                    "r95",
                    "r99",
                    "r105",
                    "r106",
                    "r107",
                    "r108",
                    "r110",
                    "r188",
                    "r199",
                    "r200",
                    "r229",
                    "r231"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]"
                            }
                        }
                    },
                "localname":  "CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/IntangibleAssetsScheduleOfIntangibleAssetsDetails"
                    ],
                "xbrltype":  "stringItemType"
                },
            "ifrs-full_CarryingAmountMember":  {
                "auth_ref":  [
                    "r60",
                    "r99",
                    "r105",
                    "r107",
                    "r108",
                    "r188",
                    "r199",
                    "r200",
                    "r229",
                    "r230"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "This member stands for the amount at which an asset is recognised in the statement of financial position (after deducting any accumulated depreciation or amortisation and accumulated impairment losses).  It also represents the standard value for the 'Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount' axis if no other member is used. [Refer:  Depreciation and amortisation expense; Impairment loss]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Carrying amount [member]"
                            }
                        }
                    },
                "localname":  "CarryingAmountMember",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/IntangibleAssetsScheduleOfIntangibleAssetsDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "ifrs-full_CashAndCashEquivalents":  {
                "auth_ref":  [
                    "r19",
                    "r125",
                    "r145"
                    ],
                "calculation":  {
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION":  {
                        "order":  40.0,
                        "parentTag":  "ifrs-full_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners",
                        "weight":  1.0
                        }
                    },
                "crdr":  "debit",
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer:  Cash; Cash equivalents]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Cash and cash equivalents",
                            "periodEndLabel":  "Cash, end of the year",
                            "periodStartLabel":  "Cash, beginning of the year",
                            "terseLabel":  "Cash",
                            "verboseLabel":  "Cash"
                            }
                        }
                    },
                "localname":  "CashAndCashEquivalents",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "ifrs-full_CashAndCashEquivalentsRecognisedAsOfAcquisitionDate":  {
                "auth_ref":  [
                    "r184"
                    ],
                "crdr":  "debit",
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The amount recognised as of the acquisition date for cash and cash equivalents acquired in a business combination. [Refer:  Cash and cash equivalents; Business combinations [member]]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Cash and cash equivalents recognised as of acquisition date",
                            "terseLabel":  "Cash and cash equivalents",
                            "totalLabel":  "Total cash",
                            "verboseLabel":  "Cash"
                            }
                        }
                    },
                "localname":  "CashAndCashEquivalentsRecognisedAsOfAcquisitionDate",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/AcquisitionOfLucidDetails1",
                    "http://www.fsdpharma.com/role/AcquisitionOfPrismicPharmaceuticalScheduleOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "ifrs-full_CashFlowsFromUsedInFinancingActivities":  {
                "auth_ref":  [
                    "r112",
                    "r127"
                    ],
                "calculation":  {
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS":  {
                        "order":  20.0,
                        "parentTag":  "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents",
                        "weight":  1.0
                        }
                    },
                "crdr":  "debit",
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Cash flows from (used in) financing activities",
                            "totalLabel":  "Cash provided by financing activities",
                            "verboseLabel":  "Cash flows from financing activities"
                            }
                        }
                    },
                "localname":  "CashFlowsFromUsedInFinancingActivities",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "label":  "Cash provided by (used in) financing activities",
                            "terseLabel":  "Financing activities"
                            }
                        }
                    },
                "localname":  "CashFlowsFromUsedInFinancingActivitiesAbstract",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
                    ],
                "xbrltype":  "stringItemType"
                },
            "ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations":  {
                "auth_ref":  [
                    "r195"
                    ],
                "calculation":  {
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS":  {
                        "order":  0.0,
                        "parentTag":  "ifrs-full_CashFlowsFromUsedInFinancingActivities",
                        "weight":  1.0
                        }
                    },
                "crdr":  "debit",
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The cash flows from (used in) the entity's financing activities, related to continuing operations. [Refer:  Continuing operations [member]; Cash flows from (used in) financing activities]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Cash flows from (used in) financing activities, continuing operations",
                            "totalLabel":  "Cash provided by continuing financing activities"
                            }
                        }
                    },
                "localname":  "CashFlowsFromUsedInFinancingActivitiesContinuingOperations",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "ifrs-full_CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations":  {
                "auth_ref":  [
                    "r195"
                    ],
                "calculation":  {
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS":  {
                        "order":  10.0,
                        "parentTag":  "ifrs-full_CashFlowsFromUsedInFinancingActivities",
                        "weight":  1.0
                        }
                    },
                "crdr":  "debit",
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The cash flows from (used in) the entity's financing activities, related to discontinued operations. [Refer:  Discontinued operations [member]; Cash flows from (used in) financing activities]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Cash flows from (used in) financing activities, discontinued operations",
                            "terseLabel":  "Cash provided by discontinued financing activities",
                            "totalLabel":  "Cash provided by discontinued financing activities"
                            }
                        }
                    },
                "localname":  "CashFlowsFromUsedInFinancingActivitiesDiscontinuedOperations",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "ifrs-full_CashFlowsFromUsedInInvestingActivities":  {
                "auth_ref":  [
                    "r112",
                    "r127"
                    ],
                "calculation":  {
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS":  {
                        "order":  10.0,
                        "parentTag":  "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents",
                        "weight":  1.0
                        }
                    },
                "crdr":  "debit",
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Cash flows from (used in) investing activities",
                            "totalLabel":  "Cash provided by (used in) investing activities"
                            }
                        }
                    },
                "localname":  "CashFlowsFromUsedInInvestingActivities",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "label":  "Cash flows from (used in) investing activities [abstract]",
                            "terseLabel":  "Investing activities"
                            }
                        }
                    },
                "localname":  "CashFlowsFromUsedInInvestingActivitiesAbstract",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
                    ],
                "xbrltype":  "stringItemType"
                },
            "ifrs-full_CashFlowsFromUsedInInvestingActivitiesContinuingOperations":  {
                "auth_ref":  [
                    "r195"
                    ],
                "calculation":  {
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS":  {
                        "order":  0.0,
                        "parentTag":  "ifrs-full_CashFlowsFromUsedInInvestingActivities",
                        "weight":  1.0
                        }
                    },
                "crdr":  "debit",
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The cash flows from (used in) the entity's investing activities, related to continuing operations. [Refer:  Continuing operations [member]; Cash flows from (used in) investing activities]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Cash flows from (used in) investing activities, continuing operations",
                            "totalLabel":  "Cash provided by continuing investing activities"
                            }
                        }
                    },
                "localname":  "CashFlowsFromUsedInInvestingActivitiesContinuingOperations",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "ifrs-full_CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations":  {
                "auth_ref":  [
                    "r195"
                    ],
                "calculation":  {
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS":  {
                        "order":  10.0,
                        "parentTag":  "ifrs-full_CashFlowsFromUsedInInvestingActivities",
                        "weight":  1.0
                        }
                    },
                "crdr":  "debit",
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The cash flows from (used in) the entity's investing activities, related to discontinued operations. [Refer:  Discontinued operations [member]; Cash flows from (used in) investing activities]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Cash flows from (used in) investing activities, discontinued operations",
                            "totalLabel":  "Cash provided by (used in) discontinued investing activities",
                            "verboseLabel":  "Cash provided by (used in) discontinued investing activities"
                            }
                        }
                    },
                "localname":  "CashFlowsFromUsedInInvestingActivitiesDiscontinuedOperations",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "ifrs-full_CashFlowsFromUsedInOperatingActivities":  {
                "auth_ref":  [
                    "r112",
                    "r127"
                    ],
                "calculation":  {
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS":  {
                        "order":  0.0,
                        "parentTag":  "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents",
                        "weight":  1.0
                        }
                    },
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities. [Refer:  Revenue]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Cash flows from (used in) operating activities",
                            "totalLabel":  "Cash used in operating activities"
                            }
                        }
                    },
                "localname":  "CashFlowsFromUsedInOperatingActivities",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "label":  "Cash flows from (used in) operating activities [abstract]",
                            "terseLabel":  "Operating activities"
                            }
                        }
                    },
                "localname":  "CashFlowsFromUsedInOperatingActivitiesAbstract",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/AssetsHeldForSaleDetails2",
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
                    ],
                "xbrltype":  "stringItemType"
                },
            "ifrs-full_CashFlowsFromUsedInOperatingActivitiesContinuingOperations":  {
                "auth_ref":  [
                    "r195"
                    ],
                "calculation":  {
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS":  {
                        "order":  0.0,
                        "parentTag":  "ifrs-full_CashFlowsFromUsedInOperatingActivities",
                        "weight":  1.0
                        }
                    },
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The cash flows from (used in) the entity's operating activities, related to continuing operations. [Refer:  Continuing operations [member]; Cash flows from (used in) operating activities]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Cash flows from (used in) operating activities, continuing operations",
                            "terseLabel":  "Cash used in continuing operating activities",
                            "totalLabel":  "Cash used in continuing operating activities"
                            }
                        }
                    },
                "localname":  "CashFlowsFromUsedInOperatingActivitiesContinuingOperations",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "ifrs-full_CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations":  {
                "auth_ref":  [
                    "r195"
                    ],
                "calculation":  {
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS":  {
                        "order":  10.0,
                        "parentTag":  "ifrs-full_CashFlowsFromUsedInOperatingActivities",
                        "weight":  1.0
                        }
                    },
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The cash flows from (used in) the entity's operating activities, related to discontinued operations. [Refer:  Discontinued operations [member]; Cash flows from (used in) operating activities]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Cash flows from (used in) operating activities, discontinued operations",
                            "terseLabel":  "Cash used in discontinued operating activities",
                            "totalLabel":  "Cash used in discontinued operating activities",
                            "verboseLabel":  "Cash used in operating activities"
                            }
                        }
                    },
                "localname":  "CashFlowsFromUsedInOperatingActivitiesDiscontinuedOperations",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/AssetsHeldForSaleDetails2",
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "ifrs-full_CashOutflowForLeases":  {
                "auth_ref":  [
                    "r159"
                    ],
                "crdr":  "credit",
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The cash outflow for leases."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Cash outflow for leases",
                            "negatedLabel":  "Less:  Lease Payments",
                            "negatedTerseLabel":  "Repayment of lease obligation",
                            "terseLabel":  "Repayment of lease obligation",
                            "verboseLabel":  "Less:  Lease Payments"
                            }
                        }
                    },
                "localname":  "CashOutflowForLeases",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/LeaseObligationsScheduleOfLeaseObligationsDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "ifrs-full_CategoriesOfRelatedPartiesAxis":  {
                "auth_ref":  [
                    "r74"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Categories of related parties [axis]"
                            }
                        }
                    },
                "localname":  "CategoriesOfRelatedPartiesAxis",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/RelatedPartyTransactionsNarrativeDetails"
                    ],
                "xbrltype":  "stringItemType"
                },
            "ifrs-full_ChangesInIntangibleAssetsOtherThanGoodwillAbstract":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "label":  "Changes in intangible assets other than goodwill [abstract]"
                            }
                        }
                    },
                "localname":  "ChangesInIntangibleAssetsOtherThanGoodwillAbstract",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "xbrltype":  "stringItemType"
                },
            "ifrs-full_ClassesOfContingentLiabilitiesAxis":  {
                "auth_ref":  [
                    "r92",
                    "r187"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Classes of contingent liabilities [axis]"
                            }
                        }
                    },
                "localname":  "ClassesOfContingentLiabilitiesAxis",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CommitmentsAndContingenciesNarrativeDetails"
                    ],
                "xbrltype":  "stringItemType"
                },
            "ifrs-full_ClassesOfFinancialInstrumentsAxis":  {
                "auth_ref":  [
                    "r199",
                    "r201",
                    "r202",
                    "r204"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Classes of financial instruments [axis]"
                            }
                        }
                    },
                "localname":  "ClassesOfFinancialInstrumentsAxis",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/OtherInvestmentsNarrativeDetails",
                    "http://www.fsdpharma.com/role/OtherInvestmentsScheduleOfOtherInvestmentsDetails"
                    ],
                "xbrltype":  "stringItemType"
                },
            "ifrs-full_ClassesOfFinancialInstrumentsMember":  {
                "auth_ref":  [
                    "r199",
                    "r201",
                    "r202",
                    "r204"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "This member stands for aggregated classes of financial instruments.  Financial instruments are contracts that give rise to a financial asset of one entity and a financial liability or equity instrument of another entity.  It also represents the standard value for the 'Classes of financial instruments' axis if no other member is used. [Refer:  Financial assets; Financial liabilities]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Financial instruments, class [member]"
                            }
                        }
                    },
                "localname":  "ClassesOfFinancialInstrumentsMember",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/OtherInvestmentsNarrativeDetails",
                    "http://www.fsdpharma.com/role/OtherInvestmentsScheduleOfOtherInvestmentsDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis":  {
                "auth_ref":  [
                    "r100"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Classes of intangible assets other than goodwill [axis]"
                            }
                        }
                    },
                "localname":  "ClassesOfIntangibleAssetsOtherThanGoodwillAxis",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/SignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfAssetsDetails"
                    ],
                "xbrltype":  "stringItemType"
                },
            "ifrs-full_ClassesOfOrdinarySharesAxis":  {
                "auth_ref":  [
                    "r86"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Classes of ordinary shares [axis]"
                            }
                        }
                    },
                "localname":  "ClassesOfOrdinarySharesAxis",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/LossPerShareDetails",
                    "http://www.fsdpharma.com/role/OtherInvestmentsNarrativeDetails",
                    "http://www.fsdpharma.com/role/SubsequentEventsNarrativeDetails"
                    ],
                "xbrltype":  "stringItemType"
                },
            "ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis":  {
                "auth_ref":  [
                    "r61"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Classes of property, plant and equipment [axis]"
                            }
                        }
                    },
                "localname":  "ClassesOfPropertyPlantAndEquipmentAxis",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/SignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfAssetsDetails"
                    ],
                "xbrltype":  "stringItemType"
                },
            "ifrs-full_ClassesOfShareCapitalAxis":  {
                "auth_ref":  [
                    "r33"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Classes of share capital [axis]"
                            }
                        }
                    },
                "localname":  "ClassesOfShareCapitalAxis",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION",
                    "http://www.fsdpharma.com/role/NotesPayableNarrativeDetails",
                    "http://www.fsdpharma.com/role/OtherInvestmentsNarrativeDetails",
                    "http://www.fsdpharma.com/role/RelatedPartyTransactionsNarrativeDetails",
                    "http://www.fsdpharma.com/role/ShareCapitalNarrativeDetails",
                    "http://www.fsdpharma.com/role/ShareCapitalScheduleOfReconciliationOfTheShareCapitalDetails",
                    "http://www.fsdpharma.com/role/WarrantsLiabilityDetailTextuals"
                    ],
                "xbrltype":  "stringItemType"
                },
            "ifrs-full_ClassesOfShareCapitalMember":  {
                "auth_ref":  [
                    "r33"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "This member stands for share capital of the entity.  It also represents the standard value for the 'Classes of share capital' axis if no other member is used."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Share capital [member]"
                            }
                        }
                    },
                "localname":  "ClassesOfShareCapitalMember",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION",
                    "http://www.fsdpharma.com/role/NotesPayableNarrativeDetails",
                    "http://www.fsdpharma.com/role/OtherInvestmentsNarrativeDetails",
                    "http://www.fsdpharma.com/role/RelatedPartyTransactionsNarrativeDetails",
                    "http://www.fsdpharma.com/role/ShareCapitalNarrativeDetails",
                    "http://www.fsdpharma.com/role/ShareCapitalScheduleOfReconciliationOfTheShareCapitalDetails",
                    "http://www.fsdpharma.com/role/WarrantsLiabilityDetailTextuals"
                    ],
                "xbrltype":  "domainItemType"
                },
            "ifrs-full_ComponentsOfEquityAxis":  {
                "auth_ref":  [
                    "r8"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Components of equity [axis]"
                            }
                        }
                    },
                "localname":  "ComponentsOfEquityAxis",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
                    "http://www.fsdpharma.com/role/ShareCapitalNarrativeDetails",
                    "http://www.fsdpharma.com/role/ShareCapitalScheduleOfReconciliationOfTheShareCapitalDetails"
                    ],
                "xbrltype":  "stringItemType"
                },
            "ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "label":  "Components of other comprehensive income that will be reclassified to profit or loss, net of tax [abstract]",
                            "verboseLabel":  "Items that may be subsequently reclassified to income (loss):"
                            }
                        }
                    },
                "localname":  "ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS"
                    ],
                "xbrltype":  "stringItemType"
                },
            "ifrs-full_ComprehensiveIncome":  {
                "auth_ref":  [
                    "r4",
                    "r36",
                    "r131",
                    "r133",
                    "r138",
                    "r141"
                    ],
                "calculation":  {
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS":  {
                        "order":  null,
                        "parentTag":  null,
                        "root":  true,
                        "weight":  null
                        }
                    },
                "crdr":  "credit",
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Comprehensive income",
                            "terseLabel":  "Loss before the undernoted",
                            "totalLabel":  "Comprehensive loss",
                            "verboseLabel":  "Comprehensive loss for the year"
                            }
                        }
                    },
                "localname":  "ComprehensiveIncome",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "ifrs-full_ComputerEquipmentMember":  {
                "auth_ref":  [
                    "r55"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "This member stands for a class of property, plant and equipment representing computer equipment. [Refer:  Property, plant and equipment]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Computer equipment [member]",
                            "terseLabel":  "Computer equipment",
                            "verboseLabel":  "Computer hardware and equipment"
                            }
                        }
                    },
                "localname":  "ComputerEquipmentMember",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/SignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfAssetsDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "ifrs-full_ConstructionInProgressMember":  {
                "auth_ref":  [
                    "r55"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "This member stands for expenditure capitalised during the construction of items of property, plant and equipment that are not yet available for use (ie not yet in the location and condition necessary for it to be capable of operating in the manner intended by the management). [Refer:  Property, plant and equipment]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Construction in progress [member]",
                            "verboseLabel":  "Facility and related"
                            }
                        }
                    },
                "localname":  "ConstructionInProgressMember",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/SignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfAssetsDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "ifrs-full_ContingentLiabilitiesMember":  {
                "auth_ref":  [
                    "r93",
                    "r187"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "This member stands for possible obligations that arise from past events and whose existence will be confirmed only by the occurrence or non-occurrence of one or more uncertain future events not wholly within the control of the entity; or, present obligations that arise from past events but are not recognised because (a) it is probable that an outflow of resources embodying economic benefits will be required to settle the obligations; or (b) the amount of the obligations cannot be measured with sufficient reliability.  It also represents the standard value for the 'Classes of contingent liabilities' axis if no other member is used."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Contingent liabilities [member]"
                            }
                        }
                    },
                "localname":  "ContingentLiabilitiesMember",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CommitmentsAndContingenciesNarrativeDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember":  {
                "auth_ref":  [
                    "r101"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "This member stands for a class of intangible assets representing copyrights, patents and other industrial property rights, service and operating rights. [Refer:  Intangible assets other than goodwill]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Copyrights, patents and other industrial property rights, service and operating rights [member]",
                            "verboseLabel":  "Intellectual Property"
                            }
                        }
                    },
                "localname":  "CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/SignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfAssetsDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "ifrs-full_CostOfSales":  {
                "auth_ref":  [
                    "r2",
                    "r45"
                    ],
                "crdr":  "debit",
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The amount of all expenses directly or indirectly attributed to the goods or services sold.  Attributed expenses include, but are not limited to, costs previously included in the measurement of inventory that has now been sold, such as depreciation and maintenance of factory buildings and equipment used in the production process, unallocated production overheads, and abnormal amounts of production costs of inventories."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Cost of sales",
                            "negatedLabel":  "Cost of revenue",
                            "verboseLabel":  "Cost of revenue"
                            }
                        }
                    },
                "localname":  "CostOfSales",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/AssetsHeldForSaleDetails1"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "ifrs-full_CurrentAssets":  {
                "auth_ref":  [
                    "r25",
                    "r138",
                    "r139"
                    ],
                "calculation":  {
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION":  {
                        "order":  40.0,
                        "parentTag":  "ifrs-full_Assets",
                        "weight":  1.0
                        }
                    },
                "crdr":  "debit",
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer:  Assets]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Current assets",
                            "totalLabel":  "Total current assets",
                            "verboseLabel":  "Total current assets"
                            }
                        }
                    },
                "localname":  "CurrentAssets",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "ifrs-full_CurrentAssetsAbstract":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "label":  "Current Assets Abstract",
                            "terseLabel":  "Current assets"
                            }
                        }
                    },
                "localname":  "CurrentAssetsAbstract",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
                    ],
                "xbrltype":  "stringItemType"
                },
            "ifrs-full_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners":  {
                "auth_ref":  [
                    "r25"
                    ],
                "calculation":  {
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION":  {
                        "order":  0.0,
                        "parentTag":  "ifrs-full_CurrentAssets",
                        "weight":  1.0
                        }
                    },
                "crdr":  "debit",
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The amount of current assets other than non-current assets or disposal groups classified as held for sale or as held for distribution to owners. [Refer:  Current assets; Disposal groups classified as held for sale [member]; Non-current assets or disposal groups classified as held for sale; Non-current assets or disposal groups classified as held for distribution to owners]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Current assets other than non-current assets or disposal groups classified as held for sale or as held for distribution to owners",
                            "terseLabel":  "Current assets other than assets held for sale",
                            "totalLabel":  "Current assets other than assets held for sale"
                            }
                        }
                    },
                "localname":  "CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "ifrs-full_CurrentAssetsRecognisedAsOfAcquisitionDate":  {
                "auth_ref":  [
                    "r184"
                    ],
                "crdr":  "debit",
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "Expiry date 2022-01-01:  The amount recognised as of the acquisition date for current assets acquired in a business combination. [Refer:  Business combinations [member]]\nEffective 2022-01-01:  The amount recognised as of the acquisition date for current assets acquired in a business combination. [Refer:  Current assets; Business combinations [member]]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Current assets recognised as of acquisition date",
                            "terseLabel":  "Prepaid expenses and deposits",
                            "verboseLabel":  "Prepaid expenses and deposits"
                            }
                        }
                    },
                "localname":  "CurrentAssetsRecognisedAsOfAcquisitionDate",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/AcquisitionOfLucidDetails1",
                    "http://www.fsdpharma.com/role/AcquisitionOfPrismicPharmaceuticalScheduleOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "ifrs-full_CurrentBiologicalAssets":  {
                "auth_ref":  [
                    "r17"
                    ],
                "calculation":  {
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION":  {
                        "order":  30.0,
                        "parentTag":  "ifrs-full_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners",
                        "weight":  1.0
                        }
                    },
                "crdr":  "debit",
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The amount of current biological assets. [Refer:  Biological assets]"
                            }
                        }
                    },
                "localname":  "CurrentBiologicalAssets",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "xbrltype":  "monetaryItemType"
                },
            "ifrs-full_CurrentDerivativeFinancialLiabilities":  {
                "auth_ref":  [
                    "r22"
                    ],
                "calculation":  {
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION":  {
                        "order":  20.0,
                        "parentTag":  "ifrs-full_CurrentLiabilities",
                        "weight":  1.0
                        }
                    },
                "crdr":  "credit",
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The amount of current derivative financial liabilities. [Refer:  Derivative financial liabilities]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Current derivative financial liabilities",
                            "verboseLabel":  "Derivative liability"
                            }
                        }
                    },
                "localname":  "CurrentDerivativeFinancialLiabilities",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION",
                    "http://www.fsdpharma.com/role/OtherInvestmentsNarrativeDetails",
                    "http://www.fsdpharma.com/role/ShareCapitalNarrativeDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "ifrs-full_CurrentInvestments":  {
                "auth_ref":  [
                    "r22"
                    ],
                "calculation":  {
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION":  {
                        "order":  0.0,
                        "parentTag":  "ifrs-full_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners",
                        "weight":  1.0
                        }
                    },
                "crdr":  "debit",
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The amount of current investments."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Current investments",
                            "terseLabel":  "Current",
                            "totalLabel":  "Total current inventories",
                            "verboseLabel":  "Investments"
                            }
                        }
                    },
                "localname":  "CurrentInvestments",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION",
                    "http://www.fsdpharma.com/role/OtherInvestmentsScheduleOfOtherInvestmentsDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "ifrs-full_CurrentLeaseLiabilities":  {
                "auth_ref":  [
                    "r156"
                    ],
                "calculation":  {
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION":  {
                        "order":  10.0,
                        "parentTag":  "ifrs-full_CurrentLiabilities",
                        "weight":  1.0
                        }
                    },
                "crdr":  "credit",
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The amount of current lease liabilities. [Refer:  Lease liabilities]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Current lease liabilities",
                            "terseLabel":  "Current",
                            "verboseLabel":  "Lease obligations"
                            }
                        }
                    },
                "localname":  "CurrentLeaseLiabilities",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION",
                    "http://www.fsdpharma.com/role/LeaseObligationsScheduleOfLeaseObligationsDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "ifrs-full_CurrentLiabilities":  {
                "auth_ref":  [
                    "r26",
                    "r138",
                    "r140"
                    ],
                "calculation":  {
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION":  {
                        "order":  10.0,
                        "parentTag":  "ifrs-full_Liabilities",
                        "weight":  1.0
                        }
                    },
                "crdr":  "credit",
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "Expiry date 2023-01-01:  The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have an unconditional right to defer settlement for at least twelve months after the reporting period.\nEffective 2023-01-01:  The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Current liabilities",
                            "totalLabel":  "Total current liabilities",
                            "verboseLabel":  "Total current liabilities"
                            }
                        }
                    },
                "localname":  "CurrentLiabilities",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "ifrs-full_CurrentLiabilitiesAbstract":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "label":  "Current Liabilities Abstract",
                            "terseLabel":  "Current liabilities"
                            }
                        }
                    },
                "localname":  "CurrentLiabilitiesAbstract",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
                    ],
                "xbrltype":  "stringItemType"
                },
            "ifrs-full_CurrentNotesAndDebenturesIssuedAndCurrentPortionOfNoncurrentNotesAndDebenturesIssued":  {
                "auth_ref":  [
                    "r10"
                    ],
                "calculation":  {
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION":  {
                        "order":  30.0,
                        "parentTag":  "ifrs-full_CurrentLiabilities",
                        "weight":  1.0
                        }
                    },
                "crdr":  "credit",
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The amount of current notes and debentures issued and the current portion of non-current notes and debentures issued. [Refer:  Notes and debentures issued]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Current notes and debentures issued and current portion of non-current notes and debentures issued",
                            "terseLabel":  "Balance as at December 31, 2019",
                            "verboseLabel":  "Notes payable"
                            }
                        }
                    },
                "localname":  "CurrentNotesAndDebenturesIssuedAndCurrentPortionOfNoncurrentNotesAndDebenturesIssued",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION",
                    "http://www.fsdpharma.com/role/NotesPayableScheduleOfNotesPayableDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "ifrs-full_CurrentPrepaidExpenses":  {
                "auth_ref":  [
                    "r10"
                    ],
                "calculation":  {
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION":  {
                        "order":  10.0,
                        "parentTag":  "ifrs-full_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners",
                        "weight":  1.0
                        },
                    "http://www.fsdpharma.com/role/PrepaidExpensesAndDepositsDetails":  {
                        "order":  null,
                        "parentTag":  null,
                        "root":  true,
                        "weight":  null
                        }
                    },
                "crdr":  "debit",
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The amount recognised as a current asset for expenditures made prior to the period when the economic benefit will be realised."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Current prepaid expenses",
                            "terseLabel":  "Prepaids",
                            "totalLabel":  "Prepaid expenses and deposits",
                            "verboseLabel":  "Prepaid expenses and deposits"
                            }
                        }
                    },
                "localname":  "CurrentPrepaidExpenses",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION",
                    "http://www.fsdpharma.com/role/PrepaidExpensesAndDepositsDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "ifrs-full_DeferredTaxExpenseIncome":  {
                "auth_ref":  [
                    "r51"
                    ],
                "calculation":  {
                    "http://www.fsdpharma.com/role/IncomeTaxesScheduleOfProvisionForIncomeTaxesDetails":  {
                        "order":  null,
                        "parentTag":  null,
                        "root":  true,
                        "weight":  null
                        }
                    },
                "crdr":  "debit",
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The amount of tax expense (income) relating to changes in deferred tax liabilities and deferred tax assets. [Refer:  Deferred tax assets; Deferred tax liabilities]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Deferred income tax provision (recovery)",
                            "totalLabel":  "Total Income tax expense",
                            "verboseLabel":  "Deferred income tax provision (recovery)"
                            }
                        }
                    },
                "localname":  "DeferredTaxExpenseIncome",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/IncomeTaxesScheduleOfProvisionForIncomeTaxesDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "ifrs-full_DepreciationAndAmortisationExpense":  {
                "auth_ref":  [
                    "r1",
                    "r3",
                    "r45",
                    "r146",
                    "r213",
                    "r219"
                    ],
                "calculation":  {
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS":  {
                        "order":  50.0,
                        "parentTag":  "ifrs-full_ExpenseByNature",
                        "weight":  1.0
                        }
                    },
                "crdr":  "debit",
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The amount of depreciation and amortisation expense.  Depreciation and amortisation are the systematic allocations of depreciable amounts of assets over their useful lives."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Depreciation and amortisation expense",
                            "negatedLabel":  "Depreciation and amortisation expense",
                            "terseLabel":  "Depreciation and amortization",
                            "totalLabel":  "Total depreciation and amortisation expense"
                            }
                        }
                    },
                "localname":  "DepreciationAndAmortisationExpense",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/AssetsHeldForSaleDetails1",
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "ifrs-full_DepreciationMethodPropertyPlantAndEquipment":  {
                "auth_ref":  [
                    "r56"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The depreciation method used for property, plant and equipment. [Refer:  Property, plant and equipment]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Depreciation method, property, plant and equipment",
                            "verboseLabel":  "Method of amortized"
                            }
                        }
                    },
                "localname":  "DepreciationMethodPropertyPlantAndEquipment",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/SignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfAssetsDetails"
                    ],
                "xbrltype":  "stringItemType"
                },
            "ifrs-full_DepreciationRightofuseAssets":  {
                "auth_ref":  [
                    "r157"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The amount of depreciation of right-of-use assets. [Refer:  Depreciation and amortisation expense; Right-of-use assets]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Depreciation, right-of-use assets",
                            "negatedLabel":  "Amortization",
                            "terseLabel":  "Amortization",
                            "verboseLabel":  "Depreciation on right of use assets"
                            }
                        }
                    },
                "localname":  "DepreciationRightofuseAssets",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/RightofuseAssetScheduleOfRightofuseAssetDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "ifrs-full_DerivativeFinancialLiabilities":  {
                "auth_ref":  [
                    "r22"
                    ],
                "crdr":  "credit",
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The amount of financial liabilities classified as derivative instruments. [Refer:  Financial assets; Derivatives [member]]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Derivative financial liabilities"
                            }
                        }
                    },
                "localname":  "DerivativeFinancialLiabilities",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/OtherInvestmentsNarrativeDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "ifrs-full_DescriptionOfAccountingPolicyForDiscontinuedOperationsExplanatory":  {
                "auth_ref":  [
                    "r11"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The description of the entity's accounting policy for discontinued operations. [Refer:  Discontinued operations [member]]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Description of accounting policy for discontinued operations [text block]",
                            "verboseLabel":  "Discontinued operations"
                            }
                        }
                    },
                "localname":  "DescriptionOfAccountingPolicyForDiscontinuedOperationsExplanatory",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/SignificantAccountingPoliciesPolicies"
                    ],
                "xbrltype":  "textBlockItemType"
                },
            "ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory":  {
                "auth_ref":  [
                    "r11"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The description of the entity's accounting policy for earnings per share."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Earnings/loss per share",
                            "verboseLabel":  "Net Loss per Share"
                            }
                        }
                    },
                "localname":  "DescriptionOfAccountingPolicyForEarningsPerShareExplanatory",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/SignificantAccountingPoliciesPolicies"
                    ],
                "xbrltype":  "textBlockItemType"
                },
            "ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory":  {
                "auth_ref":  [
                    "r11"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The description of the entity's accounting policy for financial instruments. [Refer:  Financial instruments, class [member]]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Description of accounting policy for financial instruments [text block]",
                            "verboseLabel":  "Financial Instruments"
                            }
                        }
                    },
                "localname":  "DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/SignificantAccountingPoliciesPolicies"
                    ],
                "xbrltype":  "textBlockItemType"
                },
            "ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory":  {
                "auth_ref":  [
                    "r11"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The description of the entity's accounting policy for foreign currency translation."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Description of accounting policy for foreign currency translation [text block]",
                            "verboseLabel":  "Foreign Currency Translation"
                            }
                        }
                    },
                "localname":  "DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/SignificantAccountingPoliciesPolicies"
                    ],
                "xbrltype":  "textBlockItemType"
                },
            "ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory":  {
                "auth_ref":  [
                    "r11"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The description of the entity's accounting policy for the impairment of assets."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Description of accounting policy for impairment of assets [text block]",
                            "terseLabel":  "Impairment of long-lived assets"
                            }
                        }
                    },
                "localname":  "DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/SignificantAccountingPoliciesPolicies"
                    ],
                "xbrltype":  "textBlockItemType"
                },
            "ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory":  {
                "auth_ref":  [
                    "r11"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The description of the entity's accounting policy for income tax."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Income taxes",
                            "terseLabel":  "Income Taxes"
                            }
                        }
                    },
                "localname":  "DescriptionOfAccountingPolicyForIncomeTaxExplanatory",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/SignificantAccountingPoliciesPolicies"
                    ],
                "xbrltype":  "textBlockItemType"
                },
            "ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory":  {
                "auth_ref":  [
                    "r11"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The description of the entity's accounting policy for intangible assets other than goodwill. [Refer:  Intangible assets other than goodwill]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Description of accounting policy for intangible assets other than goodwill [text block]",
                            "verboseLabel":  "Intangible Assets"
                            }
                        }
                    },
                "localname":  "DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/SignificantAccountingPoliciesPolicies"
                    ],
                "xbrltype":  "textBlockItemType"
                },
            "ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory":  {
                "auth_ref":  [
                    "r11"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The description of the entity's accounting policy for leases.  A lease is an agreement whereby the lessor conveys to the lessee in return for a payment or series of payments the right to use an asset for an agreed period of time."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Description of accounting policy for leases [text block]",
                            "verboseLabel":  "Leases"
                            }
                        }
                    },
                "localname":  "DescriptionOfAccountingPolicyForLeasesExplanatory",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/SignificantAccountingPoliciesPolicies"
                    ],
                "xbrltype":  "textBlockItemType"
                },
            "ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories":  {
                "auth_ref":  [
                    "r66"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The description of the entity's accounting policy for measuring inventories. [Refer:  Inventories]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Inventory",
                            "verboseLabel":  "Inventories"
                            }
                        }
                    },
                "localname":  "DescriptionOfAccountingPolicyForMeasuringInventories",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/SignificantAccountingPoliciesPolicies"
                    ],
                "xbrltype":  "textBlockItemType"
                },
            "ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory":  {
                "auth_ref":  [
                    "r11"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The description of the entity's accounting policy for property, plant and equipment. [Refer:  Property, plant and equipment]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Description Of Accounting Policy For Property Plant And Equipment Explanatory",
                            "terseLabel":  "Property, Plant and Equipment"
                            }
                        }
                    },
                "localname":  "DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/SignificantAccountingPoliciesPolicies"
                    ],
                "xbrltype":  "textBlockItemType"
                },
            "ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue":  {
                "auth_ref":  [
                    "r11"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The description of the entity's accounting policy for recognising revenue. [Refer:  Revenue]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Description of accounting policy for recognition of revenue [text block]",
                            "verboseLabel":  "Revenue Recognition"
                            }
                        }
                    },
                "localname":  "DescriptionOfAccountingPolicyForRecognitionOfRevenue",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/SignificantAccountingPoliciesPolicies"
                    ],
                "xbrltype":  "textBlockItemType"
                },
            "ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory":  {
                "auth_ref":  [
                    "r11"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The description of the entity's accounting policy for research and development expense. [Refer:  Research and development expense]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Description of accounting policy for research and development expense [text block]",
                            "verboseLabel":  "External research and development"
                            }
                        }
                    },
                "localname":  "DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/SignificantAccountingPoliciesPolicies"
                    ],
                "xbrltype":  "textBlockItemType"
                },
            "ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory":  {
                "auth_ref":  [
                    "r11"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The description of the entity's accounting policy for transactions in which the entity: (a) receives goods or services from the supplier of those goods or services (including an employee) in a share-based payment arrangement; or (b) incurs an obligation to settle the transaction with the supplier in a share-based payment arrangement when another group entity receives those goods or services. [Refer:  Share-based payment arrangements [member]]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Description Of Accounting Policy For Sharebased Payment Transactions Explanatory",
                            "terseLabel":  "Description of accounting policy for share-based payment transactions [text block]",
                            "verboseLabel":  "Share-based Compensation"
                            }
                        }
                    },
                "localname":  "DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/SignificantAccountingPoliciesPolicies"
                    ],
                "xbrltype":  "textBlockItemType"
                },
            "ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents":  {
                "auth_ref":  [
                    "r126"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The description of the entity's accounting policy used to determine the components of cash and cash equivalents. [Refer:  Cash and cash equivalents]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Description Of Accounting Policy To Determine Components Of Cash And Cash Equivalents",
                            "terseLabel":  "Description of accounting policy for determining components of cash and cash equivalents [text block]",
                            "verboseLabel":  "Cash"
                            }
                        }
                    },
                "localname":  "DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/SignificantAccountingPoliciesPolicies"
                    ],
                "xbrltype":  "textBlockItemType"
                },
            "ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted":  {
                "auth_ref":  [
                    "r179"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The expected volatility of the share price used to calculate the fair value of the share options granted.  Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period.  The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Expected volatility, share options granted",
                            "positiveLabel":  "Expected volatility",
                            "terseLabel":  "Annualized volatility",
                            "verboseLabel":  "Expected Volatility Range"
                            }
                        }
                    },
                "localname":  "DescriptionOfExpectedVolatilityShareOptionsGranted",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/AcquisitionOfLucidDetails",
                    "http://www.fsdpharma.com/role/AcquisitionOfPrismicPharmaceuticalScheduleOfBlackScholesOptionsPricingModelDetails",
                    "http://www.fsdpharma.com/role/SharebasedCompensationNarrativeDetails",
                    "http://www.fsdpharma.com/role/SharebasedCompensationScheduleOfFairValueAssumptionsOfShareOptionsGrantedDetails"
                    ],
                "xbrltype":  "percentItemType"
                },
            "ifrs-full_DescriptionOfOptionLifeShareOptionsGranted":  {
                "auth_ref":  [
                    "r179"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The option life of share options granted."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Option life, share options granted",
                            "terseLabel":  "Expected maturity",
                            "verboseLabel":  "Expected life (years)"
                            }
                        }
                    },
                "localname":  "DescriptionOfOptionLifeShareOptionsGranted",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/AcquisitionOfLucidDetails",
                    "http://www.fsdpharma.com/role/AcquisitionOfPrismicPharmaceuticalScheduleOfBlackScholesOptionsPricingModelDetails",
                    "http://www.fsdpharma.com/role/SharebasedCompensationScheduleOfFairValueAssumptionsOfShareOptionsGrantedDetails"
                    ],
                "xbrltype":  "decimalItemType"
                },
            "ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted":  {
                "auth_ref":  [
                    "r179"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer:  Government [member]]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Risk free interest rate, share options granted",
                            "terseLabel":  "Risk free interest rate",
                            "verboseLabel":  "Risk Free Interest Rate"
                            }
                        }
                    },
                "localname":  "DescriptionOfRiskFreeInterestRateShareOptionsGranted",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/AcquisitionOfLucidDetails",
                    "http://www.fsdpharma.com/role/AcquisitionOfPrismicPharmaceuticalScheduleOfBlackScholesOptionsPricingModelDetails",
                    "http://www.fsdpharma.com/role/SharebasedCompensationNarrativeDetails",
                    "http://www.fsdpharma.com/role/SharebasedCompensationScheduleOfFairValueAssumptionsOfShareOptionsGrantedDetails"
                    ],
                "xbrltype":  "percentItemType"
                },
            "ifrs-full_DescriptionOfUsefulLifeIntangibleAssetsOtherThanGoodwill":  {
                "auth_ref":  [
                    "r94"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "Description of useful life used for intangible assets other than goodwill. [Refer:  Intangible assets other than goodwill]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Description of useful life, intangible assets other than goodwill",
                            "verboseLabel":  "Estimated useful lives for intangible assets"
                            }
                        }
                    },
                "localname":  "DescriptionOfUsefulLifeIntangibleAssetsOtherThanGoodwill",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/SignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfAssetsDetails"
                    ],
                "xbrltype":  "stringItemType"
                },
            "ifrs-full_DescriptionOfUsefulLifePropertyPlantAndEquipment":  {
                "auth_ref":  [
                    "r57"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "Description of useful life used for property, plant and equipment. [Refer:  Property, plant and equipment]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Description of useful life, property, plant and equipment",
                            "verboseLabel":  "Estimated useful lives"
                            }
                        }
                    },
                "localname":  "DescriptionOfUsefulLifePropertyPlantAndEquipment",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/SignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfAssetsDetails"
                    ],
                "xbrltype":  "stringItemType"
                },
            "ifrs-full_DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares":  {
                "auth_ref":  [
                    "r89"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The number of dilutive potential ordinary shares that relate to the assumed conversion of the entity's convertible instruments."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Dilutive effect of convertible instruments on number of ordinary shares",
                            "verboseLabel":  "Dilutive effect of convertible instruments on number of ordinary shares"
                            }
                        }
                    },
                "localname":  "DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/LossPerShareDetails"
                    ],
                "xbrltype":  "sharesItemType"
                },
            "ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares":  {
                "auth_ref":  [
                    "r89"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The number of dilutive potential ordinary shares that relate to the assumed exercise of the entity's share options."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Dilutive effect of share options on number of ordinary shares"
                            }
                        }
                    },
                "localname":  "DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/LossPerShareDetails"
                    ],
                "xbrltype":  "sharesItemType"
                },
            "ifrs-full_DirectorsRemunerationExpense":  {
                "auth_ref":  [
                    "r10"
                    ],
                "crdr":  "debit",
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The amount of remuneration paid or payable to the entity's directors."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Directors remuneration expense",
                            "verboseLabel":  "Directors remuneration expense"
                            }
                        }
                    },
                "localname":  "DirectorsRemunerationExpense",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/RelatedPartyTransactionsNarrativeDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "ifrs-full_DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory":  {
                "auth_ref":  [
                    "r0"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The disclosure of accrued expenses and other liabilities. [Refer:  Accruals; Other liabilities]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Disclosure of accrued expenses and other liabilities [text block]",
                            "terseLabel":  "Schedule of accrued liabilities"
                            }
                        }
                    },
                "localname":  "DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/TradeAndOtherPayablesTables"
                    ],
                "xbrltype":  "textBlockItemType"
                },
            "ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory":  {
                "auth_ref":  [
                    "r0"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The disclosure of the basis used for the preparation of the financial statements."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Disclosure of basis of preparation of financial statements [text block]",
                            "verboseLabel":  "Basis of presentation"
                            }
                        }
                    },
                "localname":  "DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/BasisOfPresentation"
                    ],
                "xbrltype":  "textBlockItemType"
                },
            "ifrs-full_DisclosureOfBorrowingsExplanatory":  {
                "auth_ref":  [
                    "r0"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The disclosure of borrowings. [Refer:  Borrowings]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Disclosure of borrowings [text block]",
                            "terseLabel":  "Notes payable"
                            }
                        }
                    },
                "localname":  "DisclosureOfBorrowingsExplanatory",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/NotesPayable"
                    ],
                "xbrltype":  "textBlockItemType"
                },
            "ifrs-full_DisclosureOfBusinessCombinationsAbstract":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "label":  "Disclosure of detailed information about business combination [abstract]",
                            "verboseLabel":  "Nature of business"
                            }
                        }
                    },
                "localname":  "DisclosureOfBusinessCombinationsAbstract",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "xbrltype":  "stringItemType"
                },
            "ifrs-full_DisclosureOfBusinessCombinationsExplanatory":  {
                "auth_ref":  [
                    "r191"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The entire disclosure for business combinations."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Disclosure of business combinations [text block]",
                            "terseLabel":  "Acquisition of Prismic",
                            "verboseLabel":  "Acquisition of Lucid"
                            }
                        }
                    },
                "localname":  "DisclosureOfBusinessCombinationsExplanatory",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/AcquisitionOfLucid",
                    "http://www.fsdpharma.com/role/AcquisitionOfPrismicPharmaceutical"
                    ],
                "xbrltype":  "textBlockItemType"
                },
            "ifrs-full_DisclosureOfBusinessCombinationsLineItems":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "Line items represent concepts included in a table.  These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Disclosure of detailed information about business combination [line items]"
                            }
                        }
                    },
                "localname":  "DisclosureOfBusinessCombinationsLineItems",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/AcquisitionOfLucid",
                    "http://www.fsdpharma.com/role/AcquisitionOfLucidDetailTextuals",
                    "http://www.fsdpharma.com/role/AcquisitionOfLucidDetails",
                    "http://www.fsdpharma.com/role/AcquisitionOfLucidDetails1",
                    "http://www.fsdpharma.com/role/AcquisitionOfLucidTables",
                    "http://www.fsdpharma.com/role/AcquisitionOfPrismicPharmaceutical",
                    "http://www.fsdpharma.com/role/AcquisitionOfPrismicPharmaceuticalNarrativeDetails",
                    "http://www.fsdpharma.com/role/AcquisitionOfPrismicPharmaceuticalScheduleOfBlackScholesOptionsPricingModelDetails",
                    "http://www.fsdpharma.com/role/AcquisitionOfPrismicPharmaceuticalScheduleOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedDetails",
                    "http://www.fsdpharma.com/role/AcquisitionOfPrismicPharmaceuticalTables"
                    ],
                "xbrltype":  "stringItemType"
                },
            "ifrs-full_DisclosureOfBusinessCombinationsTable":  {
                "auth_ref":  [
                    "r186"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "Schedule disclosing information related to details of business combinations."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Disclosure of detailed information about business combination [table]"
                            }
                        }
                    },
                "localname":  "DisclosureOfBusinessCombinationsTable",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/AcquisitionOfLucid",
                    "http://www.fsdpharma.com/role/AcquisitionOfLucidDetailTextuals",
                    "http://www.fsdpharma.com/role/AcquisitionOfLucidDetails",
                    "http://www.fsdpharma.com/role/AcquisitionOfLucidDetails1",
                    "http://www.fsdpharma.com/role/AcquisitionOfLucidTables",
                    "http://www.fsdpharma.com/role/AcquisitionOfPrismicPharmaceutical",
                    "http://www.fsdpharma.com/role/AcquisitionOfPrismicPharmaceuticalNarrativeDetails",
                    "http://www.fsdpharma.com/role/AcquisitionOfPrismicPharmaceuticalScheduleOfBlackScholesOptionsPricingModelDetails",
                    "http://www.fsdpharma.com/role/AcquisitionOfPrismicPharmaceuticalScheduleOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedDetails",
                    "http://www.fsdpharma.com/role/AcquisitionOfPrismicPharmaceuticalTables"
                    ],
                "xbrltype":  "stringItemType"
                },
            "ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory":  {
                "auth_ref":  [
                    "r33"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The disclosure of classes of share capital. [Refer:  Share capital [member]]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Disclosure of classes of share capital [text block]",
                            "verboseLabel":  "Schedule of changes in share capital"
                            }
                        }
                    },
                "localname":  "DisclosureOfClassesOfShareCapitalExplanatory",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/ShareCapitalTables"
                    ],
                "xbrltype":  "textBlockItemType"
                },
            "ifrs-full_DisclosureOfClassesOfShareCapitalLineItems":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "Line items represent concepts included in a table.  These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Disclosure of classes of share capital [line items]"
                            }
                        }
                    },
                "localname":  "DisclosureOfClassesOfShareCapitalLineItems",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/ShareCapitalNarrativeDetails",
                    "http://www.fsdpharma.com/role/ShareCapitalScheduleOfReconciliationOfTheShareCapitalDetails"
                    ],
                "xbrltype":  "stringItemType"
                },
            "ifrs-full_DisclosureOfClassesOfShareCapitalTable":  {
                "auth_ref":  [
                    "r33"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "Schedule disclosing information related to classes of share capital."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Disclosure of classes of share capital [table]"
                            }
                        }
                    },
                "localname":  "DisclosureOfClassesOfShareCapitalTable",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/ShareCapitalNarrativeDetails",
                    "http://www.fsdpharma.com/role/ShareCapitalScheduleOfReconciliationOfTheShareCapitalDetails"
                    ],
                "xbrltype":  "stringItemType"
                },
            "ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory":  {
                "auth_ref":  [
                    "r0"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The disclosure of commitments and contingent liabilities. [Refer:  Contingent liabilities [member]]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Disclosure of commitments and contingent liabilities [text block]",
                            "verboseLabel":  "Commitments and contingencies"
                            }
                        }
                    },
                "localname":  "DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CommitmentsAndContingencies"
                    ],
                "xbrltype":  "textBlockItemType"
                },
            "ifrs-full_DisclosureOfContingentLiabilitiesAbstract":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "label":  "Disclosure of contingent liabilities [abstract]"
                            }
                        }
                    },
                "localname":  "DisclosureOfContingentLiabilitiesAbstract",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "xbrltype":  "stringItemType"
                },
            "ifrs-full_DisclosureOfContingentLiabilitiesLineItems":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "Line items represent concepts included in a table.  These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Disclosure of contingent liabilities [line items]"
                            }
                        }
                    },
                "localname":  "DisclosureOfContingentLiabilitiesLineItems",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CommitmentsAndContingenciesNarrativeDetails",
                    "http://www.fsdpharma.com/role/CommitmentsAndContingenciesScheduleOfQuantitiesOfCannabisAvailableToSupplyByFiscalPeriodDetails"
                    ],
                "xbrltype":  "stringItemType"
                },
            "ifrs-full_DisclosureOfContingentLiabilitiesTable":  {
                "auth_ref":  [
                    "r92"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "Schedule disclosing information related to contingent liabilities."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Disclosure of contingent liabilities [table]"
                            }
                        }
                    },
                "localname":  "DisclosureOfContingentLiabilitiesTable",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CommitmentsAndContingenciesNarrativeDetails",
                    "http://www.fsdpharma.com/role/CommitmentsAndContingenciesScheduleOfQuantitiesOfCannabisAvailableToSupplyByFiscalPeriodDetails"
                    ],
                "xbrltype":  "stringItemType"
                },
            "ifrs-full_DisclosureOfDeferredTaxesExplanatory":  {
                "auth_ref":  [
                    "r0"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The disclosure of deferred taxes. [Refer:  Deferred tax liabilities; Deferred tax assets]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Disclosure of deferred taxes [text block]",
                            "terseLabel":  "Schedule of deferred tax assets (liabilities)"
                            }
                        }
                    },
                "localname":  "DisclosureOfDeferredTaxesExplanatory",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/IncometaxesTables"
                    ],
                "xbrltype":  "textBlockItemType"
                },
            "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsAbstract":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "label":  "Disclosure of detailed information about borrowings [abstract]"
                            }
                        }
                    },
                "localname":  "DisclosureOfDetailedInformationAboutBorrowingsAbstract",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "xbrltype":  "stringItemType"
                },
            "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory":  {
                "auth_ref":  [
                    "r206"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The disclosure of detailed information about borrowings. [Refer:  Borrowings]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Disclosure of detailed information about borrowings [text block]",
                            "terseLabel":  "Notes Payable",
                            "verboseLabel":  "Schedule of notes payable"
                            }
                        }
                    },
                "localname":  "DisclosureOfDetailedInformationAboutBorrowingsExplanatory",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/NotesPayableTables"
                    ],
                "xbrltype":  "textBlockItemType"
                },
            "ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory":  {
                "auth_ref":  [
                    "r192"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The disclosure of detailed information about business combinations. [Refer:  Business combinations [member]]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Disclosure of detailed information about business combination [text block]",
                            "terseLabel":  "Schedule of identifiable assets acquired and liabilities assumed",
                            "verboseLabel":  "Acquisition of Prismic Pharmaceutical"
                            }
                        }
                    },
                "localname":  "DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/AcquisitionOfLucidTables",
                    "http://www.fsdpharma.com/role/AcquisitionOfPrismicPharmaceuticalTables"
                    ],
                "xbrltype":  "textBlockItemType"
                },
            "ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory":  {
                "auth_ref":  [
                    "r100"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The disclosure of detailed information about intangible assets. [Refer:  Intangible assets other than goodwill]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Disclosure of detailed information about intangible assets [text block]",
                            "verboseLabel":  "Schedule of intangible assets"
                            }
                        }
                    },
                "localname":  "DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/IntangibleAssetsTables"
                    ],
                "xbrltype":  "textBlockItemType"
                },
            "ifrs-full_DisclosureOfEarningsPerShareExplanatory":  {
                "auth_ref":  [
                    "r90"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The entire disclosure for earnings per share."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Disclosure of earnings per share [text block]",
                            "terseLabel":  "Loss per share",
                            "verboseLabel":  "Basic and diluted loss per share"
                            }
                        }
                    },
                "localname":  "DisclosureOfEarningsPerShareExplanatory",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/LossPerShare"
                    ],
                "xbrltype":  "textBlockItemType"
                },
            "ifrs-full_DisclosureOfFinancialInstrumentsAbstract":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "label":  "Disclosure of detailed information about financial instruments [abstract]"
                            }
                        }
                    },
                "localname":  "DisclosureOfFinancialInstrumentsAbstract",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "xbrltype":  "stringItemType"
                },
            "ifrs-full_DisclosureOfFinancialInstrumentsExplanatory":  {
                "auth_ref":  [
                    "r211"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The entire disclosure for financial instruments."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Disclosure of financial instruments [text block]",
                            "verboseLabel":  "Financial Instruments and Risk Management"
                            }
                        }
                    },
                "localname":  "DisclosureOfFinancialInstrumentsExplanatory",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/FinancialInstrumentsAndRiskManagement"
                    ],
                "xbrltype":  "textBlockItemType"
                },
            "ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory":  {
                "auth_ref":  [
                    "r0"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The disclosure of general and administrative expenses. [Refer:  Administrative expenses]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Disclosure of general and administrative expense [text block]",
                            "terseLabel":  "General and administrative",
                            "verboseLabel":  "Schedule of general and administrative expense"
                            }
                        }
                    },
                "localname":  "DisclosureOfGeneralAndAdministrativeExpenseExplanatory",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/GeneralAndAdministrative"
                    ],
                "xbrltype":  "textBlockItemType"
                },
            "ifrs-full_DisclosureOfIncomeTaxExplanatory":  {
                "auth_ref":  [
                    "r52"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The entire disclosure for income taxes."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Disclosure of income tax [text block]",
                            "verboseLabel":  "Income taxes"
                            }
                        }
                    },
                "localname":  "DisclosureOfIncomeTaxExplanatory",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/IncomeTaxes"
                    ],
                "xbrltype":  "textBlockItemType"
                },
            "ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory":  {
                "auth_ref":  [
                    "r180"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The disclosure of information about indirect, by reference to the fair value of the equity instruments granted, measurement of the fair value of goods or services received as consideration for the entity's share options."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Disclosure of indirect measurement of fair value of goods or services received, share options granted during period [text block]",
                            "verboseLabel":  "Schedule of fair values of options granted using the Black-Scholes option pricing model"
                            }
                        }
                    },
                "localname":  "DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/SharebasedCompensationTables"
                    ],
                "xbrltype":  "textBlockItemType"
                },
            "ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory":  {
                "auth_ref":  [
                    "r0"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The disclosure of information about key management personnel. [Refer:  Key management personnel of entity or parent [member]]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Disclosure of information about key management personnel [text block]",
                            "terseLabel":  "Schedule of key management personnel compensation"
                            }
                        }
                    },
                "localname":  "DisclosureOfInformationAboutKeyManagementPersonnelExplanatory",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/RelatedPartyTransactionsTables"
                    ],
                "xbrltype":  "textBlockItemType"
                },
            "ifrs-full_DisclosureOfIntangibleAssetsExplanatory":  {
                "auth_ref":  [
                    "r103"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The entire disclosure for intangible assets."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Disclosure of intangible assets [text block]",
                            "verboseLabel":  "Intangible assets"
                            }
                        }
                    },
                "localname":  "DisclosureOfIntangibleAssetsExplanatory",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/IntangibleAssets"
                    ],
                "xbrltype":  "textBlockItemType"
                },
            "ifrs-full_DisclosureOfIntangibleAssetsLineItems":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "Line items represent concepts included in a table.  These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Disclosure of detailed information about intangible assets [line items]"
                            }
                        }
                    },
                "localname":  "DisclosureOfIntangibleAssetsLineItems",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/IntangibleAssetsNarrativeDetails",
                    "http://www.fsdpharma.com/role/IntangibleAssetsScheduleOfIntangibleAssetsDetails"
                    ],
                "xbrltype":  "stringItemType"
                },
            "ifrs-full_DisclosureOfIntangibleAssetsTable":  {
                "auth_ref":  [
                    "r100"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "Schedule disclosing information related to details of intangible assets."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Disclosure of detailed information about intangible assets [table]"
                            }
                        }
                    },
                "localname":  "DisclosureOfIntangibleAssetsTable",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/IntangibleAssetsNarrativeDetails",
                    "http://www.fsdpharma.com/role/IntangibleAssetsScheduleOfIntangibleAssetsDetails"
                    ],
                "xbrltype":  "stringItemType"
                },
            "ifrs-full_DisclosureOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory":  {
                "auth_ref":  [
                    "r0"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The disclosure of investments other than investments accounted for using the equity method. [Refer:  Investments other than investments accounted for using equity method]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Disclosure of investments other than investments accounted for using equity method [text block]",
                            "verboseLabel":  "Investments"
                            }
                        }
                    },
                "localname":  "DisclosureOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/OtherInvestments"
                    ],
                "xbrltype":  "textBlockItemType"
                },
            "ifrs-full_DisclosureOfLeasesExplanatory":  {
                "auth_ref":  [
                    "r165",
                    "r166"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The entire disclosure for leases."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Disclosure of leases [text block]",
                            "verboseLabel":  "Lease obligations"
                            }
                        }
                    },
                "localname":  "DisclosureOfLeasesExplanatory",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/LeaseObligations"
                    ],
                "xbrltype":  "textBlockItemType"
                },
            "ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory":  {
                "auth_ref":  [
                    "r164"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The disclosure of a maturity analysis of operating lease payments.  Operating lease is a lease that does not transfer substantially all the risks and rewards incidental to ownership of an underlying asset."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Disclosure of maturity analysis of operating lease payments [text block]",
                            "terseLabel":  "Schedule of maturity analysis of operating lease payments",
                            "verboseLabel":  "Schedule of office lease commitments"
                            }
                        }
                    },
                "localname":  "DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/LeaseObligationsTables"
                    ],
                "xbrltype":  "textBlockItemType"
                },
            "ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "Line items represent concepts included in a table.  These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Disclosure of maturity analysis of operating lease payments [line items]"
                            }
                        }
                    },
                "localname":  "DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/LeaseObligationsScheduleOfMaturityAnalysisOfOperatingLeasePaymentsDetails"
                    ],
                "xbrltype":  "stringItemType"
                },
            "ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable":  {
                "auth_ref":  [
                    "r164"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "Schedule disclosing information related to the maturity analysis of operating lease payments."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Disclosure of maturity analysis of operating lease payments [table]"
                            }
                        }
                    },
                "localname":  "DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/LeaseObligationsScheduleOfMaturityAnalysisOfOperatingLeasePaymentsDetails"
                    ],
                "xbrltype":  "stringItemType"
                },
            "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "label":  "Disclosure of non-adjusting events after reporting period [abstract]"
                            }
                        }
                    },
                "localname":  "DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "xbrltype":  "stringItemType"
                },
            "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory":  {
                "auth_ref":  [
                    "r47"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The disclosure of non-adjusting events after the reporting period. [Refer:  Non-adjusting events after reporting period [member]]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Disclosure of non-adjusting events after reporting period [text block]",
                            "verboseLabel":  "Subsequent events"
                            }
                        }
                    },
                "localname":  "DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/SubsequentEvents"
                    ],
                "xbrltype":  "textBlockItemType"
                },
            "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "Line items represent concepts included in a table.  These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Disclosure of non-adjusting events after reporting period [line items]"
                            }
                        }
                    },
                "localname":  "DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/SubsequentEventsNarrativeDetails"
                    ],
                "xbrltype":  "stringItemType"
                },
            "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable":  {
                "auth_ref":  [
                    "r47"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "Schedule disclosing information related to non-adjusting events after the reporting period."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Disclosure of non-adjusting events after reporting period [table]"
                            }
                        }
                    },
                "localname":  "DisclosureOfNonadjustingEventsAfterReportingPeriodTable",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/SubsequentEventsNarrativeDetails"
                    ],
                "xbrltype":  "stringItemType"
                },
            "ifrs-full_DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory":  {
                "auth_ref":  [
                    "r197"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The entire disclosure for non-current assets held for sale and discontinued operations."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Disclosure of non-current assets held for sale and discontinued operations [text block]",
                            "verboseLabel":  "Assets held for sale"
                            }
                        }
                    },
                "localname":  "DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/AssetsHeldForSale"
                    ],
                "xbrltype":  "textBlockItemType"
                },
            "ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory":  {
                "auth_ref":  [
                    "r176"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The disclosure of the number and weighted average exercise prices of share options. [Refer:  Weighted average [member]]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Disclosure of number and weighted average exercise prices of share options [text block]",
                            "verboseLabel":  "Schedule of stock options granted"
                            }
                        }
                    },
                "localname":  "DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/SharebasedCompensationTables"
                    ],
                "xbrltype":  "textBlockItemType"
                },
            "ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory":  {
                "auth_ref":  [
                    "r177"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The disclosure of the number and weighted average remaining contractual life of outstanding share options. [Refer:  Weighted average [member]]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Disclosure of number and weighted average remaining contractual life of outstanding share options [text block]",
                            "verboseLabel":  "Schedule of number and weighted average remaining contractual life of outstanding and exercisable share options"
                            }
                        }
                    },
                "localname":  "DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/SharebasedCompensationTables"
                    ],
                "xbrltype":  "textBlockItemType"
                },
            "ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory":  {
                "auth_ref":  [
                    "r13"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The disclosure of information that enables users of financial statements to evaluate the entity's objectives, policies and processes for managing capital."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Disclosure of objectives, policies and processes for managing capital [text block]",
                            "verboseLabel":  "Capital Management"
                            }
                        }
                    },
                "localname":  "DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CapitalManagement"
                    ],
                "xbrltype":  "textBlockItemType"
                },
            "ifrs-full_DisclosureOfOperatingSegmentsAbstract":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "label":  "Disclosure of operating segments [abstract]"
                            }
                        }
                    },
                "localname":  "DisclosureOfOperatingSegmentsAbstract",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "xbrltype":  "stringItemType"
                },
            "ifrs-full_DisclosureOfOperatingSegmentsExplanatory":  {
                "auth_ref":  [
                    "r214"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The disclosure of operating segments. [Refer:  Operating segments [member]]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Disclosure of operating segments [text block]",
                            "terseLabel":  "Segmented information"
                            }
                        }
                    },
                "localname":  "DisclosureOfOperatingSegmentsExplanatory",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/SegmentedInformation"
                    ],
                "xbrltype":  "textBlockItemType"
                },
            "ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "Line items represent concepts included in a table.  These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Disclosure of detailed information about property, plant and equipment [line items]"
                            }
                        }
                    },
                "localname":  "DisclosureOfPropertyPlantAndEquipmentLineItems",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/SignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfAssetsDetails"
                    ],
                "xbrltype":  "stringItemType"
                },
            "ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsAbstract":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "label":  "Disclosure of quantitative information about right-of-use assets [abstract]"
                            }
                        }
                    },
                "localname":  "DisclosureOfQuantitativeInformationAboutRightofuseAssetsAbstract",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "xbrltype":  "stringItemType"
                },
            "ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory":  {
                "auth_ref":  [
                    "r162"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The disclosure of quantitative information about right-of-use assets. [Refer:  Right-of-use assets]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Disclosure of quantitative information about right-of-use assets [text block]",
                            "terseLabel":  "Right-of-use asset"
                            }
                        }
                    },
                "localname":  "DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/RightofuseAsset"
                    ],
                "xbrltype":  "textBlockItemType"
                },
            "ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "Line items represent concepts included in a table.  These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Disclosure of reconciliation of liabilities arising from financing activities [line items]"
                            }
                        }
                    },
                "localname":  "DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/NotesPayableNarrativeDetails",
                    "http://www.fsdpharma.com/role/NotesPayableScheduleOfNotesPayableDetails"
                    ],
                "xbrltype":  "stringItemType"
                },
            "ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable":  {
                "auth_ref":  [
                    "r124"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "Schedule disclosing information related to the reconciliation of liabilities arising from financing activities."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Disclosure of reconciliation of liabilities arising from financing activities [table]"
                            }
                        }
                    },
                "localname":  "DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/NotesPayableNarrativeDetails",
                    "http://www.fsdpharma.com/role/NotesPayableScheduleOfNotesPayableDetails"
                    ],
                "xbrltype":  "stringItemType"
                },
            "ifrs-full_DisclosureOfRelatedPartyExplanatory":  {
                "auth_ref":  [
                    "r77"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The entire disclosure for related parties."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Disclosure of related party [text block]",
                            "verboseLabel":  "Related party transactions"
                            }
                        }
                    },
                "localname":  "DisclosureOfRelatedPartyExplanatory",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/RelatedPartyTransactions"
                    ],
                "xbrltype":  "textBlockItemType"
                },
            "ifrs-full_DisclosureOfReservesWithinEquityAbstract":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "label":  "Disclosure of reserves within equity [abstract]"
                            }
                        }
                    },
                "localname":  "DisclosureOfReservesWithinEquityAbstract",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "xbrltype":  "stringItemType"
                },
            "ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory":  {
                "auth_ref":  [
                    "r34"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The entire disclosure for share capital, reserves and other equity interest."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Disclosure of share capital, reserves and other equity interest [text block]",
                            "terseLabel":  "Share capital",
                            "verboseLabel":  "Share capital and reserves"
                            }
                        }
                    },
                "localname":  "DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/ShareCapital"
                    ],
                "xbrltype":  "textBlockItemType"
                },
            "ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory":  {
                "auth_ref":  [
                    "r167"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The entire disclosure for share-based payment arrangements."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Disclosure of share-based payment arrangements [text block]",
                            "verboseLabel":  "Share-based compensation"
                            }
                        }
                    },
                "localname":  "DisclosureOfSharebasedPaymentArrangementsExplanatory",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/SharebasedCompensation"
                    ],
                "xbrltype":  "textBlockItemType"
                },
            "ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory":  {
                "auth_ref":  [
                    "r81",
                    "r84",
                    "r147"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The disclosure of subsidiaries. [Refer:  Subsidiaries [member]]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Disclosure of subsidiaries [text block]",
                            "verboseLabel":  "Schedule of ownership percentage in subsidiaries"
                            }
                        }
                    },
                "localname":  "DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/NatureOfBusinessTable"
                    ],
                "xbrltype":  "textBlockItemType"
                },
            "ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "Line items represent concepts included in a table.  These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Disclosure of subsidiaries [line items]"
                            }
                        }
                    },
                "localname":  "DisclosureOfSignificantInvestmentsInSubsidiariesLineItems",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/NatureOfBusinessScheduleOfOwnershipPercentageInSubsidiariesDetails"
                    ],
                "xbrltype":  "stringItemType"
                },
            "ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable":  {
                "auth_ref":  [
                    "r81",
                    "r84",
                    "r147"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "Schedule disclosing information related to subsidiaries."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Disclosure of subsidiaries [table]"
                            }
                        }
                    },
                "localname":  "DisclosureOfSignificantInvestmentsInSubsidiariesTable",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/NatureOfBusinessScheduleOfOwnershipPercentageInSubsidiariesDetails"
                    ],
                "xbrltype":  "stringItemType"
                },
            "ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory":  {
                "auth_ref":  [
                    "r12"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The entire disclosure for significant accounting policies applied by the entity."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Disclosure of significant accounting policies [text block]",
                            "verboseLabel":  "Significant accounting policies"
                            }
                        }
                    },
                "localname":  "DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/SignificantAccountingPolicies"
                    ],
                "xbrltype":  "textBlockItemType"
                },
            "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "label":  "Disclosure of terms and conditions of share-based payment arrangement [abstract]"
                            }
                        }
                    },
                "localname":  "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "xbrltype":  "stringItemType"
                },
            "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "Line items represent concepts included in a table.  These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Disclosure of terms and conditions of share-based payment arrangement [line items]"
                            }
                        }
                    },
                "localname":  "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/SharebasedCompensationNarrativeDetails",
                    "http://www.fsdpharma.com/role/SharebasedCompensationScheduleOfChangesInNumberOfShareOptionsDetails",
                    "http://www.fsdpharma.com/role/SharebasedCompensationScheduleOfExercisePriceAndWeightedAverageContractualTermOfShareOptionsOutstandingAndExercisableDetails",
                    "http://www.fsdpharma.com/role/SharebasedCompensationScheduleOfFairValueAssumptionsOfShareOptionsGrantedDetails",
                    "http://www.fsdpharma.com/role/SharebasedCompensationScheduleOfSharebasedCompensationDetails"
                    ],
                "xbrltype":  "stringItemType"
                },
            "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable":  {
                "auth_ref":  [
                    "r178"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "Schedule disclosing information related to terms and conditions of share-based payment arrangements."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Disclosure of terms and conditions of share-based payment arrangement [table]"
                            }
                        }
                    },
                "localname":  "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/SharebasedCompensationNarrativeDetails",
                    "http://www.fsdpharma.com/role/SharebasedCompensationScheduleOfChangesInNumberOfShareOptionsDetails",
                    "http://www.fsdpharma.com/role/SharebasedCompensationScheduleOfExercisePriceAndWeightedAverageContractualTermOfShareOptionsOutstandingAndExercisableDetails",
                    "http://www.fsdpharma.com/role/SharebasedCompensationScheduleOfFairValueAssumptionsOfShareOptionsGrantedDetails",
                    "http://www.fsdpharma.com/role/SharebasedCompensationScheduleOfSharebasedCompensationDetails"
                    ],
                "xbrltype":  "stringItemType"
                },
            "ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory":  {
                "auth_ref":  [
                    "r0"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The disclosure of trade and other payables. [Refer:  Trade and other payables]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Disclosure of trade and other payables [text block]",
                            "terseLabel":  "Trade and other payables"
                            }
                        }
                    },
                "localname":  "DisclosureOfTradeAndOtherPayablesExplanatory",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/TradeAndOtherPayables"
                    ],
                "xbrltype":  "textBlockItemType"
                },
            "ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory":  {
                "auth_ref":  [
                    "r0"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The disclosure of trade and other receivables. [Refer:  Trade and other receivables]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Disclosure of trade and other receivables [text block]",
                            "verboseLabel":  "Other receivables"
                            }
                        }
                    },
                "localname":  "DisclosureOfTradeAndOtherReceivablesExplanatory",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/TradeAndOtherReceivables"
                    ],
                "xbrltype":  "textBlockItemType"
                },
            "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "label":  "Disclosure of transactions between related parties [abstract]"
                            }
                        }
                    },
                "localname":  "DisclosureOfTransactionsBetweenRelatedPartiesAbstract",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "xbrltype":  "stringItemType"
                },
            "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "Line items represent concepts included in a table.  These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Disclosure of transactions between related parties [line items]"
                            }
                        }
                    },
                "localname":  "DisclosureOfTransactionsBetweenRelatedPartiesLineItems",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/RelatedPartyTransactionsNarrativeDetails"
                    ],
                "xbrltype":  "stringItemType"
                },
            "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable":  {
                "auth_ref":  [
                    "r74"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "Schedule disclosing information related to transactions between related parties."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Disclosure of transactions between related parties [table]"
                            }
                        }
                    },
                "localname":  "DisclosureOfTransactionsBetweenRelatedPartiesTable",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/RelatedPartyTransactionsNarrativeDetails"
                    ],
                "xbrltype":  "stringItemType"
                },
            "ifrs-full_DisposalGroupsClassifiedAsHeldForSaleMember":  {
                "auth_ref":  [
                    "r196",
                    "r197"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "This member stands for groups of assets, which are to be disposed of together as a group in a single transaction, and the liabilities directly associated with those assets that will be transferred in the transaction."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Disposal groups classified as held for sale [member]",
                            "verboseLabel":  "Cobourg facility"
                            }
                        }
                    },
                "localname":  "DisposalGroupsClassifiedAsHeldForSaleMember",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/AssetsHeldForSaleDetailTextuals",
                    "http://www.fsdpharma.com/role/AssetsHeldForSaleDetails",
                    "http://www.fsdpharma.com/role/AssetsHeldForSaleDetails1",
                    "http://www.fsdpharma.com/role/AssetsHeldForSaleDetails2"
                    ],
                "xbrltype":  "domainItemType"
                },
            "ifrs-full_EarningsPerShareAbstract":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "label":  "Earnings per share [abstract]",
                            "verboseLabel":  "Income (loss) per Class B share:"
                            }
                        }
                    },
                "localname":  "EarningsPerShareAbstract",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "xbrltype":  "stringItemType"
                },
            "ifrs-full_EarningsPerShareExplanatory":  {
                "auth_ref":  [
                    "r86"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The disclosure of earnings per share."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Earnings per share [text block]",
                            "terseLabel":  "Schedule of loss per share",
                            "verboseLabel":  "Schedule of basic and diluted loss per share"
                            }
                        }
                    },
                "localname":  "EarningsPerShareExplanatory",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/LossPerShareTables"
                    ],
                "xbrltype":  "textBlockItemType"
                },
            "ifrs-full_EarningsPerShareLineItems":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "Line items represent concepts included in a table.  These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Earnings per share [line items]"
                            }
                        }
                    },
                "localname":  "EarningsPerShareLineItems",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/LossPerShareDetails"
                    ],
                "xbrltype":  "stringItemType"
                },
            "ifrs-full_EarningsPerShareTable":  {
                "auth_ref":  [
                    "r86"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "Schedule disclosing information related to earnings per share."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Earnings per share [table]"
                            }
                        }
                    },
                "localname":  "EarningsPerShareTable",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/LossPerShareDetails"
                    ],
                "xbrltype":  "stringItemType"
                },
            "ifrs-full_EntitysTotalForBusinessCombinationsMember":  {
                "auth_ref":  [
                    "r186",
                    "r189"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "This member stands for the standard value for the 'Business combinations' axis if no other member is used."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Entitys total for business combinations [member]"
                            }
                        }
                    },
                "localname":  "EntitysTotalForBusinessCombinationsMember",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/AcquisitionOfLucidDetailTextuals",
                    "http://www.fsdpharma.com/role/AcquisitionOfPrismicPharmaceuticalNarrativeDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "ifrs-full_EntitysTotalForRelatedPartiesMember":  {
                "auth_ref":  [
                    "r74"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "This member stands for the standard value for the 'Categories of related parties' axis if no other member is used."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Entity's total for related parties [member]"
                            }
                        }
                    },
                "localname":  "EntitysTotalForRelatedPartiesMember",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/RelatedPartyTransactionsNarrativeDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "ifrs-full_EntitysTotalForSubsidiariesMember":  {
                "auth_ref":  [
                    "r81",
                    "r84",
                    "r147"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "This member stands for the standard value for the 'Subsidiaries' axis if no other member is used."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Entitys total for subsidiaries [member]"
                            }
                        }
                    },
                "localname":  "EntitysTotalForSubsidiariesMember",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/NatureOfBusinessScheduleOfOwnershipPercentageInSubsidiariesDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "ifrs-full_Equity":  {
                "auth_ref":  [
                    "r22",
                    "r30",
                    "r130",
                    "r132",
                    "r148",
                    "r149",
                    "r150"
                    ],
                "calculation":  {
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION":  {
                        "order":  10.0,
                        "parentTag":  "ifrs-full_EquityAndLiabilities",
                        "weight":  1.0
                        }
                    },
                "crdr":  "credit",
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The amount of residual interest in the assets of the entity after deducting all its liabilities."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Equity",
                            "periodEndLabel":  "Ending balance",
                            "periodStartLabel":  "Beginning balance",
                            "terseLabel":  "Balances",
                            "totalLabel":  "Total equity",
                            "verboseLabel":  "Total equity"
                            }
                        }
                    },
                "localname":  "Equity",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION",
                    "http://www.fsdpharma.com/role/ShareCapitalScheduleOfReconciliationOfTheShareCapitalDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "ifrs-full_EquityAbstract":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "label":  "SHAREHOLDERS EQUITY",
                            "terseLabel":  "SHAREHOLDER'S EQUITY"
                            }
                        }
                    },
                "localname":  "EquityAbstract",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
                    ],
                "xbrltype":  "stringItemType"
                },
            "ifrs-full_EquityAndLiabilities":  {
                "auth_ref":  [
                    "r22"
                    ],
                "calculation":  {
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION":  {
                        "order":  null,
                        "parentTag":  null,
                        "root":  true,
                        "weight":  null
                        }
                    },
                "crdr":  "credit",
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The amount of the entity's equity and liabilities. [Refer:  Equity; Liabilities]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Equity and liabilities",
                            "totalLabel":  "Total equity and liabilities"
                            }
                        }
                    },
                "localname":  "EquityAndLiabilities",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "ifrs-full_EquityAndLiabilitiesAbstract":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "label":  "Equity And Liabilities Abstract",
                            "terseLabel":  "Equity and liabilities [abstract]"
                            }
                        }
                    },
                "localname":  "EquityAndLiabilitiesAbstract",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
                    ],
                "xbrltype":  "stringItemType"
                },
            "ifrs-full_EquityInterestsOfAcquirer":  {
                "auth_ref":  [
                    "r182"
                    ],
                "crdr":  "credit",
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The fair value, at the acquisition date, of equity interests of the acquirer transferred as consideration in a business combination. [Refer:  Business combinations [member]]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Equity interests of acquirer",
                            "netLabel":  "Consideration transferred, acquisition-date fair value",
                            "terseLabel":  "Total consideration",
                            "totalLabel":  "Total consideration transferred, acquisition-date fair value",
                            "verboseLabel":  "Exchange of Class B shares"
                            }
                        }
                    },
                "localname":  "EquityInterestsOfAcquirer",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/AcquisitionOfLucidDetailTextuals",
                    "http://www.fsdpharma.com/role/AcquisitionOfPrismicPharmaceuticalNarrativeDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "ifrs-full_EquityMember":  {
                "auth_ref":  [
                    "r8"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "This member stands for the residual interest in the assets of the entity after deducting all its liabilities.  It also represents the standard value for the 'Components of equity' axis if no other member is used."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Equity [member]"
                            }
                        }
                    },
                "localname":  "EquityMember",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
                    "http://www.fsdpharma.com/role/ShareCapitalNarrativeDetails",
                    "http://www.fsdpharma.com/role/ShareCapitalScheduleOfReconciliationOfTheShareCapitalDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "ifrs-full_ExercisePriceShareOptionsGranted2019":  {
                "auth_ref":  [
                    "r179"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The exercise price of share options granted."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Exercise price, share options granted",
                            "verboseLabel":  "Exercise price"
                            }
                        }
                    },
                "localname":  "ExercisePriceShareOptionsGranted2019",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/AcquisitionOfLucidDetails",
                    "http://www.fsdpharma.com/role/AcquisitionOfPrismicPharmaceuticalScheduleOfBlackScholesOptionsPricingModelDetails",
                    "http://www.fsdpharma.com/role/SharebasedCompensationNarrativeDetails",
                    "http://www.fsdpharma.com/role/SharebasedCompensationScheduleOfFairValueAssumptionsOfShareOptionsGrantedDetails"
                    ],
                "xbrltype":  "perShareItemType"
                },
            "ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted":  {
                "auth_ref":  [
                    "r179"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The percentage of an expected dividend used to calculate the fair value of share options granted."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Expected dividend as percentage, share options granted",
                            "terseLabel":  "Expected dividend yield",
                            "verboseLabel":  "Expected dividend yield"
                            }
                        }
                    },
                "localname":  "ExpectedDividendAsPercentageShareOptionsGranted",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/AcquisitionOfLucidDetails",
                    "http://www.fsdpharma.com/role/AcquisitionOfPrismicPharmaceuticalScheduleOfBlackScholesOptionsPricingModelDetails",
                    "http://www.fsdpharma.com/role/SharebasedCompensationScheduleOfFairValueAssumptionsOfShareOptionsGrantedDetails"
                    ],
                "xbrltype":  "percentItemType"
                },
            "ifrs-full_ExpenseByNature":  {
                "auth_ref":  [
                    "r45"
                    ],
                "calculation":  {
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS":  {
                        "order":  null,
                        "parentTag":  null,
                        "root":  true,
                        "weight":  null
                        }
                    },
                "crdr":  "debit",
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The amount of expenses aggregated according to their nature (for example, depreciation, purchases of materials, transport costs, employee benefits and advertising costs), and not reallocated among functions within the entity."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Expenses, by nature",
                            "totalLabel":  "Total operating expenses"
                            }
                        }
                    },
                "localname":  "ExpenseByNature",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "ifrs-full_ExpenseByNatureAbstract":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "label":  "Expenses by nature [abstract]",
                            "terseLabel":  "Expenses",
                            "verboseLabel":  "Allocated to:"
                            }
                        }
                    },
                "localname":  "ExpenseByNatureAbstract",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS",
                    "http://www.fsdpharma.com/role/GeneralAndAdministrativeDetails"
                    ],
                "xbrltype":  "stringItemType"
                },
            "ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees":  {
                "auth_ref":  [
                    "r10"
                    ],
                "calculation":  {
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS":  {
                        "order":  20.0,
                        "parentTag":  "ifrs-full_ExpenseByNature",
                        "weight":  1.0
                        }
                    },
                "crdr":  "debit",
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The amount of expense from share-based payment transactions with employees. [Refer:  Expense from share-based payment transactions]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Expense from share-based payment transactions with employees",
                            "terseLabel":  "Share-based compensation expenses",
                            "verboseLabel":  "Share-based payments"
                            }
                        }
                    },
                "localname":  "ExpenseFromSharebasedPaymentTransactionsWithEmployees",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS",
                    "http://www.fsdpharma.com/role/SharebasedCompensationNarrativeDetails",
                    "http://www.fsdpharma.com/role/SharebasedCompensationScheduleOfSharebasedCompensationDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "ifrs-full_FinanceCosts":  {
                "auth_ref":  [
                    "r38"
                    ],
                "calculation":  {
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS":  {
                        "order":  40.0,
                        "parentTag":  "ifrs-full_ProfitLossFromContinuingOperations",
                        "weight":  -1.0
                        }
                    },
                "crdr":  "debit",
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The amount of costs associated with financing activities of the entity."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Finance costs",
                            "negatedLabel":  "Finance expense",
                            "terseLabel":  "Finance expense"
                            }
                        }
                    },
                "localname":  "FinanceCosts",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "ifrs-full_FixturesAndFittingsMember":  {
                "auth_ref":  [
                    "r54"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "This member stands for a class of property, plant and equipment representing fixtures and fittings that are not permanently attached to real property. [Refer:  Property, plant and equipment]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Fixtures and fittings [member]",
                            "verboseLabel":  "Furniture and fixtures"
                            }
                        }
                    },
                "localname":  "FixturesAndFittingsMember",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/SignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfAssetsDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives":  {
                "auth_ref":  [
                    "r40"
                    ],
                "calculation":  {
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS":  {
                        "order":  60.0,
                        "parentTag":  "ifrs-full_ProfitLossFromContinuingOperations",
                        "weight":  1.0
                        }
                    },
                "crdr":  "credit",
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The gains (losses) resulting from change in the fair value of derivatives recognised in profit or loss. [Refer:  Derivatives [member]]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Gains (losses) on change in fair value of derivatives",
                            "negatedLabel":  "Loss (gain) on change in fair value of warrants and derivative liability",
                            "netLabel":  "Net gains (losses) on change in fair value of derivatives",
                            "verboseLabel":  "Loss (gain) on change in fair value of warrants and derivative liability"
                            }
                        }
                    },
                "localname":  "GainsLossesOnChangeInFairValueOfDerivatives",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "ifrs-full_GainsLossesOnDisposalsOfInvestments":  {
                "auth_ref":  [
                    "r43"
                    ],
                "crdr":  "credit",
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The gains (losses) on disposals of investments."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Gains (losses) on disposals of investments",
                            "negatedLabel":  "Gain (loss) on sale of investment",
                            "netLabel":  "Net gains (losses) on disposals of investments",
                            "verboseLabel":  "Gain (loss) on sale of investment"
                            }
                        }
                    },
                "localname":  "GainsLossesOnDisposalsOfInvestments",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/OtherInvestmentsNarrativeDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss":  {
                "auth_ref":  [
                    "r14",
                    "r67"
                    ],
                "crdr":  "credit",
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The amount of exchange differences recognised in profit or loss that arise from foreign currency transactions, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer:  At fair value [member]; Financial instruments, class [member]]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Foreign exchange gain (loss)",
                            "negatedLabel":  "Foreign exchange gain (loss)",
                            "netLabel":  "Net foreign exchange gain (loss)",
                            "terseLabel":  "Foreign exchange loss",
                            "verboseLabel":  "Foreign exchange gain"
                            }
                        }
                    },
                "localname":  "GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/GeneralAndAdministrativeDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "ifrs-full_GainsLossesOnFairValueAdjustmentAttributableToPriceChangesBiologicalAssets":  {
                "auth_ref":  [
                    "r109",
                    "r111"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The gains (losses) arising from changes in fair value less costs to sell of biological assets due to price changes in the market. [Refer:  Biological assets]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Gains (losses) on fair value adjustment attributable to price changes, biological assets",
                            "negatedLabel":  "Unrealized loss on changes in fair value of biological assets",
                            "verboseLabel":  "Unrealized loss on changes in fair value of biological assets"
                            }
                        }
                    },
                "localname":  "GainsLossesOnFairValueAdjustmentAttributableToPriceChangesBiologicalAssets",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/AssetsHeldForSaleDetails1"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "ifrs-full_GainsLossesRecognisedInProfitOrLossAttributableToChangeInUnrealisedGainsOrLossesForAssetsHeldAtEndOfPeriodFairValueMeasurement":  {
                "auth_ref":  [
                    "r151"
                    ],
                "calculation":  {
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS":  {
                        "order":  10.0,
                        "parentTag":  "ifrs-full_ProfitLossFromContinuingOperations",
                        "weight":  1.0
                        }
                    },
                "crdr":  "credit",
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The gains (losses) recognised in profit or loss for assets measured at fair value that are attributable to the change in unrealised gains or losses relating to those assets held at the end of the reporting period. [Refer:  At fair value [member]]"
                            }
                        }
                    },
                "localname":  "GainsLossesRecognisedInProfitOrLossAttributableToChangeInUnrealisedGainsOrLossesForAssetsHeldAtEndOfPeriodFairValueMeasurement",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "xbrltype":  "monetaryItemType"
                },
            "ifrs-full_GeneralAndAdministrativeExpense":  {
                "auth_ref":  [
                    "r10"
                    ],
                "calculation":  {
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS":  {
                        "order":  0.0,
                        "parentTag":  "ifrs-full_ExpenseByNature",
                        "weight":  1.0
                        }
                    },
                "crdr":  "debit",
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The amount of expense relating to general and administrative activities of the entity."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "General and administrative expense",
                            "terseLabel":  "General and administrative",
                            "totalLabel":  "Profit (loss) from continuing operations",
                            "verboseLabel":  "Continuing operations"
                            }
                        }
                    },
                "localname":  "GeneralAndAdministrativeExpense",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/AssetsHeldForSaleDetails1",
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS",
                    "http://www.fsdpharma.com/role/GeneralAndAdministrativeDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "ifrs-full_GrossCarryingAmountMember":  {
                "auth_ref":  [
                    "r58",
                    "r95",
                    "r106",
                    "r110",
                    "r188",
                    "r200",
                    "r202",
                    "r203",
                    "r229",
                    "r231"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "This member stands for the amount at which an asset is recognised before deducting any accumulated depreciation (amortisation) and accumulated impairment losses thereon. [Refer:  Depreciation and amortisation expense; Impairment loss]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Gross carrying amount [member]",
                            "terseLabel":  "Cost",
                            "verboseLabel":  "Cost:"
                            }
                        }
                    },
                "localname":  "GrossCarryingAmountMember",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/IntangibleAssetsScheduleOfIntangibleAssetsDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "ifrs-full_GrossProfit":  {
                "auth_ref":  [
                    "r2"
                    ],
                "crdr":  "credit",
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The amount of revenue less cost of sales. [Refer:  Cost of sales; Revenue]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Gross profit",
                            "netLabel":  "Gross profit",
                            "totalLabel":  "Gross loss",
                            "verboseLabel":  "Gross loss"
                            }
                        }
                    },
                "localname":  "GrossProfit",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/AssetsHeldForSaleDetails1"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate":  {
                "auth_ref":  [
                    "r184",
                    "r190"
                    ],
                "crdr":  "debit",
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The amount recognised as of the acquisition date for identifiable intangible assets acquired in a business combination. [Refer:  Intangible assets other than goodwill; Business combinations [member]]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Identifiable intangible assets recognised as of acquisition date",
                            "periodEndLabel":  "Intangible assets other than goodwill at end of period",
                            "periodStartLabel":  "Intangible assets other than goodwill at beginning of period",
                            "terseLabel":  "Intangible assets",
                            "totalLabel":  "Total intangible assets other than goodwill",
                            "verboseLabel":  "Intangible assets, net"
                            }
                        }
                    },
                "localname":  "IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/AcquisitionOfLucidDetails1",
                    "http://www.fsdpharma.com/role/AcquisitionOfPrismicPharmaceuticalScheduleOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedDetails",
                    "http://www.fsdpharma.com/role/IntangibleAssetsNarrativeDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment":  {
                "auth_ref":  [
                    "r42",
                    "r59"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The amount of impairment loss recognised in profit or loss for property, plant and equipment. [Refer:  Impairment loss recognised in profit or loss; Property, plant and equipment]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Impairment loss recognised in profit or loss, property, plant and equipment",
                            "negatedLabel":  "Impairment",
                            "verboseLabel":  "Impairment of equipment"
                            }
                        }
                    },
                "localname":  "ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/AssetsHeldForSaleDetails1"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "ifrs-full_IncomeStatementAbstract":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "label":  "Income Statement [abstract]"
                            }
                        }
                    },
                "localname":  "IncomeStatementAbstract",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "xbrltype":  "stringItemType"
                },
            "ifrs-full_IncomeTaxesPaidRefundAbstract":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "label":  "Income taxes paid (refund) [abstract]"
                            }
                        }
                    },
                "localname":  "IncomeTaxesPaidRefundAbstract",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "xbrltype":  "stringItemType"
                },
            "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents":  {
                "auth_ref":  [
                    "r125"
                    ],
                "calculation":  {
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS":  {
                        "order":  null,
                        "parentTag":  null,
                        "root":  true,
                        "weight":  null
                        }
                    },
                "crdr":  "debit",
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The increase (decrease) in cash and cash equivalents after the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer:  Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Net increase (decrease) in cash and cash equivalents",
                            "totalLabel":  "Net increase (decrease)"
                            }
                        }
                    },
                "localname":  "IncreaseDecreaseInCashAndCashEquivalents",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "ifrs-full_IncreaseDecreaseThroughAcquisitionOfSubsidiary":  {
                "auth_ref":  [
                    "r7"
                    ],
                "crdr":  "credit",
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The increase (decrease) in equity resulting from the acquisition of subsidiaries. [Refer:  Subsidiaries [member]]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Increase (decrease) through acquisition of subsidiary, equity",
                            "terseLabel":  "Lucid acquisition"
                            }
                        }
                    },
                "localname":  "IncreaseDecreaseThroughAcquisitionOfSubsidiary",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
                    "http://www.fsdpharma.com/role/ShareCapitalScheduleOfReconciliationOfTheShareCapitalDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "ifrs-full_IncreaseDecreaseThroughExerciseOfOptions":  {
                "auth_ref":  [
                    "r7"
                    ],
                "crdr":  "credit",
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The increase (decrease) in equity resulting from the exercise of options."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Increase (decrease) through exercise of options, equity",
                            "terseLabel":  "Share options exercised",
                            "verboseLabel":  "Value of stock options exercised"
                            }
                        }
                    },
                "localname":  "IncreaseDecreaseThroughExerciseOfOptions",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
                    "http://www.fsdpharma.com/role/ShareCapitalScheduleOfReconciliationOfTheShareCapitalDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity":  {
                "auth_ref":  [
                    "r7"
                    ],
                "crdr":  "credit",
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The increase (decrease) in equity resulting from the exercise of warrants."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Increase (decrease) through exercise of warrants, equity",
                            "terseLabel":  "Warrants exercised",
                            "verboseLabel":  "Warrants exercised"
                            }
                        }
                    },
                "localname":  "IncreaseDecreaseThroughExerciseOfWarrantsEquity",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
                    "http://www.fsdpharma.com/role/ShareCapitalScheduleOfReconciliationOfTheShareCapitalDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill":  {
                "auth_ref":  [
                    "r98"
                    ],
                "crdr":  "debit",
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The increase (decrease) in intangible assets other than goodwill resulting from net exchange differences arising on the translation of the financial statements from the functional currency into a different presentation currency, including the translation of a foreign operation into the presentation currency of the reporting entity. [Refer:  Intangible assets other than goodwill]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Increase (decrease) through net exchange differences, intangible assets other than goodwill",
                            "verboseLabel":  "Effects of foreign exchange"
                            }
                        }
                    },
                "localname":  "IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/IntangibleAssetsScheduleOfIntangibleAssetsDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions":  {
                "auth_ref":  [
                    "r6"
                    ],
                "crdr":  "credit",
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The increase (decrease) in equity resulting from share-based payment transactions. [Refer:  Equity]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Increase (decrease) through share-based payment transactions, equity",
                            "positiveLabel":  "Fair value of shares issued as share-based compensation",
                            "terseLabel":  "Increase in share-based compensation expense",
                            "verboseLabel":  "Share based payments"
                            }
                        }
                    },
                "localname":  "IncreaseDecreaseThroughSharebasedPaymentTransactions",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
                    "http://www.fsdpharma.com/role/ShareCapitalNarrativeDetails",
                    "http://www.fsdpharma.com/role/ShareCapitalScheduleOfReconciliationOfTheShareCapitalDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "ifrs-full_IntangibleAssetsOtherThanGoodwill":  {
                "auth_ref":  [
                    "r16",
                    "r99"
                    ],
                "calculation":  {
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION":  {
                        "order":  0.0,
                        "parentTag":  "ifrs-full_Assets",
                        "weight":  1.0
                        }
                    },
                "crdr":  "debit",
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The amount of identifiable non-monetary assets without physical substance.  This amount does not include goodwill. [Refer:  Goodwill]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Intangible assets other than goodwill",
                            "periodEndLabel":  "Ending balance",
                            "periodStartLabel":  "Beginning balance",
                            "terseLabel":  "Intellectual Property",
                            "totalLabel":  "Total intangible assets other than goodwill",
                            "verboseLabel":  "Intangible assets, net"
                            }
                        }
                    },
                "localname":  "IntangibleAssetsOtherThanGoodwill",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION",
                    "http://www.fsdpharma.com/role/IntangibleAssetsScheduleOfIntangibleAssetsDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "ifrs-full_IntangibleAssetsOtherThanGoodwillMember":  {
                "auth_ref":  [
                    "r91",
                    "r100",
                    "r162"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "This member stands for intangible assets other than goodwill.  It also represents the standard value for the 'Classes of intangible assets other than goodwill' axis if no other member is used. [Refer:  Intangible assets other than goodwill]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Intangible assets other than goodwill [member]"
                            }
                        }
                    },
                "localname":  "IntangibleAssetsOtherThanGoodwillMember",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/SignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfAssetsDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "ifrs-full_InterestExpenseOnBorrowings":  {
                "auth_ref":  [
                    "r10"
                    ],
                "crdr":  "debit",
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The amount of interest expense on borrowings. [Refer:  Interest expense; Borrowings]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Interest expense on borrowings"
                            }
                        }
                    },
                "localname":  "InterestExpenseOnBorrowings",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/NotesPayableNarrativeDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "ifrs-full_InterestExpenseOnLeaseLiabilities":  {
                "auth_ref":  [
                    "r158"
                    ],
                "crdr":  "debit",
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The amount of interest expense on lease liabilities. [Refer:  Lease liabilities]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Interest expense on lease liabilities",
                            "terseLabel":  "Interest expense on lease liabilities",
                            "verboseLabel":  "Add:  Interest Expense"
                            }
                        }
                    },
                "localname":  "InterestExpenseOnLeaseLiabilities",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/LeaseObligationsScheduleOfLeaseObligationsDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "ifrs-full_InterestReceivable":  {
                "auth_ref":  [
                    "r10"
                    ],
                "calculation":  {
                    "http://www.fsdpharma.com/role/TradeAndOtherReceivablesScheduleOfTradeAndOtherReceivablesDetails":  {
                        "order":  10.0,
                        "parentTag":  "ifrs-full_TradeAndOtherReceivables",
                        "weight":  1.0
                        }
                    },
                "crdr":  "debit",
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The amount of interest recognised as a receivable."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Interest receivable",
                            "verboseLabel":  "Interest receivable"
                            }
                        }
                    },
                "localname":  "InterestReceivable",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "xbrltype":  "monetaryItemType"
                },
            "ifrs-full_InvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod":  {
                "auth_ref":  [
                    "r22"
                    ],
                "crdr":  "debit",
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The amount of investments other than investments accounted for using the equity method. [Refer:  Investments accounted for using equity method]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Investments other than investments accounted for using equity method",
                            "periodEndLabel":  "Ending balance",
                            "periodStartLabel":  "Beginning balance",
                            "terseLabel":  "Fair value of the shares",
                            "totalLabel":  "Investments",
                            "verboseLabel":  "Investments"
                            }
                        }
                    },
                "localname":  "InvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/OtherInvestmentsNarrativeDetails",
                    "http://www.fsdpharma.com/role/OtherInvestmentsScheduleOfOtherInvestmentsDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "ifrs-full_IssueOfEquity":  {
                "auth_ref":  [
                    "r6"
                    ],
                "crdr":  "credit",
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The increase in equity through the issue of equity instruments."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Issue of equity",
                            "terseLabel":  "Shares issued",
                            "verboseLabel":  "Number of shares issued"
                            }
                        }
                    },
                "localname":  "IssueOfEquity",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
                    "http://www.fsdpharma.com/role/ShareCapitalScheduleOfReconciliationOfTheShareCapitalDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "ifrs-full_IssuedCapital":  {
                "auth_ref":  [
                    "r30"
                    ],
                "calculation":  {
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION":  {
                        "order":  20.0,
                        "parentTag":  "ifrs-full_Equity",
                        "weight":  1.0
                        }
                    },
                "crdr":  "credit",
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The nominal value of capital issued."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Issued capital",
                            "periodEndLabel":  "Share Capital, ending balance",
                            "periodStartLabel":  "Share Capital, beginning balance",
                            "verboseLabel":  "Share capital"
                            }
                        }
                    },
                "localname":  "IssuedCapital",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION",
                    "http://www.fsdpharma.com/role/CapitalManagementNarrativeDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "ifrs-full_KeyManagementPersonnelCompensation":  {
                "auth_ref":  [
                    "r71"
                    ],
                "calculation":  {
                    "http://www.fsdpharma.com/role/RelatedPartyTransactionsScheduleOfKeyManagementPersonnelCompensationDetails":  {
                        "order":  null,
                        "parentTag":  null,
                        "root":  true,
                        "weight":  null
                        }
                    },
                "crdr":  "debit",
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The amount of compensation to key management personnel. [Refer:  Key management personnel of entity or parent [member]]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Key management personnel compensation",
                            "totalLabel":  "Total",
                            "verboseLabel":  "Salaries and benefits"
                            }
                        }
                    },
                "localname":  "KeyManagementPersonnelCompensation",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/RelatedPartyTransactionsScheduleOfKeyManagementPersonnelCompensationDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment":  {
                "auth_ref":  [
                    "r70"
                    ],
                "calculation":  {
                    "http://www.fsdpharma.com/role/RelatedPartyTransactionsScheduleOfKeyManagementPersonnelCompensationDetails":  {
                        "order":  10.0,
                        "parentTag":  "ifrs-full_KeyManagementPersonnelCompensation",
                        "weight":  1.0
                        }
                    },
                "crdr":  "debit",
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The amount of compensation to key management personnel in the form of share-based payments. [Refer:  Key management personnel of entity or parent [member]]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Key management personnel compensation, share-based payment",
                            "positiveLabel":  "Share-based payments",
                            "terseLabel":  "Salaries, benefits, bonuses and consulting fees",
                            "verboseLabel":  "Share-based payments expense"
                            }
                        }
                    },
                "localname":  "KeyManagementPersonnelCompensationSharebasedPayment",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/RelatedPartyTransactionsNarrativeDetails",
                    "http://www.fsdpharma.com/role/RelatedPartyTransactionsScheduleOfKeyManagementPersonnelCompensationDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits":  {
                "auth_ref":  [
                    "r69"
                    ],
                "calculation":  {
                    "http://www.fsdpharma.com/role/RelatedPartyTransactionsScheduleOfKeyManagementPersonnelCompensationDetails":  {
                        "order":  0.0,
                        "parentTag":  "ifrs-full_KeyManagementPersonnelCompensation",
                        "weight":  1.0
                        }
                    },
                "crdr":  "debit",
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The amount of compensation to key management personnel in the form of short-term employee benefits. [Refer:  Key management personnel of entity or parent [member]]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Key management personnel compensation, short-term employee benefits",
                            "positiveTerseLabel":  "Salaries, benefits, bonuses and consulting fees",
                            "terseLabel":  "Bonuses",
                            "verboseLabel":  "Amount of bonus"
                            }
                        }
                    },
                "localname":  "KeyManagementPersonnelCompensationShorttermEmployeeBenefits",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/RelatedPartyTransactionsScheduleOfKeyManagementPersonnelCompensationDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "ifrs-full_LandMember":  {
                "auth_ref":  [
                    "r53"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "This member stands for a class of property, plant and equipment representing land held by the entity for use in operations. [Refer:  Property, plant and equipment]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Land [member]",
                            "verboseLabel":  "Land"
                            }
                        }
                    },
                "localname":  "LandMember",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/SignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfAssetsDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "ifrs-full_LaterThanFiveYearsMember":  {
                "auth_ref":  [
                    "r163",
                    "r164",
                    "r207",
                    "r208",
                    "r210",
                    "r227"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "This member stands for a time band of later than five years."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Later than five years [member]",
                            "terseLabel":  "Therafter",
                            "verboseLabel":  "More than 5 years"
                            }
                        }
                    },
                "localname":  "LaterThanFiveYearsMember",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/LeaseObligationsScheduleOfMaturityAnalysisOfOperatingLeasePaymentsDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember":  {
                "auth_ref":  [
                    "r10",
                    "r163",
                    "r164",
                    "r207",
                    "r210",
                    "r227"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "This member stands for a time band of later than one year and not later than two years."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Later than one year and not later than two years [member]",
                            "terseLabel":  "More than one year and not later than two years",
                            "verboseLabel":  "One to two years"
                            }
                        }
                    },
                "localname":  "LaterThanOneYearAndNotLaterThanTwoYearsMember",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/LeaseObligationsScheduleOfMaturityAnalysisOfOperatingLeasePaymentsDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember":  {
                "auth_ref":  [
                    "r10",
                    "r163",
                    "r164",
                    "r207",
                    "r210",
                    "r227"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "This member stands for a time band of later than three years and not later than four years."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Later than three years and not later than four years [member]",
                            "terseLabel":  "More than three year and not later than four years",
                            "verboseLabel":  "Three to four years"
                            }
                        }
                    },
                "localname":  "LaterThanThreeYearsAndNotLaterThanFourYearsMember",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/LeaseObligationsScheduleOfMaturityAnalysisOfOperatingLeasePaymentsDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember":  {
                "auth_ref":  [
                    "r10",
                    "r163",
                    "r164",
                    "r207",
                    "r210",
                    "r227"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "This member stands for a time band of later than two years and not later than three years."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Later than two years and not later than three years [member]",
                            "terseLabel":  "More than two year and not later than three years",
                            "verboseLabel":  "Two to three years"
                            }
                        }
                    },
                "localname":  "LaterThanTwoYearsAndNotLaterThanThreeYearsMember",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/LeaseObligationsScheduleOfMaturityAnalysisOfOperatingLeasePaymentsDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "ifrs-full_LeaseLiabilities":  {
                "auth_ref":  [
                    "r156"
                    ],
                "crdr":  "credit",
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The amount of liabilities related to the entity's leases.  Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Lease liabilities",
                            "periodEndLabel":  "Balance",
                            "periodStartLabel":  "Balance",
                            "positiveVerboseLabel":  "Balance",
                            "terseLabel":  "Balance as at December 31, 2021",
                            "totalLabel":  "Total lease liabilities",
                            "verboseLabel":  "Lease obligation"
                            }
                        }
                    },
                "localname":  "LeaseLiabilities",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/LeaseObligationsScheduleOfLeaseObligationsDetails",
                    "http://www.fsdpharma.com/role/LeaseObligationsScheduleOfMaturityAnalysisOfOperatingLeasePaymentsDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "ifrs-full_LeaseLiabilitiesAbstract":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "label":  "Lease liabilities [abstract]"
                            }
                        }
                    },
                "localname":  "LeaseLiabilitiesAbstract",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "xbrltype":  "stringItemType"
                },
            "ifrs-full_LegalProceedingsContingentLiabilityMember":  {
                "auth_ref":  [
                    "r93"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "This member stands for a contingent liability for legal proceedings. [Refer:  Contingent liabilities [member]]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Legal proceedings contingent liability [member]",
                            "verboseLabel":  "Legal proceedings contingent liability"
                            }
                        }
                    },
                "localname":  "LegalProceedingsContingentLiabilityMember",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CommitmentsAndContingenciesNarrativeDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "ifrs-full_Level1OfFairValueHierarchyMember":  {
                "auth_ref":  [
                    "r63",
                    "r149"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Level 1 of fair value hierarchy [member]",
                            "verboseLabel":  "Level 1"
                            }
                        }
                    },
                "localname":  "Level1OfFairValueHierarchyMember",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/OtherInvestmentsNarrativeDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "ifrs-full_Level2OfFairValueHierarchyMember":  {
                "auth_ref":  [
                    "r149"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Level 2 of fair value hierarchy [member]",
                            "verboseLabel":  "Level 2"
                            }
                        }
                    },
                "localname":  "Level2OfFairValueHierarchyMember",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/WarrantsLiabilityDetailTextuals"
                    ],
                "xbrltype":  "domainItemType"
                },
            "ifrs-full_LevelsOfFairValueHierarchyAxis":  {
                "auth_ref":  [
                    "r63",
                    "r149"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Levels of fair value hierarchy [axis]"
                            }
                        }
                    },
                "localname":  "LevelsOfFairValueHierarchyAxis",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/OtherInvestmentsNarrativeDetails",
                    "http://www.fsdpharma.com/role/WarrantsLiabilityDetailTextuals"
                    ],
                "xbrltype":  "stringItemType"
                },
            "ifrs-full_Liabilities":  {
                "auth_ref":  [
                    "r22",
                    "r148",
                    "r149",
                    "r150",
                    "r214",
                    "r218"
                    ],
                "calculation":  {
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION":  {
                        "order":  0.0,
                        "parentTag":  "ifrs-full_EquityAndLiabilities",
                        "weight":  1.0
                        }
                    },
                "crdr":  "credit",
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The amount of a present obligation of the entity to transfer an economic resource as a result of past events.  Economic resource is a right that has the potential to produce economic benefits."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Liabilities",
                            "negatedLabel":  "Liabilities",
                            "periodEndLabel":  "Liabilities at end of period",
                            "periodStartLabel":  "Liabilities at beginning of period",
                            "terseLabel":  "Balance as at December 31, 2019",
                            "totalLabel":  "Total liabilities",
                            "verboseLabel":  "Total Liabilities"
                            }
                        }
                    },
                "localname":  "Liabilities",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "ifrs-full_LiabilitiesAbstract":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "label":  "Liabilities Abstract",
                            "terseLabel":  "LIABILITIES"
                            }
                        }
                    },
                "localname":  "LiabilitiesAbstract",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
                    ],
                "xbrltype":  "stringItemType"
                },
            "ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis":  {
                "auth_ref":  [
                    "r124"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Liabilities arising from financing activities [axis]"
                            }
                        }
                    },
                "localname":  "LiabilitiesArisingFromFinancingActivitiesAxis",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/NotesPayableNarrativeDetails",
                    "http://www.fsdpharma.com/role/NotesPayableScheduleOfNotesPayableDetails"
                    ],
                "xbrltype":  "stringItemType"
                },
            "ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember":  {
                "auth_ref":  [
                    "r124"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "This member stands for liabilities arising from financing activities.  It also represents the standard value for the 'Liabilities arising from financing activities' axis if no other member is used. [Refer:  Liabilities arising from financing activities]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Liabilities arising from financing activities [member]"
                            }
                        }
                    },
                "localname":  "LiabilitiesArisingFromFinancingActivitiesMember",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/NotesPayableNarrativeDetails",
                    "http://www.fsdpharma.com/role/NotesPayableScheduleOfNotesPayableDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "ifrs-full_LossesOnChangeInFairValueOfDerivatives":  {
                "auth_ref":  [
                    "r40"
                    ],
                "crdr":  "debit",
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The losses resulting from changes in the fair value of derivatives recognised in profit or loss. [Refer:  Derivatives [member]]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Losses on change in fair value of derivatives",
                            "negatedLabel":  "Losses on change in fair value of derivatives",
                            "verboseLabel":  "Loss on change in fair value of derivative liability"
                            }
                        }
                    },
                "localname":  "LossesOnChangeInFairValueOfDerivatives",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/OtherInvestmentsNarrativeDetails",
                    "http://www.fsdpharma.com/role/ShareCapitalNarrativeDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "ifrs-full_MaturityAxis":  {
                "auth_ref":  [
                    "r24",
                    "r64",
                    "r155",
                    "r163",
                    "r164",
                    "r198",
                    "r205",
                    "r207",
                    "r223",
                    "r224",
                    "r226",
                    "r227"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Maturity [axis]"
                            }
                        }
                    },
                "localname":  "MaturityAxis",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/LeaseObligationsScheduleOfMaturityAnalysisOfOperatingLeasePaymentsDetails"
                    ],
                "xbrltype":  "stringItemType"
                },
            "ifrs-full_MeasurementAxis":  {
                "auth_ref":  [
                    "r104",
                    "r108",
                    "r148"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Measurement [axis]"
                            }
                        }
                    },
                "localname":  "MeasurementAxis",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/OtherInvestmentsScheduleOfOtherInvestmentsDetails"
                    ],
                "xbrltype":  "stringItemType"
                },
            "ifrs-full_NetDeferredTaxAssets":  {
                "auth_ref":  [
                    "r50"
                    ],
                "calculation":  {
                    "http://www.fsdpharma.com/role/IncomeTaxesScheduleOfTemporaryDifferencesForWhichDeferredTaxAssetsNotRecognisedDetails":  {
                        "order":  null,
                        "parentTag":  null,
                        "root":  true,
                        "weight":  null
                        }
                    },
                "crdr":  "debit",
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The amount of deferred tax assets net of deferred tax liabilities, when the absolute amount of deferred tax assets is greater than the absolute amount of deferred tax liabilities. [Refer:  Deferred tax assets; Deferred tax liabilities]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Net deferred tax assets",
                            "negatedTotalLabel":  "Total",
                            "terseLabel":  "Total deferred tax asset",
                            "totalLabel":  "Total"
                            }
                        }
                    },
                "localname":  "NetDeferredTaxAssets",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/IncomeTaxesScheduleOfTemporaryDifferencesForWhichDeferredTaxAssetsNotRecognisedDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "ifrs-full_NetForeignExchangeGain":  {
                "auth_ref":  [
                    "r14",
                    "r67"
                    ],
                "crdr":  "credit",
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The net gain arising from exchange differences recognised in profit or loss, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer:  Foreign exchange gain (loss)]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Net foreign exchange gain",
                            "terseLabel":  "Foreign exchange loss",
                            "verboseLabel":  "Foreign exchange gain"
                            }
                        }
                    },
                "localname":  "NetForeignExchangeGain",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/OtherInvestmentsScheduleOfOtherInvestmentsDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "ifrs-full_NonadjustingEventsAfterReportingPeriodAxis":  {
                "auth_ref":  [
                    "r47"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Non-adjusting events after reporting period [axis]"
                            }
                        }
                    },
                "localname":  "NonadjustingEventsAfterReportingPeriodAxis",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/OtherInvestmentsNarrativeDetails",
                    "http://www.fsdpharma.com/role/SubsequentEventsNarrativeDetails"
                    ],
                "xbrltype":  "stringItemType"
                },
            "ifrs-full_NonadjustingEventsMember":  {
                "auth_ref":  [
                    "r47"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "This member stands for events that occur between the end of the reporting period and the date when the financial statements are authorised for issue and are indicative of conditions that arose after the reporting period.  It also represents the standard value for the 'Non-adjusting events after reporting period' axis if no other member is used."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Non-adjusting events after reporting period [member]"
                            }
                        }
                    },
                "localname":  "NonadjustingEventsMember",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/OtherInvestmentsNarrativeDetails",
                    "http://www.fsdpharma.com/role/SubsequentEventsNarrativeDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "ifrs-full_NoncurrentAssetsAbstract":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "label":  "Non-current assets [abstract]",
                            "verboseLabel":  "Non-current assets"
                            }
                        }
                    },
                "localname":  "NoncurrentAssetsAbstract",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
                    ],
                "xbrltype":  "stringItemType"
                },
            "ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners":  {
                "auth_ref":  [
                    "r20"
                    ],
                "calculation":  {
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION":  {
                        "order":  10.0,
                        "parentTag":  "ifrs-full_CurrentAssets",
                        "weight":  1.0
                        }
                    },
                "crdr":  "debit",
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The amount of non-current assets or disposal groups classified as held for sale or as held for distribution to owners. [Refer:  Non-current assets or disposal groups classified as held for distribution to owners; Non-current assets or disposal groups classified as held for sale]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Non-current assets or disposal groups classified as held for sale or as held for distribution to owners",
                            "terseLabel":  "Assets held for sale"
                            }
                        }
                    },
                "localname":  "NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "ifrs-full_NoncurrentInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod":  {
                "auth_ref":  [
                    "r22"
                    ],
                "calculation":  {
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION":  {
                        "order":  30.0,
                        "parentTag":  "ifrs-full_Assets",
                        "weight":  1.0
                        }
                    },
                "crdr":  "debit",
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The amount of non-current investments other than investments accounted for using the equity method. [Refer:  Investments accounted for using equity method; Non-current assets; Investments other than investments accounted for using equity method]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Non-current investments other than investments accounted for using equity method",
                            "periodEndLabel":  "Ending balance",
                            "periodStartLabel":  "Beginning balance",
                            "terseLabel":  "Non-Current",
                            "verboseLabel":  "Investments"
                            }
                        }
                    },
                "localname":  "NoncurrentInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION",
                    "http://www.fsdpharma.com/role/OtherInvestmentsScheduleOfOtherInvestmentsDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "ifrs-full_NoncurrentLeaseLiabilities":  {
                "auth_ref":  [
                    "r156"
                    ],
                "calculation":  {
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION":  {
                        "order":  0.0,
                        "parentTag":  "ifrs-full_Liabilities",
                        "weight":  1.0
                        }
                    },
                "crdr":  "credit",
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The amount of non-current lease liabilities. [Refer:  Lease liabilities]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Non-current lease liabilities",
                            "terseLabel":  "Non-current",
                            "verboseLabel":  "Lease obligations"
                            }
                        }
                    },
                "localname":  "NoncurrentLeaseLiabilities",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION",
                    "http://www.fsdpharma.com/role/LeaseObligationsScheduleOfLeaseObligationsDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "ifrs-full_NoncurrentLiabilitiesAbstract":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "label":  "Non-current liabilities [abstract]",
                            "terseLabel":  "Non-current liabilities"
                            }
                        }
                    },
                "localname":  "NoncurrentLiabilitiesAbstract",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
                    ],
                "xbrltype":  "stringItemType"
                },
            "ifrs-full_NotLaterThanOneYearMember":  {
                "auth_ref":  [
                    "r23",
                    "r163",
                    "r164",
                    "r207",
                    "r210",
                    "r227"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "This member stands for a time band of not later than one year."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Not later than one year [member]",
                            "terseLabel":  "2019",
                            "verboseLabel":  "Less than one year"
                            }
                        }
                    },
                "localname":  "NotLaterThanOneYearMember",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/LeaseObligationsScheduleOfMaturityAnalysisOfOperatingLeasePaymentsDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement":  {
                "auth_ref":  [
                    "r168",
                    "r181"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The number of instruments granted in share-based payment arrangement."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Number of instruments granted in share-based payment arrangement",
                            "verboseLabel":  "Number of share issued for share-based bonus expense"
                            }
                        }
                    },
                "localname":  "NumberOfInstrumentsGrantedInSharebasedPaymentArrangement",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/RelatedPartyTransactionsNarrativeDetails"
                    ],
                "xbrltype":  "decimalItemType"
                },
            "ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable":  {
                "auth_ref":  [
                    "r182"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The number of instruments or interests issued or issuable at acquisition date for equity interests of the acquirer transferred as consideration in a business combination."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Number of instruments or interests issued or issuable",
                            "verboseLabel":  "Number of shares issued"
                            }
                        }
                    },
                "localname":  "NumberOfInstrumentsOrInterestsIssuedOrIssuable",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/AcquisitionOfLucidDetailTextuals",
                    "http://www.fsdpharma.com/role/AcquisitionOfPrismicPharmaceuticalNarrativeDetails"
                    ],
                "xbrltype":  "decimalItemType"
                },
            "ifrs-full_NumberOfOutstandingShareOptions":  {
                "auth_ref":  [
                    "r169",
                    "r174",
                    "r177"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The number of share options outstanding in a share-based payment arrangement."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Number of share options outstanding in share-based payment arrangement",
                            "periodEndLabel":  "Closing Balance",
                            "periodStartLabel":  "Opening Balance",
                            "verboseLabel":  "Number of share options outstanding and issued"
                            }
                        }
                    },
                "localname":  "NumberOfOutstandingShareOptions",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/SharebasedCompensationScheduleOfChangesInNumberOfShareOptionsDetails",
                    "http://www.fsdpharma.com/role/SharebasedCompensationScheduleOfExercisePriceAndWeightedAverageContractualTermOfShareOptionsOutstandingAndExercisableDetails"
                    ],
                "xbrltype":  "decimalItemType"
                },
            "ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement":  {
                "auth_ref":  [
                    "r175"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The number of share options exercisable in a share-based payment arrangement."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Number of share options exercisable in share-based payment arrangement",
                            "periodStartLabel":  "Opening Balance",
                            "verboseLabel":  "Exercisable"
                            }
                        }
                    },
                "localname":  "NumberOfShareOptionsExercisableInSharebasedPaymentArrangement",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/SharebasedCompensationScheduleOfChangesInNumberOfShareOptionsDetails",
                    "http://www.fsdpharma.com/role/SharebasedCompensationScheduleOfExercisePriceAndWeightedAverageContractualTermOfShareOptionsOutstandingAndExercisableDetails"
                    ],
                "xbrltype":  "decimalItemType"
                },
            "ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement":  {
                "auth_ref":  [
                    "r172"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The number of share options exercised in a share-based payment arrangement."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Number of share options exercised in share-based payment arrangement",
                            "negatedLabel":  "Exercised",
                            "terseLabel":  "Exercised",
                            "verboseLabel":  "Number of stock options exercised"
                            }
                        }
                    },
                "localname":  "NumberOfShareOptionsExercisedInSharebasedPaymentArrangement",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/SharebasedCompensationScheduleOfChangesInNumberOfShareOptionsDetails"
                    ],
                "xbrltype":  "decimalItemType"
                },
            "ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement":  {
                "auth_ref":  [
                    "r173"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The number of share options expired in a share-based payment arrangement."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Number of share options expired in share-based payment arrangement",
                            "negatedLabel":  "Cancelled",
                            "terseLabel":  "Number of share options cancelled",
                            "verboseLabel":  "Expired / cancelled"
                            }
                        }
                    },
                "localname":  "NumberOfShareOptionsExpiredInSharebasedPaymentArrangement",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/SharebasedCompensationNarrativeDetails",
                    "http://www.fsdpharma.com/role/SharebasedCompensationScheduleOfChangesInNumberOfShareOptionsDetails"
                    ],
                "xbrltype":  "decimalItemType"
                },
            "ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement":  {
                "auth_ref":  [
                    "r171"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The number of share options forfeited in a share-based payment arrangement."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Number of share options forfeited in share-based payment arrangement",
                            "negatedLabel":  "Forfeited",
                            "verboseLabel":  "Forfeited"
                            }
                        }
                    },
                "localname":  "NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/SharebasedCompensationScheduleOfChangesInNumberOfShareOptionsDetails"
                    ],
                "xbrltype":  "decimalItemType"
                },
            "ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement":  {
                "auth_ref":  [
                    "r170"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The number of share options granted in a share-based payment arrangement."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Number of share options granted in share-based payment arrangement",
                            "positiveLabel":  "Number of share options issued",
                            "terseLabel":  "Number of stock options granted",
                            "verboseLabel":  "Granted"
                            }
                        }
                    },
                "localname":  "NumberOfShareOptionsGrantedInSharebasedPaymentArrangement",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/SharebasedCompensationNarrativeDetails",
                    "http://www.fsdpharma.com/role/SharebasedCompensationScheduleOfChangesInNumberOfShareOptionsDetails"
                    ],
                "xbrltype":  "decimalItemType"
                },
            "ifrs-full_NumberOfSharesIssued":  {
                "auth_ref":  [
                    "r7"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The number of shares issued by the entity."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Number of shares issued",
                            "periodEndLabel":  "Number of Shares, ending balance",
                            "periodStartLabel":  "Number of Shares, beginning balance",
                            "positiveTerseLabel":  "Number of shares sold",
                            "terseLabel":  "Number of shares subscribed",
                            "totalLabel":  "Total number of shares issued",
                            "verboseLabel":  "Number of Shares"
                            }
                        }
                    },
                "localname":  "NumberOfSharesIssued",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/OtherInvestmentsNarrativeDetails",
                    "http://www.fsdpharma.com/role/ShareCapitalNarrativeDetails"
                    ],
                "xbrltype":  "sharesItemType"
                },
            "ifrs-full_NumberOfSharesOutstanding":  {
                "auth_ref":  [
                    "r32"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer:  Treasury shares]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Number of shares outstanding",
                            "periodEndLabel":  "Ending balance (shares)",
                            "periodStartLabel":  "Beginning balance (shares)",
                            "terseLabel":  "Number of Class B shares",
                            "verboseLabel":  "Balance, beginning of year"
                            }
                        }
                    },
                "localname":  "NumberOfSharesOutstanding",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
                    "http://www.fsdpharma.com/role/ShareCapitalScheduleOfReconciliationOfTheShareCapitalDetails"
                    ],
                "xbrltype":  "sharesItemType"
                },
            "ifrs-full_OperatingExpense":  {
                "auth_ref":  [
                    "r40"
                    ],
                "crdr":  "debit",
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The amount of all operating expenses."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Operating expense",
                            "verboseLabel":  "Total operating expenses"
                            }
                        }
                    },
                "localname":  "OperatingExpense",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/AssetsHeldForSaleDetails1"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "ifrs-full_OrdinarySharesMember":  {
                "auth_ref":  [
                    "r33",
                    "r86"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "This member stands for equity instruments that are subordinate to all other classes of equity instruments.  It also represents the standard value for the 'Classes of ordinary shares' axis if no other member is used."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Ordinary shares [member]",
                            "verboseLabel":  "Shares"
                            }
                        }
                    },
                "localname":  "OrdinarySharesMember",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/LossPerShareDetails",
                    "http://www.fsdpharma.com/role/OtherInvestmentsNarrativeDetails",
                    "http://www.fsdpharma.com/role/OtherInvestmentsScheduleOfOtherInvestmentsDetails",
                    "http://www.fsdpharma.com/role/SubsequentEventsNarrativeDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "ifrs-full_OtherComprehensiveIncomeAbstract":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "label":  "Other comprehensive loss",
                            "terseLabel":  "Other comprehensive income (loss)"
                            }
                        }
                    },
                "localname":  "OtherComprehensiveIncomeAbstract",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS"
                    ],
                "xbrltype":  "stringItemType"
                },
            "ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation":  {
                "auth_ref":  [
                    "r27",
                    "r41"
                    ],
                "calculation":  {
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS":  {
                        "order":  0.0,
                        "parentTag":  "ifrs-full_ComprehensiveIncome",
                        "weight":  1.0
                        }
                    },
                "crdr":  "credit",
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The amount of other comprehensive income, net of tax, after reclassification adjustments, related to exchange differences when financial statements of foreign operations are translated. [Refer:  Other comprehensive income]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Other comprehensive income, net of tax, exchange differences on translation",
                            "negatedLabel":  "Exchange gain (loss) on translation of foreign operations",
                            "totalLabel":  "Exchange loss on translation of foreign operations",
                            "verboseLabel":  "Exchange gain (loss) on translation of foreign operations"
                            }
                        }
                    },
                "localname":  "OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "ifrs-full_OtherCurrentPayables":  {
                "auth_ref":  [
                    "r22"
                    ],
                "calculation":  {
                    "http://www.fsdpharma.com/role/TradeAndOtherPayablesDetails":  {
                        "order":  0.0,
                        "parentTag":  "ifrs-full_TradeAndOtherCurrentPayables",
                        "weight":  1.0
                        }
                    },
                "crdr":  "credit",
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The amount of current payables that the entity does not separately disclose in the same statement or note."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Other current payables",
                            "terseLabel":  "Other payables"
                            }
                        }
                    },
                "localname":  "OtherCurrentPayables",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/TradeAndOtherPayablesDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "ifrs-full_OtherIncome":  {
                "auth_ref":  [
                    "r1",
                    "r2",
                    "r78"
                    ],
                "calculation":  {
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS":  {
                        "order":  50.0,
                        "parentTag":  "ifrs-full_ProfitLossFromContinuingOperations",
                        "weight":  1.0
                        }
                    },
                "crdr":  "credit",
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The amount of operating income that the entity does not separately disclose in the same statement or note."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Other income",
                            "negatedLabel":  "Other income",
                            "terseLabel":  "Other income",
                            "verboseLabel":  "Other income"
                            }
                        }
                    },
                "localname":  "OtherIncome",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/AssetsHeldForSaleDetails1",
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "ifrs-full_OtherReceivables":  {
                "auth_ref":  [
                    "r29"
                    ],
                "calculation":  {
                    "http://www.fsdpharma.com/role/TradeAndOtherReceivablesScheduleOfTradeAndOtherReceivablesDetails":  {
                        "order":  20.0,
                        "parentTag":  "ifrs-full_TradeAndOtherReceivables",
                        "weight":  1.0
                        }
                    },
                "crdr":  "debit",
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The amount receivable by the entity that it does not separately disclose in the same statement or note."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Other receivables",
                            "terseLabel":  "Other"
                            }
                        }
                    },
                "localname":  "OtherReceivables",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/TradeAndOtherReceivablesScheduleOfTradeAndOtherReceivablesDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "ifrs-full_PaymentsForShareIssueCosts":  {
                "auth_ref":  [
                    "r118"
                    ],
                "crdr":  "credit",
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The cash outflow for share issue costs."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Payments for share issue costs",
                            "negatedLabel":  "Share issue costs",
                            "negatedTerseLabel":  "Costs of issue",
                            "verboseLabel":  "Share issue costs"
                            }
                        }
                    },
                "localname":  "PaymentsForShareIssueCosts",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/ShareCapitalNarrativeDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities":  {
                "auth_ref":  [
                    "r117"
                    ],
                "calculation":  {
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS":  {
                        "order":  0.0,
                        "parentTag":  "ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations",
                        "weight":  -1.0
                        }
                    },
                "crdr":  "credit",
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The cash outflow for payment of lease liabilities, classified as financing activities. [Refer:  Lease liabilities]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Payments of lease liabilities, classified as financing activities",
                            "negatedLabel":  "Repayment of lease obligation",
                            "negatedTerseLabel":  "Payments of lease liabilities"
                            }
                        }
                    },
                "localname":  "PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary":  {
                "auth_ref":  [
                    "r79",
                    "r82",
                    "r134",
                    "r135"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The principal place of business of a subsidiary. [Refer:  Principal place of business; Subsidiaries [member]]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Principal place of business of subsidiary",
                            "verboseLabel":  "Country"
                            }
                        }
                    },
                "localname":  "PrincipalPlaceOfBusinessOfSubsidiary",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/NatureOfBusinessScheduleOfOwnershipPercentageInSubsidiariesDetails"
                    ],
                "xbrltype":  "stringItemType"
                },
            "ifrs-full_ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations":  {
                "auth_ref":  [
                    "r115"
                    ],
                "crdr":  "debit",
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The cash inflow from the disposal of non-current assets or disposal groups classified as held for sale and discontinued operations. [Refer:  Discontinued operations [member]; Disposal groups classified as held for sale [member]; Non-current assets or disposal groups classified as held for sale]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Proceeds from disposal of assets held for sale"
                            }
                        }
                    },
                "localname":  "ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/AssetsHeldForSaleDetailTextuals"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "ifrs-full_ProceedsFromExerciseOfOptions":  {
                "auth_ref":  [
                    "r118"
                    ],
                "calculation":  {
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS":  {
                        "order":  30.0,
                        "parentTag":  "ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations",
                        "weight":  1.0
                        }
                    },
                "crdr":  "debit",
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The cash inflow from the exercise of options."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Proceeds from exercise of options",
                            "terseLabel":  "Proceeds from exercise of share-options",
                            "verboseLabel":  "Stock options exercised"
                            }
                        }
                    },
                "localname":  "ProceedsFromExerciseOfOptions",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "ifrs-full_ProceedsFromExerciseOfWarrants":  {
                "auth_ref":  [
                    "r118"
                    ],
                "calculation":  {
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS":  {
                        "order":  40.0,
                        "parentTag":  "ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations",
                        "weight":  1.0
                        }
                    },
                "crdr":  "debit",
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The cash inflow from the exercise of share purchase warrants."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Proceeds from exercise of warrants",
                            "terseLabel":  "Proceeds from exercise of warrants"
                            }
                        }
                    },
                "localname":  "ProceedsFromExerciseOfWarrants",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "ifrs-full_ProceedsFromIssuingOtherEquityInstruments":  {
                "auth_ref":  [
                    "r116"
                    ],
                "crdr":  "debit",
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The cash inflow from issuing equity instruments that the entity does not separately disclose in the same statement or note."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Proceeds from issuing other equity instruments",
                            "terseLabel":  "Proceeds from direct offering",
                            "verboseLabel":  "Proceeds from equity issuance"
                            }
                        }
                    },
                "localname":  "ProceedsFromIssuingOtherEquityInstruments",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/ShareCapitalNarrativeDetails",
                    "http://www.fsdpharma.com/role/WarrantsLiabilityDetailTextuals"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "ifrs-full_ProceedsFromIssuingShares":  {
                "auth_ref":  [
                    "r116"
                    ],
                "calculation":  {
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS":  {
                        "order":  10.0,
                        "parentTag":  "ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations",
                        "weight":  1.0
                        }
                    },
                "crdr":  "debit",
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The cash inflow from issuing shares."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Proceeds from issuing shares",
                            "positiveLabel":  "Proceeds from issuance of shares",
                            "terseLabel":  "Proceeds from issuing shares",
                            "verboseLabel":  "Proceeds from issuance of shares, net"
                            }
                        }
                    },
                "localname":  "ProceedsFromIssuingShares",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
                    "http://www.fsdpharma.com/role/OtherInvestmentsNarrativeDetails",
                    "http://www.fsdpharma.com/role/ShareCapitalNarrativeDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "ifrs-full_ProceedsFromSalesOfInvestmentProperty":  {
                "auth_ref":  [
                    "r115"
                    ],
                "crdr":  "debit",
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The cash inflow from sales of investment property. [Refer:  Investment property]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Proceeds from sales of investment property",
                            "verboseLabel":  "Consideration for the sale of the Facility and the Facility Property"
                            }
                        }
                    },
                "localname":  "ProceedsFromSalesOfInvestmentProperty",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/SubsequentEventsNarrativeDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "ifrs-full_ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod":  {
                "auth_ref":  [
                    "r115"
                    ],
                "calculation":  {
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS":  {
                        "order":  10.0,
                        "parentTag":  "ifrs-full_CashFlowsFromUsedInInvestingActivitiesContinuingOperations",
                        "weight":  1.0
                        }
                    },
                "crdr":  "debit",
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The cash inflow from sales of investments other than investments accounted for using the equity method. [Refer:  Investments accounted for using equity method; Investments other than investments accounted for using equity method]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Proceeds from sales of investments other than investments accounted for using equity method",
                            "terseLabel":  "Proceeds from sale of investments",
                            "verboseLabel":  "Proceeds from sale"
                            }
                        }
                    },
                "localname":  "ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
                    "http://www.fsdpharma.com/role/OtherInvestmentsNarrativeDetails",
                    "http://www.fsdpharma.com/role/OtherInvestmentsScheduleOfOtherInvestmentsDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities":  {
                "auth_ref":  [
                    "r114"
                    ],
                "crdr":  "debit",
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The cash inflow from sales of property, plant and equipment, classified as investing activities. [Refer:  Property, plant and equipment]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Proceeds from sales of property, plant and equipment, classified as investing activities",
                            "terseLabel":  "Proceeds from sale of facility and the facility property",
                            "verboseLabel":  "Proceeds from sale of equipment"
                            }
                        }
                    },
                "localname":  "ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/AssetsHeldForSaleDetailTextuals"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "ifrs-full_ProfessionalFeesExpense":  {
                "auth_ref":  [
                    "r10"
                    ],
                "crdr":  "debit",
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The amount of fees paid or payable for professional services."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Professional fees expense",
                            "terseLabel":  "Professional fees"
                            }
                        }
                    },
                "localname":  "ProfessionalFeesExpense",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/GeneralAndAdministrativeDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "ifrs-full_ProfitLoss":  {
                "auth_ref":  [
                    "r5",
                    "r35",
                    "r119",
                    "r131",
                    "r133",
                    "r138",
                    "r214",
                    "r216",
                    "r225",
                    "r228"
                    ],
                "calculation":  {
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS":  {
                        "order":  10.0,
                        "parentTag":  "ifrs-full_ComprehensiveIncome",
                        "weight":  1.0
                        }
                    },
                "crdr":  "credit",
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer:  Other comprehensive income]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Profit (loss)",
                            "positiveLabel":  "Net loss",
                            "terseLabel":  "Net loss",
                            "totalLabel":  "Net loss",
                            "verboseLabel":  "Net comprehensive loss for the year"
                            }
                        }
                    },
                "localname":  "ProfitLoss",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "ifrs-full_ProfitLossFromContinuingOperations":  {
                "auth_ref":  [
                    "r35",
                    "r143",
                    "r214",
                    "r216"
                    ],
                "calculation":  {
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS":  {
                        "order":  110.0,
                        "parentTag":  "ifrs-full_CashFlowsFromUsedInOperatingActivitiesContinuingOperations",
                        "weight":  1.0
                        },
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS":  {
                        "order":  10.0,
                        "parentTag":  "ifrs-full_ProfitLoss",
                        "weight":  1.0
                        }
                    },
                "crdr":  "credit",
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The profit (loss) from continuing operations. [Refer:  Continuing operations [member]; Profit (loss)]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Profit (loss) from continuing operations",
                            "terseLabel":  "Net loss from continuing operations",
                            "totalLabel":  "Net loss from continuing operations",
                            "verboseLabel":  "Continuing operations"
                            }
                        }
                    },
                "localname":  "ProfitLossFromContinuingOperations",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "ifrs-full_ProfitLossFromDiscontinuedOperations":  {
                "auth_ref":  [
                    "r39",
                    "r44",
                    "r144",
                    "r193"
                    ],
                "calculation":  {
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS":  {
                        "order":  0.0,
                        "parentTag":  "ifrs-full_ProfitLoss",
                        "weight":  1.0
                        }
                    },
                "crdr":  "credit",
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The profit (loss) from discontinued operations. [Refer:  Discontinued operations [member]; Profit (loss)]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Profit (loss) from discontinued operations",
                            "terseLabel":  "Net loss from discontinued operations",
                            "verboseLabel":  "Discontinued operations"
                            }
                        }
                    },
                "localname":  "ProfitLossFromDiscontinuedOperations",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/AssetsHeldForSaleDetails1",
                    "http://www.fsdpharma.com/role/AssetsHeldForSaleDetails2",
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "ifrs-full_ProfitLossFromOperatingActivities":  {
                "auth_ref":  [
                    "r40",
                    "r85"
                    ],
                "calculation":  {
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS":  {
                        "order":  0.0,
                        "parentTag":  "ifrs-full_ProfitLossFromContinuingOperations",
                        "weight":  1.0
                        }
                    },
                "crdr":  "credit",
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The profit (loss) from operating activities of the entity. [Refer:  Profit (loss)]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Profit (loss) from operating activities",
                            "negatedLabel":  "Loss from continuing operations",
                            "terseLabel":  "Loss from continuing operations",
                            "totalLabel":  "Loss from continuing operations"
                            }
                        }
                    },
                "localname":  "ProfitLossFromOperatingActivities",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "ifrs-full_PropertyPlantAndEquipment":  {
                "auth_ref":  [
                    "r15",
                    "r60"
                    ],
                "calculation":  {
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION":  {
                        "order":  10.0,
                        "parentTag":  "ifrs-full_Assets",
                        "weight":  1.0
                        }
                    },
                "crdr":  "debit",
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Property, plant and equipment",
                            "periodEndLabel":  "Property, plant and equipment at end of period",
                            "periodStartLabel":  "Property, plant and equipment at beginning of period",
                            "terseLabel":  "Property, plant and equipment, net",
                            "totalLabel":  "Total property, plant and equipment",
                            "verboseLabel":  "Property and plant"
                            }
                        }
                    },
                "localname":  "PropertyPlantAndEquipment",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/AssetsHeldForSaleDetails",
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "ifrs-full_PropertyPlantAndEquipmentMember":  {
                "auth_ref":  [
                    "r61",
                    "r91",
                    "r162"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "This member stands for property, plant and equipment.  It also represents the standard value for the 'Classes of property, plant and equipment' axis if no other member is used. [Refer:  Property, plant and equipment]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Property, plant and equipment [member]"
                            }
                        }
                    },
                "localname":  "PropertyPlantAndEquipmentMember",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/SignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesOfAssetsDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "ifrs-full_ProportionOfOwnershipInterestInAssociate":  {
                "auth_ref":  [
                    "r80",
                    "r83",
                    "r137"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The proportion of ownership interest in an associate attributable to the entity. [Refer:  Associates [member]]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Proportion of ownership interest in associate",
                            "verboseLabel":  "Ownership interest"
                            }
                        }
                    },
                "localname":  "ProportionOfOwnershipInterestInAssociate",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/AcquisitionOfLucidDetailTextuals"
                    ],
                "xbrltype":  "percentItemType"
                },
            "ifrs-full_ProportionOfOwnershipInterestInSubsidiary":  {
                "auth_ref":  [
                    "r80",
                    "r83",
                    "r136"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The proportion of ownership interest in a subsidiary attributable to the entity. [Refer:  Subsidiaries [member]]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Proportion of ownership interest in subsidiary",
                            "verboseLabel":  "Ownership percentage"
                            }
                        }
                    },
                "localname":  "ProportionOfOwnershipInterestInSubsidiary",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/NatureOfBusinessScheduleOfOwnershipPercentageInSubsidiariesDetails"
                    ],
                "xbrltype":  "percentItemType"
                },
            "ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities":  {
                "auth_ref":  [
                    "r113"
                    ],
                "calculation":  {
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS":  {
                        "order":  20.0,
                        "parentTag":  "ifrs-full_CashFlowsFromUsedInInvestingActivitiesContinuingOperations",
                        "weight":  -1.0
                        }
                    },
                "crdr":  "credit",
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The cash outflow for the purchases of intangible assets, classified as investing activities. [Refer:  Intangible assets other than goodwill]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Purchase of intangible assets, classified as investing activities",
                            "negatedLabel":  "Additions to intangible assets",
                            "negatedTerseLabel":  "Purchase of intangible assets"
                            }
                        }
                    },
                "localname":  "PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod":  {
                "auth_ref":  [
                    "r115"
                    ],
                "crdr":  "credit",
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The cash outflow for the purchase of investments other than investments accounted for using equity method. [Refer:  Investments accounted for using equity method; Investments other than investments accounted for using equity method]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Purchase of investments other than investments accounted for using equity method",
                            "negatedLabel":  "Purchase of other investments",
                            "verboseLabel":  "Additions"
                            }
                        }
                    },
                "localname":  "PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/OtherInvestmentsScheduleOfOtherInvestmentsDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "ifrs-full_RangeAxis":  {
                "auth_ref":  [
                    "r152",
                    "r153",
                    "r154",
                    "r177",
                    "r206",
                    "r226"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Range [axis]"
                            }
                        }
                    },
                "localname":  "RangeAxis",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/AcquisitionOfLucidDetails",
                    "http://www.fsdpharma.com/role/AcquisitionOfPrismicPharmaceuticalScheduleOfBlackScholesOptionsPricingModelDetails",
                    "http://www.fsdpharma.com/role/CommitmentsAndContingenciesNarrativeDetails",
                    "http://www.fsdpharma.com/role/ShareCapitalScheduleOfFairValueAssumptionsOfWarrantsDetails",
                    "http://www.fsdpharma.com/role/SharebasedCompensationScheduleOfFairValueAssumptionsOfShareOptionsGrantedDetails"
                    ],
                "xbrltype":  "stringItemType"
                },
            "ifrs-full_RangesMember":  {
                "auth_ref":  [
                    "r152",
                    "r153",
                    "r154",
                    "r177",
                    "r206",
                    "r226"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "This member stands for aggregate ranges.  It also represents the standard value for the 'Range' axis if no other member is used."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Ranges [member]"
                            }
                        }
                    },
                "localname":  "RangesMember",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/AcquisitionOfLucidDetails",
                    "http://www.fsdpharma.com/role/AcquisitionOfPrismicPharmaceuticalScheduleOfBlackScholesOptionsPricingModelDetails",
                    "http://www.fsdpharma.com/role/CommitmentsAndContingenciesNarrativeDetails",
                    "http://www.fsdpharma.com/role/ShareCapitalScheduleOfFairValueAssumptionsOfWarrantsDetails",
                    "http://www.fsdpharma.com/role/SharebasedCompensationScheduleOfFairValueAssumptionsOfShareOptionsGrantedDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis":  {
                "auth_ref":  [
                    "r177"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Ranges of exercise prices for outstanding share options [axis]"
                            }
                        }
                    },
                "localname":  "RangesOfExercisePricesForOutstandingShareOptionsAxis",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/SharebasedCompensationScheduleOfExercisePriceAndWeightedAverageContractualTermOfShareOptionsOutstandingAndExercisableDetails"
                    ],
                "xbrltype":  "stringItemType"
                },
            "ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember":  {
                "auth_ref":  [
                    "r177"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "This member stands for aggregated ranges of exercise prices for outstanding share options that are meaningful for assessing the number and timing of additional shares that may be issued and the cash that may be received upon exercise of those options.  It also represents the standard value for the 'Ranges of exercise prices for outstanding share options' axis if no other member is used. [Refer:  Ranges [member]]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Ranges of exercise prices for outstanding share options [member]"
                            }
                        }
                    },
                "localname":  "RangesOfExercisePricesForOutstandingShareOptionsMember",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/SharebasedCompensationScheduleOfExercisePriceAndWeightedAverageContractualTermOfShareOptionsOutstandingAndExercisableDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "ifrs-full_RepaymentsOfBondsNotesAndDebentures":  {
                "auth_ref":  [
                    "r118"
                    ],
                "calculation":  {
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS":  {
                        "order":  20.0,
                        "parentTag":  "ifrs-full_CashFlowsFromUsedInFinancingActivitiesContinuingOperations",
                        "weight":  -1.0
                        }
                    },
                "crdr":  "credit",
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The cash outflow for repayments of bonds, notes and debentures."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Repayments of bonds, notes and debentures",
                            "negatedLabel":  "Repayment of notes payable"
                            }
                        }
                    },
                "localname":  "RepaymentsOfBondsNotesAndDebentures",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "ifrs-full_ResearchAndDevelopmentExpense":  {
                "auth_ref":  [
                    "r102"
                    ],
                "calculation":  {
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS":  {
                        "order":  10.0,
                        "parentTag":  "ifrs-full_ExpenseByNature",
                        "weight":  1.0
                        }
                    },
                "crdr":  "debit",
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The amount of expenditure directly attributable to research or development activities, recognised in profit or loss."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Research and development expense",
                            "terseLabel":  "External research and development fees"
                            }
                        }
                    },
                "localname":  "ResearchAndDevelopmentExpense",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "ifrs-full_ReserveOfExchangeDifferencesOnTranslation":  {
                "auth_ref":  [
                    "r68"
                    ],
                "calculation":  {
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION":  {
                        "order":  40.0,
                        "parentTag":  "ifrs-full_Equity",
                        "weight":  1.0
                        }
                    },
                "crdr":  "credit",
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "A component of equity representing exchange differences on translation of financial statements recognised in other comprehensive income and accumulated in equity. [Refer:  Other comprehensive income]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Reserve of exchange differences on translation",
                            "verboseLabel":  "Foreign exchange translation reserve"
                            }
                        }
                    },
                "localname":  "ReserveOfExchangeDifferencesOnTranslation",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember":  {
                "auth_ref":  [
                    "r9",
                    "r68"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "This member stands for a component of equity representing accumulated exchange differences on the translation of financial statements recognised in other comprehensive income. [Refer:  Other comprehensive income]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Reserve of exchange differences on translation [member]",
                            "terseLabel":  "Foreign exchange translation reserve",
                            "verboseLabel":  "exchange translation"
                            }
                        }
                    },
                "localname":  "ReserveOfExchangeDifferencesOnTranslationMember",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
                    ],
                "xbrltype":  "domainItemType"
                },
            "ifrs-full_ReserveOfSharebasedPaymentsMember":  {
                "auth_ref":  [
                    "r9"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "This member stands for a component of equity resulting from share-based payments."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Reserve of share-based payments [member]",
                            "terseLabel":  "Contributed surplus"
                            }
                        }
                    },
                "localname":  "ReserveOfSharebasedPaymentsMember",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
                    ],
                "xbrltype":  "domainItemType"
                },
            "ifrs-full_RetainedEarnings":  {
                "auth_ref":  [
                    "r30",
                    "r46"
                    ],
                "calculation":  {
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION":  {
                        "order":  30.0,
                        "parentTag":  "ifrs-full_Equity",
                        "weight":  1.0
                        }
                    },
                "crdr":  "credit",
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "A component of equity representing the entity's cumulative undistributed earnings or deficit."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Retained earnings",
                            "negatedLabel":  "Deficit",
                            "positiveLabel":  "Accumulated deficit",
                            "terseLabel":  "Accumulated deficit",
                            "verboseLabel":  "Accumulated deficit"
                            }
                        }
                    },
                "localname":  "RetainedEarnings",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "ifrs-full_RetainedEarningsMember":  {
                "auth_ref":  [
                    "r8",
                    "r9"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "This member stands for a component of equity representing an entity's cumulative undistributed earnings or deficit."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Retained earnings [member]",
                            "terseLabel":  "Accumulated deficit"
                            }
                        }
                    },
                "localname":  "RetainedEarningsMember",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
                    ],
                "xbrltype":  "domainItemType"
                },
            "ifrs-full_Revenue":  {
                "auth_ref":  [
                    "r1",
                    "r2",
                    "r37",
                    "r138",
                    "r142",
                    "r194",
                    "r212",
                    "r215",
                    "r220",
                    "r221",
                    "r222"
                    ],
                "crdr":  "credit",
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The income arising in the course of an entity's ordinary activities.  Income is increases in assets, or decreases in liabilities, that result in increases in equity, other than those relating to contributions from holders of equity claims."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Revenue",
                            "totalLabel":  "Total revenue"
                            }
                        }
                    },
                "localname":  "Revenue",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/AssetsHeldForSaleDetails1"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "ifrs-full_RightofuseAssets":  {
                "auth_ref":  [
                    "r161"
                    ],
                "calculation":  {
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION":  {
                        "order":  20.0,
                        "parentTag":  "ifrs-full_Assets",
                        "weight":  1.0
                        }
                    },
                "crdr":  "debit",
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The amount of assets that represent a lessee's right to use an underlying asset for the lease term.  Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Right-of-use assets",
                            "periodEndLabel":  "Ending balance",
                            "periodStartLabel":  "Beginning balance",
                            "terseLabel":  "Right-of-use asset balance",
                            "verboseLabel":  "Right-of-use asset, net"
                            }
                        }
                    },
                "localname":  "RightofuseAssets",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION",
                    "http://www.fsdpharma.com/role/RightofuseAssetNarrativeDetails",
                    "http://www.fsdpharma.com/role/RightofuseAssetScheduleOfRightofuseAssetDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "ifrs-full_SellingGeneralAndAdministrativeExpenseAbstract":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "label":  "Selling, general and administrative expense [abstract]"
                            }
                        }
                    },
                "localname":  "SellingGeneralAndAdministrativeExpenseAbstract",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "xbrltype":  "stringItemType"
                },
            "ifrs-full_SettlementOfLiabilitiesByEntityOnBehalfOfRelatedPartyRelatedPartyTransactions":  {
                "auth_ref":  [
                    "r76"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The amount of liabilities settled by the entity on behalf of a related party in related party transactions. [Refer:  Related parties [member]]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Settlement of liabilities by entity on behalf of related party, related party transactions",
                            "terseLabel":  "Other prismic related liabilities"
                            }
                        }
                    },
                "localname":  "SettlementOfLiabilitiesByEntityOnBehalfOfRelatedPartyRelatedPartyTransactions",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/NotesPayableNarrativeDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "ifrs-full_ShareIssueRelatedCost":  {
                "auth_ref":  [
                    "r7"
                    ],
                "crdr":  "debit",
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The amount of cost related to the issuance of shares."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Share issue related cost",
                            "negatedLabel":  "Shares issued",
                            "positiveLabel":  "Share issuance costs",
                            "terseLabel":  "Shareholder and public company costs",
                            "verboseLabel":  "Commissions and corporate finance fees"
                            }
                        }
                    },
                "localname":  "ShareIssueRelatedCost",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/ShareCapitalScheduleOfReconciliationOfTheShareCapitalDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "ifrs-full_SharePremium":  {
                "auth_ref":  [
                    "r30"
                    ],
                "calculation":  {
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION":  {
                        "order":  0.0,
                        "parentTag":  "ifrs-full_Equity",
                        "weight":  1.0
                        }
                    },
                "crdr":  "credit",
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The amount received or receivable from the issuance of the entity's shares in excess of nominal value."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Contributed surplus"
                            }
                        }
                    },
                "localname":  "SharePremium",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "ifrs-full_SharebasedPaymentArrangementsMember":  {
                "auth_ref":  [
                    "r178"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "This member stands for an agreement between the entity or another group entity or any shareholder of the group entity and another party (including an employee) that entitles the other party to receive (a) cash or other assets of the entity for amounts that are based on the price (or value) of equity instruments (including shares or share options) of the entity or another group entity; or (b) equity instruments (including shares or share options) of the entity or another group entity, provided that the specified vesting conditions, if any, are met.  It also represents the standard value for the 'Types of share-based payment arrangements' axis if no other member is used."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Share-based payment arrangements [member]"
                            }
                        }
                    },
                "localname":  "SharebasedPaymentArrangementsMember",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/SharebasedCompensationNarrativeDetails",
                    "http://www.fsdpharma.com/role/SharebasedCompensationScheduleOfChangesInNumberOfShareOptionsDetails",
                    "http://www.fsdpharma.com/role/SharebasedCompensationScheduleOfExercisePriceAndWeightedAverageContractualTermOfShareOptionsOutstandingAndExercisableDetails",
                    "http://www.fsdpharma.com/role/SharebasedCompensationScheduleOfFairValueAssumptionsOfShareOptionsGrantedDetails",
                    "http://www.fsdpharma.com/role/SharebasedCompensationScheduleOfSharebasedCompensationDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "ifrs-full_ShorttermBorrowingsMember":  {
                "auth_ref":  [
                    "r123",
                    "r129"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "This member stands for short-term borrowings. [Refer:  Borrowings]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Short-term borrowings [member]",
                            "terseLabel":  "Short-term notes"
                            }
                        }
                    },
                "localname":  "ShorttermBorrowingsMember",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/NotesPayableNarrativeDetails",
                    "http://www.fsdpharma.com/role/NotesPayableScheduleOfNotesPayableDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "ifrs-full_SignificantInvestmentsInSubsidiariesAxis":  {
                "auth_ref":  [
                    "r81",
                    "r84",
                    "r147"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Subsidiaries [axis]"
                            }
                        }
                    },
                "localname":  "SignificantInvestmentsInSubsidiariesAxis",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/NatureOfBusinessScheduleOfOwnershipPercentageInSubsidiariesDetails"
                    ],
                "xbrltype":  "stringItemType"
                },
            "ifrs-full_StatementOfCashFlowsAbstract":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "label":  "Statement of cash flows [abstract]"
                            }
                        }
                    },
                "localname":  "StatementOfCashFlowsAbstract",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "xbrltype":  "stringItemType"
                },
            "ifrs-full_StatementOfChangesInEquityAbstract":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "label":  "Statement of changes in equity [abstract]"
                            }
                        }
                    },
                "localname":  "StatementOfChangesInEquityAbstract",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "xbrltype":  "stringItemType"
                },
            "ifrs-full_StatementOfChangesInEquityLineItems":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "Line items represent concepts included in a table.  These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Statement of changes in equity [line items]"
                            }
                        }
                    },
                "localname":  "StatementOfChangesInEquityLineItems",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
                    ],
                "xbrltype":  "stringItemType"
                },
            "ifrs-full_StatementOfChangesInEquityTable":  {
                "auth_ref":  [
                    "r8"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "Schedule disclosing information related to changes in equity."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Statement of changes in equity [table]"
                            }
                        }
                    },
                "localname":  "StatementOfChangesInEquityTable",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
                    ],
                "xbrltype":  "stringItemType"
                },
            "ifrs-full_StatementOfFinancialPositionAbstract":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "label":  "Statement of financial position [abstract]"
                            }
                        }
                    },
                "localname":  "StatementOfFinancialPositionAbstract",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "xbrltype":  "stringItemType"
                },
            "ifrs-full_SubsidiariesMember":  {
                "auth_ref":  [
                    "r73",
                    "r81",
                    "r84",
                    "r147"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "This member stands for entities that are controlled by another entity."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Subsidiaries [member]",
                            "verboseLabel":  "FSD Biosciences Inc."
                            }
                        }
                    },
                "localname":  "SubsidiariesMember",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/NatureOfBusinessScheduleOfOwnershipPercentageInSubsidiariesDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss":  {
                "auth_ref":  [
                    "r48"
                    ],
                "calculation":  {
                    "http://www.fsdpharma.com/role/IncomeTaxesScheduleOfProvisionForIncomeTaxesDetails":  {
                        "order":  40.0,
                        "parentTag":  "ifrs-full_DeferredTaxExpenseIncome",
                        "weight":  1.0
                        }
                    },
                "crdr":  "debit",
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to expenses not deductible in determining taxable profit (tax loss). [Refer:  Accounting profit]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Tax effect of expense not deductible in determining taxable profit (tax loss)",
                            "terseLabel":  "Permanent differences",
                            "verboseLabel":  "Non-deductible expense"
                            }
                        }
                    },
                "localname":  "TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/IncomeTaxesScheduleOfProvisionForIncomeTaxesDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "ifrs-full_TaxEffectOfForeignTaxRates":  {
                "auth_ref":  [
                    "r48"
                    ],
                "calculation":  {
                    "http://www.fsdpharma.com/role/IncomeTaxesScheduleOfProvisionForIncomeTaxesDetails":  {
                        "order":  20.0,
                        "parentTag":  "ifrs-full_DeferredTaxExpenseIncome",
                        "weight":  1.0
                        }
                    },
                "crdr":  "debit",
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to foreign tax rates. [Refer:  Accounting profit]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Tax effect of foreign tax rates",
                            "verboseLabel":  "Foreign exchange"
                            }
                        }
                    },
                "localname":  "TaxEffectOfForeignTaxRates",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/IncomeTaxesScheduleOfProvisionForIncomeTaxesDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "ifrs-full_TaxExpenseIncomeAtApplicableTaxRate":  {
                "auth_ref":  [
                    "r48"
                    ],
                "calculation":  {
                    "http://www.fsdpharma.com/role/IncomeTaxesScheduleOfProvisionForIncomeTaxesDetails":  {
                        "order":  30.0,
                        "parentTag":  "ifrs-full_DeferredTaxExpenseIncome",
                        "weight":  1.0
                        }
                    },
                "crdr":  "debit",
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The product of the accounting profit multiplied by the applicable tax rate(s). [Refer:  Accounting profit; Applicable tax rate]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Tax expense (income) at applicable tax rate",
                            "verboseLabel":  "Income tax recovery at the statutory tax rate"
                            }
                        }
                    },
                "localname":  "TaxExpenseIncomeAtApplicableTaxRate",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/IncomeTaxesScheduleOfProvisionForIncomeTaxesDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "ifrs-full_TopOfRangeMember":  {
                "auth_ref":  [
                    "r152",
                    "r153",
                    "r154",
                    "r177",
                    "r206",
                    "r226"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "This member stands for top of a range."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Top of range [member]",
                            "terseLabel":  "Maximum",
                            "verboseLabel":  "Top of range"
                            }
                        }
                    },
                "localname":  "TopOfRangeMember",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/AcquisitionOfLucidDetails",
                    "http://www.fsdpharma.com/role/AcquisitionOfPrismicPharmaceuticalScheduleOfBlackScholesOptionsPricingModelDetails",
                    "http://www.fsdpharma.com/role/CommitmentsAndContingenciesNarrativeDetails",
                    "http://www.fsdpharma.com/role/ShareCapitalScheduleOfFairValueAssumptionsOfWarrantsDetails",
                    "http://www.fsdpharma.com/role/SharebasedCompensationScheduleOfFairValueAssumptionsOfShareOptionsGrantedDetails"
                    ],
                "xbrltype":  "domainItemType"
                },
            "ifrs-full_TradeAndOtherCurrentPayables":  {
                "auth_ref":  [
                    "r21"
                    ],
                "calculation":  {
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION":  {
                        "order":  0.0,
                        "parentTag":  "ifrs-full_CurrentLiabilities",
                        "weight":  1.0
                        },
                    "http://www.fsdpharma.com/role/TradeAndOtherPayablesDetails":  {
                        "order":  null,
                        "parentTag":  null,
                        "root":  true,
                        "weight":  null
                        }
                    },
                "crdr":  "credit",
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The amount of current trade payables and current other payables. [Refer:  Current trade payables; Other current payables]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Trade and other current payables",
                            "totalLabel":  "Total trade and other current payables",
                            "verboseLabel":  "Trade and other payables"
                            }
                        }
                    },
                "localname":  "TradeAndOtherCurrentPayables",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION",
                    "http://www.fsdpharma.com/role/TradeAndOtherPayablesDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "ifrs-full_TradeAndOtherCurrentPayablesAbstract":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "label":  "Trade and other current payables [abstract]"
                            }
                        }
                    },
                "localname":  "TradeAndOtherCurrentPayablesAbstract",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "xbrltype":  "stringItemType"
                },
            "ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers":  {
                "auth_ref":  [
                    "r28",
                    "r31"
                    ],
                "calculation":  {
                    "http://www.fsdpharma.com/role/TradeAndOtherPayablesDetails":  {
                        "order":  10.0,
                        "parentTag":  "ifrs-full_TradeAndOtherCurrentPayables",
                        "weight":  1.0
                        }
                    },
                "crdr":  "credit",
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The current amount of payment due to suppliers for goods and services used in entity's business. [Refer:  Current liabilities; Trade payables]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Current trade payables",
                            "terseLabel":  "Trade payables"
                            }
                        }
                    },
                "localname":  "TradeAndOtherCurrentPayablesToTradeSuppliers",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/TradeAndOtherPayablesDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "ifrs-full_TradeAndOtherCurrentReceivables":  {
                "auth_ref":  [
                    "r18",
                    "r29"
                    ],
                "calculation":  {
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION":  {
                        "order":  20.0,
                        "parentTag":  "ifrs-full_CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners",
                        "weight":  1.0
                        }
                    },
                "crdr":  "debit",
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The amount of current trade receivables and current other receivables. [Refer:  Current trade receivables; Other current receivables]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Trade and other current receivables",
                            "terseLabel":  "Other receivables",
                            "totalLabel":  "Total trade and other current receivables",
                            "verboseLabel":  "Trade and other receivables"
                            }
                        }
                    },
                "localname":  "TradeAndOtherCurrentReceivables",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "ifrs-full_TradeAndOtherPayablesAbstract":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "label":  "Trade and other payables [abstract]"
                            }
                        }
                    },
                "localname":  "TradeAndOtherPayablesAbstract",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "xbrltype":  "stringItemType"
                },
            "ifrs-full_TradeAndOtherPayablesRecognisedAsOfAcquisitionDate":  {
                "auth_ref":  [
                    "r184"
                    ],
                "crdr":  "credit",
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The amount recognised as of the acquisition date for trade and other payables assumed in a business combination. [Refer:  Trade and other payables; Business combinations [member]]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Trade and other payables recognised as of acquisition date",
                            "negatedLabel":  "Trade and other payables",
                            "terseLabel":  "Trade and other payables",
                            "totalLabel":  "Total trade and other payables"
                            }
                        }
                    },
                "localname":  "TradeAndOtherPayablesRecognisedAsOfAcquisitionDate",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/AcquisitionOfLucidDetails1",
                    "http://www.fsdpharma.com/role/AcquisitionOfPrismicPharmaceuticalScheduleOfIdentifiableAssetsAcquiredAndLiabilitiesAssumedDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "ifrs-full_TradeAndOtherReceivables":  {
                "auth_ref":  [
                    "r18",
                    "r29"
                    ],
                "calculation":  {
                    "http://www.fsdpharma.com/role/TradeAndOtherReceivablesScheduleOfTradeAndOtherReceivablesDetails":  {
                        "order":  null,
                        "parentTag":  null,
                        "root":  true,
                        "weight":  null
                        }
                    },
                "crdr":  "debit",
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The amount of trade receivables and other receivables. [Refer:  Trade receivables; Other receivables]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Trade and other receivables",
                            "totalLabel":  "Total trade and other receivables",
                            "verboseLabel":  "Trade and other receivables"
                            }
                        }
                    },
                "localname":  "TradeAndOtherReceivables",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/TradeAndOtherReceivablesScheduleOfTradeAndOtherReceivablesDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "ifrs-full_TradeAndOtherReceivablesAbstract":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "label":  "Trade and other receivables [abstract]",
                            "verboseLabel":  "Other receivables"
                            }
                        }
                    },
                "localname":  "TradeAndOtherReceivablesAbstract",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "xbrltype":  "stringItemType"
                },
            "ifrs-full_TypesOfSharebasedPaymentArrangementsAxis":  {
                "auth_ref":  [
                    "r178"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Types of share-based payment arrangements [axis]"
                            }
                        }
                    },
                "localname":  "TypesOfSharebasedPaymentArrangementsAxis",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/SharebasedCompensationNarrativeDetails",
                    "http://www.fsdpharma.com/role/SharebasedCompensationScheduleOfChangesInNumberOfShareOptionsDetails",
                    "http://www.fsdpharma.com/role/SharebasedCompensationScheduleOfExercisePriceAndWeightedAverageContractualTermOfShareOptionsOutstandingAndExercisableDetails",
                    "http://www.fsdpharma.com/role/SharebasedCompensationScheduleOfFairValueAssumptionsOfShareOptionsGrantedDetails",
                    "http://www.fsdpharma.com/role/SharebasedCompensationScheduleOfSharebasedCompensationDetails"
                    ],
                "xbrltype":  "stringItemType"
                },
            "ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill":  {
                "auth_ref":  [
                    "r94"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The useful life, measured as period of time, used for intangible assets other than goodwill. [Refer:  Intangible assets other than goodwill]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Useful life measured as period of time, intangible assets other than goodwill",
                            "verboseLabel":  "Useful life of intellectual property"
                            }
                        }
                    },
                "localname":  "UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/IntangibleAssetsNarrativeDetails"
                    ],
                "xbrltype":  "durationItemType"
                },
            "ifrs-full_WagesAndSalaries":  {
                "auth_ref":  [
                    "r65"
                    ],
                "crdr":  "debit",
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "A class of employee benefits expense that represents wages and salaries. [Refer:  Employee benefits expense]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Wages and salaries",
                            "terseLabel":  "Salaries, wages and benefits"
                            }
                        }
                    },
                "localname":  "WagesAndSalaries",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/GeneralAndAdministrativeDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019":  {
                "auth_ref":  [
                    "r175"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The weighted average exercise price of share options exercisable in a share-based payment arrangement. [Refer:  Weighted average [member]]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Weighted average exercise price of share options exercisable in share-based payment arrangement",
                            "positiveVerboseLabel":  "Share option exercise price",
                            "terseLabel":  "Exercise price of exercisable Share options",
                            "verboseLabel":  "Weighted average exercise price, Exercisable"
                            }
                        }
                    },
                "localname":  "WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/SharebasedCompensationScheduleOfChangesInNumberOfShareOptionsDetails",
                    "http://www.fsdpharma.com/role/SharebasedCompensationScheduleOfExercisePriceAndWeightedAverageContractualTermOfShareOptionsOutstandingAndExercisableDetails"
                    ],
                "xbrltype":  "perShareItemType"
                },
            "ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019":  {
                "auth_ref":  [
                    "r172"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The weighted average exercise price of share options exercised in a share-based payment arrangement. [Refer:  Weighted average [member]]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Weighted average exercise price of share options exercised in share-based payment arrangement",
                            "verboseLabel":  "Weighted average exercise price, Exercised"
                            }
                        }
                    },
                "localname":  "WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/SharebasedCompensationScheduleOfChangesInNumberOfShareOptionsDetails"
                    ],
                "xbrltype":  "perShareItemType"
                },
            "ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019":  {
                "auth_ref":  [
                    "r173"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The weighted average exercise price of share options expired in a share-based payment arrangement. [Refer:  Weighted average [member]]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Weighted average exercise price of share options expired in share-based payment arrangement",
                            "terseLabel":  "Weighted average exercise price, Cancelled"
                            }
                        }
                    },
                "localname":  "WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/SharebasedCompensationScheduleOfChangesInNumberOfShareOptionsDetails"
                    ],
                "xbrltype":  "perShareItemType"
                },
            "ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019":  {
                "auth_ref":  [
                    "r171"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The weighted average exercise price of share options forfeited in a share-based payment arrangement. [Refer:  Weighted average [member]]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Weighted average exercise price of share options forfeited in share-based payment arrangement",
                            "verboseLabel":  "Weighted average exercise price, Forfeited"
                            }
                        }
                    },
                "localname":  "WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/SharebasedCompensationScheduleOfChangesInNumberOfShareOptionsDetails"
                    ],
                "xbrltype":  "perShareItemType"
                },
            "ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019":  {
                "auth_ref":  [
                    "r170"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The weighted average exercise price of share options granted in a share-based payment arrangement. [Refer:  Weighted average [member]]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Weighted average exercise price of share options granted in share-based payment arrangement",
                            "terseLabel":  "Share option exercise price",
                            "verboseLabel":  "Weighted average exercise price, Granted"
                            }
                        }
                    },
                "localname":  "WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/SharebasedCompensationNarrativeDetails",
                    "http://www.fsdpharma.com/role/SharebasedCompensationScheduleOfChangesInNumberOfShareOptionsDetails"
                    ],
                "xbrltype":  "perShareItemType"
                },
            "ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019":  {
                "auth_ref":  [
                    "r169",
                    "r174"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The weighted average exercise price of share options outstanding in a share-based payment arrangement. [Refer:  Weighted average [member]]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Weighted average exercise price of share options outstanding in share-based payment arrangement",
                            "periodEndLabel":  "Weighted average exercise price of share options outstanding in share-based payment arrangement at end of period",
                            "periodStartLabel":  "Weighted average exercise price of share options outstanding in share-based payment arrangement at beginning of period",
                            "verboseLabel":  "Exercise price of options outstanding"
                            }
                        }
                    },
                "localname":  "WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/SharebasedCompensationScheduleOfChangesInNumberOfShareOptionsDetails",
                    "http://www.fsdpharma.com/role/SharebasedCompensationScheduleOfExercisePriceAndWeightedAverageContractualTermOfShareOptionsOutstandingAndExercisableDetails"
                    ],
                "xbrltype":  "perShareItemType"
                },
            "ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted":  {
                "auth_ref":  [
                    "r180"
                    ],
                "crdr":  "credit",
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The weighted average fair value of share options granted during the period at the measurement date. [Refer:  Weighted average [member]]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Weighted average fair value at measurement date, share options granted",
                            "terseLabel":  "Incremental grant date fair value of share options",
                            "verboseLabel":  "Fair Values"
                            }
                        }
                    },
                "localname":  "WeightedAverageFairValueAtMeasurementDateShareOptionsGranted",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/SharebasedCompensationNarrativeDetails"
                    ],
                "xbrltype":  "monetaryItemType"
                },
            "ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019":  {
                "auth_ref":  [
                    "r177"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The weighted average remaining contractual life of outstanding share options. [Refer:  Weighted average [member]]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Weighted average remaining contractual life of outstanding share options"
                            }
                        }
                    },
                "localname":  "WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/SharebasedCompensationScheduleOfExercisePriceAndWeightedAverageContractualTermOfShareOptionsOutstandingAndExercisableDetails"
                    ],
                "xbrltype":  "durationItemType"
                },
            "ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019":  {
                "auth_ref":  [
                    "r179"
                    ],
                "lang":  {
                    "en":  {
                        "role":  {
                            "documentation":  "The weighted average share price used as input to the option pricing model to calculate the fair value of share options granted. [Refer:  Option pricing model [member]; Weighted average [member]]"
                            }
                        },
                    "en-us":  {
                        "role":  {
                            "label":  "Weighted average share price, share options granted",
                            "positiveLabel":  "Underlying share price",
                            "terseLabel":  "Share issued price per share",
                            "verboseLabel":  "Grant date share price"
                            }
                        }
                    },
                "localname":  "WeightedAverageSharePriceShareOptionsGranted2019",
                "nsuri":  "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
                "presentation":  [
                    "http://www.fsdpharma.com/role/AcquisitionOfLucidDetails",
                    "http://www.fsdpharma.com/role/AcquisitionOfPrismicPharmaceuticalScheduleOfBlackScholesOptionsPricingModelDetails",
                    "http://www.fsdpharma.com/role/SharebasedCompensationNarrativeDetails",
                    "http://www.fsdpharma.com/role/SharebasedCompensationScheduleOfFairValueAssumptionsOfShareOptionsGrantedDetails"
                    ],
                "xbrltype":  "perShareItemType"
                },
            "srt_CounterpartyNameAxis":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "label":  "Counterparty Name [Axis]"
                            }
                        }
                    },
                "localname":  "CounterpartyNameAxis",
                "nsuri":  "http://fasb.org/srt/2021-01-31",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CommitmentsAndContingenciesNarrativeDetails",
                    "http://www.fsdpharma.com/role/CommitmentsAndContingenciesScheduleOfQuantitiesOfCannabisAvailableToSupplyByFiscalPeriodDetails"
                    ],
                "xbrltype":  "stringItemType"
                },
            "srt_RepurchaseAgreementCounterpartyNameDomain":  {
                "auth_ref":  [
                    ],
                "lang":  {
                    "en-us":  {
                        "role":  {
                            "label":  "Counterparty Name [Domain]"
                            }
                        }
                    },
                "localname":  "RepurchaseAgreementCounterpartyNameDomain",
                "nsuri":  "http://fasb.org/srt/2021-01-31",
                "presentation":  [
                    "http://www.fsdpharma.com/role/CommitmentsAndContingenciesNarrativeDetails",
                    "http://www.fsdpharma.com/role/CommitmentsAndContingenciesScheduleOfQuantitiesOfCannabisAvailableToSupplyByFiscalPeriodDetails"
                    ],
                "xbrltype":  "domainItemType"
                }
            },
        "unitCount":  9
        }
    },
"std_ref":  {
    "r0":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IAS",
        "Number":  "1",
        "Paragraph":  "10",
        "Subparagraph":  "e",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_10_e&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r1":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IAS",
        "Number":  "1",
        "Paragraph":  "102",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_102&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r10":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IAS",
        "Number":  "1",
        "Paragraph":  "112",
        "Subparagraph":  "c",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_112_c&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r100":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IAS",
        "Number":  "38",
        "Paragraph":  "118",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=38&code=ifrs-tx-2021-en-r&anchor=para_118&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r101":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IAS",
        "Number":  "38",
        "Paragraph":  "119",
        "Subparagraph":  "e",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=38&code=ifrs-tx-2021-en-r&anchor=para_119_e&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r102":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IAS",
        "Number":  "38",
        "Paragraph":  "126",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=38&code=ifrs-tx-2021-en-r&anchor=para_126&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r103":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IAS",
        "Number":  "38",
        "Section":  "Disclosure",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=38&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IAS38_g118-128_TI",
        "URIDate":  "2021-03-24"
        },
    "r104":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IAS",
        "Number":  "40",
        "Paragraph":  "32A",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=40&code=ifrs-tx-2021-en-r&anchor=para_32A&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r105":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IAS",
        "Number":  "40",
        "Paragraph":  "76",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=40&code=ifrs-tx-2021-en-r&anchor=para_76&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r106":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IAS",
        "Number":  "40",
        "Paragraph":  "79",
        "Subparagraph":  "c",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=40&code=ifrs-tx-2021-en-r&anchor=para_79_c&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r107":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IAS",
        "Number":  "40",
        "Paragraph":  "79",
        "Subparagraph":  "d",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=40&code=ifrs-tx-2021-en-r&anchor=para_79_d&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r108":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IAS",
        "Number":  "41",
        "Paragraph":  "50",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=41&code=ifrs-tx-2021-en-r&anchor=para_50&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r109":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IAS",
        "Number":  "41",
        "Paragraph":  "51",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=41&code=ifrs-tx-2021-en-r&anchor=para_51&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r11":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IAS",
        "Number":  "1",
        "Paragraph":  "117",
        "Subparagraph":  "b",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_117_b&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r110":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IAS",
        "Number":  "41",
        "Paragraph":  "54",
        "Subparagraph":  "f",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=41&code=ifrs-tx-2021-en-r&anchor=para_54_f&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r111":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IAS",
        "Number":  "41",
        "Section":  "Example 1 XYZ Dairy Ltd",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=41&code=ifrs-tx-2021-en-r&doctype=Illustrative%20Examples&dita_xref=IAS41_IE_ex1__IAS41_IE_ex1_TI",
        "URIDate":  "2021-03-24"
        },
    "r112":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IAS",
        "Number":  "7",
        "Paragraph":  "10",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_10&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r113":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IAS",
        "Number":  "7",
        "Paragraph":  "16",
        "Subparagraph":  "a",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_16_a&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r114":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IAS",
        "Number":  "7",
        "Paragraph":  "16",
        "Subparagraph":  "b",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_16_b&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r115":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IAS",
        "Number":  "7",
        "Paragraph":  "16",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_16&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r116":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IAS",
        "Number":  "7",
        "Paragraph":  "17",
        "Subparagraph":  "a",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_17_a&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r117":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IAS",
        "Number":  "7",
        "Paragraph":  "17",
        "Subparagraph":  "e",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_17_e&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r118":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IAS",
        "Number":  "7",
        "Paragraph":  "17",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_17&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r119":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IAS",
        "Number":  "7",
        "Paragraph":  "18",
        "Subparagraph":  "b",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_18_b&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r12":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IAS",
        "Number":  "1",
        "Paragraph":  "117",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_117&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r120":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IAS",
        "Number":  "7",
        "Paragraph":  "20",
        "Subparagraph":  "a",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_20_a&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r121":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IAS",
        "Number":  "7",
        "Paragraph":  "20",
        "Subparagraph":  "b",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_20_b&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r122":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IAS",
        "Number":  "7",
        "Paragraph":  "20",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_20&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r123":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IAS",
        "Number":  "7",
        "Paragraph":  "44C",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_44C&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r124":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IAS",
        "Number":  "7",
        "Paragraph":  "44D",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_44D&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r125":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IAS",
        "Number":  "7",
        "Paragraph":  "45",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_45&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r126":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IAS",
        "Number":  "7",
        "Paragraph":  "46",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_46&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r127":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IAS",
        "Number":  "7",
        "Paragraph":  "50",
        "Subparagraph":  "d",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_50_d&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r128":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IAS",
        "Number":  "7",
        "Section":  "A Statement of cash flows for an entity other than a financial institution",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&doctype=Illustrative%20Examples&dita_xref=IAS07_IE_A__IAS07_IE_A_TI",
        "URIDate":  "2021-03-24"
        },
    "r129":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IAS",
        "Number":  "7",
        "Section":  "C Reconciliation of liabilities arising from financing activities",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&doctype=Illustrative%20Examples&dita_xref=IAS07_IE_C__IAS07_IE_C_TI",
        "URIDate":  "2021-03-24"
        },
    "r13":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IAS",
        "Number":  "1",
        "Paragraph":  "134",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_134&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r130":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IFRS",
        "Number":  "1",
        "Paragraph":  "24",
        "Subparagraph":  "a",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2021-en-r&anchor=para_24_a&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r131":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IFRS",
        "Number":  "1",
        "Paragraph":  "24",
        "Subparagraph":  "b",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2021-en-r&anchor=para_24_b&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r132":  {
        "Clause":  "i",
        "IssueDate":  "2021-01-01",
        "Name":  "IFRS",
        "Number":  "1",
        "Paragraph":  "32",
        "Subparagraph":  "a",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2021-en-r&anchor=para_32_a_i&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r133":  {
        "Clause":  "ii",
        "IssueDate":  "2021-01-01",
        "Name":  "IFRS",
        "Number":  "1",
        "Paragraph":  "32",
        "Subparagraph":  "a",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2021-en-r&anchor=para_32_a_ii&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r134":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IFRS",
        "Number":  "12",
        "Paragraph":  "12",
        "Subparagraph":  "b",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_12_b&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r135":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IFRS",
        "Number":  "12",
        "Paragraph":  "19B",
        "Subparagraph":  "b",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_19B_b&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r136":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IFRS",
        "Number":  "12",
        "Paragraph":  "19B",
        "Subparagraph":  "c",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_19B_c&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r137":  {
        "Clause":  "iv",
        "IssueDate":  "2021-01-01",
        "Name":  "IFRS",
        "Number":  "12",
        "Paragraph":  "21",
        "Subparagraph":  "a",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_21_a_iv&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r138":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IFRS",
        "Number":  "12",
        "Paragraph":  "B10",
        "Subparagraph":  "b",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B",
        "URIDate":  "2021-03-24"
        },
    "r139":  {
        "Clause":  "i",
        "IssueDate":  "2021-01-01",
        "Name":  "IFRS",
        "Number":  "12",
        "Paragraph":  "B12",
        "Subparagraph":  "b",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B12_b_i&doctype=Appendix&subtype=B",
        "URIDate":  "2021-03-24"
        },
    "r14":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IAS",
        "Number":  "1",
        "Paragraph":  "35",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_35&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r140":  {
        "Clause":  "iii",
        "IssueDate":  "2021-01-01",
        "Name":  "IFRS",
        "Number":  "12",
        "Paragraph":  "B12",
        "Subparagraph":  "b",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B12_b_iii&doctype=Appendix&subtype=B",
        "URIDate":  "2021-03-24"
        },
    "r141":  {
        "Clause":  "ix",
        "IssueDate":  "2021-01-01",
        "Name":  "IFRS",
        "Number":  "12",
        "Paragraph":  "B12",
        "Subparagraph":  "b",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B12_b_ix&doctype=Appendix&subtype=B",
        "URIDate":  "2021-03-24"
        },
    "r142":  {
        "Clause":  "v",
        "IssueDate":  "2021-01-01",
        "Name":  "IFRS",
        "Number":  "12",
        "Paragraph":  "B12",
        "Subparagraph":  "b",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B12_b_v&doctype=Appendix&subtype=B",
        "URIDate":  "2021-03-24"
        },
    "r143":  {
        "Clause":  "vi",
        "IssueDate":  "2021-01-01",
        "Name":  "IFRS",
        "Number":  "12",
        "Paragraph":  "B12",
        "Subparagraph":  "b",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B12_b_vi&doctype=Appendix&subtype=B",
        "URIDate":  "2021-03-24"
        },
    "r144":  {
        "Clause":  "vii",
        "IssueDate":  "2021-01-01",
        "Name":  "IFRS",
        "Number":  "12",
        "Paragraph":  "B12",
        "Subparagraph":  "b",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B12_b_vii&doctype=Appendix&subtype=B",
        "URIDate":  "2021-03-24"
        },
    "r145":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IFRS",
        "Number":  "12",
        "Paragraph":  "B13",
        "Subparagraph":  "a",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B13_a&doctype=Appendix&subtype=B",
        "URIDate":  "2021-03-24"
        },
    "r146":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IFRS",
        "Number":  "12",
        "Paragraph":  "B13",
        "Subparagraph":  "d",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B13_d&doctype=Appendix&subtype=B",
        "URIDate":  "2021-03-24"
        },
    "r147":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IFRS",
        "Number":  "12",
        "Paragraph":  "B4",
        "Subparagraph":  "a",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B4_a&doctype=Appendix&subtype=B",
        "URIDate":  "2021-03-24"
        },
    "r148":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IFRS",
        "Number":  "13",
        "Paragraph":  "93",
        "Subparagraph":  "a",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_93_a&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r149":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IFRS",
        "Number":  "13",
        "Paragraph":  "93",
        "Subparagraph":  "b",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_93_b&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r15":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IAS",
        "Number":  "1",
        "Paragraph":  "54",
        "Subparagraph":  "a",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_a&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r150":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IFRS",
        "Number":  "13",
        "Paragraph":  "93",
        "Subparagraph":  "e",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_93_e&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r151":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IFRS",
        "Number":  "13",
        "Paragraph":  "93",
        "Subparagraph":  "f",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_93_f&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r152":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IFRS",
        "Number":  "13",
        "Paragraph":  "B6",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_B6&doctype=Appendix&subtype=B",
        "URIDate":  "2021-03-24"
        },
    "r153":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IFRS",
        "Number":  "13",
        "Paragraph":  "IE63",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_IE63&doctype=Illustrative%20Examples",
        "URIDate":  "2021-03-24"
        },
    "r154":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IFRS",
        "Number":  "14",
        "Paragraph":  "33",
        "Subparagraph":  "b",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=14&code=ifrs-tx-2021-en-r&anchor=para_33_b&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r155":  {
        "Clause":  "i",
        "IssueDate":  "2021-01-01",
        "Name":  "IFRS",
        "Number":  "15",
        "Paragraph":  "120",
        "Subparagraph":  "b",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&anchor=para_120_b_i&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r156":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IFRS",
        "Number":  "16",
        "Paragraph":  "47",
        "Subparagraph":  "b",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_47_b&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r157":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IFRS",
        "Number":  "16",
        "Paragraph":  "53",
        "Subparagraph":  "a",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_53_a&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r158":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IFRS",
        "Number":  "16",
        "Paragraph":  "53",
        "Subparagraph":  "b",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_53_b&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r159":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IFRS",
        "Number":  "16",
        "Paragraph":  "53",
        "Subparagraph":  "g",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_53_g&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r16":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IAS",
        "Number":  "1",
        "Paragraph":  "54",
        "Subparagraph":  "c",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_c&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r160":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IFRS",
        "Number":  "16",
        "Paragraph":  "53",
        "Subparagraph":  "h",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_53_h&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r161":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IFRS",
        "Number":  "16",
        "Paragraph":  "53",
        "Subparagraph":  "j",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_53_j&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r162":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IFRS",
        "Number":  "16",
        "Paragraph":  "53",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_53&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r163":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IFRS",
        "Number":  "16",
        "Paragraph":  "94",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_94&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r164":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IFRS",
        "Number":  "16",
        "Paragraph":  "97",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_97&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r165":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IFRS",
        "Number":  "16",
        "Section":  "Disclosure",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IFRS16_g51-60_TI",
        "URIDate":  "2021-03-24"
        },
    "r166":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IFRS",
        "Number":  "16",
        "Section":  "Presentation",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IFRS16_g47-50_TI",
        "URIDate":  "2021-03-24"
        },
    "r167":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IFRS",
        "Number":  "2",
        "Paragraph":  "44",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_44&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r168":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IFRS",
        "Number":  "2",
        "Paragraph":  "45",
        "Subparagraph":  "a",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45_a&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r169":  {
        "Clause":  "i",
        "IssueDate":  "2021-01-01",
        "Name":  "IFRS",
        "Number":  "2",
        "Paragraph":  "45",
        "Subparagraph":  "b",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45_b_i&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r17":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IAS",
        "Number":  "1",
        "Paragraph":  "54",
        "Subparagraph":  "f",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_f&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r170":  {
        "Clause":  "ii",
        "IssueDate":  "2021-01-01",
        "Name":  "IFRS",
        "Number":  "2",
        "Paragraph":  "45",
        "Subparagraph":  "b",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45_b_ii&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r171":  {
        "Clause":  "iii",
        "IssueDate":  "2021-01-01",
        "Name":  "IFRS",
        "Number":  "2",
        "Paragraph":  "45",
        "Subparagraph":  "b",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45_b_iii&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r172":  {
        "Clause":  "iv",
        "IssueDate":  "2021-01-01",
        "Name":  "IFRS",
        "Number":  "2",
        "Paragraph":  "45",
        "Subparagraph":  "b",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45_b_iv&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r173":  {
        "Clause":  "v",
        "IssueDate":  "2021-01-01",
        "Name":  "IFRS",
        "Number":  "2",
        "Paragraph":  "45",
        "Subparagraph":  "b",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45_b_v&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r174":  {
        "Clause":  "vi",
        "IssueDate":  "2021-01-01",
        "Name":  "IFRS",
        "Number":  "2",
        "Paragraph":  "45",
        "Subparagraph":  "b",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45_b_vi&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r175":  {
        "Clause":  "vii",
        "IssueDate":  "2021-01-01",
        "Name":  "IFRS",
        "Number":  "2",
        "Paragraph":  "45",
        "Subparagraph":  "b",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45_b_vii&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r176":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IFRS",
        "Number":  "2",
        "Paragraph":  "45",
        "Subparagraph":  "b",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45_b&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r177":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IFRS",
        "Number":  "2",
        "Paragraph":  "45",
        "Subparagraph":  "d",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45_d&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r178":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IFRS",
        "Number":  "2",
        "Paragraph":  "45",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r179":  {
        "Clause":  "i",
        "IssueDate":  "2021-01-01",
        "Name":  "IFRS",
        "Number":  "2",
        "Paragraph":  "47",
        "Subparagraph":  "a",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_47_a_i&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r18":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IAS",
        "Number":  "1",
        "Paragraph":  "54",
        "Subparagraph":  "h",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_h&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r180":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IFRS",
        "Number":  "2",
        "Paragraph":  "47",
        "Subparagraph":  "a",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_47_a&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r181":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IFRS",
        "Number":  "2",
        "Paragraph":  "IG23",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_IG23&doctype=Implementation%20Guidance",
        "URIDate":  "2021-03-24"
        },
    "r182":  {
        "Clause":  "iv",
        "IssueDate":  "2021-01-01",
        "Name":  "IFRS",
        "Number":  "3",
        "Paragraph":  "B64",
        "Subparagraph":  "f",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2021-en-r&anchor=para_B64_f_iv&doctype=Appendix&subtype=B",
        "URIDate":  "2021-03-24"
        },
    "r183":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IFRS",
        "Number":  "3",
        "Paragraph":  "B64",
        "Subparagraph":  "f",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2021-en-r&anchor=para_B64_f&doctype=Appendix&subtype=B",
        "URIDate":  "2021-03-24"
        },
    "r184":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IFRS",
        "Number":  "3",
        "Paragraph":  "B64",
        "Subparagraph":  "i",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2021-en-r&anchor=para_B64_i&doctype=Appendix&subtype=B",
        "URIDate":  "2021-03-24"
        },
    "r185":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IFRS",
        "Number":  "3",
        "Paragraph":  "B64",
        "Subparagraph":  "m",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2021-en-r&anchor=para_B64_m&doctype=Appendix&subtype=B",
        "URIDate":  "2021-03-24"
        },
    "r186":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IFRS",
        "Number":  "3",
        "Paragraph":  "B64",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2021-en-r&anchor=para_B64&doctype=Appendix&subtype=B",
        "URIDate":  "2021-03-24"
        },
    "r187":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IFRS",
        "Number":  "3",
        "Paragraph":  "B67",
        "Subparagraph":  "c",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2021-en-r&anchor=para_B67_c&doctype=Appendix&subtype=B",
        "URIDate":  "2021-03-24"
        },
    "r188":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IFRS",
        "Number":  "3",
        "Paragraph":  "B67",
        "Subparagraph":  "d",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2021-en-r&anchor=para_B67_d&doctype=Appendix&subtype=B",
        "URIDate":  "2021-03-24"
        },
    "r189":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IFRS",
        "Number":  "3",
        "Paragraph":  "B67",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2021-en-r&anchor=para_B67&doctype=Appendix&subtype=B",
        "URIDate":  "2021-03-24"
        },
    "r19":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IAS",
        "Number":  "1",
        "Paragraph":  "54",
        "Subparagraph":  "i",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_i&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r190":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IFRS",
        "Number":  "3",
        "Paragraph":  "IE72",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2021-en-r&anchor=para_IE72&doctype=Illustrative%20Examples",
        "URIDate":  "2021-03-24"
        },
    "r191":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IFRS",
        "Number":  "3",
        "Section":  "Disclosures",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IFRS03_g59-63__IFRS03_g59-63_TI",
        "URIDate":  "2021-03-24"
        },
    "r192":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IFRS",
        "Number":  "3",
        "Section":  "Disclosures application of paragraphs 59 and 61",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2021-en-r&doctype=Appendix&subtype=B&dita_xref=IFRS03_gB64-B67_TI",
        "URIDate":  "2021-03-24"
        },
    "r193":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IFRS",
        "Number":  "5",
        "Paragraph":  "33",
        "Subparagraph":  "a",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2021-en-r&anchor=para_33_a&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r194":  {
        "Clause":  "i",
        "IssueDate":  "2021-01-01",
        "Name":  "IFRS",
        "Number":  "5",
        "Paragraph":  "33",
        "Subparagraph":  "b",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2021-en-r&anchor=para_33_b_i&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r195":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IFRS",
        "Number":  "5",
        "Paragraph":  "33",
        "Subparagraph":  "c",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2021-en-r&anchor=para_33_c&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r196":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IFRS",
        "Number":  "5",
        "Paragraph":  "38",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2021-en-r&anchor=para_38&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r197":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IFRS",
        "Number":  "5",
        "Section":  "Presentation and disclosure",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IFRS05_g30-42_TI",
        "URIDate":  "2021-03-24"
        },
    "r198":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IFRS",
        "Number":  "7",
        "Paragraph":  "23B",
        "Subparagraph":  "a",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_23B_a&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r199":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IFRS",
        "Number":  "7",
        "Paragraph":  "35H",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_35H&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r2":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IAS",
        "Number":  "1",
        "Paragraph":  "103",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_103&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r20":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IAS",
        "Number":  "1",
        "Paragraph":  "54",
        "Subparagraph":  "j",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_j&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r200":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IFRS",
        "Number":  "7",
        "Paragraph":  "35I",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_35I&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r201":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IFRS",
        "Number":  "7",
        "Paragraph":  "35K",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_35K&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r202":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IFRS",
        "Number":  "7",
        "Paragraph":  "35M",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_35M&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r203":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IFRS",
        "Number":  "7",
        "Paragraph":  "35N",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_35N&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r204":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IFRS",
        "Number":  "7",
        "Paragraph":  "36",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_36&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r205":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IFRS",
        "Number":  "7",
        "Paragraph":  "42E",
        "Subparagraph":  "e",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_42E_e&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r206":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IFRS",
        "Number":  "7",
        "Paragraph":  "7",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_7&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r207":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IFRS",
        "Number":  "7",
        "Paragraph":  "B11",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_B11&doctype=Appendix&subtype=B",
        "URIDate":  "2021-03-24"
        },
    "r208":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IFRS",
        "Number":  "7",
        "Paragraph":  "B35",
        "Subparagraph":  "g",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_B35_g&doctype=Appendix&subtype=B",
        "URIDate":  "2021-03-24"
        },
    "r209":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IFRS",
        "Number":  "7",
        "Paragraph":  "B35",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_B35&doctype=Appendix&subtype=B",
        "URIDate":  "2021-03-24"
        },
    "r21":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IAS",
        "Number":  "1",
        "Paragraph":  "54",
        "Subparagraph":  "k",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_k&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r210":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IFRS",
        "Number":  "7",
        "Paragraph":  "IG31A",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_IG31A&doctype=Implementation%20Guidance",
        "URIDate":  "2021-03-24"
        },
    "r211":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IFRS",
        "Number":  "7",
        "Section":  "Scope",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IFRS07_g3-5A_TI",
        "URIDate":  "2021-03-24"
        },
    "r212":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IFRS",
        "Number":  "8",
        "Paragraph":  "23",
        "Subparagraph":  "a",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_23_a&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r213":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IFRS",
        "Number":  "8",
        "Paragraph":  "23",
        "Subparagraph":  "e",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_23_e&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r214":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IFRS",
        "Number":  "8",
        "Paragraph":  "23",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_23&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r215":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IFRS",
        "Number":  "8",
        "Paragraph":  "28",
        "Subparagraph":  "a",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_28_a&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r216":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IFRS",
        "Number":  "8",
        "Paragraph":  "28",
        "Subparagraph":  "b",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_28_b&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r217":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IFRS",
        "Number":  "8",
        "Paragraph":  "28",
        "Subparagraph":  "c",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_28_c&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r218":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IFRS",
        "Number":  "8",
        "Paragraph":  "28",
        "Subparagraph":  "d",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_28_d&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r219":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IFRS",
        "Number":  "8",
        "Paragraph":  "28",
        "Subparagraph":  "e",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_28_e&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r22":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IAS",
        "Number":  "1",
        "Paragraph":  "55",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_55&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r220":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IFRS",
        "Number":  "8",
        "Paragraph":  "32",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_32&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r221":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IFRS",
        "Number":  "8",
        "Paragraph":  "33",
        "Subparagraph":  "a",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_33_a&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r222":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IFRS",
        "Number":  "8",
        "Paragraph":  "34",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_34&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r223":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IFRS",
        "Note":  "Effective 2023-01-01",
        "Number":  "17",
        "Paragraph":  "109",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_109&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r224":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IFRS",
        "Note":  "Effective 2023-01-01",
        "Number":  "17",
        "Paragraph":  "109A",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_109A&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r225":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IFRS",
        "Note":  "Effective 2023-01-01",
        "Number":  "17",
        "Paragraph":  "113",
        "Subparagraph":  "b",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_113_b&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r226":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IFRS",
        "Note":  "Effective 2023-01-01",
        "Number":  "17",
        "Paragraph":  "120",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_120&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r227":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IFRS",
        "Note":  "Effective 2023-01-01",
        "Number":  "17",
        "Paragraph":  "132",
        "Subparagraph":  "b",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_132_b&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r228":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IFRS",
        "Note":  "Effective on first application of IFRS 9",
        "Number":  "4",
        "Paragraph":  "39L",
        "Subparagraph":  "e",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=4&code=ifrs-tx-2021-en-b&anchor=para_39L_e&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r229":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IFRS",
        "Note":  "Expiry date 2023-01-01",
        "Number":  "7",
        "Paragraph":  "37",
        "Subparagraph":  "b",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_37_b&doctype=Standard&book=b",
        "URIDate":  "2021-03-24"
        },
    "r23":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IAS",
        "Number":  "1",
        "Paragraph":  "61",
        "Subparagraph":  "a",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_61_a&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r230":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IFRS",
        "Note":  "Expiry date 2023-01-01",
        "Number":  "7",
        "Paragraph":  "IG29",
        "Subparagraph":  "a",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_IG29_a&doctype=Implementation%20Guidance&book=b",
        "URIDate":  "2021-03-24"
        },
    "r231":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IFRS",
        "Note":  "Expiry date 2023-01-01",
        "Number":  "7",
        "Paragraph":  "IG29",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_IG29&doctype=Implementation%20Guidance&book=b",
        "URIDate":  "2021-03-24"
        },
    "r232":  {
        "Name":  "Exchange Act",
        "Number":  "240",
        "Publisher":  "SEC",
        "Section":  "12"
        },
    "r233":  {
        "Name":  "Exchange Act",
        "Number":  "240",
        "Publisher":  "SEC",
        "Section":  "12",
        "Subsection":  "b"
        },
    "r234":  {
        "Name":  "Exchange Act",
        "Number":  "240",
        "Publisher":  "SEC",
        "Section":  "12",
        "Subsection":  "b-2"
        },
    "r235":  {
        "Name":  "Exchange Act",
        "Number":  "240",
        "Publisher":  "SEC",
        "Section":  "12",
        "Subsection":  "d1-1"
        },
    "r236":  {
        "Name":  "Form 10-K",
        "Number":  "249",
        "Publisher":  "SEC",
        "Section":  "310"
        },
    "r237":  {
        "Name":  "Form 20-F",
        "Number":  "249",
        "Publisher":  "SEC",
        "Section":  "220",
        "Subsection":  "f"
        },
    "r238":  {
        "Name":  "Form 40-F",
        "Number":  "249",
        "Publisher":  "SEC",
        "Section":  "240",
        "Subsection":  "f"
        },
    "r239":  {
        "Name":  "Forms 10-K, 10-Q, 20-F",
        "Number":  "240",
        "Publisher":  "SEC",
        "Section":  "13",
        "Subsection":  "a-1"
        },
    "r24":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IAS",
        "Number":  "1",
        "Paragraph":  "61",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_61&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r240":  {
        "Name":  "Regulation S-T",
        "Number":  "232",
        "Publisher":  "SEC",
        "Section":  "405"
        },
    "r241":  {
        "Name":  "Securities Act",
        "Number":  "230",
        "Publisher":  "SEC",
        "Section":  "405"
        },
    "r242":  {
        "Name":  "Securities Act",
        "Number":  "7A",
        "Publisher":  "SEC",
        "Section":  "B",
        "Subsection":  "2"
        },
    "r25":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IAS",
        "Number":  "1",
        "Paragraph":  "66",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_66&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r26":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IAS",
        "Number":  "1",
        "Paragraph":  "69",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_69&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r27":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IAS",
        "Number":  "1",
        "Paragraph":  "7",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_7&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r28":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IAS",
        "Number":  "1",
        "Paragraph":  "70",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_70&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r29":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IAS",
        "Number":  "1",
        "Paragraph":  "78",
        "Subparagraph":  "b",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_78_b&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r3":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IAS",
        "Number":  "1",
        "Paragraph":  "104",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_104&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r30":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IAS",
        "Number":  "1",
        "Paragraph":  "78",
        "Subparagraph":  "e",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_78_e&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r31":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IAS",
        "Number":  "1",
        "Paragraph":  "78",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_78&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r32":  {
        "Clause":  "iv",
        "IssueDate":  "2021-01-01",
        "Name":  "IAS",
        "Number":  "1",
        "Paragraph":  "79",
        "Subparagraph":  "a",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_79_a_iv&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r33":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IAS",
        "Number":  "1",
        "Paragraph":  "79",
        "Subparagraph":  "a",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_79_a&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r34":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IAS",
        "Number":  "1",
        "Paragraph":  "79",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_79&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r35":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IAS",
        "Number":  "1",
        "Paragraph":  "81A",
        "Subparagraph":  "a",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_81A_a&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r36":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IAS",
        "Number":  "1",
        "Paragraph":  "81A",
        "Subparagraph":  "c",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_81A_c&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r37":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IAS",
        "Number":  "1",
        "Paragraph":  "82",
        "Subparagraph":  "a",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_82_a&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r38":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IAS",
        "Number":  "1",
        "Paragraph":  "82",
        "Subparagraph":  "b",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_82_b&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r39":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IAS",
        "Number":  "1",
        "Paragraph":  "82",
        "Subparagraph":  "ea",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_82_ea&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r4":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IAS",
        "Number":  "1",
        "Paragraph":  "106",
        "Subparagraph":  "a",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_106_a&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r40":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IAS",
        "Number":  "1",
        "Paragraph":  "85",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_85&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r41":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IAS",
        "Number":  "1",
        "Paragraph":  "91",
        "Subparagraph":  "a",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_91_a&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r42":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IAS",
        "Number":  "1",
        "Paragraph":  "98",
        "Subparagraph":  "a",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_98_a&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r43":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IAS",
        "Number":  "1",
        "Paragraph":  "98",
        "Subparagraph":  "d",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_98_d&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r44":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IAS",
        "Number":  "1",
        "Paragraph":  "98",
        "Subparagraph":  "e",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_98_e&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r45":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IAS",
        "Number":  "1",
        "Paragraph":  "99",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_99&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r46":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IAS",
        "Number":  "1",
        "Paragraph":  "IG6",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_IG6&doctype=Implementation%20Guidance",
        "URIDate":  "2021-03-24"
        },
    "r47":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IAS",
        "Number":  "10",
        "Paragraph":  "21",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=10&code=ifrs-tx-2021-en-r&anchor=para_21&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r48":  {
        "Clause":  "i",
        "IssueDate":  "2021-01-01",
        "Name":  "IAS",
        "Number":  "12",
        "Paragraph":  "81",
        "Subparagraph":  "c",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2021-en-r&anchor=para_81_c_i&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r49":  {
        "Clause":  "ii",
        "IssueDate":  "2021-01-01",
        "Name":  "IAS",
        "Number":  "12",
        "Paragraph":  "81",
        "Subparagraph":  "c",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2021-en-r&anchor=para_81_c_ii&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r5":  {
        "Clause":  "i",
        "IssueDate":  "2021-01-01",
        "Name":  "IAS",
        "Number":  "1",
        "Paragraph":  "106",
        "Subparagraph":  "d",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_106_d_i&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r50":  {
        "Clause":  "i",
        "IssueDate":  "2021-01-01",
        "Name":  "IAS",
        "Number":  "12",
        "Paragraph":  "81",
        "Subparagraph":  "g",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2021-en-r&anchor=para_81_g_i&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r51":  {
        "Clause":  "ii",
        "IssueDate":  "2021-01-01",
        "Name":  "IAS",
        "Number":  "12",
        "Paragraph":  "81",
        "Subparagraph":  "g",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2021-en-r&anchor=para_81_g_ii&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r52":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IAS",
        "Number":  "12",
        "Section":  "Disclosure",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IAS12_g79-88_TI",
        "URIDate":  "2021-03-24"
        },
    "r53":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IAS",
        "Number":  "16",
        "Paragraph":  "37",
        "Subparagraph":  "a",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_37_a&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r54":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IAS",
        "Number":  "16",
        "Paragraph":  "37",
        "Subparagraph":  "g",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_37_g&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r55":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IAS",
        "Number":  "16",
        "Paragraph":  "37",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_37&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r56":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IAS",
        "Number":  "16",
        "Paragraph":  "73",
        "Subparagraph":  "b",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_73_b&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r57":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IAS",
        "Number":  "16",
        "Paragraph":  "73",
        "Subparagraph":  "c",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_73_c&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r58":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IAS",
        "Number":  "16",
        "Paragraph":  "73",
        "Subparagraph":  "d",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_73_d&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r59":  {
        "Clause":  "v",
        "IssueDate":  "2021-01-01",
        "Name":  "IAS",
        "Number":  "16",
        "Paragraph":  "73",
        "Subparagraph":  "e",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_73_e_v&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r6":  {
        "Clause":  "iii",
        "IssueDate":  "2021-01-01",
        "Name":  "IAS",
        "Number":  "1",
        "Paragraph":  "106",
        "Subparagraph":  "d",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_106_d_iii&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r60":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IAS",
        "Number":  "16",
        "Paragraph":  "73",
        "Subparagraph":  "e",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_73_e&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r61":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IAS",
        "Number":  "16",
        "Paragraph":  "73",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_73&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r62":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IAS",
        "Number":  "16",
        "Paragraph":  "75",
        "Subparagraph":  "b",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_75_b&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r63":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IAS",
        "Number":  "19",
        "Paragraph":  "142",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=19&code=ifrs-tx-2021-en-r&anchor=para_142&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r64":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IAS",
        "Number":  "19",
        "Paragraph":  "147",
        "Subparagraph":  "c",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=19&code=ifrs-tx-2021-en-r&anchor=para_147_c&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r65":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IAS",
        "Number":  "19",
        "Paragraph":  "9",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=19&code=ifrs-tx-2021-en-r&anchor=para_9&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r66":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IAS",
        "Number":  "2",
        "Paragraph":  "36",
        "Subparagraph":  "a",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=2&code=ifrs-tx-2021-en-r&anchor=para_36_a&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r67":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IAS",
        "Number":  "21",
        "Paragraph":  "52",
        "Subparagraph":  "a",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=21&code=ifrs-tx-2021-en-r&anchor=para_52_a&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r68":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IAS",
        "Number":  "21",
        "Paragraph":  "52",
        "Subparagraph":  "b",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=21&code=ifrs-tx-2021-en-r&anchor=para_52_b&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r69":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IAS",
        "Number":  "24",
        "Paragraph":  "17",
        "Subparagraph":  "a",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&anchor=para_17_a&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r7":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IAS",
        "Number":  "1",
        "Paragraph":  "106",
        "Subparagraph":  "d",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_106_d&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r70":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IAS",
        "Number":  "24",
        "Paragraph":  "17",
        "Subparagraph":  "e",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&anchor=para_17_e&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r71":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IAS",
        "Number":  "24",
        "Paragraph":  "17",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&anchor=para_17&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r72":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IAS",
        "Number":  "24",
        "Paragraph":  "18",
        "Subparagraph":  "b",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&anchor=para_18_b&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r73":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IAS",
        "Number":  "24",
        "Paragraph":  "19",
        "Subparagraph":  "c",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&anchor=para_19_c&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r74":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IAS",
        "Number":  "24",
        "Paragraph":  "19",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&anchor=para_19&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r75":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IAS",
        "Number":  "24",
        "Paragraph":  "20",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&anchor=para_20&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r76":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IAS",
        "Number":  "24",
        "Paragraph":  "21",
        "Subparagraph":  "j",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&anchor=para_21_j&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r77":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IAS",
        "Number":  "24",
        "Section":  "Disclosures",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IAS24_g13-24_TI",
        "URIDate":  "2021-03-24"
        },
    "r78":  {
        "Clause":  "iv",
        "IssueDate":  "2021-01-01",
        "Name":  "IAS",
        "Number":  "26",
        "Paragraph":  "35",
        "Subparagraph":  "b",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=26&code=ifrs-tx-2021-en-r&anchor=para_35_b_iv&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r79":  {
        "Clause":  "ii",
        "IssueDate":  "2021-01-01",
        "Name":  "IAS",
        "Number":  "27",
        "Paragraph":  "16",
        "Subparagraph":  "b",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=27&code=ifrs-tx-2021-en-r&anchor=para_16_b_ii&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r8":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IAS",
        "Number":  "1",
        "Paragraph":  "106",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_106&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r80":  {
        "Clause":  "iii",
        "IssueDate":  "2021-01-01",
        "Name":  "IAS",
        "Number":  "27",
        "Paragraph":  "16",
        "Subparagraph":  "b",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=27&code=ifrs-tx-2021-en-r&anchor=para_16_b_iii&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r81":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IAS",
        "Number":  "27",
        "Paragraph":  "16",
        "Subparagraph":  "b",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=27&code=ifrs-tx-2021-en-r&anchor=para_16_b&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r82":  {
        "Clause":  "ii",
        "IssueDate":  "2021-01-01",
        "Name":  "IAS",
        "Number":  "27",
        "Paragraph":  "17",
        "Subparagraph":  "b",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=27&code=ifrs-tx-2021-en-r&anchor=para_17_b_ii&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r83":  {
        "Clause":  "iii",
        "IssueDate":  "2021-01-01",
        "Name":  "IAS",
        "Number":  "27",
        "Paragraph":  "17",
        "Subparagraph":  "b",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=27&code=ifrs-tx-2021-en-r&anchor=para_17_b_iii&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r84":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IAS",
        "Number":  "27",
        "Paragraph":  "17",
        "Subparagraph":  "b",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=27&code=ifrs-tx-2021-en-r&anchor=para_17_b&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r85":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IAS",
        "Number":  "32",
        "Paragraph":  "IE33",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=32&code=ifrs-tx-2021-en-r&anchor=para_IE33&doctype=Illustrative%20Examples",
        "URIDate":  "2021-03-24"
        },
    "r86":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IAS",
        "Number":  "33",
        "Paragraph":  "66",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=33&code=ifrs-tx-2021-en-r&anchor=para_66&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r87":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IAS",
        "Number":  "33",
        "Paragraph":  "67",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=33&code=ifrs-tx-2021-en-r&anchor=para_67&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r88":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IAS",
        "Number":  "33",
        "Paragraph":  "68",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=33&code=ifrs-tx-2021-en-r&anchor=para_68&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r89":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IAS",
        "Number":  "33",
        "Paragraph":  "70",
        "Subparagraph":  "b",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=33&code=ifrs-tx-2021-en-r&anchor=para_70_b&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r9":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IAS",
        "Number":  "1",
        "Paragraph":  "108",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_108&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r90":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IAS",
        "Number":  "33",
        "Section":  "Disclosure",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=33&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IAS33_g70-73A_TI",
        "URIDate":  "2021-03-24"
        },
    "r91":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IAS",
        "Number":  "36",
        "Paragraph":  "127",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=36&code=ifrs-tx-2021-en-r&anchor=para_127&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r92":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IAS",
        "Number":  "37",
        "Paragraph":  "86",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=37&code=ifrs-tx-2021-en-r&anchor=para_86&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r93":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IAS",
        "Number":  "37",
        "Paragraph":  "88",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=37&code=ifrs-tx-2021-en-r&anchor=para_88&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r94":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IAS",
        "Number":  "38",
        "Paragraph":  "118",
        "Subparagraph":  "a",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=38&code=ifrs-tx-2021-en-r&anchor=para_118_a&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r95":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IAS",
        "Number":  "38",
        "Paragraph":  "118",
        "Subparagraph":  "c",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=38&code=ifrs-tx-2021-en-r&anchor=para_118_c&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r96":  {
        "Clause":  "i",
        "IssueDate":  "2021-01-01",
        "Name":  "IAS",
        "Number":  "38",
        "Paragraph":  "118",
        "Subparagraph":  "e",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=38&code=ifrs-tx-2021-en-r&anchor=para_118_e_i&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r97":  {
        "Clause":  "vi",
        "IssueDate":  "2021-01-01",
        "Name":  "IAS",
        "Number":  "38",
        "Paragraph":  "118",
        "Subparagraph":  "e",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=38&code=ifrs-tx-2021-en-r&anchor=para_118_e_vi&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r98":  {
        "Clause":  "vii",
        "IssueDate":  "2021-01-01",
        "Name":  "IAS",
        "Number":  "38",
        "Paragraph":  "118",
        "Subparagraph":  "e",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=38&code=ifrs-tx-2021-en-r&anchor=para_118_e_vii&doctype=Standard",
        "URIDate":  "2021-03-24"
        },
    "r99":  {
        "IssueDate":  "2021-01-01",
        "Name":  "IAS",
        "Number":  "38",
        "Paragraph":  "118",
        "Subparagraph":  "e",
        "URI":  "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=38&code=ifrs-tx-2021-en-r&anchor=para_118_e&doctype=Standard",
        "URIDate":  "2021-03-24"
        }
    },
"version":  "2.1"
}

2 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 4/02/24  FSD Pharma Inc.                   20-F       12/31/23  120:15M                                    Blueprint/FA
 3/31/23  FSD Pharma Inc.                   20-F       12/31/22  119:14M                                    Newsfile Corp./FA

5 Previous Filings that this Filing References

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 9/21/21  FSD Pharma Inc.                   6-K         9/21/21    4:674K                                   Business Wire/FA
 5/05/21  FSD Pharma Inc.                   6-K         5/14/21    3:914K                                   Newsfile Corp./FA
 2/11/21  FSD Pharma Inc.                   6-K         2/11/21    2:217K                                   Newsfile Corp./FA
 3/18/20  FSD Pharma Inc.                   6-K         3/18/20    2:17M                                    Newsfile Corp./FA
12/06/19  FSD Pharma Inc.                   40FR12B               52:25M                                    Newsfile Corp./FA
↑Top
Filing Submission 0001062993-22-009034   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)
Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
About — Privacy — Redactions — Help — Wed., May 15, 7:31:01.4pm ET